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Abstract 
Since 2009, when the Signal Amplification By Reversible Exchange (SABRE) 
process, which transfers polarisation from parahydrogen to substrates in a non-
hydrogenative manner, was first published, substantial efforts have been made in 
method optimisation and catalyst development. This work presents multi-step syntheses 
and studies on a series of novel neutral bidentate iridium carbene complexes, 
[Ir(COD)(R-NHC-O)]. The carbene ligands have a pendent phenolate group, 
incorporating the electron-withdrawing substituents, NO2, COOMe, Cl and H. The 
reactivity of each complex with substrate and hydrogen has enabled the identification of 
several intermediates, including dihydride COD complexes, [Ir(H)2(COD)(R-NHC-O)]. 
COD hydrogenation facilitates the formation of SABRE-active pyridyl dihydride 
species with structures dependent on the R substituent and solvent used. In DCM, the Ir-
O bond is stable and complexes of [Ir(H)2(R-NHC-O)(py)2] form. However, in 
methanol, when the electron density is increased as R is changed to an H substituent, 
complete Ir-O bond cleavage occurs to form [Ir(H)2(H-NHC-O)
−(py)3]
+. 
When studied with parahydrogen, these complexes act as efficient SABRE 
catalysts for a variety of substrates in a range of polarity solvents. They undergo the 
necessary substrate and hydrogen exchange processes, leading to the observation of 
enhanced NMR signals for pyridine, nicotinamide, nicotine and nicotinaldehyde. The 
SABRE activity of these neutral catalysts has been optimised and expanded, as 
polarisation transfer to several amine molecules, including phenethylamine and 
tryptamine has been demonstrated in DCM. However, selectivity is reduced, as 
SABRE-active species, C-H activated products and iridium dimer complexes form, 
particularly at low substrate concentrations. Addition of phosphine ligands to the 
mixtures inhibits dimer formation and leads to greater 1H NMR signal enhancements 
due to stabilisation of the metal complexes. 
A study into the parahydrogenation of phenylacetylene using the NO2-
containing catalyst has also been completed. Although it was less reactive than 
Crabtree’s catalyst it proved more stable due to minimal degradation over time. 
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1. Introduction 
This work focuses on improving the sensitivity of NMR spectroscopy via 
hyperpolarisation. The introduction starts with a discussion of the principles of NMR 
and gives an overview of the hyperpolarisation techniques that can be used to increase 
NMR signal intensities. These methods are known as optical pumping, Dynamic 
Nuclear Polarisation (DNP) and Parahydrogen Induced Polarisation (PHIP). The 
emphasis of this work is on PHIP, which can be hydrogenative or non-hydrogenative, 
and which requires the use of a metal catalyst. Initial PHIP studies used a rhodium-
based phosphine complex but developments since then have focused on iridium-based 
phosphine and subsequently iridium-based carbene complexes, due to their greater 
activity. These developments are detailed, along with a review of current research in the 
area of the non-hydrogenative Signal Amplification By Reversible Exchange (SABRE) 
process. This technique leads to signal enhancements of NMR-active nuclei within 
suitable substrate molecules such as pyridine, when reacted with parahydrogen in 
solution. A description of the reaction route to form the SABRE-active charged iridium 
carbene catalysts is given. In these complexes the carbene ligands are symmetric and 
monodentate. Neutral complexes containing multidentate asymmetric carbene ligands 
have thus far not been explored. Furthermore, the potential application of SABRE to 
improve Magnetic Resonance Imaging (MRI) is reviewed with details of heterogeneous 
iridium catalysts. The aim of this thesis, using parahydrogen and neutral iridium 
carbene complexes to improve NMR sensitivity, is then presented. 
  
45 
 
1.1. NMR and the use of hyperpolarisation 
Nuclear Magnetic Resonance (NMR) is a hugely important technique for 
chemists as it enables molecular characterisation based on the environments of different 
spins within a system. Every nucleus with a non-zero spin quantum number has a 
magnetic dipole which possesses spin angular momentum.1 The magnetic moment, μ, of 
a nucleus is directly proportional to the spin angular momentum and the gyromagnetic 
ratio, γ. For example, a 1H nucleus has a magnetic spin quantum number, I, of ½. When 
a 1H nucleus is placed inside a magnetic field the nucleus can be aligned in two different 
orientations; either with the direction of the external magnetic field, B0, or against it. 
These orientations equate to the magnetic quantum number, m, which has 2I + 1 values 
and therefore for a spin-½ nuclei, m has two values, equal to +½ (α), ‘spin up’ and –½ 
(β), ‘spin down’ as shown in Figure 1. When there is no applied magnetic field, these 
two orientations have the same energy, however, when a magnetic field is applied they 
separate out so that each orientation has a slightly different energy, with the energy 
difference, ∆E. This is due to the Zeeman effect, where, as the strength of the magnetic 
field increases, the energy difference between the levels is also increased. The +½ (α) 
state is aligned with the field therefore is the most stable so has the lowest energy and 
the –½ (β) state is aligned against the field. The chemical shift (frequency, ω) of 
different nuclei within a magnetic field depends on both the field strength, B, and the 
gyromagnetic ratio, γ, of the nucleus that is probed, as shown by 𝜔 = 𝛾𝐵. 
 
Figure 1: Energy levels present when a sample containing spin-½ nuclei is in a magnetic field 
and the Zeeman effect that occurs when the magnetic field is increased 
For NMR, the spin transitions can only occur from a more populated state to a 
less populated state, so for example, when only one spin changes from the +½ level to 
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the –½ level, to produce an observable single quantum coherence signal. Because the 
energy difference between the two levels is small when in an applied field (lower 
energy than kT where k is the Boltzmann constant and T is the temperature), the 
transition requires a small amount of energy. The levels are populated according to the 
Boltzmann distribution, meaning that there is only a slight excess of spins in the lower 
energy level. 
𝑁𝛽
𝑁𝛼
=  𝑒−∆𝐸/𝑘𝑇 
This means that the energy difference for protons with a gyromagnetic ratio of 
2.675 x 108 rad s−1 T−1 in a 9.4 T magnetic field strength is equal to 2.65 x 10−25 J and 
therefore the population difference is approximately one spin in every 31000 at 298 K.  
∆𝐸 =  
𝛾ℎ𝐵
2𝜋
=
2.675 × 108 𝑟𝑎𝑑 𝑠−1 𝑇−1  ×  6.626 ×  10−34 𝑚2 𝑘𝑔 𝑠−1  ×  9.4 𝑇
2𝜋
= 2.65 × 10−25 𝐽 
𝑁𝛽
𝑁𝛼
=  𝑒−2.65 ×10
−25 𝐽  1.38 ×10−23𝐽 𝐾−1 × 298 𝐾⁄ = 0.9999356 =  
15520
15519
 
Therefore, the number of transitions that are observed is small, which means that 
NMR is inherently insensitive.2 There are a few ways to combat this although there are 
associated problems;  
1. use a large number of scans which takes a longer amount of time  
2. use a large amount of sample which is not necessarily available  
3. use a stronger magnet which is expensive  
4. use chemical means to polarise samples 
This last method, termed hyperpolarisation, is when a population difference is 
altered so that it is much larger than normal. Therefore, the number of transitions that 
can now be observed is considerably larger. There are several methods that exist to 
artificially enhance the population difference within a sample; optical pumping, 
Dynamic Nuclear Polarisation (DNP) or the use of spin isomers. 
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1.1.1. Optical pumping  
Optical pumping is a method used to increase the nuclear spin polarisation of a 
sample above its thermal equilibrium, using light. For NMR experiments, the nuclei that 
can be polarised are limited to spin-½ noble gas isotopes such as 3He and 129Xe. For the 
optical pumping procedure, a glass cell is used, which contains the noble gas of interest, 
an alkali metal vapour which acts as an important polarisation intermediate,3 and 
nitrogen gas. During the optical pumping process, circularly polarised laser light is used 
to excite electrons that are present in the alkali metal, such as rubidium, which then 
enables polarisation of the 3He or 129Xe nuclei via collisions.4 The wavelength of the 
laser light must be tuned to the correct wavelength for it to be absorbed by the alkali 
metal, which is about 795 nm for rubidium. Both the electron spin and the nuclear spin 
of the alkali metal are polarised. The process works because of the exchange of angular 
momentum from the polarised photons to the nuclei of rubidium.5 The inert nitrogen 
must be present to quench excited atoms that would otherwise undergo radiative decay 
and depolarise the noble gas.6 Hyperpolarised 129Xe has shown promise in MRI studies 
as an agent for lung imaging.7-8 Figure 2 shows how rubidium absorbs the circularly 
polarised light which leads to polarisation build-up of one rubidium electronic ground 
state.8 
 
Figure 2: Optical pumping of rubidium due to its absorption of circularly polarised light8 
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1.1.2. Dynamic Nuclear Polarisation (DNP) 
Like optical pumping, DNP involves the transfer of polarisation from unpaired 
electron spins to nuclear spins, in either solids or liquids. The gyromagnetic ratio of an 
electron is about 660 times larger than that of a proton spin, meaning the maximum 
theoretical enhancement of a proton signal using DNP is about 660 times the thermal 
signal.9 The DNP process uses an NMR sample which is doped with a species 
containing an unpaired electron, which acts as the polarisation source. Typically, a 
stable organic radical such as those shown in Figure 3 is used,10 which must be 
homogeneously distributed throughout the sample. The sample is then frozen at very 
low temperature (< 100 K) and polarisation transfer is achieved via microwave 
irradiation of the sample, as the energy differences between electron spin states are 
considerably larger than for proton spins and the irradiation must be near or at the 
electron paramagnetic resonance (EPR) transition. Commonly, hours of polarising time 
are needed to build-up polarisation in the sample. Before acquisition of a hyperpolarised 
NMR spectrum, dissolution of the sample and transfer to an NMR spectrometer must 
occur.11 
 
Figure 3: Structures of organic radicals used for DNP10 
Several polarising mechanisms are possible in DNP experiments where electron 
and nuclear spins are strongly coupled. For liquids, the Overhauser effect operates9 
whilst for solids, the solid effect (a two-spin process between an electron and a 
nucleus),12-14 the cross effect13-14 and thermal mixing (three-spin processes between two 
coupled electrons and a nucleus)10 are possible. For high magnetic fields, the cross 
effect dominates if the linewidth and breadth of the electron EPR spectrum are larger 
than the Larmor frequency of the nuclei to be polarised. Spin diffusion can then disperse 
the polarisation throughout the sample.10 However, the equipment needed to polarise 
samples is particularly expensive as well as the polarisation time being long. 
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1.1.3. Hydrogen and its spin isomers 
Hydrogen is a homonuclear diatomic molecule. Each hydrogen atom has a 
nucleus with one spin and spin order of ±½ and therefore for molecular hydrogen, H2, 
with two spins, H1 and H2, there are four spin isomers (Table 1), depending on the 
orientation of the two spins. In order to distinguish between αβ and βα, the linear 
combinations are taken and normalised.15 
Table 1: The spin isomers of molecular hydrogen 
 H1 H2 H1 H2 H1 H2 H1 H2 
Spins 
↑↑ ↑↓ ↓↑ ↓↓ 
α1 α2 α1 β2 β1 α2 β1 β2 
α  α α  β β  α β  β 
M +1 0 0 −1 
Linear combinations 
for 4 spin isomers 
𝛼𝛼 
1
√2
(𝛼𝛽 +  𝛽𝛼) 
1
√2
(𝛼𝛽 −  𝛽𝛼) 𝛽𝛽 
Spin isomer ortho ortho para ortho 
 
These four isomers correspond to two different states, known as orthohydrogen 
and parahydrogen. There are three isomers of orthohydrogen, αα, ββ and 1/√2 (αβ + 
βα) and these are triply degenerate. They are symmetric with respect to exchange of the 
nuclei and the spins are aligned so they have an overall magnetic moment and are NMR 
active.1 The fourth isomer, parahydrogen, 1/√2 (αβ – βα), is antisymmetric with respect 
to exchange of the nuclei and the spins are opposed so there is no overall magnetic 
moment and therefore parahydrogen is NMR silent.1 
These isomers derive from the Pauli Exclusion Principle which states that two 
identical fermions cannot occupy the same quantum state simultaneously. The total 
wavefunction for the two identical fermions must be antisymmetric with respect to 
exchange of the nuclei. The total wavefunction of hydrogen contains electronic, 
translational, vibrational, rotational and nuclear parts.16 The electronic, translational, 
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and vibrational parts are all symmetric and therefore the product of the rotational and 
nuclear parts has to be antisymmetric.  
𝛹𝑡𝑜𝑡𝑎𝑙 = 𝛹𝑒𝑙𝑒𝑐𝛹𝑡𝑟𝑎𝑛𝑠𝛹𝑣𝑖𝑏𝛹𝑟𝑜𝑡𝛹𝑛𝑢𝑐 
This means that for an antisymmetric nuclear configuration i.e. parahydrogen, 
the rotational levels are symmetric i.e. J = 0, 2, 4... and for the symmetric nuclear 
configuration i.e. orthohydrogen, the rotational levels are antisymmetric i.e. J = 1, 3, 
5....16 Because parahydrogen occupies the lower rotational states, it is more stable and 
this fact is exploited in the production of parahydrogen from normal hydrogen. At room 
temperature with normal hydrogen, each of the four spin isomer energy levels are 
equally populated, so 75 % of H2 is orthohydrogen and 25 % is parahydrogen.
17 
However, as the temperature is lowered and the spin-flip from orthohydrogen to 
parahydrogen is made possible by the use of a paramagnetic silica/FeCl3 catalyst, the 
percentage of parahydrogen in the mixture increases up until about 99 % at 20 K.16 The 
paramagnetic catalyst aids the required spin conversion of hydrogen, by interactions 
between its own inhomogeneous magnetic field, formed due to its spin magnetic 
moments, and the magnetic moments of the hydrogen molecule.18-19 The set-up required 
to form parahydrogen is shown in Figure 4 and the percentage of parahydrogen in 
relation to the temperature is shown in Figure 5. 
 
Figure 4: Apparatus used to form parahydrogen from normal hydrogen (Reprinted from 
Duckett, S. B.; Wood, N. J. Coord. Chem. Rev. 2008, 252, 2278, Copyright © 2008 with 
permission from Elsevier)16 
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Figure 5: The proportion of parahydrogen increases as the temperature decreases (Reprinted 
from Green, R. A.; Adams, R. W.; Duckett, S. B.; Mewis, R. E.; Williamson, D. C.; Green, G. G. 
R. Prog. Nucl. Magn. Reson. Spectrosc. 2012, 67, 1, Copyright © 2012 with permission from 
Elsevier)1 
For a two-spin system, such as an alkene that contains two protons, there are 
four energy levels and the transitions that are observable in NMR are single quantum 
coherence transitions where only one spin flips. Other transitions, where more than one 
spin changes, are not allowed by the normal selection rule; however, higher quantum 
coherence transitions do occur. For example, in an alkene where double quantum 
coherence and zero quantum coherence transitions exist, these must be converted into 
single quantum coherence transitions using a specific pulse sequence to be observed. 
These different spin transitions for a two-spin system are shown in Figure 6. 
 
Figure 6: The possible transitions in a two-spin system 
When a sample that just contains normal hydrogen is in a magnetic field, all four 
states are approximately equally populated with only a slight excess in the lower energy 
states. Only transitions from the lowest energy ortho states to the higher energy ortho 
states give rise to the observed signal (see Figure 7). With parahydrogen only the 
α α 
α β β α 
β β 
Single Quantum Coherence 
Zero Quantum Coherence 
Double Quantum Coherence 
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singlet state is occupied, which is symmetric and NMR silent so no signal is seen for 
pure parahydrogen (see Figure 7).20 Only when the symmetry of the parahydrogen is 
broken and the H-H bond is split i.e. into two hydrides or incorporated into a 
hydrogenated product, does it becomes NMR active and able to cause large 1H NMR 
signal enhancements within a sample. 
 
Figure 7: The populated spin states of normal H2 and p-H2 and their corresponding NMR 
spectra resulting from the spin transitions shown 
For parahydrogen to be split, a metal catalyst is commonly used. For example, a 
metal could accept hydrogen in a concerted cis fashion to form two hydrides21-22 and 
then act as a hydrogenation catalyst to hydrogenate an alkene to an alkane. However, a 
metal could also accept hydrogen as two hydrides and not transfer these hydrides into 
an organic product, but instead transfer the polarisation present in the parahydrogen-
derived hydrides to an organic product, without changing the chemical identity of the 
product. 
Many metal catalysts used contain carbene ligands, where a metal-carbon double 
bond may exist. A carbene is a compound that contains a carbon atom that is neutral and 
divalent with six electrons in its valence shell.23 Since the early 1960s, significant 
research has led to the discovery of a variety of stable carbene complexes. 
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1.2. Metal carbene and phosphine complexes 
Metal carbene complexes typically contain metal-carbon double bonds. The first 
example of this type of complex was discovered by E. O. Fischer in 1964.24 Addition of 
a methyl group to [W(CO)6] using LiCH3, followed by protonation then methylation 
using CH2N2, was found to form the diamagnetic complex [W(CO)5(COCH3(CH3))]. 
Upon subsequent analysis, it was shown that the structure contained a tungsten-carbon 
double bond.24 The same process occurred using LiPh (see Figure 8), to gain the 
tungsten-carbon double-bonded [W(CO)5(COCH3(Ph))] complex. It was shown that the 
incoming anion adds to one of the initial CO ligands to form the carbene from the CO 
ligand, without ligand substitution.23 
 
Figure 8: Formation of [W(CO)5(COCH3(Ph))]
23 
Since then, other carbenes with this similar structure have been known as 
Fischer-type carbenes.25-26 The metal centre is in a low oxidation state and is therefore 
electron rich. This means that the carbene ligand contains an electrophilic carbon that is 
prone to nucleophilic attack.27 The bonding in a Fischer carbene has σ-donor and π-
acceptor characteristics and the carbene can either be stabilised by π-back donation from 
the metal d-orbitals into the empty carbene p-orbital or by π-donation from heteroatom 
substituents on the carbene itself. This stabilisation means that the singlet form is 
favoured so the carbene itself has two spin-paired electrons. Resonance structures, such 
as in Figure 9, can be drawn to show the importance of the electron-donating 
heteroatom substituents.27 This leads to a metal-carbon bond order of between one and 
two, which depends on the π-donor capabilities of the carbene substituents.  
 
Figure 9: Resonance structures for Fischer-type carbenes 
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More recently, a specific type of Fischer carbene has been described, called an 
N-heterocyclic carbene (NHC), which contains very strongly electron-donating 
substituents, so that only a formal single bond is formed between the carbon and the 
metal centre.23 One of these highly stable NHCs was first produced in 1991 by A. J. 
Arduengo, hence these are sometimes referred to as Arduengo carbenes.28 The 1,3-di-1-
adamantylimidazol-2-ylidene was formed via deprotonation of 1,3-di-1-
adamantylimidazolium chloride, as shown in Figure 10, and was obtained as a 
crystalline solid.  
 
Figure 10: Formation of the stable Arduengo carbene, 1,3-di-1-adamantylimidazol-2-ylidene28 
These types of carbenes are singlet carbenes and are often considered to only act 
as σ-donor ligands due to poor π-back donation from the metal to the carbon. This is 
because the carbene is strongly stabilised by π-donating nitrogen groups that donate 
electron density into the empty p-orbital of the carbene. The imidazole ring retains its 
aromaticity as there is a delocalised π-system across the N-C-N bonds and so these are 
highly stable carbenes with a metal-carbon bond order considered to be one. 
Because NHCs are strong σ-donor ligands and very unreactive, they are 
commonly compared to phosphine ligands, which also have good σ-donor 
characteristics and often act as spectator ligands within a reaction. However, studies by 
Huang et al.29 have shown that NHCs often have stronger M-C bonds than the 
comparable M-P bonds and therefore form more stable metal complexes. The electronic 
and steric effects of phosphine donor ligands are strongly affected by the groups 
attached to the phosphorus donor, because they interact directly. In 1977, Tolman 
published data describing how the steric and electronic properties of the phosphine 
ligand, PR3, in a metal complex were affected when the R groups were altered.
30 He 
analysed the effect of different R groups on the stretching frequencies of the CO bond in 
[Ni(CO)3(PR3)] complexes, in relation to the reference phosphine, P
tBu3. This showed 
that the greater σ-donor properties of the R groups, the lower the stretching frequencies 
of the CO bonds. The Tolman Electronic Parameter describes this. Phosphines also have 
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varying steric bulk depending on the R groups in [Ni(CO)3(PR3)] complexes and the 
Tolman Steric Parameter describes this, where the Ni-P bond length is fixed. The PR3 
ligand forms a cone shape, as depicted in Figure 11, and the steric effect is measured 
based on the cone angle, θ, thus the bulkier the R groups, the larger the angle. 
 
Figure 11: Tolman Cone Angle for phosphine ligands30 
These two factors, electronic and steric, are related and thus it is difficult to fine 
tune one property without altering the other. For NHCs however, the R groups attached 
to each nitrogen atom of the heterocycle are much further away from the bonding 
carbene. Therefore, electronic effects are subtler and it is steric effects that mainly 
dominate the bonding in NHCs. The bulkier the R groups of an NHC, the longer and 
weaker the M-C bond.31 
 Another type of carbene complex was described in 1974 by R. R. Schrock,32 but 
this complex did not contain a stabilised carbene. The reaction of LiCH2C(CH3)3 with 
[Ta(CH2C(CH3)3)3Cl2] was shown to form a carbene complex containing a tantalum-
carbon bond via α-H abstraction (Figure 12).23, 32  
 
Figure 12:  Formation of [Ta(CHC(CH3)3)(CH2C(CH3)3)3]
23, 32 
In comparison to Fischer carbenes, Schrock carbenes, as they have come to be 
known, contain a high oxidation state metal centre and therefore the carbene carbon is 
nucleophilic and able to react with electrophiles. Schrock carbenes contain no 
stabilising substituents and thus the triplet state, containing two unpaired electrons, is 
θ 
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favoured. Therefore, in Schrock carbenes, the double bond between the metal and the 
carbene arises due to mutual π-donation. Bonding in all three carbene types is shown in 
Figure 13. 
 
Figure 13: Bonding in Fischer, Schrock and N-heterocyclic carbenes 
Schrock carbenes have emerged as being important in alkene metathesis. For 
example, the series of alkene metathesis catalysts first developed by R. H. Grubbs33 all 
contain a ruthenium-carbon double bond, with the carbon bonded to an H and a phenyl 
derivative. The first generation catalysts also contain a phosphine ligand which is 
replaced by an NHC in the second generation catalysts (see Figure 14).34 This makes the 
catalysts more stable to air and water so that they can be more easily handled.35 This is 
particularly important for catalysts which are routinely used both for academic research 
and industrial applications. 
 
Figure 14: First generation (A) and second generation (B) Grubbs catalysts containing Schrock 
carbenes33-34 
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1.3. Other coordinating ligands 
Many metal phosphine-containing and NHC-containing catalysts exist, 
particularly those of late transition metals, which have a wide variety of uses varying 
from homonuclear and heteronuclear bond formation reactions to carrying out catalytic 
reductions of substrates.36-43 As well as phosphines and NHCs, some other ligands that 
are commonly used in metal complexes include amines, carbonyls, alkenes, halides and 
alkoxides. These are often desirable due to their labile nature or required reactivity. For 
example, Crabtree’s catalyst contains a cyclooctadiene ligand which can easily be 
hydrogenated during a reaction to enable the binding of other substrate ligands.44 A 
number of binding modes are possible depending on the type of ligand, as shown in 
Figure 15. For example, amines act as σ-donor ligands due to the nitrogen lone pair 
donating into a metal orbital. No back donation can occur as the other p-orbitals are 
already involved in bonding. Alkenes bind to metal centres because a σ-donor 
interaction exists from the centre of the double bonds to the metal and a π-acceptor 
interaction exists as the metal can back donate electron density into the π* antibonding 
orbital of the alkenes. This type of bonding also exists for CO ligands. Alkoxides act as 
both σ-donor and π-donor ligands because their lone pair can donate into the empty 
metal d-orbital. These bonding interactions should be considered when choosing and 
optimising ligands for desired catalytic activity. 
 
Figure 15: Bonding interactions for ligands commonly used in metal catalysts 
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1.4. Hydrogenation reactions 
Many studies involving the hydrogenation of unsaturated substrates have been 
conducted using hydrogen as the direct source of H atoms. Typically, double or triple 
bonds are hydrogenated using H2 gas and a catalyst where both the substrate and H2 can 
bind to a metal centre. This acts as a site for hydrogenation which enables the addition 
of hydrogen across a multiple bond. When normal hydrogen is used to hydrogenate a 
multiple bond, all the states are approximately equally populated so transitions can 
occur from each lower energy state and the resulting signal intensities are small as 
shown in Figure 16. 
 
 
Figure 16: Transitions and spectrum resulting from hydrogenation of e.g. an alkene using 
normal hydrogen 
The catalysts used for hydrogenation reactions are typically inorganic metal 
complexes, however, several non-metal main group systems have also been described. 
Frustrated Lewis Pairs45-48 are a major area of research with one specific example being 
the hydrogenation of carbon dioxide using an aminoborane complex as shown in Figure 
17.47 This leads to the formation of several reduced CO2 borate species as depicted in 
Figure 17.  
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Figure 17: Reduction of CO2 with H2 using an aminoborane complex
47 
A catalyst-free hydrogenation of an aromatic triphosphabenzene has also been 
described by Longobardi et al.48 in 2014, where H2 adds to a phosphorus-carbon double 
bond. Subsequent rearrangement leads to the formation of a bicyclo product, due to a 
hydride shift which causes the formation of a P-P bond and ring contraction. This 
contraction is irreversible, although H2 addition before the hydride shift is reversible. 
This is shown in Figure 18. 
 
Figure 18: H2 addition to an aromatic triphosphabenzene leads to P=C bond hydrogenation 
followed by a hydride shift leading to a bicyclo product (Reprinted with permission from 
Longobardi, L. E.; Russell, C. A.; Green, M.; Townsend, N. S.; Wang, K.; Holmes, A. J.; 
Duckett, S. B.; McGrady, J. E.; Stephan, D. W., J. Am. Chem. Soc. 2014, 136 (38), 13453 
Copyright © 2014 American Chemical Society) 
However, the work described herein focuses on inorganic metal complexes and 
these can be either heterogeneous or homogeneous complexes. 
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1.4.1. Heterogeneous catalysts 
Heterogeneous catalysts are typically solid phase, being dispersed within a 
reaction solution. The first major breakthrough in heterogeneous catalysis was made by 
Paul Sabatier in the early 1900s when he was investigating the addition of hydrogen to 
organic molecules and found that the reaction could be improved by the addition of a 
small amount of nickel to a reaction flask.49-52 This led to the development of the 
Sabatier process for which he was awarded the Nobel Prize in Chemistry in 1912. The 
Sabatier process involves the reduction of CO2 to methane and water using H2 gas and a 
nickel catalyst.53 Since then, the range of solid-supported catalysts used has grown, with 
typical heterogeneous catalysts now using precious metals such as palladium, platinum, 
rhodium and ruthenium; however, less expensive alternatives like nickel can still be 
used. Common examples are Lindlar’s catalyst, which contains palladium on calcium 
carbonate as the main structure and acts as a selective alkyne to alkene hydrogenation 
catalyst,54 and Raney nickel, which has a wider scope.55-57 Important industrial uses of 
heterogeneous catalysts are the Fischer-Tropsch process for creating hydrocarbons from 
carbon monoxide and hydrogen (typically using Co, Fe or Ru based catalysts) and the 
Haber-Bosch process for creating ammonia from nitrogen and hydrogen (typically using 
Fe or Ru based catalysts). Many of these catalyst applications require high pressures 
and/or temperatures. It can be difficult to determine exact mechanisms for 
hydrogenation reactions using heterogeneous catalysts although it is widely accepted 
that both hydrogen and the substrate adsorb to the surface of a solid and then the H 
atoms are transferred stepwise to each atom of a multiple bond (see Figure 19).58-59 Due 
to the reversibility of step B, atom scrambling can occur if D2 is used instead of H2, as 
an H atom can transfer back to the support and lead to the formation of isomer mixtures. 
Only very weak interactions exist between the metal surface and the saturated substrate 
so that it leaves the surface site, ready for a new reaction to occur. 
 
Figure 19: Steps involved in heterogeneous hydrogenation of a double bond on a metal 
surface59  
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1.4.2. Homogeneous catalysts 
In 1965, in the field of homogeneous catalysis, Wilkinson and Coffey 
independently discovered [RhCl(PPh3)3] which was shown to act as a very efficient 
hydrogenation catalyst at low temperatures and pressures.60-62 This was to become 
known as Wilkinson’s catalyst and was followed by a number of other multiple 
phosphine-containing rhodium and ruthenium complexes, developed by Wilkinson, 
Schrock and Osborn.63-67 The mechanism of hydrogenation using these catalysts is well 
studied and understood, involving ligand loss and solvent stabilisation, and then 
oxidative addition of hydrogen to form a dihydride species, followed by substrate 
binding. Migratory insertion of one hydride to one end of the multiple bond occurs, 
which is then followed by reductive elimination to reform the active catalytic complex 
(see Figure 20).68 
 
Figure 20: Mechanism for hydrogenation using [RhCl(PPh3)3]
68 
These complexes are typically solvent-stabilised and can be limited and 
inhibited by the ligand dissociation that is required.44 In the 1970s Crabtree developed 
an iridium analogue of Wilkinson’s catalyst containing only one phosphine ligand and 
the easily hydrogenated bidentate ligand cyclooctadiene (COD). He deduced that since 
heterogeneous catalytic systems do not require a ligand loss step in order for substrate 
coordination to occur, homogeneous catalysis could potentially be improved by using 
non-coordinating solvents and enabling easy access to the metal centre by reducing the 
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number of other binding ligands.44 This proved successful with the production of 
Crabtree’s complex, [Ir(COD)(PCy3)(py)][PF6], with the mechanism now able to 
continually cycle once the initial activation via COD hydrogenation has occurred (see 
Figure 21).69 This time the mechanism proceeds via initial binding of the alkene 
substrate followed by oxidative addition of hydrogen. This is common for these 
complexes where the starting pre-catalyst cannot be regenerated because of the ligand 
hydrogenation.68 
 
Figure 21: Mechanism for hydrogenation using [Ir(COD)(L)2]
+69 
Since then, numerous homogeneous catalysts have been developed containing 
more specialised chiral ligands to enable enantioselective catalysis of functional groups 
such as alkenes and ketones.70-73 Many of the ligands are chelating chiral phosphines or 
C-N bidentate ligands that are chiral to induce chirality within the product. Examples 
include BINAP, which is used in the Noyori asymmetric hydrogenation of ketones for 
which Noyori, Knowles and Sharpless were awarded the Nobel Prize in 2001, as well as 
PHOX derived ligands (see Figure 22). However, these specially modified ligands can 
get complicated and thus expensive, particularly for major industrial uses. 
 
Figure 22: Chiral ligands R-BINAP (A) and PHOX (B) used for enantioselective synthesis  
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1.4.3. PASADENA and ALTADENA 
One method used to monitor homogeneous hydrogenation reactions is 1H NMR 
spectroscopy. Changing the nature of hydrogen used for hydrogenation, from normal H2 
to p-H2, can have several benefits when analysing reactions by NMR. When p-H2 is 
reacted with a substrate, different magnetic states evolve from its initial 1/√2 (αβ – βα) 
singlet state. This means the initial singlet state can occupy the αβ and/or the βα state so 
that a large population difference is created. This can lead to signal enhancements 
within a sample and therefore previously undetectable reactive intermediates as well as 
enhanced products can be observed by NMR.74-76 This can prove particularly useful for 
mechanistic studies and identifying low concentration analytes. Two NMR methods of 
visualising hyperpolarisation exist, known as PASADENA and ALTADENA, 
depending on whether the experiment is conducted in a high or low magnetic field. 
 
1.4.3.1. PASADENA 
When a reaction with a substrate, a metal catalyst and parahydrogen occurs 
within the high field of a spectrometer, the initial parahydrogen singlet state, αβ – βα, 
mixes with one triplet state, αβ + βα, and evolves to occupy both the αβ and βα states 
approximately equally because, within the high magnetic field, these two states are 
similar in energy. Therefore, transitions from these states form a pair of antiphase 
doublets due to emission from both states to the αα state and absorption from both states 
to the ββ state, as shown in Figure 23. This is known as Parahydrogen And Synthesis 
Allow Dramatically Enhanced Nuclear Alignment (PASADENA).77  
 
1.4.3.2. ALTADENA 
When a reaction with a substrate, a metal catalyst and parahydrogen occurs in 
the low magnetic field outside of a spectrometer the initial parahydrogen singlet state, 
αβ – βα, remains intact. It cannot mix with the initial triplet state because the energy 
difference is too great. Therefore, only the βα state remains populated. This means that 
an absorption peak at one chemical shift is observed due to the transition to the ββ state 
and an emission peak at a different chemical shift is observed due to the transition to the 
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αα state (see Figure 23). This is called Adiabatic Longitudinal Transport After 
Dissociation Engenders Net Alignment (ALTADENA).78 
 
 
Figure 23: The populated spin states, transitions and resulting spectra from hydrogenation 
using parahydrogen under PASADENA conditions (A) and ALTADENA conditions (B) 
Both PASADENA and ALTADENA are hydrogenative processes where the 
enhancement is observed due to incorporation of the H atoms from parahydrogen into 
the product molecule. However, another process that does not involve any chemical 
transformation of substrates is called Signal Amplification By Reversible Exchange 
(SABRE).2 This can be thought of as equivalent to ALTADENA, as it occurs at low 
magnetic field, but it is non-hydrogenative. 
Orthohydrogen can also be used for polarisation but it is not as powerful as 
parahydrogen because there is a smaller population difference as both the αα and the ββ 
states are populated and the 1/√2 (αβ + βα) state splits to half occupy the αβ state and 
half occupy the βα state.15 
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1.5. NMR and catalysis with parahydrogen 
As discussed in Sections 1.4.1 and 1.4.2, many carbene and phosphine 
complexes have been shown to act as catalysts for a variety of different applications. 
Catalysts have been used in reactions involving parahydrogen, to give enhanced signals 
and monitor reaction intermediates and products, as lower concentration intermediates 
can be more easily observed when signals derived from them are enhanced.79-81 
Parahydrogen-Induced Polarisation (PHIP) was first predicted by Bowers and 
Weitekamp in 198620 and a year later they published work on the hydrogenation of 
acrylonitrile to propionitrile using Wilkinson’s catalyst and parahydrogen (see Figure 
24).77 This reaction was conducted in the high field of the magnet and is an example of 
the PASADENA process.77 
 
 
Figure 24: Hydrogenation of acrylonitrile to propionitrile to demonstrate signal enhancements 
using p-H2. 
1H NMR spectra before reaction was conducted (a), during hydrogenation (b), after 
the enhancement had decayed (c) and a simulation of the enhanced spectra from the theory (d) 
(Reprinted with permission from Bowers, C. R.; Weitekamp, D. P. J. Am. Chem. Soc. 1987, 109, 
5541. Copyright © 1987 American Chemical Society)77 
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Other more recent examples of PHIP include the formation of intermediates on 
hydrogenation pathways, such as the palladium bis-phosphine vinyl hydride 
intermediates shown in Figure 25.82 Without the use of p-H2, signals for these low 
concentration complexes would not be observable and mechanistic studies of 
hydrogenation would be more difficult to follow and identify. 
 
Figure 25: Vinyl hydride and alkyl hydride intermediates on the pathway to hydrogenation of 
diphenylacetylene using [Pd(PEt3)2(OTf)2] with p-H2
82 
The most recent development in this field of PHIP is the non-hydrogenative use 
of p-H2 as a polarisation source in the SABRE technique. 
  
67 
 
1.6. Signal Amplification By Reversible 
Exchange 
In SABRE, the substrate, metal complex and parahydrogen are mixed in the low 
magnetic field outside of the spectrometer, as for ALTADENA, but without 
hydrogenation taking place.83 The substrate and parahydrogen bind to an iridium 
complex, as shown in Figure 26, and polarisation is transferred from the hydrides, 
originating from parahydrogen, to the substrate protons, via J-coupling. The substrate 
used remains chemically unchanged during the catalysis.83 The catalysts employed for 
SABRE have been shown to take the form of cationic iridium complexes, which possess 
either phosphine83-86 or NHC ligands.87-88 
 
Figure 26: The route to polarisation transfer via SABRE 
For efficient polarisation transfer, the chemical shift difference, between the 
hydride ligands and the nuclei on the substrate which are to be polarised, has to be 
approximately equal to the J-coupling between the hydride ligands.89 For example, a 
typical value for the J-coupling between hydride ligands is about 5-10 Hz and the 
chemical shift difference between these hydrides and protons on a substrate is 
commonly about 30-40 ppm. This equates to a minimum of 12000 Hz chemical shift 
difference between hydride ligands and substrate protons on a 400 MHz spectrometer. 
Thus, for optimum transfer, low fields are required; for proton nuclei at 6.5 mT (0.277 
MHz), the chemical shift difference of 30 ppm is now equivalent to about 8.3 Hz which 
closely matches the 2JHH coupling between the hydride ligands. This is detailed in 
Figure 27. This can also be explained using the Level Anti-Crossing approach, where at 
low field, the energies of the spin states become close, which enables mixing of these 
states so that polarisation transfer can occur efficiently.90-91 The Polarisation Transfer 
Field (PTF) also affects the energies of magnetic spin states that are populated during 
magnetisation transfer and thus affects the appearance of enhanced proton spectra. 
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Figure 27: Schematic for how chemical shift differences between nuclei increase as the 
magnetic field is increased 
The first example of a pre-catalyst that reversibly binds hydrogen and can thus 
be used for SABRE87 was Crabtree’s complex, developed by R. Crabtree in 197944 
whilst looking into iridium derivatives of Wilkinson’s catalyst, [RhCl(PPh3)3].60, 75 
Wilkinson’s catalyst is an efficient hydrogenation catalyst, that also undergoes PHIP,75 
and Crabtree was further investigating these species. Whilst in the development stages, 
George Morris, a graduate student who was working for Crabtree, observed that 
[Ir(COD)(PCy3)(py)][PF6] could reversibly bind hydrogen. Crabtree’s catalyst, as it 
became known, was shown to carry out hydrogenation reactions of sterically bulky 
alkenes, be stable to oxidation and be more active than Wilkinson’s catalyst.44, 92 In 
2009, it was also shown to act as a pre-catalyst for SABRE, being able to transfer 
polarisation from p-H2 to protons of a substrate, without chemically transforming the 
substrate.2  
Since 2009, several different SABRE catalysts have been discovered and 
developed in order to find the most efficient polarisation transfer catalyst for different 
applications and in different solvent systems.86-88 
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1.7. Polarisation transfer catalysts 
One of the most successful hyperpolarisation transfer pre-catalysts used to date 
is [Ir(COD)(IMes)Cl] (where COD is cyclooctadiene and IMes is 1,3-bis(2,4,6-
trimethylphenyl)imidazole-2-ylidene) which contains an N-heterocyclic carbene 
motif.87-88 Upon the addition of a substrate, the labile chloride can be displaced and a 
substrate binds in its place to form species of the kind [Ir(COD)(IMes)(substrate)]Cl.93-
94 When shaken with parahydrogen and a substrate the COD is hydrogenated and the 
catalyst forms the active species [Ir(H)2(IMes)(substrate)3]Cl as shown in Figure 28.
88 
Parahydrogen adds as two hydride ligands which are magnetically inequivalent but 
chemically equivalent and three substrate ligands also bind to the iridium centre to 
create a charged octahedral complex. Polarisation is then transferred to the substrates 
that are in the trans positions to the hydride ligands. This complex has proved active for 
a wide range of substrates which include pyridine,88 nicotinamide,95-96 isoniazid,97 
pyrazinamide,97 pyrazole84 and acetonitrile.86 Exchange between the substrates being 
free in solution and bound to the complex means that polarisation is transferred to the 
substrates. This results in visible hyperpolarisation in the substrate molecules in 
solution. Multiple visits of the substrate and reintroduction of fresh p-H2 to the catalyst 
centre results in build-up of polarisation of the substrate so can lead to even greater 
signal enhancements being observed for free substrate molecules in solution.1 The use 
of the NHC ligand in the catalyst dramatically increased the enhancement levels relative 
to those with PCy3 as shown for Crabtree’s catalyst.2, 87-88, 97 Many other pre-catalysts of 
the same class as [Ir(COD)(IMes)Cl] have been developed with modified symmetric 
NHC ligands to alter the steric and electronic properties and affect the overall catalyst 
reactivity.87 
 
Figure 28: [Ir(H)2(IMes)(sub)3]Cl formed upon activation of  [Ir(COD)(IMes)Cl] with substrate 
and H2, via intermediate [Ir(COD)(IMes)(sub)]Cl 
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An alternative catalyst system has also been reported that is based on 
[Ir(H)2(IMes)(PCy3)(substrate)2][BF4].
86 The substrates are now pyridine and 
acetonitrile. The mixed substrate-containing catalyst, 
[Ir(H)2(IMes)(PCy3)(pyridine)(CH3CN)][BF4], which is also charged, proved most 
effective for SABRE even though it contains a pair of chemically and magnetically 
inequivalent hydride ligands (see Figure 29). These results confirmed that it is possible 
to block two coordination sites in the SABRE catalyst with non-labile ligands, without 
suppressing activity and whilst retaining a charged system. Species such as 
[Ir(H)2(IMes)(PCy3)(pyridine)2][BF4] with magnetically inequivalent but chemically 
equivalent hydride ligands, whilst being directly related to [Ir(H)2(IMes)(substrate)3]Cl, 
proved less effective due to poor ligand exchange. 
 
Figure 29: Formation of the mixed substrate species 
[Ir(H)2(IMes)(PCy3)(pyridine)(CH3CN)][BF4] and equilibration with the 
[Ir(H)2(IMes)(PCy3)(substrate)2][BF4] complexes (where Mes = 2,4,6-trimethylphenyl)
86 
More recently a different charged iridium system has been developed, 
containing a further blocking site in its coordination sphere. Here, a pincer ligand binds 
through two phosphine sites which are bridged via a pyridyl linker to create a PNP 
chelate.98 The activated cis-dihydride complex reacts with p-H2 and enables polarisation 
transfer to pyridine via SABRE. However, limited signal enhancement is seen due to 
slow ligand exchange and rapid p-H2 consumption due to the [Ir(H)2(H2)(PNP)][BF4] 
intermediate in solution (see Figure 30). This again proves how catalyst development 
can be very important for designing optimised systems. 
 
Figure 30: [Ir(H)2(PNP)(py)][BF4] and the formation of the dihydride-dihydrogen intermediate 
[Ir(H)2(H2)(PNP)][BF4]
98  
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1.8. Molecules suitable for polarisation transfer 
The vast majority of the substrates that have been polarised via SABRE contain 
N-heterocycles with the most common motif being that of a pyridyl ring.84, 94, 96-97 Other 
species that have been used more recently, still bind to the metal centre via a nitrogen 
atom but contain a cyano group, such as acetonitrile and benzonitrile.99 This is due to 
the binding and lability characteristics that are suitable to enable exchange with free 
substrate in solution rather than the binding being too strong which would inhibit 
exchange. 
Most studies involve direct proton polarisation, either by p-H2 incorporation or 
SABRE polarisation transfer and this is becoming particularly well optimised,97 but 
development towards achieving stronger polarisation of heteronuclei such as 13C, 15N 
and 31P is currently limited. Analysis of these nuclei has advantages in that their spin 
relaxation times are longer, hence the hyperpolarised signal lasts longer, and in contrast 
to 1H NMR, the background signal is comparably smaller.100  
Polarisation transfer to heteronuclei was first observed by Morris and Freeman 
in 1979 for a 13C NMR spectrum of pyridine.101 They described a new NMR method 
called Insensitive Nuclei Enhanced by Polarisation Transfer (INEPT) which enabled 
transfer of polarisation from thermally equilibrated proton nuclei to carbon nuclei. 
However, this requires a specially modified pulse sequence at high field under 
PASADENA conditions. Since then, this technique has been used with p-H2 to further 
enhance heteronuclei signals such as 15N, 13C and 29Si.85, 102-104 
In 1989, direct observation of polarised 31P was observed by Eisenschmid et al. 
using PHIP.105 The oxidative addition of p-H2 to a square planar iridium(I) complex 
containing a chelating phosphine ligand demonstrated 31P polarisation through nOe 
interactions between phosphine ligands and the hydrides that were p-H2 derived. Direct 
31P NMR analysis showed antiphase phosphorus signals for the phosphine ligands. This 
concept has since been expanded to include other heteronuclei such as 13C. For 
example, hydrogenation of a suitable substrate, such as dimethyl acetylenedicarboxylate 
to produce dimethyl maleate, shown in Figure 31, enables observation of enhanced 
carbon signals under PASADENA conditions (see Figure 32).102, 106 
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Figure 31: The formation of dimethyl maleate from the parahydrogenation of dimethyl 
acetylenedicarboxylate with the p-H2 derived protons labelled with an asterisk. Cat. = 
[Rh(COD)(dppb)(PPh3)2][BF4] where dppb is 1,4-bis(diphenylphosphino)butane
102, 106 
 
Figure 32: 50 MHz 13C NMR spectrum of dimethyl maleate produced from the 
parahydrogenation of dimethyl acetylenedicarboxylate (Reprinted with permission from 
Barkemeyer, J.; Haake, M.; Bargon, J. J. Am. Chem. Soc. 1995, 117, 2927. Copyright © 1995 
American Chemical Society)106 
More recently, polarisation transfer via SABRE to 13C, 15N, 19F and 31P has been 
reported to occur at very low magnetic fields outside of the spectrometer and be readily 
observed directly.2, 89, 100, 107-108 Polarisation using the common SABRE pre-catalyst, 
[Ir(COD)(IMes)Cl] has been used to facilitate 15N NMR polarisation,107-108 as well as 
31P NMR polarisation, with phosphorus-substituted pyridine substrates, such as diethyl 
3-pyridylphosphonate, demonstrating up to 3500-times greater 31P NMR signal when 
compared to a thermal spectrum.109 Direct phosphine polarisation has also been 
observed when using [Ir(H)2(PPh3)3Cl] with p-H2 at elevated temperatures to initiate 
phosphine exchange.110 
Another factor that is being explored is the effect of deuteration of both substrate 
and catalyst protons within systems.86, 88, 95, 109, 111 It has been shown that a reduction in 
the number of protons on a substrate, that can accept polarisation, results in increased 
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enhancement observed for the remaining proton sites. This is because there are fewer 
protons to share the polarisation.84 In addition, deuterated substrates can also exhibit 
longer lifetimes due to less proton coupling, resulting in longer T1 relaxation times. 
Furthermore, deuteration of the other catalyst ligands, such as NHCs and phosphines, 
also leads to significantly increased signal being transferred to the desired substrate 
proton sites.86 For example, Figure 33 shows how the enhanced proton signal for 
acetonitrile, using the catalyst system [Ir(H)2(IMes)(PPh3)(pyridine)(acetonitrile)][BF4], 
is increased upon deuteration of the other catalyst ligands.86 
 
Figure 33: A plot showing how the 1H NMR signal enhancement for acetonitrile varies when 
using [Ir(H)2(IMes)(PPh3)(pyridine)(acetonitrile)][BF4] at different polarisation transfer fields 
and how using deuterated ligands affects the observed enhancement levels (Reprinted with 
permission from Fekete, M.; Bayfield, O.; Duckett, S. B.; Hart, S.; Mewis, R. E.; Pridmore, N.; 
Rayner, P. J.; Whitwood, A., Inorg. Chem. 2013, 52 (23), 13453-13461. Copyright © 2013 
American Chemical Society AuthorChoice via Creative Commons CC-BY agreement 
http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html)86 
Deuteration has also been shown to affect polarisation transfer to heteronuclei 
via SABRE. Burns et al.109 have demonstrated that deuteration of ethyl groups in a 
phosphonate ethyl ester species prevents leaching of polarisation from the 31P to the 1H 
atoms, due to the larger frequency difference that is present between phosphorus and 
deuterium. These are significant advances as they could ensure that the most optimised 
systems can be developed and used.  
74 
 
1.9. Potential for MRI 
In comparison to the obvious experimental benefits of using p-H2 to analyse 
reaction intermediates, kinetics and mechanisms, the potential use of PHIP in MRI has 
been realised more recently. Advantages of the enhanced signal in MRI are higher 
sensitivity images with improved signal-to-noise and better resolution which could 
greatly aid clinicians by potentially enabling earlier diagnosis of disease.112 
Much of the testing completed for many catalysts and different substrates has 
been carried out in methanol as the solvent of choice. However, in order to expand 
SABRE for use in clinical diagnosis, more biocompatible solvent systems have to be 
used, such as ethanol97 and ethanol/water mixtures.95, 113 This raises the issue of catalyst 
solubility in water. In order to overcome this, a number of water-soluble systems have 
been developed incorporating solubilising groups such as sulfonates, amines, alcohols 
and polyethylene glycol (PEG) chains as shown in Figure 34.114-116 Some of these 
systems have been charged which further aids water solubility. However, they also 
suffer due to the lower solubility of hydrogen in water.  
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Figure 34: Water-soluble phosphine and NHC ligands incorporated into catalysts114-115 
Another factor to consider prior to injection for a clinical use is the toxicity of 
the catalyst. The effect of the catalyst on the patient must be minimised, whether that 
means total removal of the catalyst before injection or only being able to administer 
very low concentrations. One recent study has shown that deactivation of the catalyst is 
possible without quenching the polarisation level of the substrate. Binding of a bidentate 
ligand such as bipyridine or 1,10-phenanthroline disables the ligand exchange and thus 
blocks the catalyst.117 However, this can be wasteful as the catalyst is rendered inactive 
and therefore cannot be reused for further polarisation tests. 
Studies to aid catalyst removal have therefore explored the option of using 
heterogeneous catalysts instead of the more developed, more commonly used 
homogeneous catalysts. This would enable easier removal of the catalyst by filtration 
followed by injection of the polarised substrate in solution. The catalyst could then be 
reused upon addition of more substrate and solution.  
One example of a heterogeneous system involves the use of polymer microbeads 
with bound 4-dimethylaminopyridine groups to bind the [Ir(COD)(IMes)][PF6] pre-
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catalyst.118 Other nanoscale heterogeneous catalysts, one with a nanoparticulate 
structure containing a TiO2 core functionalised with PMAA (poly(methacrylic acid))
119 
and one with a polymer ‘comb’ type structure made of PVP (polyvinylpyridine),119 have 
also been tested. However, for all catalysts, the levels of enhancement were markedly 
reduced in comparison to using free [Ir(COD)(IMes)Cl], although the use of the 
TiO2/PMAA-derived pre-catalyst proved to be the most efficient with up to 40-fold 
enhancements observed for pyridine. One promising observation was that no catalyst 
leaching occurred during the SABRE reactions and therefore all enhancements could be 
attributed to the heterogeneous catalyst. Furthermore, the possibility of reusing the 
catalyst was investigated and proved to be feasible.119 More development of this could 
prove promising for taking SABRE towards clinical use. The structures of these 
heterogeneous catalysts are depicted in Figure 35. 
 
Figure 35: Heterogeneous SABRE catalysts118-119 
Another problem to overcome for MRI use is the short lifetime of the 
hyperpolarised state which means high quality images must be collected rapidly before 
the signal decays back to thermal equilibrium. Several studies have been carried out 
investigating T1 relaxation and lengthening the lifetime of the hyperpolarised state. This 
can be achieved in a number of ways, such as specific substrate design and synthesis109 
and the use of heteronuclei which take longer to relax.107-108 Another area which enables 
longer detection times and which could prove particularly important, is the use of 
hyperpolarised long-lived states which can be harnessed to provide enhanced signals.120-
124 Overall, this is a major challenge that needs to be addressed in order for SABRE to 
be efficiently exploited in the field of MRI.  
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1.10. Project aims 
The aim of this project is to investigate the effect of blocking a binding site 
within the catalyst coordination sphere, using a non-labile ligand to see whether a 
reduction in the number of substrates, as depicted in Figure 36, would enable 
polarisation to be distributed among fewer substrates so greater enhancements could be 
observed. Also, the analysis of ligand exchange rates within the bidentate species could 
enable the determination of the optimal exchange for most effective polarisation 
transfer. This is the principle behind using bidentate NHCs. 
Several bidentate species could be synthesised to address a number of different 
issues such as exchange rates, magnetic and chemical inequivalence, solubility and 
activation. The chelating pendent arm could be varied to contain different functional 
groups to determine the electronic and steric effects on polarisation transfer. 
 
Figure 36: A potential framework for a bidentate NHC-containing iridium complex 
The blocking of this substrate binding site could also enable stabilisation of the 
complexes and therefore more weakly binding ligands could be used as substrates. This 
may enable the polarisation of more labile substrate species. It is known that the 
efficiency of polarisation transfer is affected by a number of variables, such as 
concentrations of each reactant, ligand exchange rates and subsequent substrate 
relaxation rates.91 Specific catalyst design could enable better manipulation of some of 
these catalyst and system dependent parameters. 
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2. Development of neutral bidentate 
iridium carbene complexes 
2.1. Introduction 
The incorporation of N-heterocyclic carbenes into polarisation transfer catalysts 
for use in SABRE has so far involved monodentate, symmetric carbenes.87, 93 The most 
efficient pre-catalyst which incorporates one of these symmetric NHC ligands, is 
[Ir(COD)(IMes)Cl] (where COD is cyclooctadiene and IMes is 1,3-bis(2,4,6-
trimethylphenyl)imidazole-2-ylidene), although many others are known, containing 
both aromatic and aliphatic groups as indicated in Figure 37.93 
The general synthetic route to create iridium-based pre-catalysts containing 
carbene ligands involves the formation of an imidazolium salt, followed by 
complexation with the metal to create the pre-catalyst. The carbene itself is formed from 
an imidazole ring, where the carbon atom sandwiched between the two nitrogen atoms 
forms the carbene centre that bonds to the metal. Typically, a strong base is used to 
deprotonate the carbon atom to form the free carbene, before reaction with an iridium 
metal source, commonly either [Ir(COD)Cl]2 or [Ir(COD)OMe]2. A general synthetic 
route to produce such iridium carbene complexes is shown in Figure 37. 
 
Figure 37: General synthetic route to form symmetric iridium carbene complexes 
The formation of the imidazole ring occurs via a Debus-Radziszewski type 
multi-component reaction with glyoxal, formaldehyde, and two equivalent amine 
precursors. Figure 38 shows the mechanism of imidazole formation when two different 
amine sources are used.125-126 This reaction proceeds with initial formation of a di-imine 
via condensation of the mesityl amine and ammonia with glyoxal and subsequent 
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elimination of water. This di-imine then undergoes condensation with formaldehyde and 
further loss of water to form the imidazole ring. 
 
Figure 38: The mechanism for formation of the imidazole ring of mesityl imidazole 
The large range of symmetric iridium carbene complexes that have been 
produced have been synthesised using two equivalents of the same amine precursor.127 
However, this synthetic route (see Figure 37) does not easily allow for modification of 
the carbene backbone to produce asymmetric carbene variants. 
Several different routes exist for forming asymmetric imidazolium salt 
precursors which can then be used to produce asymmetric NHC ligands for specialist 
catalytic applications. One involves the initial formation of one side of the backbone, 
such as the mesityl imidazole shown in Figure 38, followed by a nucleophilic 
substitution reaction with a compound containing a good leaving group, such as a 
halide. This procedure allows for a larger scope when deciding what other substituents 
or groups to include in the coordination sphere of iridium.128 
A second possible method, with a recent example described by He et al.,129 
involves the stepwise coupling of two distinct amine compounds with a central 
molecule that forms part of the imidazole ring, using Buchwald-Hartwig coupling, as 
shown in Figure 39. This enables the incorporation of multiple amine molecules to 
introduce differing functionalities on the imidazole ring.129 
 
Figure 39: Synthetic route to form asymmetric imidazolium salts used by He et al.129 
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A third method, developed by Fürstner et al.,130 is a modular approach where 
different substituents can be incorporated into the resulting imidazolium salt. The initial 
formation of an oxazolium salt is followed by a heterocycle-interconversion step. This 
is achieved by reacting the oxazolium salt with a desired primary amine to form the 
required substituted imidazolium salt, as shown in Figure 40. 
 
Figure 40: Synthetic route to form asymmetric iridium carbene complexes used by Fürstner et 
al.130 
To achieve more selective reactivity, the incorporation of multi-dentate ligands 
in the synthesis of metal complexes has become particularly important in the area of 
asymmetric catalysis, where chelating complexes can be used.131-132 Carbonylation is 
one such synthetic step, which is important in reactions such as hydroformylation, 
where typically carbon monoxide is reacted with hydrogen and a carbon-carbon double 
bond to introduce functionality. The development of specialised chelating chiral 
phosphine ligands and their use as directing ligands, such as those shown in Figure 41 
for the asymmetric hydroformylation of styrene,133 can impart chirality into the organic 
products. 
 
Figure 41: Chiral bidentate phosphorus-derived ligands for asymmetric hydroformylation133 
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More specifically, carbonylation reactions have been studied using iridium 
alkoxide complexes as the catalysts of choice, with the formation of carbon-oxygen 
bonds being achieved via the reaction of CO with the bound alkoxide ligand. In the 
1980s, Rees et al.134-135 demonstrated the formation of carboalkoxy compounds of the 
form trans-[Ir(CO)(PPh3)2(ROCO)] (where R = Me, 
nPr, tBu or Ph), via the direct 
addition of CO to the corresponding alkoxide as shown in Figure 42.136 The formation 
proceeds via nucleophilic attack of the alkoxide anion on the intermediate 
[Ir(CO)3(PPh3)2]
+, with phenoxide being the least reactive of the series due to its 
weakest nucleophilicity. Further reactivity of trans-[Ir(CO)(PPh3)2(MeO)] was probed 
via the addition of tetracyanoethylene (TCNE), to isolate the penta-coordinate distorted 
trigonal bipyramidal alkoxy-alkene complex [Ir(CO)(PPh3)2(MeO)(TCNE)] as shown in 
Figure 42.137 This demonstrates the stability of these complexes with electron deficient 
alkene ligands, due to π-back donation into the alkene double bond. 
 
Figure 42: Reaction of trans-[Ir(CO)(PPh3)2(OR)] with CO and TCNE
134-135 
Further development of NHC and alkoxide ligands for catalysis has led to 
combining the two, to form chelating alkoxide-carbene complexes, with a number of 
transition metal, lanthanide and group 13 metal examples described in the literature.125, 
138-144 These can be used to catalyse synthetic steps such as polymerisation138-139 and 
amination140 reactions. One particular example described by Weinberg et al.144 contains 
an NHC alkoxide which can bind to iridium in either a bidentate or a tridentate pincer 
fashion, forming both Ir(I) and Ir(III) complexes as shown in Figure 43. The Ir(I) 
complex adopts a square planar conformation and the related Ir(III) COD complex acts 
as a hydrogenation catalyst for the reduction of cyclohexene to cyclohexane.144 
82 
 
 
Figure 43: Iridium(I) NHC phenoxide complex and its conversion to an iridium(III) bis-
phenolate COD species and an iridium(III) bis-phenolate acetonitrile complex, as described by 
Weinberg et al.144 
This chapter describes the synthesis of several asymmetric imidazolium salts, 
exploiting the first asymmetric synthetic route described above. Multi-step synthetic 
procedures are then used to form a series of neutral bidentate iridium carbene 
complexes, with a pendent phenolate arm and NO2, H, COOMe and Cl substituents in 
the para position with respect to the phenolate. These substituents were chosen in 
accordance with the need to produce a range of complexes with electron-withdrawing 
effects as shown by the Hammett parameters in Table 2 (see Section 3.1 for an 
explanation of the different Hammett parameters). The imidazolium salts formed are 
then used to produce novel NHC alkoxide iridium complexes by a transmetallation 
reaction with [Ir(COD)Cl]2. These complexes are fully characterised and their reactivity 
with pyridine and hydrogen discussed. Full characterisation data for the compounds 
synthesised on the routes to these NHC alkoxide iridium complexes can be found in the 
Experimental Sections 8.5, 8.6, 8.7, 8.8 and 8.9. 
Table 2: Hammett parameters, σp and σp
−, for the four substituents NO2, COOMe, Cl and H 
showing the increase in their electron-donating capabilities from NO2 to H, with H being the 
most electron-donating group145 
Substituent Hammett parameter, σp Hammett parameter, σp− 
NO2 0.78 1.27 
COOMe 0.45 0.75 
Cl 0.23 0.19 
H 0.00 0.00 
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2.2. Synthesis of pre-catalyst derivatives 
The synthesis of complex, 1, containing an NO2 substituent in the para position 
to the phenolate, used 2-hydroxy-5-nitrobenzyl bromide as the starting material. This  
creates an asymmetric imidazolium salt following a known procedure as shown in 
Figure 44.125 NO2 is an electron-withdrawing group that could stabilise the phenolate 
anion that subsequently binds to the iridium centre to create the proposed chelate 
complex. To create the imidazolium salt, the reaction of mesityl imidazole with 2-
hydroxy-5-nitrobenzyl bromide was undertaken which formed the imidazolium bromide 
in high yield. Upon heating with silver(I) oxide in THF/toluene, formation of the silver 
carbene was observed along with the production of a variety of silver salts, which were 
removed via filtration through Celite and washing with DCM.125 A transmetallation 
reaction with [Ir(COD)Cl]2 led to the desired air-stable iridium product, 1 (see Section 
2.3 for a discussion of the characterisation data), along with precipitation of the silver 
chloride by-product.146 
 
Figure 44: Synthetic route to the NO2-containing complex, 1 
The [Ir(COD)Cl]2 used in the transmetallation step to synthesise all the iridium 
complexes, was formed by heating a mixture of IrCl3.3H2O and COD in a solution of 
propan-2-ol and water at 90 °C for 3 hours, under an atmosphere of nitrogen.146 The 
initially dark grey solution turned red on production of the desired iridium dimer, 
[Ir(COD)Cl]2, which precipitated from the solution on cooling, in a yield of 62 %. 
A more complicated route was used to synthesise the phenyl-based pre-catalyst 
2, as shown in Figure 45, as the benzyl bromide starting material was not commercially 
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available. Initial protection of the phenol was achieved using benzyl bromide.147 This 
was followed by reduction of the aldehyde to the primary alcohol with NaBH4 in 
methanol148 and subsequent substitution to create the protected benzyl bromide.149 
Reaction of this with preformed mesityl imidazole led to the imidazolium bromide 
salt125 which underwent benzyl cleavage with Pearlman’s catalyst. Hydrogenation at 
room temperature, under 5 bars of H2, proved very slow, so heating at 60 °C for 6 hours 
was carried out to drive the reaction to completion. Reaction with silver(I) oxide at 
room temperature, followed by transmetallation, afforded the air-sensitive iridium 
carbene complex, 2, in 42 % yield as a dark orange solid.  
 
Figure 45: Synthetic procedure to form complexes 2 and 3 
The same synthetic route used for 2 was followed to make the COOMe-
containing pre-catalyst, 3, as the ester was stable to hydrogenolysis. A methyl ester was 
introduced to try and improve catalyst stability but maintain reactivity, as its electron-
withdrawing Hammett parameter lies between that of NO2 and H as detailed in Table 2. 
For the last step of this synthesis, isolation of the silver carbene complex was not 
conducted. Instead, the silver carbene was reacted in situ, following confirmation of its 
production via mass spectrometry. This approach was followed as the silver carbene is 
unstable and showed very broad signals by 1H NMR spectroscopy. When [Ir(COD)Cl]2 
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was added to the COOMe silver carbene solution, rapid transmetallation occurred to 
produce the desired iridium carbene complex, 3, in 79 % yield. The air/moisture 
stability of 3 lies between that of 1 and 2, consistent with its Hammett parameter; 
decomposition in solution under air takes days rather than minutes, as occurs for 2. The 
pre-catalyst is, however, stable as a solid and in solution when stored under a nitrogen 
atmosphere.  
For the synthesis of the Cl-containing derivative, 4, on a small scale, the same 
route to make 2 and 3 was initially followed as this had proven successful before. 
However, upon scale-up, the use of acetone as a solvent for the benzyl protection step, 
combined with heating at 40 °C for 3 days led to an aldol condensation reaction 
occurring, as shown in Figure 46, with a yield of 82 %. This was evident from the 
corresponding 1H NMR spectrum as also shown in Figure 46. 
 
 
Figure 46: Reaction scheme to form the aldol condensation product along with its 1H NMR 
spectrum showing its 1H NMR resonances and splitting patterns (labelled structure inset) 
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In the 1H NMR spectrum in Figure 46, a singlet exists for the methyl protons of 
the aldol product at δ 2.16. Signals for three inequivalent coupled protons are at δ 2.71, 
2.98 and 5.45; the signals at δ 2.71 and 2.98 share a large 2J-coupling constant of 17.6 
Hz, indicative of their close bonding proximity. Each one is also coupled to the single 
proton signal at δ 5.45. Due to this undesired reaction, the solvent was changed to DMF. 
For the aldehyde reduction step, methanol is commonly used, however, on scale-
up this formed the dimethyl acetal benzaldehyde product, which was converted back to 
the aldehyde using catalytic paratoluenesulfonic acid in toluene. THF was the solvent 
used for the subsequent reduction step to form the benzyl alcohol. The bromination and 
imidazolium salt formation proved successful, however, no selective deprotection step 
for the benzyl ether cleavage was found. Instead, LCMS analysis confirmed a mixture 
of debenzylated product at m/z 327.2 (M-Br-Bn+H)+, dechlorinated product at m/z 
383.3 (M-Br-Cl+H)+ and a product no longer containing either the chlorine or benzyl 
group at m/z 293.2 (M-Br-Cl-Bn+2H)+. To overcome this, it was decided to complete 
the synthesis from the 5-chlorosalicylaldehyde product using tert-
butyldimethylsilylchloride (TBDMSCl) to form the TBDMS protecting group as shown 
in Figure 47. This could then be cleaved further down the line, using solid supported 
tert-butylammonium fluoride (TBAF). 
Whilst testing the reaction which forms the imidazolium bromide salt, it was 
found that after heating at 70 °C for 24 hours, just over half of the product had also had 
the TBDMS group cleaved. Therefore, rather than using TBAF to cleave this group, the 
reaction on a larger scale was heated at 110 °C for 48 hours to ensure full deprotection 
of the phenol substituent, as well as imidazolium salt formation. The silver carbene was 
not isolated but reacted in situ to produce the desired iridium pre-catalyst, 4, as shown 
in Figure 47, with an overall yield of 15 % for the five-step route. 
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Figure 47: Modified synthetic procedure to form complex 4 using TBDMSCl to create the 
TBDMS phenol protecting group 
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2.3. Characterisation of pre-catalyst derivatives  
Comparison of the 1H NMR spectroscopic data for 1 (Figure 48) at 298 K in 
CD2Cl2 revealed that its proton chemical shifts are strongly temperature dependent.  
 
Figure 48: Labels for complex 1, as referred to in the text 
At 298 K, protons in the aliphatic range and the COD alkene protons yield very 
broad signals so that it is not easy to make specific proton assignments. Signals for the 
CH2 linker protons in position 7 (see Figure 48) are also broadened into the baseline. As 
the temperature is lowered from 298 K to 253 K all the signals sharpen, as depicted in 
Figure 49. The CH2 linker protons are now clearly inequivalent and appear as two 
doublets at δ 6.60 and 4.79 with a coupling constant of 14.0 Hz. This behaviour is a 
consequence of the fact that these protons are diastereotopic, with hindered rotation 
about the Ir-Ccarbene bond. They become equivalent by inversion of the conformation of 
the seven-membered ring through ring-flip and alkoxide lone pair inversion.144 The 
large chemical shift difference arises due to their exo and endo orientations with respect 
to the seven-membered metallocycle.150 Full characterisation data are presented in the 
Experimental Section 8.6.3. 
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Figure 49: Comparison of the 1H NMR spectra, at 253 K and 298 K, for complex 1 in CD2Cl2. 
Regions of interest, where the fluxional behaviour slows to allow the detection of separate 
peaks, are indicated with the dashed lines. The labels indicate the proton resonances as shown 
in Figure 48 with the specific changes referred to in the text 
A separate dynamic process involves intramolecular ring rotation of the mesityl 
group. At 298 K, the two protons that correspond to positions 12 and 15 appear as a 
broad singlet at ~ δ 7.03 but on cooling to 253 K, two singlets resolve at δ 7.06 and 
6.96. This corresponds to hindered rotation of the mesityl ring around the single C-N 
bond that connects it to the imidazole ring. Full analysis of this dynamic behaviour is 
possible by examining the temperature dependence of exchange and the NMR 
linewidths.151 This has been achieved using the experimentally determined NMR 
spectra exemplified in Figure 50 and involves measuring both the linewidth at half the 
maximum peak height when exchange does not occur, ho, and the chemical shift 
difference between the signals of interest, Δνo. Calculation of rate constants at each 
temperature, which are detailed in Table 3, is possible using the equations shown in 
Figure 50. Estimation of the activation parameters for this process was achieved using 
both Arrhenius and Eyring-Polanyi equations which are fully described in the 
Experimental Section 8.1.2. 
12 and 15 7 
COD C-H 
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Slow exchange 𝑘 = 𝜋(ℎ𝑒 − ℎ𝑜) 
 
Intermediate exchange 𝑘 =
𝜋√(∆𝜈𝑜2 − ∆𝜈𝑒2)
√2
 
Coalescence 𝑘 =
𝜋∆𝜈𝑜
√2
 
Fast exchange 𝑘 =
𝜋∆𝜈𝑜
2
2(ℎ𝑒 − ℎ𝑜)
 
where: 𝑘 = rate constant / s−1 
 ℎ𝑒 = peak width at half height with exchange 
 ℎ𝑜 = peak width at half height with no exchange / 5.03 s
−1 
 ∆𝜈𝑒 = peak frequency difference with exchange 
 ∆𝜈𝑜 = peak frequency difference with no exchange / 50.46 s
−1 
Figure 50: Lineshape analysis equations151 and corresponding 1H NMR spectra used to 
calculate the mesityl group rotation rates 
 For this mesityl rotation, the Arrhenius equation gave an activation energy (ΔHǂ) 
of 67.8 ± 3.1 kJ mol−1 with an R2 value of 0.9958, which compares to 65.5 ± 3.1 kJ 
mol−1 from the Eyring-Polanyi equation with R2 being 0.9954. The small but positive 
ΔHǂ values are commensurate with a rotation process.152-153 The Eyring-Polanyi 
equation also enables calculation of the activation entropy for the process, which was 
calculated to be 28.0 ± 10.9 J K−1 mol−1 with an R2 value of 0.9954 (Figure 51). This 
small positive entropy value is also consistent with an intramolecular rotation 
process,152-153 suggesting no large change in order as would be expected for a reaction. 
The corresponding Gibbs Free Energy for the process at 300 K was calculated to be 
57.1 ± 1.0 kJ mol−1. All the activation parameters are calculated from data that uses 
twice the value for the experimental rate constant because at the transition state the 
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reaction has an equal probability of continuing forward to the products or back to the 
reactants. 
Table 3: Experimentally calculated rate data for mestiyl group rotation in complex 1 as a 
function of temperature 
T / K 1/T / K−1 k / s−1 ln(2k / s−1) ln(2k/T / s−1 K−1) 
248 0.00403 0 - - 
258 0.00388 3.77 2.02 −3.53 
268 0.00373 15.7 3.45 −2.14 
278 0.00360 48.8 4.58 −1.05 
288 0.00347 112 5.41 −0.25 
298 0.00336 260 6.26 0.56 
308 0.00325 766 7.33 1.60 
 
 
Figure 51: Eyring-Polanyi plot of rate data calculated from experimental 1H NMR spectra for 
mesityl rotation in complex 1 as a function of temperature 
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Analysis of the 13C{1H} spectrum of complex 1 shows that the carbon 
resonances are also temperature dependent due to its fluxional behaviour in solution 
(see Figure 52). At 298 K, the 13C{1H} spectrum contains broad peaks and not all the 
expected carbon nuclei are observable, but on cooling to 243 K, the signals resolve. 
Two specific regions of interest are depicted in Figure 52. Firstly, at 298 K the peak for 
the carbene carbon is not visible, but at 243 K it appears in the same region as the peak 
for the quaternary carbon of C-OIr at ~ δ 175. Secondly, 13C NMR signals for two of the 
COD alkene carbon atoms also sharpen upon cooling to 243 K, as shown in Figure 52. 
 
Figure 52: 13C{1H} NMR spectra of 1 at 243 K and 298 K specifically depicting the resolved 13C 
signals for the C-Ir atom at ~ δ 175 and two COD C-H atoms at ~ δ 85 
 
Figure 53: ORTEP plot of 1 with H atoms removed for clarity and the thermal ellipsoids set at a 
50 % probability level 
The structure of 1 was further confirmed by X-ray diffraction, in collaboration 
with Adrian Whitwood, Sam Hart and Rachel Bean in the XRD department at York. A 
C-Ir 
COD C-H 
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suitable single crystal was grown via the slow diffusion of hexane into a concentrated 
DCM solution of 1. It crystallised in the P21/n space group, yielding unit cell parameters 
for a, b and c of 8.7533(3), 19.4098(11) and 13.9131(4) Å respectively and for α, β and 
γ of 90, 90.472(3) and 90 ° respectively. The crystal exhibited both pseudomerohedral 
and multicrystal twinning, indicated by the high residual electron density of 8 e Å−3. 
This was significantly reduced to 1.81 e Å−3 when a partially occupied iridium site was 
included in the model. Figure 53 shows the corresponding ORTEP plot of complex 1, 
determined at 110 K. Key data for bond lengths and angles are shown in Table 4. The 
geometry around the iridium centre is distorted square planar with the corresponding 
bond angles all being close to 90 °. 
Table 4: Selected bond lengths and angles for complex 1 
Atoms Length / Å Atoms Angle / ˚ 
Ir-O 2.067(3) C(carbene)-Ir-O 92.88(14) 
Ir-C(carbene) 2.049(4) O-Ir-C(COD t O) 159.87(16) 
Ir-C(COD t O) 2.111(5) O-Ir-C(COD t O) 158.95(17) 
Ir-C(COD t O) 2.101(5) O-Ir-C(COD t carbene) 89.92(16) 
Ir-C(COD t carbene) 2.185(4) O-Ir-C(COD t carbene) 86.12(15) 
Ir-C(COD t carbene) 2.183(4) C(carbene)-Ir-C(COD t O) 96.10(17) 
C-C(COD t O) 1.444(7) C(carbene)-Ir-C(COD t O) 87.03(17) 
C-C(COD t carbene) 1.393(7) C(carbene)-Ir-C(COD t carbene) 154.46(18) 
  C(carbene)-Ir-C(COD t carbene) 168.35(17) 
  C(COD t O)-Ir-C(COD t carbene) 89.69(18) 
  C(COD t O)-Ir-C(COD t carbene) 81.46(17) 
  C(COD t O)-Ir-C(COD t carbene) 81.48(18) 
  C(COD t O)-Ir-C(COD t carbene) 98.06(18) 
  C(phenyl ring)-O-Ir 132.6(3) 
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Complex 1 (detailed in Table 4) can be compared to two related distorted square 
planar complexes, [Ir(COD)(IMes)(OSiMe3)] containing a siloxide ligand and 
[Ir(COD)(IMes)(py)]+ containing a pyridine ligand (see Table 5).154-155  
Table 5: Selected bond lengths for complex 1, [Ir(COD)(IMes)(OSiMe3)] and 
[Ir(COD)(IMes)(py)]+ where X denotes O or N as detailed for each of the three complexes 
 
1 
X = O 
[Ir(COD)(IMes)(OSiMe3)] 
X = O154 
[Ir(COD)(IMes)(py)]+  
X = N155 
Atoms Length / Å Length / Å Length / Å 
Ir-X 2.067(3) 2.020(4) 2.0954(17) 
Ir-C(carbene) 2.049(4) 2.050(5) 2.0762(19) 
Ir-C(COD t X) 2.111(5) 2.107(5) 2.1259(19) 
Ir-C(COD t X) 2.101(5) 2.125(6) 2.137(2) 
Ir-C(COD t 
carbene) 
2.185(4) 2.181(5) 2.136(2) 
Ir-C(COD t 
carbene) 
2.183(4) 2.150(6) 2.193(2) 
C=C(COD t X) 1.444(7) 1.407(5) 1.399(3) 
C=C(COD t 
carbene) 
1.393(7) 1.375(6) 1.402(3) 
 
Complex 1 has an Ir-O bond length of 2.067(3) Å which compares well to that 
of 2.020(4) Å reported for the siloxide complex. Furthermore, in both oxygen-
containing complexes, the Ir-COD bond distances, trans to O, are short and the C=C 
bonds of the COD ligand are lengthened. The same effect occurs in the pyridine-
containing complex. For 1 the Ir-C(COD t O) bond lengths are 2.111(5) Å and 2.101(5) 
Å which are the same, within error, as those of the siloxide complex (2.125(6) Å and 
2.107(5) Å). The C=C(COD t O) bond of the alkoxide complex (1.444(7) Å) is 
lengthened slightly more than the siloxide complex (1.407(5) Å) due to more electron 
donation from the metal centre into the π* antibonding orbitals of the C=C bond. This 
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means the Ir-O alkoxide donates the most electron density to iridium which then 
donates more into the bound alkene. The Ir-O siloxide bond is more ionic in character 
so donates less electron density. For both the alkoxide and siloxide complexes, the 
C=C(COD t carbene) bonds are shortened (1.393(7) Å and 1.375(6) Å respectively) 
showing that the carbene also donates electron density to the metal centre. In the 
pyridine complex, the C=C bond lengths of the COD group are 1.399(3) Å and 1.402(3) 
Å which are very similar and show there is no significant difference in back donation 
into these from either the carbene or the nitrogen atom of the pyridine ligand. 
Consequently, the phenoxide ligand in 1 is the most electron-donating ligand of this 
series and its iridium metal centre is therefore the most electron rich. 
Table 6: Selected bond angles for complex 1, [Ir(COD)(IMes)(OSiMe3)] and 
[Ir(COD)(IMes)(py)]+ where X denotes O or N as detailed for each of the three complexes 
 
1 
X = O 
[Ir(COD)(IMes)(OSiMe3)] 
X = O154 
[Ir(COD)(IMes)(py)]+ 
X = N155 
Atoms Angle / ˚ Angle / ˚ Angle / ˚ 
C(carbene)-Ir-X 92.88(14) 88.2(2) 94.45(7) 
X-Ir-C(COD t X) 159.87(16) 167.3(2) 165.08(7) 
X-Ir-C(COD t X) 158.95(17) 153.8(2) 154.83(8) 
X-Ir-C(COD t 
carbene) 
89.92(16) 92.6(2) 88.73(7) 
X-Ir-C(COD t 
carbene) 
86.12(15) 91.3(2) 87.68(7) 
C(carbene)-Ir-
C(COD t X) 
96.10(17) 95.9(2) 93.25(8) 
C(carbene)-Ir-
C(COD t X) 
87.03(17) 91.5(2) 90.13(8) 
C(carbene)-Ir-
C(COD t carbene) 
154.46(18) 150.7(2) 151.59(8) 
C(carbene)-Ir-
C(COD t carbene) 
168.35(17) 172.3(2) 170.12(8) 
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The bond angles for these three complexes can also be compared (see Table 6). 
Complex 1 has a smaller bond angle between the C(carbene)-Ir-O compared to the 
C(carbene)-Ir-N as the chelate locks the complex in place and forces a smaller bite 
angle. However, this angle is not as small as for the siloxide complex, due to steric bulk 
of the bidentate ligand forcing the angle to be slightly wider. With the smaller bond 
angle of [Ir(COD)(IMes)(OSiMe3)], the orbital overlap will be increased which may 
also be a slight contributing factor to explain why it has the shorter, stronger Ir-O bond 
in comparison to 1, where the angle is forced larger and thus leads to a slightly lower 
orbital overlap and reduced bond length. 
On changing the substituent from NO2 to H, the 
1H NMR spectrum in CD2Cl2 at 
298 K alters considerably. For complex 2, as labelled in Figure 54, the 1H NMR 
spectrum is shown in Figure 55 and full characterisation data are included in the 
Experimental Section 8.7.7. In the presence of air/moisture, complex 2 was not stable 
and rapid decomposition occurs, unlike stable complex 1. This is accompanied by a 
colour change, from bright orange to brown. However, complex 2 can be stored 
indefinitely in a glovebox as a solid and is stable in solution under a nitrogen 
atmosphere. Signals for the CH2 linker protons of complex 2 appear in the 
1H NMR 
spectrum at δ 6.55 and 5.15 at 294 K, with a mutual coupling constant of 14.9 Hz, 
demonstrating their diastereotopic nature, as seen for 1. At 294 K, all the expected 
proton resonances of 2 are resolved. Four inequivalent COD alkene protons are visible 
as multiplet signals at δ 4.39 (2H), 3.22 and 2.78. 
 
Figure 54: Line drawing of complex 2 showing the labelling scheme employed 
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Figure 55:  1H NMR spectrum of 2 in CD2Cl2 at 298 K, showing the inequivalent CH2 linker 
protons, labelled as 7 and the COD alkene protons (* indicates the residual solvent peak) 
In contrast, the proton spectrum of 3 resembles that of 1, as at room temperature 
the CH2 linker protons are not visible and the two CHmesityl protons appear as a very 
broad singlet, but on cooling they resolve. A single crystal of 3, suitable for X-ray 
diffraction grew via the slow diffusion of hexane into a concentrated DCM solution of 
3. It crystallised into the P-1 space group, yielding unit cell parameters for a, b and c of 
13.7657(5), 14.4796(6) and 14.5701(6) Å respectively and for α, β and γ of 61.959(4), 
87.209(3) and 80.925(3) ° respectively. The residual electron density was 1 e Å−3.  
 
Figure 56: ORTEP plot of 3 with H atoms removed for clarity and the thermal ellipsoids set at a 
50 % probability level 
7 COD C-H 
* 
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Figure 56 shows the corresponding ORTEP plot of complex 3, determined in 
collaboration with Adrian Whitwood, Sam Hart and Rachel Bean in the XRD 
department at York, and measured at 110 K, with key data shown in Table 7. The 
geometry around the iridium centre is distorted square planar with the corresponding 
bond angles all close to 90 °. The COOMe substituent in 3 is slightly less electron-
withdrawing than the NO2 group in 1 but there are no significant differences between 
the complexes’ bond lengths or angles. The 1H NMR spectrum of 4 is also like 1 and 3, 
with broad signals at 298 K for the COD CH protons and the CH2 linker protons. At 243 
K, the four COD CH protons are visible at δ 4.32, 4.27, 3.09 and 2.26 with the two CH2 
linker protons at δ 6.44 and 4.60 sharing a common 2J-coupling of 13.7 Hz. 
Table 7: Selected bond lengths and angles for complex 3 
Atoms Length / Å Atoms Angle / ˚ 
Ir-O 2.060(3) C(carbene)-Ir-O 90.25(14) 
Ir-C(carbene) 2.047(4) O-Ir-C(COD t O) 163.50(15) 
Ir-C(COD t O) 2.119(4) O-Ir-C(COD t O) 155.50(15) 
Ir-C(COD t O) 2.097(4) O-Ir-C(COD t carbene) 86.94(15) 
Ir-C(COD t carbene) 2.143(4) O-Ir-C(COD t carbene) 88.07(14) 
Ir-C(COD t carbene) 2.184(4) C(carbene)-Ir-C(COD t O) 93.45(16) 
C-C(COD t O) 1.430(6) C(carbene)-Ir-C(COD t O) 96.44(16) 
C-C(COD t carbene) 1.394(6) C(carbene)-Ir-C(COD t carbene) 151.05(17) 
  C(carbene)-Ir-C(COD t carbene) 171.06(16) 
  C(COD t O)-Ir-C(COD t carbene) 82.05(17) 
  C(COD t O)-Ir-C(COD t carbene) 90.62(16) 
  C(COD t O)-Ir-C(COD t carbene) 81.67(17) 
  C(COD t O)-Ir-C(COD t carbene) 97.97(17) 
  C(phenyl ring)-O-Ir 136.4(3) 
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2.4. Reactivity of pre-catalyst derivatives 
2.4.1. Reactivity of 1 in CD2Cl2 and C6D6 
Addition of normal hydrogen to 1 in CD2Cl2 at 298 K showed no observable 
change in the 1H NMR spectrum. However, on cooling to 253 K two broad hydride 
signals are visible. This, along with a very broad signal for free hydrogen in solution, 
suggests very rapid hydride exchange at 298 K and that the dihydride complex forms 
immediately. The hydride peaks have very low intensity but two pairs are visible at 253 
K, one sharp set at δ −9.81 and −21.48 and another broad set at δ −10.86 and −21.53 
(Figure 57), which are consistent with sites trans to alkene (~ δ −10) and trans to 
oxygen (~ δ −21). These products, two isomers of 5 which form due to differing 
conformations of the seven-membered metallocycle, are due to oxidative addition of H2 
to the iridium centre, as shown in Figure 57, and they exist in equilibrium with 1 where 
a steady-state of just 5 % conversion is achieved under these conditions, precluding 
their full characterisation.  
 
Figure 57: Oxidative addition of H2 to 1 in CD2Cl2 leads to the formation of two isomers of 5, 
5A and 5B. These species yield the diagnostic temperature-sensitive hydride resonances shown 
in the 1H NMR spectra on the right 
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At 253 K four signals are still present for the bound COD alkene protons of 1 so 
COD is not labile under a hydrogen atmosphere. A 1H COSY NMR spectrum showed 
no coupling between the hydride resonances although this may be due to their low 
signal intensities. It is proposed that the two pairs differ due to their arrangement with 
respect to the conformation of the seven-membered metallocycle as depicted in Figure 
57. The rapid reaction with H2 demonstrates the potential for the complex to have 
hydrogenation activity. 
Details of similar iridium COD dihydride species have been published 
previously.69, 156-159 Such a complex is formed when [Ir(COD)(NCCH3)(PMe3)][BF4] 
binds H2 as two hydride ligands as shown in Figure 58, and comparable spectral 
changes to those described for H2 addition to 1 have been reported.
158 For the dihydride 
complex [Ir(H)2(COD)(NCCH3)(PMe3)][BF4] the hydride resonances appear at δ 
−12.70 and −17.01 in the 1H NMR spectrum in CD2Cl2 at 243 K.158 In this species, the 
dihydrogen adds across the alkene-Ir-NCCH3 axis to form the dihydride product. This 
occurs as the H2 adds across the ligand axis which contains the weakest π-acid and is 
therefore the most electron rich.160 Hence the iridium centre contains enough electron 
density to back donate into the σ* antibonding orbital of dihydrogen to break its sigma 
bond and create two hydride ligands. Hydrogen addition to complex 1 occurs in a 
similar manner by adding across the alkene-Ir-O bond. Furthermore, work by Crabtree 
et al.156-157 in the late 1970s has also shown these dihydride-dialkene complexes to be 
important intermediates in homogeneous hydrogenation reactions which is discussed 
further in Section 6.1. 
 
Figure 58: [Ir(H)2(COD)(NCCH3)(PMe3)][BF4] formed when H2 adds to 
[Ir(COD)(NCCH3)(PMe3)][BF4]
158 
Another species that demonstrates reversible binding of hydrogen contains the 
strong anionic pyrrolide ligand159 as shown in Figure 59, which is similar to the hard 
anionic phenolate ligand in 1. This complex is neutral overall, containing an electron 
rich metal centre that facilitates oxidative addition and reductive elimination of H2. 
101 
 
 
Figure 59: An example of an iridium-pyridylpyrrolide complex which exhibits reversible 
binding of H2
159
 
The reactivity of 1 with pyridine was also investigated, however, in CD2Cl2 at 
298 K only very minor changes in the 1H NMR spectra were seen, as well as an increase 
in the signals for free COD in solution. After 6 days, the signals for 1 dominate and the 
clean conversion to a single identifiable product was not observed. These data show that 
the COD ligand of 1 is labile161 so that other ligands can bind,162 or decomposition 
occurs, but in this case the Ir-O bond is not cleaved. On cooling to 243 K, the signals in 
the 1H NMR spectrum for the bound COD CH protons of 1 are still present. If the 
phenolate ligand was displaced by a pyridine ligand, to form a zwitterionic-type species, 
then two of the signals for these COD CH protons would be expected to shift upfield, 
due to no longer being in a trans position to the electronegative oxygen atom. Upon 
subsequent addition of H2 to this solution, the formation of a new dihydride species, 6, 
in approximately 60 % yield was observed after a further three days of reaction. This 
reveals that although reactivity with substrate alone is limited, once hydrogen is present 
to hydrogenate the COD ligand to COE and then COA, which no longer binds to the 
iridium centre, pyridine binding becomes possible. 
 
Figure 60: The reaction of 1 with pyridine and hydrogen forms 6 in CD2Cl2 
When 1 was reacted with pyridine and hydrogen in a freshly prepared CD2Cl2 
solution, the slow but complete conversion to 6 was observed. After 6 hours at 298 K, 
the 1H NMR spectrum at 253 K showed only a slight reduction in the intensity of the 
bound COD alkene peaks of 1 along with a signal for free COD and COE in solution. 
After 24 hours, the 1H NMR spectrum at 253 K again showed reduced intensity signals 
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for 1 and larger peaks for free COD and COE in solution. The 13C{1H} NMR spectrum 
at 253 K, followed the same trend. The 1H COSY NMR spectrum showed peaks for 
bound pyridine and carbene ligands at different chemical shifts to those of 1, indicating 
partial conversion to 6. After 17 days, the 1H NMR spectrum at 253 K showed 100 % 
conversion to form 6, containing two bound pyridine ligands (see Figure 60) and two 
very broad hydride signals, along with COE and COA in solution. Cooling further to 
223 K enabled the hydride signals to resolve which revealed two isomers of 6, the major 
form 6A (83 %) and the minor form 6B (17 %), due to different conformations of the 
seven-membered metallocycle. These are discussed in detail in Section 3.2.1. At 
temperatures greater than 253 K, where an averaged signal is observed, the complex is 
referred to as 6. It is likely that the time taken for full activation is lengthened, when 
compared to [Ir(COD)(IMes)Cl], due to no initial counter ion displacement. Table 8 
shows how the ratios of 1 and 6 vary as a function of reaction time. 
Table 8: Ratios showing how the relative proportions of 1 and 6 change during the reaction of a 
CD2Cl2 solution containing 12 mol% 1 and 0.22 M pyridine under 3 bars of H2 seen at 253 K 
Reaction time Complex 1 (δ 7.95 signal) / % Complex 6 (δ 8.04 signal) / % 
0 hours 100 0 
6 hours 78 22 
24 hours 60 40 
6 days 25 75 
17 days 0 100 
  
On cooling to 233 K the signals for the pyridine ligands of the major isomer, 6A, 
are well resolved, however, at 298 K, there is a considerable difference in the 
appearance of the signals for the bound pyridine ligands. Those of the ligand in the cis 
position to the hydrides (py2) remain sharp, but those of the ligand in the trans position 
to a hydride (py1) become much broader and difficult to distinguish. This suggests that 
the latter pyridine undergoes rapid exchange at 298 K and thus averaged 1H NMR 
signals are observed. The chemical shifts of py1 appear at δ 8.31, 6.97 and ~ 7.04 whilst 
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those for py2 appear at δ 8.96, 7.11 and 7.66. The ortho proton peak of py1 shifts 
slightly with temperature, due to inhibition of exchange, whilst the py2 signals do not. 
The hydride signals are present at δ −21.36 and −28.88 with a common coupling of 8.9 
Hz. Full characterisation data for 6A at 233 K are given in the Experimental Section 
8.6.4. 
 
Figure 61: 1H EXSY163 NMR spectra showing nOe signals of 6A when selectively exciting the 
signal for HA (A) and the signal for HB (B). The hydride resonances for 6B are also seen 
When probing the hydride ligands using 1H EXSY NMR at 243 K as shown in 
Figure 61, HA shows an nOe interaction with the py2 ortho 
1H signal at δ 8.92 and with 
one of the CH2 linker protons at δ 6.48. This is consistent with HA lying in the 
perpendicular plane to the metallocycle containing the CH2 linker. On the other hand, 
HB lies much further away from the CH2 linker and thus shows an nOe interaction with 
both pyridine ligands which lie cis to it; the py2 ortho 
1H signal at δ 8.92 and the py1 
ortho 1H signal at δ 8.13. 
To determine if the bound phenolate ligand in 6 can be displaced, increasing 
equivalents of triethylsilane were added to a CD2Cl2 solution of 6. Any reaction to trap 
the phenolate would be apparent on analysing the hydride region of the 1H NMR spectra 
for any change in hydride signals as shown in Figure 62. However, at 298 K no change 
was observed, suggesting that the oxygen ligand of 6, under these conditions, is strongly 
py
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bound to iridium. This shows that the whole system must be evaluated, as based on 
bond dissociation energies alone, a stronger Si-O bond (800 ± 13 kJ mol−1)  would be 
anticipated to form in preference to a weaker Ir-O bond (414 ± 42 kJ mol−1).164  
 
 
  
Figure 62: Potential structure formed when 6 is reacted with Et3SiH and the corresponding 
1H 
NMR spectra of the hydride region after addition of increasing equivalents of Et3SiH, from 0 eq. 
to 5 eq. (A to F) showing no change in the hydride signals (* denotes singlet hydride species 
discussed in Section 3.2) 
 
2.4.2. Reactivity of 2 in CD2Cl2 and C6D6 
To understand the effect on reactivity when the substituent on the carbene ligand 
is changed from NO2 in complex 1 to H in complex 2, a CD2Cl2 sample of 2 was 
analysed in a similar way to that described for 1 in Section 2.4.1. Now, at 298 K, the 
four COD alkene protons of 2 could be identified at δ 4.37 (2H), 3.22 and 2.77, 
however, upon cooling to 243 K the NMR signals become very broad and unresolved. 
This means that at 298 K the complex is undergoing rapid motion that is faster than the 
NMR timescale so broadening effects are not observed. However, upon cooling, this 
motion is slowed so that the signals are no longer well defined. In C6D6, at 298 K, again 
the four COD alkene protons could be identified at δ 4.85 (2H), 3.21 and 2.90. 
H
A
 
H
B
 * 
* 
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However, no low temperature studies could be conducted in benzene due to its melting 
point of 5.5 °C. 
When H2 is added to a CD2Cl2 sample of 2 at 255 K, a limited reaction occurs. 
Four hydride signals are observed, corresponding to two species which are two isomers 
of 7. The major signals for 7A appear at δ −12.35 and −18.25 and the minor ones for 7B 
appear at δ −12.39 and −17.64. These two isomers reflect ring-flip conformers of the 
metallocycle. The structure of the major isomer is shown in Figure 63 with its low 
concentration precluding full characterisation. When the reaction is followed with p-H2 
these hydride signals do not show any PHIP enhancement. However, upon warming to 
298 K, these minor hydride signals are broadened into the baseline of the NMR 
spectrum and again the only detectable species is complex 2. Furthermore, when 
pyridine is added to a CD2Cl2 or C6D6 solution of 2 at 298 K, no reaction was observed. 
Instead, the proton peaks for 2 remain resolved. This behaviour is the same as that 
observed for complex 1, demonstrating that the pathway to full activation of these 
complexes is different to what has previously been observed, but consistent between 
these new complexes. Here, the pathway does not proceed via ligand substitution, as for 
the chloride-containing iridium carbene complexes, where the most studied and 
understood species is [Ir(COD)(IMes)Cl].94  
 
Figure 63: Reaction of 2, in CD2Cl2 / C6D6, with H2 leads to the formation of the major 
dihydride complex 7A which then forms the bis-pyridyl iridium species, 8, after COD 
hydrogenation in the presence of pyridine. 8 is a product in which the Ir-O bond is retained 
On full activation with pyridine and H2, which takes several days at 298 K, the 
detectable signals alter to those of the new iridium species, 8 (see Figure 63). In these 
aprotic solvents, two inequivalent hydride signals are visible, as shown in their 
corresponding 1H NMR spectra in Figure 64. Their signals appear in CD2Cl2 at δ −22.55 
and −25.49 with a coupling constant of 8.1 Hz and in C6D6 at δ −21.94 and −24.52 with 
a coupling constant of 7.7 Hz. This suggests that the Ir-O bond is retained in both 
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samples. This is further supported by the fact that the CH2 linker protons remain 
diastereotopic, as two distinct doublets are seen in both CD2Cl2 and C6D6. In CD2Cl2 
they are present at δ 5.76 and 5.29, with a coupling constant of 14.8 Hz, whilst in C6D6 
they appear at δ 6.30 and 5.67, with a coupling constant of 14.6 Hz. It is interesting to 
note that despite the two bound pyridine ligands existing in distinct environments in 
both CD2Cl2 and C6D6, separate signals for the ortho protons are only observed in 
CD2Cl2, whilst in C6D6 the corresponding signals appear at the same chemical shift. 
Furthermore, the 1H NMR signals in the C6D6 sample are broader than those in CD2Cl2, 
suggesting the ligands undergo exchange and that this occurs more rapidly in the less 
polar solvent (see Section 2.4.2). In both samples singlet-based hydride species are 
visible (see Figure 64), although their low concentration (< 6 %) precludes their full 
characterisation (see Section 3.2 for further discussion). In CD2Cl2 the hydride signals 
appear at δ –23.85 and −26.54, whilst in C6D6 a signal is visible at δ −23.29. 
Characterisation data for complex 8 in CD2Cl2 are given in the Experimental Section 
8.7.8. Despite extensive NMR analysis, the chemical shift of the carbene carbon could 
not be identified at 298 K. Furthermore, at 298 K the ortho and para proton signals for 
the py1 bound ligand are very broad, consistent with it undergoing rapid exchange, and 
thus this precluded determination of the chemical shifts of the corresponding 13C NMR 
signals. On cooling to 263 K, these ortho and para 13C signals are present at δ 154.4 and 
135.4. Characterisation data for 8 in C6D6 are also given in the Experimental Section 
8.7.8. 
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Figure 64: 1H NMR spectra of the aromatic and hydride regions of a solution containing 8 after 
the reaction of 2 with pyridine and hydrogen in CD2Cl2 (A) and in C6D6 (B) at 294 K (* denotes 
free pyridine in solution) 
 
2.4.3. Reactivity of 3 in CD2Cl2 and C6D6 
For complex 3 in CD2Cl2, the addition of pyridine leads to no reaction, as 
observed previously in Section 2.4.1 for 1. The reactivity of 3 with H2 is also like 1 and 
2, as two pairs of minor hydride species are observed, only under PHIP conditions or 
thermally after a considerable number of scans. These pairs are present at δ −10.79 and 
−20.79, for the most prominent COD dihydride species, 9A, and at δ −9.85 and −22.88 
for 9B. Their low concentrations (< 2 %) precluded further characterisation. 
When both pyridine and H2 are added to a CD2Cl2 solution of 3, the activation 
time is again days, however, unlike for 2, two inequivalent dihydride isomers are 
present. These are isomers of complex 10, 10A and 10B, as shown in Figure 65. 
A 
B 
HA HB 
HA HB 
* 
* 
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* 
* 
* 
Bound py Benzene 
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Figure 65: 10A and 10B formed from the reaction of 3 with pyridine and hydrogen in CD2Cl2 
 
Figure 66: 1H COSY NMR spectrum of a CD2Cl2 sample of 10A and 10B, showing coupling 
between the hydride signals at δ −21.95 and −28.48 and those at δ −22.56 and −25.47 
The two isomers again form due to ring-flip of the seven-membered 
metallocycle, and are distinguished by their hydride resonances; one broader pair of 
hydride signals exists at δ −21.95 and −28.48 with a mutual coupling of 8.3 Hz for 
complex 10A, and a sharper pair of hydride signals exists at δ −22.56 and −25.47 now 
with a common coupling of 8.0 Hz for complex 10B. The ratio of the two species was 
found to be 37: 63 respectively for a sample containing 0.07 M pyridine and 10 mol% 3. 
Figure 66 shows the corresponding 1H COSY NMR spectrum which details the hydride 
ligand connectivity. When the concentration of pyridine was reduced, such that the 
sample contained 0.04 M pyridine and 17 mol% 3, the ratio reversed to be equal to 86: 
14. At 303 K, all four hydride signals were shown to undergo exchange with each other, 
according to 2D 1H NOESY NMR experiments, as shown in Figure 67.  
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Figure 67: 2D 1H NOESY NMR experiment of a CD2Cl2 sample of 10A and 10B at 303 K 
showing exchange between all four hydride ligands of 10A and 10B 
As described for complexes 6A and 6B in Section 2.4.1, the exchange between 
the ring-flip isomers of 10 is expected to continue at low temperatures, however, on 
cooling to 273 K, the signals for 10A are broadened, precluding these studies. It is 
anticipated that at low temperature, exchange between hydride ligands on the same 
complexes is inhibited, because there is no pyridine ligand exchange, consistent with 
that observed for complexes 6A and 6B. Both species contain two bound pyridine 
ligands, with their respective ortho proton signals at δ 9.01 (trans to carbene) and 8.40 
(trans to hydride) for complex 10A and at δ 8.82 (trans to hydride) and 8.76 (trans to 
carbene) for complex 10B. Because only two pyridine environments exist for both 
complexes, and due to two of their hydride ligands exhibiting a large upfield shift, the 
Ir-O bond is retained in both species. They also both contain diastereotopic CH2 linker 
protons at δ 4.56 and 6.15 (2J(HH) = 14.0 Hz) for complex 10A and at δ 5.32 and 5.87 
(2J(HH) = 14.6 Hz) for complex 10B. After a longer time (< 2 weeks), all of complex 
10A had converted into complex 10B. Complex 10A is the kinetic isomer and complex 
10B is the more thermodynamically stable isomer. NMR characterisation data in CD2Cl2 
for species 10A and 10B are detailed in the Experimental Section 8.8.7. 
When 3 reacts with pyridine and H2 in C6D6, after 72 hours the major dihydride 
species at 298 K is 10A (~ 70 %), with two bound pyridine ligands and two hydride 
ligands; these are visible as a broad singlet at δ −21.24 and a broad doublet at δ −28.00 
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(2J(HH) = 7.7 Hz). Another broad pair of hydride signals appears at δ −21.67 and 
−28.42 (~ 10 %) which convert into signals for 10A over time. Two other monohydride 
signals are present at δ −24.03 (trans to pyridine) and −25.54 (trans to oxygen) (~ 10 
%), which are thought to be due to COD-containing intermediate species (see Section 
3.2). In C6D6, there is also a minor pair of hydride signals (~ 10 %) at δ −22.01 and 
−24.58, which couple via a 1H COSY NMR spectrum and correspond to 10B. 
 
2.4.4. Reactivity of 4 in CD2Cl2 and C6D6 
The reactivity of 4 with pyridine and hydrogen in CD2Cl2 and C6D6 is like that 
of 3 described in Section 2.4.3, as with pyridine alone it demonstrates no reactivity and, 
with hydrogen, two very minor (< 2 %) dihydride species are formed. Their signals, 
which are at δ −10.74 and −20.19 and δ −12.56 and −21.49, are only easily observed 
under PHIP conditions and correspond to COD dihydride species 11A and 11B. On 
activation with both pyridine and hydrogen, two distinct conformational isomers of 12 
form, with signals for one species being much broader than the other at 298 K (see 
Figure 68 and Figure 69). They exchange with each other as well as with hydrogen on 
the NMR timescale, thus demonstrating the same activation behaviour as for complex 3. 
NMR characterisation data, which are very similar to those for the two isomers of 10 in 
Section 2.4.3, are included in the Experimental Section 8.9.14. The exchange of py1 in 
complex 12A was too rapid to elucidate the chemical shifts of all its proton and carbon 
atoms and due to considerable peak overlap several other resonances could not be 
determined. 
 
Figure 68: Two conformational isomers, 12A and 12B present in CD2Cl2 and C6D6 
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Figure 69: 1H NMR spectra showing the aromatic and hydride regions for samples of 12A and 
12B in CD2Cl2 (A) and C6D6 (B). The inset image shows the four bound pyridine environments 
in CD2Cl2 (*) 
 
2.4.5. Reactivity of 1 in CD3OD 
For stable complex 1, when the solvent is changed to CD3OD, its reactivity is 
the same as that described in Section 2.4.1 in the solvent CD2Cl2. Activation of 1 with 
pyridine and H2 also leads to the formation of complex 6 and the same two hydride 
signals are apparent in the 1H NMR spectrum at δ −21.62 and −29.22 with a coupling 
constant of 8.7 Hz. The CH2 linker protons remain inequivalent and appear as broad 
doublets at δ 4.68 and 6.25 with a coupling constant of 13.5 Hz. 
 
2.4.6. Reactivity of 2 in CD3OD 
In the protic solvent CD3OD, 2 acts very differently when compared to similar 
solutions in CD2Cl2 and C6D6. Upon dissolving 2 in CD3OD, the corresponding 
1H 
NMR spectrum changes and the peaks all become very broad so assignment at 298 K is 
not possible. However, on cooling to 243 K the signals resolve which enables full 
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characterisation of the complex, as detailed in the Experimental Section 8.7.7. The CH2 
linker protons are visible as two doublet signals at δ 6.26 and 5.30 with a common 
coupling of 15.0 Hz, whilst the four COD alkene protons are all visible as multiplet 
signals at δ 4.39, 4.28, 3.20 and 2.86. 
Upon the subsequent addition of pyridine at 243 K, the peaks remain resolved 
and a four-coordinate square planar intermediate, 13 is formed cleanly as shown in 
Figure 70. Complex 13 contains the carbene ligand, one bound pyridine ligand and the 
bidentate COD ligand, with four inequivalent alkene protons at δ 4.02, 3.86, 3.78 and 
3.27. The upfield chemical shift of the CH protons of the bound COD ligand, compared 
to those of 2, are consistent with COD no longer binding trans to the oxygen ligand and 
thus the phenolate has dissociated. In methanol, the proposed zwitterionic structure can 
be stabilised by interactions with the solvent. Furthermore, when 15N-labelled pyridine 
is used, all four COD CH protons show long-range coupling to the pyridine nitrogen 
atom, observed via an HMQC spectrum. The CH2 linker protons remain diastereotopic, 
appearing at δ 6.40 and 5.64 with a coupling constant of 14.6 Hz, as no plane of 
symmetry exists within the molecule. Full characterisation data for 13 are given in the 
Experimental Section 8.7.9. 
 
Figure 70: Complex 2 and the intermediate, 13, formed on the addition of pyridine 
Upon addition of p-H2 to 13 at 243 K two PHIP enhanced hydride signals are 
observed at δ −12.34 and −17.50 which are shown to couple via 1H COSY NMR spectra 
and correspond to the alkene dihydride complex, 14 (see Figure 71). This reaction does 
not go to completion and instead a mixture of 13 and 14 is formed in an approximate 
ratio of 1.2: 1. The downfield chemical shifts of the hydride ligands are consistent with 
them binding trans to carbon and nitrogen respectively, commensurate with Ir-O bond 
cleavage. The hydride ligand signal at δ −17.50 also demonstrates a trans 2J-coupling to 
the pyridine nitrogen, equal to 16.8 Hz. In 14, the CH2 linker protons again remain 
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diastereotopic, appearing at δ 5.00 and 4.70 with a coupling constant of 15.2 Hz, as the 
complex contains no plane of symmetry. Full characterisation data for 14 are given in 
the Experimental Section 8.7.10. 
 
Figure 71: Formation of 14 upon addition of hydrogen to 13 and subsequent formation of 15 on 
warming the sample 
Upon warming to 265 K, a hydride signal at δ −22.18 for complex 15 (Figure 
71) is visible. By 298 K, this is the major species present in solution and the signals 
remain sharp and resolved, as shown in Figure 72. Characterisation is now possible.  
 
Figure 72: 1H NMR spectrum of the aromatic and hydride regions after the reaction of 2 with 
pyridine and hydrogen, in CD3OH, to form 15 showing the singlet hydride signal 
Overall the hydride region showed the presence of two species, with the major 
singlet at δ −22.34 reflecting 96 % of the species and the minor singlet at δ −22.43 
making up the other 4 %. The major species is the tris-pyridyl dihydride complex 15, 
where the chelating ligand is dissociated at the oxygen side arm. The two species 
undergo very rapid exchange with deuterium in solution from the CD3OD solvent and 
the signals corresponding to the major and minor hydride-deuteride complexes appear at 
δ −22.29 and −22.39 respectively. This is accompanied by the formation of HD in 
solution and 30 minutes after the addition of fresh hydrogen, both signals in the hydride 
region of the spectrum correspond to the hydride-deuteride species. Due to this rapid 
deuteration no exchange rates for hydride dissociation could be calculated in CD3OD. 
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The rest of the proton spectrum confirms the identity of 15, due to the presence 
of signals for two bound pyridine environments in a 2: 1 ratio, indicative of the two 
pyridine ligands trans to hydride ligands and the one trans to the carbene respectively. 
The CH2 linker protons now appear as one signal at δ 4.83 which integrates to two 
equivalent protons and means that these are no longer diastereotopic; the oxygen is no 
longer bound and the phenolate can freely rotate. Full characterisation data for 15 are 
given in the Experimental Section 8.7.11. Overall, the reaction from 2 to form 15 in 
CD3OH, is much faster than the equivalent reaction seen in CD2Cl2 or C6D6. 
 Upon cooling this sample to 250 K, along with the subsequent reaction with p-
H2, two very minor, very broad, weakly PHIP enhanced hydride signals are visible at δ 
−22.6 and −26.2 which must correspond to species 8, where the Ir-O bond is retained. 
However, its very low concentration and the fact that it undergoes rapid exchange, even 
at low temperature, precluded any further characterisation. 
Intermediates, 13 and 14, lie on the pathway to the formation of 15. This 
reactivity follows the same pathway as described for [Ir(COD)(IMes)Cl], which starts 
with displacement of the chloride ligand by a substrate ligand, so that the chloride 
becomes a counter ion.94 This charged 16-electron complex is stabilised by the polar 
protic solvent, methanol, which is not possible when CD2Cl2 or C6D6 are used. 
Figure 73 depicts the key 1H NMR spectroscopic changes observed on addition 
of H2 to a CD3OD solution of 13. Focusing on the aromatic region, a large chemical 
shift difference is observed between the ortho protons of the pyridine ligand bound 
trans to the COD ligand in 13 and the pyridine ligand bound trans to a hydride ligand in 
14. This large downfield shift is due to the pyridine ligand experiencing a decrease in 
electron density which occurs on oxidising the metal centre from Ir(I) to Ir(III) and thus 
leads to reduced shielding from the applied magnetic field. Similar downfield shift 
effects are observed for the CH protons of the COD ligand in 13 compared to 14, also 
shown in Figure 73. The fourth CHCOD proton of 14 overlaps with the CHCOD proton of 
13 that is visible at ~ δ 4 in Figure 73 B and the doublet signal that is present at ~ δ 4.7 
Figure 73 B corresponds to one of the protons of the CH2 linker of 14. 
115 
 
 
Figure 73: Aromatic region of the 1H NMR spectra of complex 13 (left-hand side), with signals 
for free pyridine indicated by * and the signal for the ortho proton of the bound pyridine ligand 
of complex 13 indicated by * (A). On addition of H2 the formation of 14 is indicated by a 
significant change in the chemical shift of the ortho proton of the bound pyridine ligand in 14 
shown by * (B). The meta and para protons of the bound pyridine ligands in 13 and 14 overlap 
due to incomplete conversion to 14. A similar shift is observed for the COD CH protons, shown 
on the right-hand side 
* 
* 
* 
* 
* 
* 
* 
* * 
A 
B 
3 x CHCOD of 13 
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2.4.7. Reactivity of 3 in CD3OD 
In CD3OD, complex 3 demonstrates very similar reactivity to that of 1 (see 
Section 2.4.5). For a sample containing 10 mol% 3 and 0.06 M pyridine, in CD3OD, full 
activation to the bis-pyridine species, 10A, occurs within a couple of hours and after 70 
hours significant deuteration of the ortho proton sites of pyridine has occurred. 
Approximately 40 % of the signal remained for the ortho 1H NMR signal. This 
deuteration affect was not visible in the aprotic solvents. The two signals for the hydride 
ligands of 10A appear as broad singlets at δ −21.66 and −29.04 in the 1H NMR 
spectrum. The corresponding ortho proton signals for the bound pyridine ligands appear 
at δ 8.90 (trans to carbene) and 8.23 (trans to hydride). Full NMR characterisation data 
for 10A, as shown in Figure 74, are given in the Experimental Section 8.8.7. 
 
Figure 74: 10A that forms in methanol 
When the concentration of pyridine in solution is increased, so that a sample 
contained 4 mol% 3 and 0.32 M pyridine, formation of 10A and a tris-pyridyl, Ir-O 
bond-cleaved species was observed, in an approximate ratio of 87: 13. The low 
concentration of the tris-pyridyl species and the multiple overlapping signals precluded 
its full characterisation although the signals for the hydride ligands at δ −22.40 and two 
bound pyridine environments at δ 8.41 (2 x py) and δ 8.18 (1 x py) could be identified.  
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2.4.8. Reactivity of 4 in CD3OD 
For complex 4, in CD3OD, a sample containing 5 mol% 4 and 0.16 M pyridine 
reacted to form two species; one with inequivalent hydride ligands and the other 
exhibiting equivalent hydride ligands. Two very broad signals for the inequivalent 
hydride ligands of 12A were present at δ −21.72 and −28.72 but the Ir-O bond cleaved 
product, 16, was also formed as shown in Figure 75. For complex 16 the hydride signal 
was present in the 1H NMR spectrum at δ −22.29. Due to the formation of the tris-
pyridyl dihydride species, this exhibits similar behaviour to that observed for complex 
2, as described in Section 2.4.6, and therefore, with more electron-donating substituents 
on the phenolate, the Ir-O bond becomes weaker and less stable. Full NMR 
characterisation data for 12A and 16 are included in the Experimental Sections 8.9.14 
and 8.9.15 respectively.  
 
Figure 75: 12A and 16 present in a CD3OH sample of 4 with pyridine and H2 
The four complexes described in this section all contain electron-withdrawing 
substituents in the para position to the phenolate within the carbene backbone. 
Investigations were carried out to create an imidazolium salt derivative with the 
electron-donating dimethylamino group in the para position to the phenolate. However, 
despite multiple synthesis attempts, isolation of the desired imidazolium salt was not 
possible due to decomposition of the reaction mixture during the synthesis. This rapid 
degradation, combined with the knowledge that the H-containing complex demonstrates 
reduced stability in comparison to the electron-withdrawing complex derivatives, meant 
that this route was not pursued. 
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2.5. Further investigations of complex 2 
It has been shown that the reaction of complex 2 with pyridine and H2 cleanly 
forms two different structures 8 and 15, depending on the solvent used. Therefore, to 
determine whether complexes 8 and 15 exist in equilibrium, a sample containing 2 and 
pyridine was prepared in CD2Cl2, and once activated with H2, CD3OH was added such 
that the solution contained 10 % CD3OH by volume. Both 8 and 15 were observed, 
showing that they do exist in equilibrium and that Ir-O bond cleavage and reformation 
occurs easily. To analyse this equilibrium and determine the free enthalpy and entropy 
changes between the two species, the sample was cooled from 303 K in 10 °C steps and 
the ratio of the two isomers was measured. The total sum of the integrals for the free 
pyridine ortho proton signal and the two isomers at 273 K was used to gauge the total 
amount of pyridine in the sample: this was used as the maximum for all calculations. 
The concentrations and equilibrium constants for the sample were calculated at the 
different temperatures using the equation shown in Figure 76 and the data are presented 
in Table 9. 
 
Figure 76: Equilibrium constant between 8 and 15 and the initial concentrations of 2 and 
pyridine 
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Table 9: Concentrations of iridium complexes to determine equilibrium constants at different 
temperatures in a CD2Cl2: CD3OH sample (9: 1) containing 2 and pyridine under 3 bars of H2 
 
Amounts of free py 
and complexes 8 and 
15 / % 
Iridium 
complex 
amounts / % 
Concentrations of 
free py, 8 and 15 / 
mmol dm−3 
Equilibrium 
constants / 
mol−1 dm3 
T / K Free py 8 15 8 15 [8] [15] [py] Keq lnKeq 
303 86.0 12.1 1.86 86.7 13.3 4.19 0.64 33.2 4.62 1.53 
293 84.3 12.5 3.14 79.9 20.1 3.86 0.97 32.6 7.70 2.04 
283 82.8 11.9 5.30 69.2 30.8 3.34 1.49 32.0 13.9 2.64 
273 81.2 10.2 8.58 54.3 45.7 2.62 2.21 31.4 26.9 3.29 
263 80.2 7.47 12.3 37.8 62.2 1.82 3.00 31.0 53.2 3.97 
253 78.4 5.84 15.7 27.1 72.9 1.31 3.52 30.3 88.9 4.49 
243 77.2 4.43 18.4 19.4 80.6 0.94 3.89 29.8 139 4.94 
 
To calculate the standard enthalpy (ΔHθ) and entropy (ΔSθ) changes for the 
reaction of 8 with free pyridine to form 15, the linear form of the Van’t Hoff equation is 
used as shown in Figure 77. Plots of 1/T vs lnKeq are used to determine the enthalpy and 
entropy changes from the gradient and intercept respectively (see Figure 78). 
𝑙𝑛𝐾𝑒𝑞 = −
∆𝐻𝜃
𝑅𝑇
+  
∆𝑆𝜃
𝑅
 
 
where: 𝐾𝑒𝑞 = equilibrium constant / mol
−1 dm3 
 ∆𝐻𝜃 = standard enthalpy change / kJ mol−1 
 ∆𝑆𝜃 = standard entropy change / J K−1 mol−1 
 R = Gas constant / 8.314 J K−1 mol−1 
 T = temperature / K 
Figure 77: Linear Van’t Hoff equation and reaction coordinate diagram for an exothermic 
reaction 
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Figure 78: Linear Van’t Hoff plot for calculating standard enthalpy and entropy changes for 
the equilibrium between complex 8 binding pyridine, to form complex 15 
The reaction to form 15 from 8, via Ir-O bond cleavage and pyridine binding, is 
exothermic. This is obvious from the positive gradient and negative enthalpy change of 
−36.0 ± 2.8 kJ mol−1. The standard entropy change of −105.2 ± 10.0 J K−1 mol−1 is also 
negative as expected because there is an increase in order in the system as two species 
form one. The change in Gibbs Free Energy of the system at 300 K was calculated to be 
−4.4 ± 4.1 kJ mol−1 which is very low, indicating minimal energy difference exists 
between the two species. 
As the addition of methanol to a CD2Cl2 solution of 8 promotes Ir-O bond 
cleavage, it was hypothesised that the addition of acid to another CD2Cl2 sample would 
cause the same effect. On reaction of a CD2Cl2 solution of 8 with formic acid, the two 
hydride ligands of 8, at δ −22.56 and −25.50, were slowly replaced by a hydride ligand 
at δ −22.25 due to a new species, the protonated form of 15, as shown in Figure 79. As 
the acid concentration increases, the amount of 15 increases and the hydride signals for 
8 become much broader, until 15 is the dominant species in solution. This must be 
accompanied by phenolate protonation. The chemical shifts for the protons of free 
pyridine are also pH dependent as shown in Figure 80, which is consistent with 
protonation of the pyridine in solution. Once the pyridine is protonated, SABRE is 
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hindered and testing with p-H2 leads to no signal enhancements. This is because the 
nitrogen no longer has a free lone pair of electrons available for binding to the iridium. 
 
Figure 79: Reaction of 8 with formic acid leads to Ir-O bond cleavage and the formation of 15 
now containing a protonated phenol side arm, along with production of protonated pyridine 
which inhibits SABRE 
 
Figure 80: Chemical shift changes observed on addition of increasing equivalents of formic 
acid (0 to 15 equivalents, indicated by *) to a CD2Cl2 solution of 8 to form protonated 15 and 
protonated free pyridine (labelled ortho, para and meta 1H NMR signals) (A) 0 eq., (B) 3 eq., 
(C) 6 eq., (D) 9 eq., (E) 12 eq. and (F) 15 eq. 
  
A 
 
B 
 
C 
 
D 
 
E 
 
F 
* 
ortho 
para 
meta 
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2.6. Rationalising the differences between the 
catalysts 
2.6.1. UV-visible spectroscopy analysis  
All the bidentate carbene complexes form yellow/orange coloured solutions. The 
most common pre-catalyst for SABRE, [Ir(COD)(IMes)Cl], forms a yellow methanol 
solution with three absorption bands at 374, 427 and 491 nm, with very similar 
behaviour being observed in DCM. The complexes 2, 3 and 4 also show these three 
absorption bands appearing at approximately 380, 430 and 490 nm, with molar 
absorption coefficients of between approximately 300 and 3000 dm3 mol−1 cm−1. These 
large values are consistent with charge-transfer bands. A summary of the actual 
absorption wavelengths for each complex with their corresponding absorption 
coefficients is given in Table 10. These values were calculated by applying the Beer-
Lambert law, A = εcl (where A = absorbance, ε = molar absorption coefficient and l = 
cell path length) to multiple samples of each pre-catalyst at differing concentrations (see 
Experimental Sections 8.6.3, 8.7.7, 8.8.6 and 8.9.13).  
On analysing the series of bidentate carbene complexes, based on their 
corresponding Hammett parameters, the values for the absorption bands of 2 all appear 
at shorter wavelengths, and thus higher energies, in comparison to the absorption bands 
of 3 and 4. Complex 2 contains the most electron-donating substituent (H) on the 
phenolate ring. Complexes 3 and 4, which exhibit very similar wavelength bands, have 
more electron-withdrawing substituents on the phenolate ring (COOMe and Cl 
respectively) and thus it is predicted that for complex 1, which contains the most 
electron-withdrawing NO2 substituent, the shortest wavelength absorption band would 
appear at a longer wavelength again, indicating a lower energy transition. Therefore, 
relating to the maximum absorption, the shortest wavelength band follows the trend of 4 
≈ 3 > 2 corresponding to Cl ≈ COOMe > H. However, for the longer wavelength bands, 
the differences in the absorption wavelengths are very small. This contrasts with that 
observed for the similar absorption spectra of a number of ruthenium complexes as 
shown in Figure 81, containing phosphine ligands with varying electron-donating and 
withdrawing substituents.165 For these complexes, the most electron-withdrawing 
substituent, C2F5, gives the lowest wavelength absorption bands, with the electron-
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donating substituents Et, Me and Ph exhibiting very similar wavelength bands at 
slightly longer wavelengths.165 Like the neutral iridium carbene complexes developed 
here, these ruthenium complexes each demonstrate very different reactivities with H2 
and CO due to the differing substituents. 
 
Figure 81: Ruthenium bis-phosphine complexes with substituents containing varying electron-
withdrawing and donating capabilities 
 
Table 10: Summary of the molar absorption coefficients for the detailed Ir(I) complexes 
Sample 
1 in 
DCM 
2 in DCM 
[Ir(COD)(IMes)Cl] in 
methanol 
Wavelength / nm 406 373 425 490 374 427 491 
ε / dm3 mol−1 cm−1 21060 1017 1326 249 1349 2065 457 
  3 in DCM 4 in DCM 
Wavelength / nm  380 432 491 381 430 491 
ε / dm3 mol−1 cm−1  3280 1481 427 2407 1519 429 
 
On analysing the activated solutions of [Ir(COD)(IMes)Cl] and 2 with pyridine 
and H2 in CH3OH, to form [Ir(H)2(IMes)(py)3]Cl and 15 respectively, these three 
absorption bands disappear with the maximum absorption now shifted into the UV 
region of the spectra as shown in Figure 82. This is consistent with the solutions all 
turning almost colourless once in their active dihydride forms. The same loss of colour 
is observed for 8, 10, 12 and 16. 
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Figure 82: UV-vis spectra in methanol of [Ir(COD)(IMes)Cl] (A) and 2 (C) showing the three 
absorption bands in the visible region and the disappearance of these bands upon activation 
with pyridine and hydrogen to form [Ir(H)2(IMes)(py)3]Cl (B) and 15 (D) respectively 
Some similar iridium(I) square planar complexes, also containing an anionic 
ligand, have been described by Geoffroy et al.166-168 Their discussions in the 1970s led 
them to believe that these species demonstrated metal-to-ligand charge-transfer 
transitions from occupied metal d-orbitals to molecular orbitals derived from a mix of π-
orbitals on the ligands and empty metal p-orbitals.166 An example species included 
[IrCl(CO)(PPh3)2] which shows very similar spectra to those observed for 
[Ir(COD)(IMes)Cl], 2, 3 and 4 with three distinct bands.167 It is also shown that this 
complex reversibly adds both hydrogen and oxygen and the latter species 
[IrCl(CO)(PPh3)2(O2)], is described as colourless due to loss of the characteristic visible 
absorption signals (see Figure 83).168 The bands may shift to higher energy and no 
longer lie in the visible range. However, more recent studies by Perutz et al. in the 
1990s suggest that the ligand orbitals actually play a very minor role and they assigned 
these transitions to metal d-to-p-orbital transitions.165, 169-171 Discussions show that 
complexes that demonstrate true charge-transfer transitions often show 
solvatochromism due to stabilisation of an excited or ground state due to a shift in 
charge or creation of an ion pair. However, when varying the solvent used to dissolve 2, 
the same absorption spectra in DCM, methanol and benzene were observed with the 
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three absorption bands between 350 and 500 nm visible at the same wavelengths as 
shown in Figure 84.  
 
Figure 83: UV-vis spectra for the photolysis of colourless [IrCl(CO)(PPh3)2(O2)] at 366 nm to 
reform the coloured square planar [IrCl(CO)(PPh3)2] complex with its three absorption bands 
(Reprinted with permission from Geoffroy, G. L.; Hammond, G. S.; Gray, H. B. J. Am. Chem. 
Soc. 1975, 97, 3933. Copyright © 1975 American Chemical Society)168 
 
Figure 84: The three absorption bands present for 2 in DCM, methanol and benzene with no 
indication for solvatochromism, commensurate with no change in absorption maxima in the 
different solvents 
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Figure 84 indicates that this species does not demonstrate solvatochromism and 
neither the ground state nor the excited state is stabilised by a change of solvent. This is 
inconsistent with the assignment of metal-to-ligand charge-transfer bands and instead 
demonstrates that metal d-to-p-orbital transitions are more likely. Pyridine does not 
absorb in the region between 350 and 550 nm and therefore the absorption band in the 
activated complex is due to the complex itself and not excess pyridine in solution. 
In contrast, complex 1 only exhibits one absorption band in the region between 
350 and 550 nm, at 406 nm with a considerably larger molar absorption coefficient of 
21060 dm3 mol−1 cm−1, compared to those of [Ir(COD)(IMes)Cl], 2, 3 and 4, as shown 
in Table 10. This is despite 1 containing the same iridium, COD and Ir-O core. It is 
thought that complex 1 should also exhibit the three absorption bands with similar 
wavelengths and absorption coefficients, however, they are masked by the very large 
intraligand charge-transfer band from the NO2 group in the carbene backbone. Solutions 
of 1 are a very strong orange colour, consistent with the large molar absorption 
coefficient. Analysis of the activated complex, 6, still gives a strong absorption band at 
398.6 nm with an absorption coefficient of 10975 dm3 mol−1 cm−1. Figure 85 shows the 
absorption spectra for all five complexes. Each set of data has been normalised such that 
the highest absorption value of each spectrum is equal to one. 
 
Figure 85: Comparison of the absorption spectra for the Ir(I) complexes (A) 1, (B) 3, (C) 4, (D) 
2 and (E) [Ir(COD)(IMes)Cl] 
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2.6.2. Formation of carbonyl complexes 
To analyse the electronic parameters of the different carbene complexes, the 
carbonyl derivatives were synthesised by dissolving the COD-containing carbene 
complexes in DCM and bubbling CO through each solution for 10 minutes (see 
Experimental Sections 8.6.5, 8.7.12, 8.8.8 and 8.9.16). The use of IR spectroscopy to 
measure the stretching frequencies of the two resulting carbonyl ligands can be linked to 
the strength of the electron back-donation from the iridium centre. Therefore, the 
electronic properties of the system can be probed. 
For 17, which contains an electron-withdrawing nitro group para to the 
phenoxide bond, the two CO frequencies were at 2065.5 and 1971.9 cm−1. For 18, 
where the NO2 has been replaced by a more electron-donating H atom, the two CO 
stretches were at 2058.3 and 1974.3 cm−1. These correspond to symmetric and 
asymmetric stretching frequencies of the CO ligands. Due to the electron-donating 
characteristics of the carbene and phenolate ligands, electron back-donation occurs 
which strengthens the trans Ir-CO bonds, thereby weakening the C≡O bonds, meaning 
less energy is required to vibrate them. The more electron-donating carbene phenolate 
ligand in 18 results in a slightly lower C≡O frequency of 2058.3 cm−1 compared to the 
strongly electron-withdrawing nitro derivative 17 where νCO is equal to 2065.5 cm−1 as 
less electron density is available on the iridium centre to back donate to the carbonyl 
ligand. The chlorine-containing derivative, 19, shows very similar νCO values to 
complex 18, however, the COOMe derivative, 20, shows the largest deviation in both 
CO stretching frequencies. Figure 86 shows the structure of the complexes on the left, 
with their corresponding IR spectra on the right. From analysing these values, no 
distinct trend is apparent between the electron-donating properties of the phenoxide 
ligand and the corresponding CO stretching frequencies. The CO stretching frequencies 
of each carbonyl ligand are summarised in Table 11, with a more detailed explanation 
of the Hammett parameters and corresponding electronic effects given in Section 3.1. 
The literature values for the CO stretching frequencies of [Ir(IMes)(CO)2Cl] are also 
included in Table 11, showing that the values for the iridium carbonyl complexes 
developed here are very similar to those of an established complex.172 
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Figure 86: The structure of the [Ir(R-NHC-O)(CO)2] complexes developed here (left) and their 
corresponding IR spectra of the CO region (right) 
 
Table 11: Comparisons of the CO stretching frequencies for the four complexes shown in 
Figure 86 along with the literature data for[Ir(IMes)(CO)2Cl] 
Complex R Hammett parameters  
CO stretching 
frequencies / cm−1 
  σp σp−   
17 NO2 0.78 1.27 1971.9 2065.5 
18 H 0.00 0.00 1974.3 2058.3 
19 Cl 0.23 0.19 1974.8 2058.9 
20 COOMe 0.45 0.75 1964.0 2050.2 
[Ir(IMes)(CO)2Cl]172 - - - 1979.8 2066.4 
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2.7. Conclusion 
In this chapter, several new neutral iridium complexes, each containing a 
bidentate carbene with a substituted phenolate side arm, have been described. The 
derivatives contain NO2, COOMe, Cl and H in the trans position to the phenolate. 
Multi-step synthetic routes have been designed to produce the desired complexes, with 
all of them involving the synthesis of an imidazolium bromide salt via a direct 
nucleophilic substitution reaction between mesityl imidazole and the corresponding 
benzyl bromide, to form the carbene precurser. The use of silver(I) oxide produced the 
silver carbene complex which could be easily transmetallated with [Ir(COD)Cl]2 to 
form the desired iridium complexes 1, 2, 3 and 4. In solution, NMR spectroscopy 
reveals the dynamic behaviour of these complexes, commensurate with rapid seven-
membered ring-flipping, detailed for complex 1. 
The reactivity of each complex has been investigated in both dichloromethane 
and methanol, with both the solvent and the substituent lying in the para position to the 
phenolate, having a large effect on the speciation. The stability of the Ir-O bond is also 
greatly affected. 
In CD2Cl2, all four complexes demonstrated limited reactivity with H2 with two 
minor iridium COD dihydride intermediate species being observed for each complex. 
These species form due to the orientation of the seven-membered metallocycle and are 
only visible under PHIP conditions or thermally after a considerable number of scans. 
After longer time periods (several days) and in the presence of pyridine, the COD ligand 
is hydrogenated in all cases and the Ir-O bond is retained, leading to the formation of 
bis-pyridyl dihydride isomers. As the electron-donating ability of the phenolate 
substituent increases and the substituent becomes smaller, the favoured orientation of 
the seven-membered metallocycle changes from the orientation of 6A, where the 
phenolate ring points away from the pyridine ligand, to the orientation of 8, where the 
phenolate ring points towards the pyridine ligand, with 10B and 12B being favoured and 
more thermodynamically stable than 10A and 12A. 
However, in methanol, as the substituent becomes more electron-donating, the 
stability of the Ir-O bond decreases so that for 1, the Ir-O bond is retained, whilst for 2 
the Ir-O bond is completely cleaved. For 4, higher concentrations of pyridine favour Ir-
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O bond cleavage, leading to formation of the tris-pyridyl dihydride species. The reaction 
with pyridine and H2, leading to hydrogenation of COD and formation of the activated 
dihydride complexes is much faster in methanol than CD2Cl2 (hours rather than days), 
as methanol can act to stabilise any intermediates. 
Overall, derivative 2 (H) proved to have much lower stability in comparison to 1 
(NO2) whilst the stability of the two complexes, 3 and 4 with σp− values lying between 
H and NO2 demonstrated intermediate stability. The reactivity of the COOMe 
derivative, 3, was found to be like that of complex 1 due to their Hammett parameters 
being adjacent in the series and consequently, the Cl derivative, 4, was found to share a 
similar behaviour to that of complex 2. The different structures formed in both methanol 
and dichloromethane for each of the four complexes, in order from the most electron-
withdrawing para substituent to the least electron-withdrawing para substituent, are 
summarised in Table 12. 
Table 12: Summary of the major complexes formed when the four pre-catalysts 1, 2, 3 and 4 are 
reacted with pyridine and hydrogen in methanol and dichloromethane 
Pre-
catalyst 
Major product(s) formed with 
pyridine and H2 in CD3OD 
Major product(s) formed with 
pyridine and H2 in CD2Cl2 
1 
 
3 
  
4 
  
2 
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 To compare the electronic effects of the four carbene derivatives, their UV-vis 
spectra were analysed to gain information about the electronic transitions within the 
complexes, giving rise to their individual colours. It was found that all the complexes, 1, 
2, 3 and 4 exhibit charge-transfer bands in the visible region of the spectra. The three 
complexes 2, 3 and 4 all show three bands each, at approximately 380, 430 and 490 nm, 
with molar absorption coefficients of between approximately 300 and 3000 dm3 mol−1 
cm−1. In contrast, 1 only has one band attributable to an intraligand charge-transfer band 
at 406 nm with a much higher molar absorption coefficient of ~ 21000 dm3 mol−1 cm−1. 
A study of the absorption characteristics of 2, shows that these absorption bands exhibit 
no solvatochromism and they are thus assigned as metal d-to-p-orbital transitions. 
Furthermore, reactions of the COD complexes with CO to form carbonyl complexes 
were also investigated which shows that the carbene is more electron-donating than the 
phenolate with the trans CO stretching frequencies lying at ~ 1970 and ~ 2060 cm−1 
respectively. 
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3. Reactivity of neutral bidentate 
iridium carbene complexes 
3.1. Introduction 
Understanding how reactions are affected by the electronic effects of ligand-
based substituents is important when elucidating reaction mechanisms and pathways, 
particularly when the aim is to improve a catalytic system so that it can perform 
optimally. This has been achieved for many different reactions with hydrogenation,173 
palladium-catalysed cross-coupling174 and carbonylation175-176 being three such 
examples. Focusing on hydrogenation, a review by Wang et al.173 discusses the large 
variety of homogeneous transition metal catalysts used to promote transfer 
hydrogenation reactions. Several tetradentate PNNP iron-based complexes are active, as 
shown in Figure 87, where modification of the backbone, by increasing the size of 
substituents bound to the N-centred ligands, increases catalytic activity.177 Further 
tunability can be achieved by changing the phosphorus atom substituents. There are also 
examples of transition metal complexes, using ruthenium, rhodium and iridium, with an 
iridium-containing example shown in Figure 87, which contain NHC ligands, where the 
nature of the groups on the imidazole moiety strongly affects the subsequent reactivity 
of the catalyst. 
 
Figure 87: Examples of Fe-PNNP catalysts, for transfer hydrogenation of acetophenone, and 
half-sandwich Ir-NHC complexes used for transfer hydrogenation of ketones and imines, with 
different derivatives providing different activities in each reaction173 
One transition metal which is very widely used to achieve organic 
transformations is palladium, particularly for carbonylation and cross-coupling 
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reactions. The field of cross-coupling has grown significantly over the last couple of 
decades, with the Nobel Prize in 2010 being awarded to Heck, Negishi and Suzuki for 
their contributions.178-179  
Commonly combined with phosphine ligands, the palladium catalysts produced 
are often stable, versatile and their reactivities are often tuneable, due to the wide range 
of phosphine ligands that are available. A review by Gildner et al.174 describes the 
importance of mono and bidentate phosphine ligands in palladium catalysis and how 
both the steric and electronic properties of the ligands can affect catalytic activity. 
Phosphine ligands discussed include commonly used PPh3, PCy3, P
tBu3 and the pincer 
ligands diphenylphosphinoethane and diphenylphosphinoferrocene along with the tert-
butyl and iso-propyl derivatives. One typical phosphine ligand structure used for cross-
coupling174 and carbonylation175-176 reactions is based on a biphenyl core, derivatised 
with a phosphine which can then bind to the metal centre. Further substituents on the 
biphenyl core are used to tune the catalyst so that it has the desired reactivity. These 
ligand types were developed by Buchwald and several examples are shown in Figure 
88.174, 176 A review by Gildner et al.174 shows how changing the substituents on the 
phosphine ligand affects the catalyst’s ability to couple unstable fluorine-containing 
boronic acids with activated aromatic rings. 
 
Figure 88: Palladium complexes used for cross-coupling boronic acids with an aromatic moiety 
containing a suitable leaving group, and the range of substituted Buchwald phosphine ligands 
that can be used174 
More recently, NHC ligands have been used in place of phosphine ligands, due 
to them being more robust and having stronger σ-donor capabilities. In 2014, Fang et 
al.176 published a review of palladium NHC complexes for cross-coupling reactions, 
with four examples shown in Figure 89. NHCs can exert a larger effect on the 
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coordination sphere of an active metal catalyst, when compared to phosphine ligands, 
due to their structure encasing the metal centre rather than forming a cone directed away 
from the metal centre, such as occurs with phosphine ligands.176 
 
Figure 89: Pd-NHC complexes used in cross-coupling reactions as described by Fang et al.176 
Several studies which are of direct relevance to this project, are now described. 
One study, in 2004, by Hu et al.,180 reports on a ruthenium-based catalyst that showed 
high enantioselectivities for the asymmetric hydrogenation of β-aryl ketoesters as 
shown in Figure 90. 
 
Figure 90: Asymmetric hydrogenation of β-aryl ketoesters using [RuCl2(4,4’-(R)-BINAP)] 
catalysts containing a number of different R groups180 
Here, the electronic and steric properties of several 4,4’-substituted BINAP 
derivatives were investigated. The highest enantioselectivities were achieved using the 
most sterically demanding ligands with electron-donating substituents in the four 
position whereas the introduction of phenyl substituents was found to decrease the 
selectivity. This behaviour was rationalised in terms of the stabilisation of a transition 
state; bulky groups repel the phenyl of the β-aryl ketoester substrates and thus 
destabilise the transition state, whereas π-π stacking interactions between phenyl rings 
on the catalyst and substrate stabilise the transition state. This work shows how 
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dramatic selectivity effects can easily be achieved by slight modification of a catalyst 
backbone, and how harnessing the power of catalyst optimisation can allow the 
development of highly useful and effective systems. 
The effect of electron-donating and withdrawing substituents on reaction rates is 
demonstrated in the following example. It features a study, by Zhao et al., of substituent 
effects on the rate of β-hydrogen elimination from some square planar alkoxo-
containing iridium complexes, [Ir(OR)(CO)(PPh3)2] (Figure 91).
181 The R group of the 
alkoxide contains a benzene ring with para substituents varying from an electron-
donating methoxy group to an electron-withdrawing trifluoromethyl group. 
 
Figure 91: Iridium alkoxo complexes and the β-hydrogen elimination reaction (Adapted with 
permission from Zhao, J.; Hesslink, H.; Hartwig, J. F. J. Am. Chem. Soc. 2001, 123, 7220. 
Copyright © 2001 American Chemical Society)181 
One classic way of viewing said effects is through the use of Hammett 
parameters. In the 1930s, Louis Hammett was interested in the relationship between 
reaction rates and equilibrium constants for a number of organic reactions.182-183 The 
specific reaction he focused on was the hydrolysis of benzoic ester derivatives 
containing a variety of substituents in the para position to the ester group on the ring, as 
shown in Figure 92. Using these compounds excluded competing steric effects that arise 
when using ortho substituted compounds. He analysed the hydrolysis rate of each 
benzoic acid derivative and compared them to the pKas of the corresponding acids. He 
noticed that a distinct correlation was present between the pKas of the derivatives and 
the electronic properties of the para substituent on the ring. He thus denoted a new 
parameter, σp, as detailed in Figure 92. This relates the electron-donating or 
withdrawing capabilities of a substituent, relative to H, to the ratio of the logKas of the 
substituted species and benzoic acid. Negative σp values correspond to electron-
donating substituents and positive σp values correspond to electron-withdrawing 
substituents. 
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𝜎𝑝 = 𝑙𝑜𝑔
𝐾𝑎(𝑅𝐶6𝐻4𝐶𝑂𝑂𝐻)
𝐾𝑎(𝐶6𝐻5𝐶𝑂𝑂𝐻)
= 𝑝𝐾𝑎(𝐶6𝐻5𝐶𝑂𝑂𝐻) − 𝑝𝐾𝑎(𝑅𝐶6𝐻4𝐶𝑂𝑂𝐻) 
Figure 92: Ester hydrolysis reaction studied by Hammett and the subsequent equation used to 
calculate corresponding σp values for substituents, R
182-183 
The Hammett parameter, σp, can be used in the determination of reaction 
mechanisms. When a reaction is studied using a series of compounds with different 
substituents, a plot of the corresponding σp values against log(kR/kH) gives a straight 
line, with the gradient, ρ, giving an indication of the sensitivity of the reaction to a 
change in the electronics of a substituent. When ρ is positive, the mechanism involves a 
build-up of electron density in the transition state compared to the starting material. 
Conversely, when ρ is negative there is a decrease in electron density in the transition 
state.  
Since Hammett first described the parameter σp, two modified versions have 
been developed. This is because when para substituents are conjugated with the 
reaction centre, enhanced resonance effects can be observed. The two modified values 
which are used to describe this effect are σp+ (for substituents that stabilise positive 
charges via resonance) and σp− (for substituents that stabilise negative charges via 
resonance). The σp− values are based on the ionisation of substituted phenols as shown 
in Figure 93 and they are applicable to the electron-withdrawing substituents used in 
this work, as detailed in Section 2.1. This is because as the electron-withdrawing 
capability of the para substituent decreases, more electron density is available to add 
into the metal centre via the increased electron density on the phenolate oxygen. This 
should lead to an increase in the rates of ligand loss from the complex and subsequent 
ligand exchange as mentioned in Section 2.4. However, the resonance effect may also 
lead to a change in the Ir-O bond length and influence the conformation of the seven-
membered metallocycle. This may contribute to a change in entropy and thus lead to 
other changes within the system, such as in the carbene interaction. 
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Figure 93: The ionisation of substituted phenols used to calculate the corresponding Hammett 
values, σp
−, for substituents, R, where the same equation as shown in Figure 92 is used145 
The study shown in Figure 91 investigated four different substituents, H, OMe, 
Cl and CF3 with their corresponding Hammett parameters detailed in Table 13. The 
study demonstrates that as the substituent becomes more electron-donating, the rates of 
β-hydrogen elimination increase. The Hammett plot in Figure 94 gives a ρ value of 
−0.94 which signifies a decrease in electron density in the transition state of the reaction 
which is consistent with the mechanism proceeding via PPh3 dissociation to form the 
14-electron Ir(I) transition state. This is followed by β-hydrogen elimination via 
activation of the C-H bond which is favoured when electron-donating substituents can 
increase the electron density on the proton that becomes the hydride.181 Subsequent 
associative substitution using PPh3, releases the ketone product. This shows that the 
para substituent can have a large effect on the electron density of atoms that are 
multiple bonds away. 
Table 13: Iridium alkoxo complexes with different R groups, their Hammett parameters, σp, and 
rates of β-hydrogen elimination (Adapted with permission from Zhao, J.; Hesslink, H.; Hartwig, 
J. F. J. Am. Chem. Soc. 2001, 123, 7220. Copyright © 2001 American Chemical Society)181 
Complex R substituent Hammett parameter, σp Elimination rate / kobs / x 104 
A H 0.00 3.5 
B OMe −0.27 7.3 
C Cl +0.23 2.0 
D CF3 +0.54 1.2 
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Figure 94: Hammett plot for β-hydrogen elimination from complexes A to D detailed in Table 
13 (Reprinted with permission from Zhao, J.; Hesslink, H.; Hartwig, J. F. J. Am. Chem. Soc. 
2001, 123, 7220. Copyright © 2001 American Chemical Society)181 
Overall, these studies demonstrate the importance of selecting the right ligand 
substituents. This can be related to the complexes developed here, where the change 
from a para NO2 group to a para H group on the phenolate ring of the bidentate NHC 
has a large effect on the iridium centre, leading to the varied speciation observed. In this 
chapter, the full activation pathway is analysed, along with an understanding of the 
complicated mechanisms of ligand exchange that the different active species undergo. 
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3.2. Elucidation of the reaction pathway and 
reactivity of complex 6  
In Section 2.4.1, the reactivity of 1 with pyridine and hydrogen to form complex 
6, containing two hydride ligands, two pyridine ligands and the bidentate carbene 
ligand, has been described. Here, a more detailed study into the route to form 6 from 1 
via 5 was completed to identify any other reaction intermediates on the pathway to 
COD hydrogenation, as the 1H NMR spectrum shown in Figure 95, shows other hydride 
species at δ −24.83 and −26.50, in addition to those of 6 (at ~ δ −22 and −29).  
 
Figure 95: The hydride region of the 1H NMR spectrum of a solution containing 1, pyridine and 
hydrogen in CD2Cl2 at 298 K after activation for 48 hours 
The signals at δ −24.83 and −26.50 both show nOe interactions with the carbene 
backbone and possible bound COD or COE. They do not show any nOe interaction with 
pyridine but are also not formed in the absence of pyridine, therefore, pyridine must 
play an important role in stabilising these potentially unstable intermediates and aiding 
the formation of stable 18-electron species. Their very low concentrations precluded any 
further characterisation. Furthermore, these singlet hydride signals disappear over time 
and their chemical shifts are temperature independent. Very similar singlet hydride 
signals have been observed upon activation of the other complexes, 2, 3 and 4 with 
pyridine and hydrogen, as detailed in Sections 2.4.2 and 2.4.3. Overall, these 
observations suggest that these hydride ligands are due to two monohydride isomers of 
the complex undergoing COD hydrogenation, formed after hydride migration, with the 
hydride at δ −24.83 being trans to the nitrogen atom of the bound pyridine ligand and 
the hydride at δ −26.50 being trans to the oxygen ligand of the carbene as depicted in 
Figure 96. These structures could be confirmed by identifying 15N-H couplings if 15N-
pyridine were to be used, with such an example being described by Martin et al. in 
2003.158 A full summary of the route to activation of 1 with pyridine and hydrogen is 
given in Figure 96.  
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Figure 96: Products formed by the reaction of 1 with pyridine and H2 
Overall, the activation pathway is very different to that described for 
[Ir(COD)(IMes)Cl] as no ligand displacement occurs so no complex equivalent to 
[Ir(COD)(IMes)(py)]Cl forms. Instead the bidentate complex remains neutral. 
Furthermore, H2 addition occurs directly to 1 whereas the H2 addition route which 
forms the active catalyst [Ir(H)2(IMes)(py)3]Cl is via [Ir(COD)(IMes)(py)]Cl, as that 
route is faster than the direct addition of H2 to [Ir(COD)(IMes)Cl].
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3.2.1. Hydride signals for complex 6 in CD2Cl2 
On cooling a solution of 6 in CD2Cl2, its two hydride signals exhibit temperature 
dependence as detailed in Section 2.4.1. At 233 K, both signals separate to form two 
pairs of doublet hydride signals with the major isomer, 6A, at δ −21.35 and −28.88 
(2J(HH) = 8.7 Hz) and the minor isomer, 6B, at δ −22.68 and −29.02 (2J(HH) = 7.0 Hz) 
with relative intensity 83: 17. This is exemplified in Figure 97 and is due to the 
existence of two conformational isomers of 6, where the carbene backbone orientation, 
either at the oxygen link or the CH2 linker, differ.
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Figure 97: 1H NMR spectra of the two main hydride signals for 6 showing how the peaks 
resolve as the temperature is decreased from 303 to 223 K. The rate of interconversion between 
the two conformers, 6A and 6B (drawn above) is slowed which leads to the peak resolution 
At 233 K, the 2D 1H NOESY NMR spectrum shown in Figure 98 shows that 
site-specific exchange occurs between the two conformers (blue) and that the hydride 
signals are linked via nOe interactions (red). This nOe effect is only visible between the 
two hydrides of the same complex at 233 K. This site-specific exchange is also 
observed for the two pairs of bound pyridine ligands as labelled in Figure 97; py1 
exchanges with py1’ and py2 exchanges with py2’ but at 233 K no exchange is observed 
between the two different bound pyridine sites. The formation of two conformational 
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isomers is consistent with Ir-O bond retention and differing orientations of the 
metallocycle so the exchange processes detailed here are due to intramolecular ring-flip. 
 
Figure 98:  2D 1H NOESY NMR spectrum at 233 K showing both nOe interactions (red) and 
exchange (blue) between the hydride resonances of the two conformational isomers of 6 
Analysis of data collected in a series of 1H EXSY NMR experiments at 233 K 
enabled calculation of the interconversion rates between HA (major isomer, 6A) and HA’ 
(minor isomer, 6B), using the kinetic model detailed in Figure 99. The exchange rates 
between HB and HB’ could not be calculated due to their small difference in chemical 
shift.  
 
[𝟔𝑨]𝑡 = [𝟔𝑨]0 − 𝑘𝐴−𝐴′[𝟔𝑨]𝑡 + 𝑘𝐴′−𝐴[𝟔𝑩]𝑡 
[𝟔𝑩]𝑡 = [𝟔𝑩]0 + 𝑘𝐴−𝐴′[𝟔𝑨]𝑡 − 𝑘𝐴′−𝐴[𝟔𝑩]𝑡 
Figure 99: Kinetic model for the conversion between the major isomer 6A and the minor isomer 
6B assuming a simple intramolecular interconversion 
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These 1H EXSY NMR experiments involve selectively irradiating HA and then 
HA’. The percentage proportion of each isomer is then calculated after ten different 
mixing times, from 0.005 s to 0.350 s (see Table 14). When selectively irradiating the 
hydride signal at δ −21.35, the exchange rate for conversion of HA into HA’ was 
calculated to be 4.00 ± 0.08 s−1 and an estimate of the back reaction was given as ~ 20 
s−1. When selectively irradiating the hydride signal at δ −22.68 the exchange rate for 
conversion of HA’ into HA was calculated to be 19.8 ± 0.3 s
−1 and an estimate of the 
back reaction was given as ~ 5 s−1. These exchange rate values are very similar and 
show that the major isomer converts slowly to the minor isomer and therefore this 
process is unfavourable, but once it has converted, it rapidly converts back. This can be 
rationalised in terms of unfavourable steric clashes between the NO2-substituted 
aromatic ring of the carbene and the pyridine ligand that is bound trans to a hydride 
ligand in complex 6B. In complex 6A this is minimised as the NO2-containing ring now 
points towards the much smaller hydride ligand on the complex. 
Table 14: 1H EXSY NMR data for the percentage signals present for either 6A or 6B after 
selectively exciting the indicated hydride signal at 233 K 
Selective irradiation δ −21.35 δ −22.68 
Mixing time / s [HA] / % [HA'] / % [HA] / % [HA'] / % 
0.005 97.91 2.09 90.37 9.63 
0.010 96.19 3.81 82.90 17.10 
0.050 88.42 11.58 43.77 56.23 
0.070 86.38 13.62 33.73 66.27 
0.100 85.01 14.99 26.70 73.30 
0.150 83.97 16.03 22.60 77.40 
0.200 83.76 16.24 21.21 78.79 
0.250 83.54 16.46 20.76 79.23 
0.300 83.57 16.43 20.42 79.58 
0.350 83.59 16.41 20.75 79.25 
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Figure 100: Plot showing the conversion of 6A into 6B upon the selective excitation of HA 
 
Figure 101: Plot showing the conversion of 6B into 6A upon the selective excitation of HA’ 
The two complexes 6A and 6B interconvert by a ring-flip process and the 
difference between them is only observed at low temperature when the rate of ring-flip 
is decreased. However, isomer exchange can also occur without the ring-flip occurring, 
after the exchange of a pyridine ligand and is observed at higher temperatures, as 
hypothesised in Section 3.2.3. A summary of the possible complexes present in 
solutions of these dihydride complexes is given in Figure 102. The relative orientations 
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of the CH2 linker protons are indicated and they point either towards or away from the 
oxygen depending on the orientation of the seven-membered metallocycle. 
 
Figure 102: Summary of possible isomer forms present for the bidentate iridium carbene 
dihydride complexes in solution and the intermediate that occurs on pyridine dissociation 
For these complexes when the substrate is pyridine, A and A’ are equivalent and 
B and B’ are equivalent, as pyridine is not chiral. For conversion between A and A’ or 
B and B’, pyridine loss is followed by ring-flip and subsequent rebinding of pyridine on 
the opposite side of the phenolate arm. This process leads to hydride interconversion 
between HA and HB on the same complex, with the 
1H NMR chemical shifts for these 
hydride ligands being at approximately δ −22 and −28 respectively. The equilibrium 
between A and B or A’ and B’ is due to ring-flip being the only process in operation 
and this leads to interconversion between the pyridine and hydride ligands on different 
complexes as described for 6A and 6B at low temperature. The final mechanism for 
conversion between A and B’ or A’ and B results from pyridine loss and subsequent 
rebinding of pyridine on the opposite side of the phenolate arm, but without the ring-flip 
process occurring. It is predicted that A and A’ are the most stable isomers as in this 
orientation, the metallocycle forces the aromatic ring containing the substituent to point 
away from the pyridine ligand. In both B and B’, the orientation means that the aromatic 
ring is always pointing towards the pyridine ligand. These mechanistic steps and 
exchange processes will be further considered when the other complexes, 2, 3, and 4 are 
analysed. 
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3.2.2. Ligand exchange rate analysis for 6 
At 298 K, the 2D 1H NOESY NMR spectrum shown in Figure 103 shows that 
the two hydride signals for complex 6 undergo reversible exchange as well as exchange 
with H2 in solution. The pyridine ligand in the trans position to a hydride ligand also 
undergoes exchange at 298 K, with free pyridine in solution. Now the minor isomer 
exchange is very rapid so the signals for 6A and 6B are averaged to those of 6. 
 
Figure 103: 2D 1H NOESY NMR spectrum at 298 K showing hydride ligand exchange in 6 
These exchange processes are essential for efficient SABRE and hydrogenation 
catalysis as fresh hydrogen and substrate ligands must bind to the metal centre. Pyridine 
substrates must undergo exchange with free pyridine in order for polarisation to transfer 
and be observed in the free substrates, and to refresh the polarisation source the hydride 
ligands have to exchange with free parahydrogen in solution. The exchange rates for 
these processes were calculated at 298 K in CD2Cl2 using 
1H EXSY NMR experiments 
as previously described in Section 3.2.1. It is important to optimise the ligand exchange 
rates so the catalysis can be optimised as is typically the case for catalytic reactions. For 
this system, using 6, the exchange between free pyridine and both pyridine sites were 
first calculated. For a sample containing 4 mol% 1 and 0.65 M pyridine, only the 
pyridine trans to the hydride exchanged with free pyridine on the NMR timescale with 
an experimental rate constant of 0.28 ± 0.03 s−1 and the pyridine cis to the hydrides did 
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not exchange. This was consistent with the fact that in the 1H NMR spectrum, the 
signals for py2 are better resolved than the signals for py1 as also mentioned in Section 
2.4.1. In the same sample at 298 K, the hydride signal at δ −28.88 was selectively 
excited as the signal at δ −21.8 was too broad to accurately monitor. The hydride 
dissociation rate to form H2 was 0.067 ± 0.002 s
−1, with the rate of hydride 
interconversion shown to be 0.79 ± 0.02 s−1. 
Previous studies examine these exchange processes in methanol, as it is the most 
effective solvent to use with charged complexes such as [Ir(H)2(IMes)(py)3]Cl. 
However, when CD3OD was used, hydrogen-deuterium exchange between complex 6HH 
and deuterium from the deuterated solvent occurred. This affects the hydrogenation 
potential of the system as deuterium atoms are introduced into a species rather than 
hydrogen atoms. Thus, the product identity is modified. At 243 K, in CD3OD the two 
hydride ligands of 6HH are visible as no H-D exchange on the NMR timescale occurs at 
this temperature. On warming to 270 K, the hydride signal at δ −29.22 exchanges with 
deuterium to form complex 6HD, containing one deuteride and one hydride ligand. The 
proportions of H-H complex vs H-D complex were obtained by integration and the 
concentrations as a function of time are shown in Figure 104. The rate of incorporation 
of deuterium into 6HH, was calculated to be (4.24 ± 0.06) x 10−5 s−1 and is thus very 
slow. On warming to 298 K the rate of deuterium incorporation increases to (8.19 ± 
0.08) x 10−4 s−1 which is approximately 20 times faster than the same process at 270 K. 
 
Figure 104: The proportions of 6HH and 6HD determined by integration, on analysing the 
deuterium incorporation into the hydride signal of 6HH at δ −29.22 at 270 K in CD3OD 
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It should be noted that an amount of complex 6 will also be present as the D-D 
complex, 6DD, which is not apparent in the hydride region of the 1H NMR spectra. 
However, as deuterium incorporation into 6 to form the H-D species is slow it is 
anticipated that the second incorporation of a deuterium atom to form the D-D species 
would also be very slow and not visible on the timescale studied here. It would be 
possible to analyse the relative amounts of the complexes, 6HH, 6HD and 6DD by studying 
the pyridine region of the 1H NMR spectra of these reactions. However, due to the small 
amounts of the different species, their continual exchange and overlapping signals, this 
was beyond the scope of this study. 
 When CD3OD was replaced with CD3OH, a more accurate analysis of the 
hydride-hydrogen exchange process was possible, due to inhibition of the hydride 
deuteration. For a CD3OH sample containing 9 mol% 1 and 0.05 M pyridine under H2, 
the rate of pyridine dissociation trans to the hydride ligand was 0.79 ± 0.04 s−1, again 
consistent with the signals for py2 in the 
1H NMR spectrum being more resolved than 
the signals for py1. In comparison to the pyridine dissociation rate constant of 11.7 s
−1 
per mole of pyridine when using [Ir(COD)(IMes)Cl],88 the rate here is considerably 
slower which explains why [Ir(COD)(IMes)Cl] is a better catalyst for SABRE. The rate 
of hydride interconversion was 2.05 ± 0.06 s−1 with an H2 loss rate of 0.33 ± 0.02 s
−1. 
Another important factor that affects catalytic activity is the reaction 
temperature. CD3OH was a suitable solvent to use for these studies, due to its higher 
boiling point compared to CD2Cl2. Thus, activation parameters for the pyridine and 
hydrogen dissociation steps and the hydride interconversion process detailed in Section 
3.2.3 were calculated by analysing the ligand exchange rates at increasing temperatures 
from 278 K to 303 K (see Table 15). Table 15 also details the calculated lifetimes for 6 
in CD3OH at each temperature. The lifetime of the complex is directly related to the rate 
of pyridine dissociation in solution. Therefore, for the same sample of 6 in CD3OH, 
where the pyridine dissociation rate was 0.79 ± 0.04 s−1, the lifetime of 6 was 1.28 ± 
0.05 s.  
𝐿𝑖𝑓𝑒𝑡𝑖𝑚𝑒 =  
1
𝑛 × 𝑝𝑦𝑟𝑖𝑑𝑖𝑛𝑒 𝑑𝑖𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒
 
where n = number of pyridine 
ligands that can dissociate 
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Table 15: Exchange rate and lifetime data for pyridine and H2 dissociation and hydride 
interconversion at the specified temperatures in a CD3OH sample containing 6 mol% 1 and 
0.08 M pyridine (HB δ −29.2 and HA δ −21.6) 
T / K 
Rate of pyridine 
dissociation / s−1 
Rate of H2 
dissociation from 
HB / s−1 
Rate of hydride 
interconversion 
from HB to HA / s−1 
Lifetime of 
active 
complex / s 
278 0.17 ± 0.02 0.09 ± 0.02 0.19 ± 0.02 5.88 ± 0.69 
283 0.29 ± 0.11 0.11 ± 0.01 0.52 ± 0.04 3.45 ± 1.31 
288 0.53 ± 0.04 0.19 ± 0.03 1.09 ± 0.11 1.89 ± 0.14 
293 0.83 ± 0.02 0.36 ± 0.03 1.84 ± 0.16 1.20 ± 0.02 
298 1.33 ± 0.23 0.54 ± 0.03 2.86 ± 0.18 0.76 ± 0.13 
303 2.52 ± 0.30 0.96 ± 0.06 3.59 ± 4.25 0.40 ± 0.04 
 
Here, the higher temperatures cause faster pyridine exchange and decrease the 
lifetime of 6. Activation parameters from Arrhenius and Eyring-Polanyi analyses are 
summarised in Table 16 with the Eyring-Polanyi plot in Figure 105. The rate for 
hydride interconversion at 303 K was excluded from the analysis due to its large error. 
The Eyring-Polanyi plot shows that the pyridine and hydrogen dissociation processes 
occur with a common gradient for their activation parameters. Therefore, these two 
processes are linked, with pyridine loss preceding H2 loss which must occur to create 
the 16-electron intermediate with a vacant site for fresh p-H2 binding (see Section 
3.2.3). However, the gradient for the activation parameters for the hydride 
interconversion process is slightly different, consistent with this process being affected 
by not only the pyridine dissociation, but also by another pathway, as indicated by the 
hydride interconversion rates being faster than the pyridine dissociation rates. Other 
possible exchange pathways to explain this are described in Section 3.2.3. The values 
for the activation enthalpy for pyridine and H2 dissociation are very similar within error, 
with the hydride interconversion process exhibiting a larger activation barrier. The 
values for the activation entropy demonstrate large errors and so it is impossible to state 
whether the process is dissociative or otherwise. For hydride interconversion, the 
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slightly lower Gibbs Free Energy value is commensurate with this process having faster 
exchange rates and being the most favourable process. 
Table 16: Activation parameters calculated from the Arrhenius and Eyring-Polanyi plots for 
pyridine and H2 dissociation and hydride interconversion for a CD3OH sample containing 6 
mol% 1 and 0.08 M pyridine under H2 
  
Ea / ΔHǂ / 
kJ mol−1 
ΔSǂ / J K−1 
mol−1 
R2  
ΔGǂ (300 K) 
/ kJ mol−1 
Pyridine 
dissociation 
Arrhenius  73.5 ± 3.3 - 0.9966 - 
Eyring-Polanyi  71.1 ± 3.3 2.4 ± 11.5 0.9964 70.4 ± 0.2 
Hydrogen 
dissociation 
Arrhenius  69.9 ± 7.3 - 0.9862 - 
Eyring-Polanyi 67.5 ± 7.3 −17.3 ± 24.7 0.9853 72.7 ± 0.2 
Hydride 
inter-
conversion 
Arrhenius  91.7 ± 14.4 - 0.9787 - 
Eyring-Polanyi 89.3 ± 14.4 70.5 ± 50 0.9775 68.2 ± 0.6 
 
 
Figure 105: An Eyring-Polanyi plot for pyridine and H2 dissociation and hydride 
interconversion as a function of temperature, for a CD3OH sample of 6 mol% 1 and 0.08 M 
pyridine under H2  
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3.2.3. Mechanistic studies to determine the effect 
of pyridine concentration on ligand exchange 
in 6  
To understand the full reaction mechanism that leads to the SABRE effect, 
studies on the pyridine and hydride exchange processes occurring in 6 were conducted 
in both CD2Cl2 and CD3OH. These ligand exchange rates, calculated at different 
pyridine concentrations in CD2Cl2 and CD3OH are shown in Table 17 and depicted 
graphically in Figure 106 and Figure 107.  
Table 17: Rates of pyridine and hydride ligand dissociation from 6 in CD2Cl2 at 298 K and in 
CD3OH at 294 K as a function of increasing equivalents of pyridine 
CD2Cl2: py 
equivalents by 
integration 
Rate of py 
loss / s−1 
Rate of H2 
loss / s−1 
Rate of hydride interconversion 
from δ −28.88 (HB) to −21.76 
(HA) / s−1 
15 0.28 ± 0.03 0.079 ± 0.001 0.72 ± 0.01 
25 0.28 ± 0.03 0.067 ± 0.002 0.79 ± 0.02 
30 0.31 ± 0.01 0.053 ± 0.002 0.78 ± 0.02 
50 0.28 ± 0.03 0.042 ± 0.002 0.74 ± 0.02 
CD3OH: py 
equivalents by 
integration 
Rate of py 
loss / s−1 
Rate of H2 
loss / s−1 
Rate of hydride interconversion 
from δ −29.22 (HB) to −21.62 
(HA) / s−1 
6 0.83 ± 0.06 0.850 ± 0.110 2.02 ± 0.11 
10 0.79 ± 0.04 0.330 ± 0.016 2.05 ± 0.06 
15 0.78 ± 0.02 0.230 ± 0.015 2.07 ± 0.05 
20 0.80 ± 0.02 0.162 ± 0.004 2.09 ± 0.08 
25 0.76 ± 0.04 0.092 ± 0.002 2.06 ± 0.08 
30 0.72 ± 0.01 0.072 ± 0.004 2.07 ± 0.08 
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Figure 106: The rates of pyridine and hydride loss from 6 in CD2Cl2 in relation to the number 
of equivalents of pyridine added, calculated by integration. The data for pyridine loss and 
hydride interconversion are on the left scale and the data for H2 loss are on the right scale 
 
Figure 107: The rates of pyridine and hydride loss from 6 in CD3OH in relation to the number 
of equivalents of pyridine added, calculated by integration. The data for pyridine and H2 loss 
are on the left scale and the data for hydride interconversion are on the right scale 
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For a successful catalytic system, it is imperative to know how changing 
concentrations affects the cycle as this can change its efficiency. In both CD2Cl2 and 
CD3OH the rate of pyridine dissociation was found to be independent of pyridine 
concentration. However, the addition of pyridine inhibits hydrogen loss, as the rates of 
hydrogen loss decreased upon addition of pyridine. The decrease in hydride dissociation 
rate relates to complex 6 being more likely to rebind a pyridine ligand than lose 
hydrogen when there is a larger excess of pyridine in solution. Therefore, for most 
efficient hydrogen reactivity, low concentrations of substrate should be used.  
The negative effect of pyridine concentration on H2 loss rate means that the 
process of pyridine dissociation precedes H2 loss and is therefore consistent with 
previous studies where the loss of a substrate produces a 16-electron intermediate where 
the hydride ligands are equivalent.88, 94 Several stable 16-electron iridium(III) dihydride 
species have been described in the literature, which are stabilised by phosphine-derived 
pincer ligands, such as PCP and PNP. Four examples are depicted in Figure 108, 
described by Rimoldi et al.,184 Gottker-Schnetmann et al.185-186 and Choualeb et al.187 
 
Figure 108: Four examples of stable 16-electron iridium dihydride species containing pincer 
ligands184-187 
The binding of hydrogen to the 16-electron species formed on loss of substrate, 
leads to the formation of an important dihydride-dihydrogen intermediate as predicted 
by DFT for the complex [Ir(H)2(H2)(IMes)(py)2]Cl.
88 Other similar “Ir(H)2(H2)” species 
have been described by Mediati et al. containing phosphine ligands, as shown in Figure 
109, which undergo facile exchange due to the low energy barrier of interconversion.188-
192 There are also a number of analogous pincer complexes where hydrogen addition to 
the dihydride complex leads to formation of the “Ir(H)2(H2)” complexes. Some 
examples are shown in Figure 109. Studies of the [(PCP)IrH4] and [(POCOP)IrH4] 
complexes, by Hebden et al.,193 indicate that in solution phase NMR spectra, they are 
present as dihydride-dihydrogen complexes whereas solid state methods show 
tetrahydride species. This is consistent with low energy barriers to interconversion. 
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Computational studies of the cyclohexyl-based pincer complex in Figure 109 also show 
a low energy difference of only 0.59 kJ mol−1 between the lower-lying tetrahydride 
species and the dihydride-dihydrogen complex.194 Hauger at al.195 have also described 
the rapid exchange process that occurs on addition of H2 to [Ir(H)2Br(P
tBu2Ph)2] such 
that the fluxionality of the addition product, [Ir(H)2Br(H2)(P
tBu2R)2], means it is 
unobservable. 
 
Figure 109: Iridium dihydride-dihydrogen complexes which undergo facile hydride-hydrogen 
interconversion189, 193-195 
When the 18-electron dihydride-dihydrogen intermediate loses H2, pyridine can 
rebind; if pyridine does bind, then there is an equal chance of the hydride ligands either 
swapping or retaining their positions, depending on which side of the bidentate carbene 
the pyridine ligand enters from. This hydride interconversion process is labelled 
‘Hydride interconversion route A’ in Figure 114. The rate of hydride site 
interconversion is dependent on the rate of pyridine loss and rebinding to the complex. 
If the rate of pyridine loss is subtracted from the hydride site interconversion rate, then 
the rate that remains corresponds to a different process that also enables hydride site 
interconversion to occur, without pyridine loss. Several competing pathways could be 
envisaged; 
1. Pseudorotation mechanisms such as Berry pseudorotation and turnstile 
rotation196-197 are common for penta-coordinated metal centres but due to the 
greater stereochemical rigidity of octahedral complexes these typically do not 
occur. When one of these rotation mechanisms does occur, it results in changing 
the two ‘axial’ ligands with two of the ‘equatorial’ ligands so that the ligands 
which were originally in a trans position to each other end up in a cis 
configuration as shown in Figure 110 for PF5.
198 This is prevented from 
occurring in complex 6 due to the rigid binding of the chelating ligand. 
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Figure 110: Demonstrating the Berry pseudorotation mechanism occurring in trigonal 
bipyramidal PF5, which exchanges the axial F ligands with two of the equatorial F ligands via a 
square-based pyramidal intermediate198 
2. Trigonal twist mechanisms such as the Bailar twist199 or Ray-Dutt twist200-202 are 
possible although these typically occur for complexes containing three bidentate 
ligands. The binding atoms of the sets of bidentate ligands exchange places, thus 
interconverting two chiral isomers. This is shown in Figure 111 for tris-chelated 
aluminium complexes containing α-isopropenyltropolonate or α-
isopropyltropolonate ligands described by Amati et al.,203 where their 
computational study has shown that both the Bailar and Ray-Dutt twist 
mechanisms are possible. In complex 6, these trigonal twist mechanisms would 
also lead to conversion of the other sites within 6 and since it has been shown in 
Section 3.2.2 that the pyridine ligand trans to the carbene ligand does not 
undergo any exchange, these processes are not feasible. 
 
Figure 111: Bailar and Ray-Dutt twist mechanisms for interconversion of tris-chelated 
aluminium complexes containing α-isopropenyltropolonate or α-isopropyltropolonate ligands 
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3. Elimination and rebinding of one hydride ligand via the dihydrogen bonded 
system, IrH---HO, could occur due to the presence of the Ir-O group. However, 
in protio solvents such as methanol, very rapid H/D exchange happens and thus 
if this elimination mechanism occurred it is predicted to be unobservable. A 
number of transition metal complexes exist where a hydride ligand acts as a 
proton acceptor and hydrogen bonds to a proton donor. Commonly these are NH 
or OH bonds, where short distances of approximately 2 Å between the hydride 
ligand and NH/OH functionality204-205 indicate hydrogen bonding and they can 
be either inter or intramolecular. Some complexes exhibiting intramolecular 
hydrogen bonding are shown in Figure 112. These complexes typically 
demonstrate reversible exchange between the dihydrogen form of the complex 
and can undergo elimination of H2 as also shown in Figure 112. 
 
Figure 112: Iridium complexes containing dihydrogen bonded functionalities205-207 and the 
reactivities of two specific examples showing H2 loss
208 and hydride-hydrogen 
interconversion209-210 
As these processes have been ruled out because of the reasons described, the 
extra hydride site interconversion process can be considered as intramolecular, 
proceeding via the formation of a dihydrogen complex and subsequent rotation of the 
dihydrogen ligand. It is known that complex 6 can activate dihydrogen to form a 
dihydride complex, due to the electron rich nature of the dihydrogen molecule in 
comparison to the electron poor iridium metal centre. Therefore, it is feasible that a 
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similar dihydride-dihydrogen exchange process could occur to form a dihydrogen 
complex from 6 as shown for ‘Hydride interconversion route B’ in Figure 114. 
Furthermore, as 6 is an efficient SABRE catalyst, which will be discussed in the next 
chapter, the lifetime of the dihydrogen species must be very short so as not to destroy 
the p-H2. This interconversion route must be rapid to allow the hydride interconversion 
rates to be faster than the pyridine dissociation rates. 
Some examples of dihydride-dihydrogen interconversion have been described 
for iridium complexes containing pincer ligands. Gottker-Schnetmann et al.211 have 
described the equilibrium between an iridium dihydride complex and an iridium 
dihydrogen complex, as shown in Figure 113, where the equilibrium depends on the 
polarity of the solvent. The dihydride species is favoured in CD2Cl2 whereas the 
dihydrogen complex is favoured in toluene.211  
 
Figure 113: Equilibrium between the iridium dihydride complex and the iridium dihydrogen 
complex described by Gottker-Schnetmann et al.211 
In the exchange pathway of 6, the dihydrogen-containing transition state is 
likely to be low-lying in energy, due to it being unstable because the iridium is bonded 
to very electronegative groups, and thus its simple rotation is easily achieved. In 2004, 
DFT studies by Gelabert et al.212 of [Cp*Ir(dmpm)(H2)][B(C6F5)4]2, where dmpm is bis-
dimethyldiphosphinomethane, predicted that the dihydrogen complex was only 5.9 kJ 
mol−1 higher in energy than the dihydride species, with the transition state between the 
dihydride species and the dihydrogen species lying only 1.3 kJ mol−1 higher in energy 
than the dihydrogen species. Another computational study by Hebden et al.193 analysed 
the energy differences between dihydride and dihydrogen forms of the iridium pincer 
complexes, B in Figure 109. Again, the energy differences between the species are less 
than 13 kJ mol−1, with cis-[(POCOP)Ir(H2)(H)2] being 2.0 kJ mol
−1 lower in energy than 
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[(POCOP)Ir(H)4] in cyclohexane solution. For the PCP complex, the opposite is true, 
with [(PCP)Ir(H)4] being favoured over the dihydride-dihydrogen complex.  
Other studies also show that the energy difference between a metal-H2 complex 
and a metal-dihydride complex is small.213 Li et al.213 have shown that for a number of 
Fe and Ru complexes, the dihydrogen complexes are most stable, whereas for Os, the 
dihydride species is the most stable. In relation to the bond distances between two H 
atoms, in either a dihydride species or a dihydrogen species, Morris214 has described 
many complexes where the H-H bond lengths increase as the ligands change from 
dihydrogen to dihydride species. Furthermore, when electronegative atoms such as Cl or 
O, which are σ-donor and π-donor ligands, are in a trans position to the dihydrogen 
ligand, the H-H bond is elongated in comparison to when the trans ligand is H, C, P or 
N which are only σ-donor ligands.214 Thus, complexes containing electronegative 
ligands that can be involved in σ- and π-donation are more likely to exist as dihydride 
species. 
Overall, the exchange mechanism for 6 is more complicated than the mechanism 
that has previously been described for [Ir(COD)(IMes)Cl]. The full pathway for 6 is 
depicted in Figure 114, showing pyridine loss, hydride interchange and the important 
dihydride-dihydrogen intermediate. Based on this mechanism, analysis of the 
experimental pyridine dissociation rates involves direct observation of this rate 
determining step because it is the first step in the process and is the direct loss of 
pyridine from the active complex. When looking at the hydride dissociation rate, 
however, the experimental rate is no longer the first step in the cycle as depicted in the 
mechanism shown in Figure 114. Instead, the experimentally determined rate constants, 
kobs, contain information about both the pyridine loss rate, the dihydrogen binding rate 
and then the dihydride dissociation rate.  
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Figure 114: Formation of 6 from 1 with the vacant site represented through the shaded orbital 
and the blue and magenta hydride ligand labels detailing the hydride interchange processes. 
Contributing to the rate of hydride interconversion, 𝑘ℎ𝑦𝑑𝑟𝑖𝑑𝑒 𝑖𝑛𝑡𝑒𝑟𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛, is both route A 
(including the rate of pyridine loss, 𝑘𝑝𝑦 𝑙𝑜𝑠𝑠,  and the rate of formation of the dihydrogen 
complex, 𝑘𝜂2−𝐻2 𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛) and route B (intramolecular switching)  
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3.2.4. Analysis of the effect of solvent on exchange 
In Section 3.2.2, ligand exchange rates for 6 in CD2Cl2 and CD3OD were shown 
to be considerably different and an investigation into the range of solvents that enable 
ligand exchange was therefore conducted. Pyridine and hydride dissociation rates may 
differ between solvents because of their varying polarities and therefore solvation 
capabilities. Selective 1H EXSY NMR experiments were used, as previously described 
in Section 3.2.1, and the different rates for pyridine dissociation, hydrogen dissociation 
and hydride interconversion are shown in Table 18, along with the calculated lifetimes 
of the corresponding complexes. The rates of hydride interconversion in the ethanol and 
methanol solvents are shown to be faster than pyridine dissociation, consistent with the 
previous discussion in Section 3.2.3. Here, the ligand exchange rates will also be 
affected by the H2 solubility differences between the five solvents which will affect the 
overall concentration of H2 in solution. The experimental values in ethanol and 
methanol are also more inaccurate than the previous studies due to analysis of the 
simultaneous H-D exchange which also occurs within the polar protic solvents, between 
the deuterium of the alcohol and the H2 in solution. In all solvents tested, 6 is the major 
complex in solution. Here, the least polar solvents promote faster exchange presumably 
due to their inability to bind to and solvate the 16-electron intermediate shown in 
brackets in Figure 114. 
Table 18: Pyridine and hydrogen dissociation rates and the rates of hydride interconversion for 
samples of 15 mol% 1 and 0.05 M pyridine in the specified solvents at 298 K under 3 bars of H2 
Solvent 
Rate of pyridine 
dissociation / s−1 
Rate of hydrogen 
dissociation from 
HB / s−1 
Rate of hydride 
interconversion 
from HB to HA/ s−1 
Lifetime of 
active 
complex / s 
C6D6 7.39 ± 0.05 1.03 ± 0.01 4.23 ± 0.05 0.135 ± 0.001 
THF-d8 5.97 ± 0.17 0.89 ± 0.01 2.06 ± 0.06 0.167 ± 0.005 
CD2Cl2 3.46 ± 0.07 0.51 ± 0.02 0.75 ± 0.02 0.289 ± 0.006 
Ethanol-d6 0.95 ± 0.01 0.77 ± 0.05 1.48 ± 0.03 1.053 ± 0.011 
CD3OH 1.51 ± 0.03 0.92 ± 0.02 3.88 ± 0.11 0.662 ± 0.013 
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3.3. Ligand exchange rates 
3.3.1. Ligand exchange rate analysis for 8 and 15 
In CD2Cl2 and C6D6, 2 forms 8 as described in Section 2.4.2, which is equivalent 
to the reactivity of 1. This is shown in Figure 115. 
 
Figure 115: Reaction of 2 with pyridine and hydrogen in CD2Cl2 or C6D6 to form 8 and in 
CD3OD to form 15 
Here, however, in CD2Cl2, the hydride ligands of 8 appear at δ −22.55 and 
−25.49 in the 1H NMR spectrum and it is predicted that due to no bulky substituent 
being present on the phenolate ring, the complex conformation is likely to be the B form 
as indicated in Figure 102. If the minor isomer does form, it will not be observed if very 
rapid exchange occurs. The ligand exchange rates for 8 are summarised in Table 19, and 
in both CD2Cl2 and C6D6 they are faster than those of complex 6 as given in Section 
3.2.2. This matches the prediction based on the work of Zhao et al.181 where the higher 
electron density at the metal centre promotes H2 loss. In CD3OD, complex 15 forms as 
described in Section 2.4.6. Here, the pyridine dissociation rate for 15 was measured, but 
as rapid deuteration of the hydride ligands occurs, this precluded determination of the 
hydride dissociation rates. The pyridine dissociation rate is slower in CD3OD than in 
both CD2Cl2 and C6D6 (see Table 19). 
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Table 19: Pyridine and hydrogen dissociation rates and the rates of hydride interconversion for 
samples of 15 mol% 2 and 0.05 M pyridine in the specified solvents at 294 K under 3 bars of H2 
Solvent Rate of pyridine dissociation / s−1 Lifetime of active complex / s 
C6D6 13.5 ± 0.6 0.074 ± 0.003 
CD2Cl2 3.74 ± 0.06 0.267 ± 0.004 
CD3OD 1.35 ± 0.03 0.370 ± 0.008 
 
Rate of hydrogen dissociation / 
s−1 
Rate of hydride interconversion / 
s−1 
 From HA From HB From HA to HB From HB to HA 
C6D6 3.01 ± 0.11 2.98 ± 0.06 5.52 ± 0.12 5.61 ± 0.20 
CD2Cl2 0.78 ± 0.01 0.79 ± 0.01 1.59 ± 0.03 1.57 ± 0.03 
 
Table 20: Exchange rate and lifetime data for pyridine dissociation and hydride dissociation at 
different temperatures in CD3OH for a sample containing 8 mol% 2 and 0.07 M pyridine under 
3 bars of H2 
T / K 
Rate of pyridine 
dissociation / s−1 
Observed rate of hydrogen 
dissociation / s−1 
Lifetime of active 
complex / s 
278 0.13 ± 0.01 0.08 ± 0.01 3.71 ± 0.13 
283 0.29 ± 0.01 0.10 ± 0.01 1.70 ± 0.06 
288 0.56 ± 0.02 0.26 ± 0.03 0.89 ± 0.04 
293 1.13 ± 0.07 0.48 ± 0.02 0.44 ± 0.03 
298 2.02 ± 0.08 0.88 ± 0.02 0.25 ± 0.01 
303 3.86 ± 0.12 1.71 ± 0.03 0.13 ± 0.01 
 
The activation parameters for the different processes in 15 were calculated using 
the exchange rates at six different temperatures as shown in Table 20. CD3OH was used 
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to eliminate exchange with deuterium which causes formation of the hydride-deuteride 
complex and HD in solution, as described in Section 3.2.2. 
The values for the rates of pyridine dissociation and hydride dissociation of 15 
are like those of complex 6 (see Section 3.2.2) so the activation parameters are predicted 
to be similar. As for the lifetimes of the active complexes, the same effect as described 
in Section 3.2.2 is seen.93 Furthermore, in 15, there are two substrate ligands to 
exchange compared to only one in 6. However, the errors associated with the exchange 
rates of 15 are much lower than those of complex 6 as detailed in Section 3.2.2. This 
may be due to concentration or solubility differences between the samples. Figure 116 
shows the Eyring-Polanyi plots used to determine the activation parameters, which are 
summarised in Table 21. The activation enthalpy and entropy values calculated for both 
pyridine dissociation and hydride loss are very similar (see Table 21). The entropy 
values of 71.3 ± 5.3 J K−1 mol−1 and 56.1 ± 30.6 J K−1 mol−1 for pyridine dissociation 
and hydride loss respectively are both positive and indicative of a dissociative 
mechanism. 
 
Figure 116: An Eyring-Polanyi plot for pyridine exchange and hydride-hydrogen exchange at 
differing temperatures in CD3OH for a sample containing 8 mol% 2 and 0.07 M pyridine 
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Table 21: Activation parameters calculated from the Arrhenius and Eyring-Polanyi plots for 
pyridine dissociation and hydride dissociation in CD3OH for a sample containing 8 mol% 2 and 
0.07 M pyridine. The Gibbs Free energy of activation, ΔGǂ, is calculated at 300 K using the 
Gibbs Free Energy equation (ΔGǂ = ΔHǂ – TΔSǂ) with the calculated ΔHǂ and ΔSǂ values given in 
the table 
 Pyridine dissociation Hydrogen dissociation 
 Arrhenius Eyring-Polanyi Arrhenius Eyring-Polanyi 
Ea / ΔHǂ / kJ mol−1 93.1 ± 1.5 90.7 ± 1.6 90.7 ± 9.1 88.3 ± 9.1 
ΔSǂ / J K−1 mol−1 - 71.3 ± 5.3 - 56.1 ± 30.6 
R2 value 0.9994 0.9994 0.9829 0.9821 
ΔGǂ / kJ mol−1 - 69.3 ± 0.1 - 71.5 ± 0.1 
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3.3.2. Ligand exchange rate analysis for 10A and 
10B 
For complex 3, in CD2Cl2, both 10A and 10B are formed with differing 
orientations of the metallocycle (see Figure 102). Complex 10A is equivalent to complex 
6A, whilst 10B matches complex 8. In CD2Cl2, the exchange rates for pyridine 
dissociation and hydrogen loss were calculated once all the complex had formed 10B, 
where the hydride signals at δ −22.56 and −25.47 were both sharp, and selective 
excitation of each hydride in turn was possible. However, in C6D6, very broad and 
overlapping signals for the bound pyridine ligands precluded calculation of reliable 
exchange rates, although the broad character of the signals is consistent with rapid 
exchange (faster than in CD2Cl2). In CD3OH complex 10A is formed and deuteration 
effects are eliminated. However, efficient analysis of the hydride signal HA, at ~ δ −22 
in both CD3OH and C6D6 was not possible as the signals were too broad or overlapped 
with other minor hydride signals, like that observed in 6. All the ligand exchange rates 
are detailed in Table 22. 
Table 22: Pyridine dissociation rates, complex lifetimes and hydride exchange rates of 10A and 
10B, for CD2Cl2, CD3OD, CD3OH and C6D6 samples containing 10 mol% 3 and 0.06 M pyridine 
at 298 K under 3 bars of H2 
Solvent Pyridine dissociation rate / s−1 Active complex lifetime / s 
CD2Cl2 2.63 ± 0.21 0.38 ± 0.03 
CD3OD 3.00 ± 0.09 0.33 ± 0.01 
 Rate of hydride interconversion / s−1 Rate of hydrogen dissociation / s−1 
 HA to HB HB to HA HA to H2 HB to H2 
CD2Cl2 1.33 ± 0.06 1.39 ± 0.07 1.17 ± 0.03 1.21 ± 0.03 
 HB to HA HB to H2 
CD3OH 13.7 ± 0.4 1.20 ± 0.12 
C6D6 8.09 ± 0.31 1.45 ± 0.07 
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3.3.3. Ligand exchange rate analysis for 12A, 12B 
and 16 
For complex 4, in both CD2Cl2 and C6D6, the two isomers 12A and 12B (as 
shown in Figure 102) are again seen and their corresponding ligand exchange rates are 
detailed in Table 23.  
Table 23: Exchange rate information for pyridine and hydrogen loss and hydride 
interconversion for 12A and 12B present in a CD2Cl2 sample containing 9 mol% 4 and 0.08 M 
pyridine and a C6D6 sample containing 7 mol% 4 and 0.1 M pyridine, both under 3 bars of H2 
at 298 K 
Solvent 
Rate of py loss 
from 12A / s−1 
Rate of py loss 
from 12B / s−1 
Rate of py2 
interconversion 
from 12A to 12B 
/ s−1 
Rate of py2 
interconversion 
from 12B to 12A 
/ s−1 
C6D6 Too broad and overlapped to measure 
CD2Cl2 4.15 ± 0.26 
Too broad to 
measure 
0.54 ± 0.03 0.80 ± 0.08 
 Rate of H2 loss from 12A / s−1 Rate of H2 loss from 12B / s−1 
 From HA From HB From HA’ From HB’ 
C6D6 5.50 ± 0.39 6.03 ± 0.20 Too broad to measure 
CD2Cl2 2.04 ± 0.04 2.04 ± 0.07 Too broad to measure 
 
Rate of hydride interconversion 
for 12A / s −1 
Rate of hydride interconversion 
for 12B / s−1 
 From HA to HB From HB to HA From HA’ to HB’ From HB’ to HA’ 
C6D6 6.63 ± 0.26 6.68 ± 0.18 Too broad to measure 
CD2Cl2 1.57 ± 0.05 1.81 ± 0.10 Too broad to measure 
 
As for complexes 6A and 6B at low temperature, site-specific exchange was also 
observed for isomers 12A and 12B although now at room temperature. In CD2Cl2, the 
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ratio of 12A: 12B was 1.4: 1 which equates with the rates of conversion between 12A and 
12B as calculated from the site-specific exchange between the pyridine ligands in the 
trans position to the carbene which do not undergo dissociative exchange. However, in 
C6D6 the isomers were present in a 1: 1 ratio. Despite attempts to gain information 
about the kinetics of the complexes formed in C6D6, the 2D NMR spectra were unclear. 
This is due to multiple overlapping signals for the pyridine environments and all the 
signals being very broad at 298 K. 
In CD3OD, both 12A and 16 formed, containing inequivalent and equivalent 
hydride ligands respectively, as detailed in Section 2.4.8. The rates of conversion from 
12A to 16, as detailed in the exchange rate data given in Table 24, suggest 16 is the more 
stable isomer with the ratio being like that of 1: 1.6, obtained from integration. 
Table 24: Exchange rate information for pyridine and hydrogen loss and hydride 
interconversion for 12A and 16 present in a CD3OH sample containing 5 mol% 4 and 0.16 M 
pyridine under 3 bars of H2 at 298 K 
 
Rate of py 
loss from 
12A / s−1 
Rate of py 
loss from 
16 / s−1 
Rate of py2 
interconversion from 
12A to 16 / s−1 
Rate of py2 
interconversion from 
16 to 12A / s−1 
CD3OH 7.27 ± 0.50 1.78 ± 0.07 1.74 ± 0.04 0.98 ± 0.03 
 
Rate of H2 loss from 12A / 
s−1 
Rate of hydride 
interconversion in 12A 
/ s −1 
Rate of H2 loss from 
16 / s−1 
 HA HB HA to HB HB to HA H 
CD3OH Too broad to measure Too broad to measure 1.33 ± 0.05 
 
In all three solvents, the rates of hydride site exchange between the isomers, for 
example from HA in 12A to HA in 12B in CD2Cl2, could not be measured, due to the 
signals for 12B being very broad at 298 K. The same rapid exchange was observed for 
complex 12A in CD3OH, which precluded determination of the hydride site interchange 
between complexes 12A and 16 in this solvent system.  
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3.4. Analysis of pyridine T1 relaxation times 
For a species to return to thermal equilibrium, after it is probed during an NMR 
experiment, it must undergo relaxation processes. It is known that there are several 
conditions that affect the relaxation of a system, particularly the T1 (longitudinal/spin-
lattice) relaxation. This is the release of energy from an analyte to its surroundings and 
is therefore strongly dependent on the presence of other species within the system. For 
pyridine, the effective relaxation times of its ortho, meta and para protons are 28.8 s, 
26.4 s and 30.1 s respectively.93 However, upon the addition of [Ir(COD)(IMes)Cl] and 
hydrogen to pyridine in methanol, the active catalyst that is formed dramatically 
decreases the T1 values for these protons to 12.6 s, 14.7 s and 18.9 s respectively, for a 
sample containing 0.1 M pyridine and catalyst loading of 5 mol%. This is because the 
active catalyst undergoes exchange processes which aid the relaxation of the pyridine 
signals.93 A similar effect is expected when the catalyst used is complex 1.  
However, the effect of solvent on relaxation was unknown. Therefore, T1 values 
of the protons of pyridine were calculated in the samples of different solvents, from 
non-polar benzene to polar methanol. Tests were conducted on samples containing 
pyridine (0.05 M) in air, degassed and then in the presence of 1 (15 mol%) and 3 bars of 
H2. The samples under normal air (Table 25) all contain paramagnetic oxygen which 
aids the relaxation process of analytes and as the solubility of oxygen varies with 
solvent,215 these values cannot be directly compared without taking into account the 
solubility differences. However, upon degassing the samples there are still a large range 
of T1 values (Table 25) which can therefore be attributed to the effect of the solvent 
within the system. Pyridine can participate in several different interactions, either 
between the pyridine molecules themselves or with the solvent molecules, depending on 
the characteristics of the solvent in which it is dissolved. Since pyridine is a planar 
aromatic molecule, it can form stacked systems stabilised by π-π interactions between 
rings. Furthermore, because pyridine has a very similar aromatic ring structure to 
benzene, these π-π stacking interactions are also likely to form as mixed structures and a 
number of computational studies have investigated these systems.216-218 Due to its 
nitrogen lone pair, pyridine is also known to participate in hydrogen bonding as an H-
bond acceptor.219-221 Therefore, hydrogen bonding interactions are likely to exist 
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between pyridine and the H-bond donor solvents dichloromethane, methanol and 
ethanol. Some of these potential interactions are shown in Figure 117.  
 
Figure 117: Possible interactions between pyridine and benzene, DCM, methanol and ethanol 
In addition, the differing viscosities of the solvents will affect the molecular 
motion (rotational correlation times, τc) of the pyridine molecules leading to effective 
changes in T1 values. It is known that correlation time, τc is related to the relative 
molecular mass, Mr, of a molecule, such that 𝜏𝑐 ≈  𝑀𝑟  ×  10
−12 and therefore for 
pyridine, τc ≈ 79 ps. This lies to the left of the minimum point depicted in Figure 118, 
which shows how the T1 depends on the correlation time of a molecule. However, these 
effects will be minimal. 
 
Figure 118: The dependence of the T1 relaxation time on the rotational correlation time, τc of a 
molecule. For pyridine, its τc value lies to the left of the minimum point, with an increase in 
viscosity of the solution causing a decrease in the both the correlation time and the T1 value 
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In relation to Figure 118, solvents with a higher viscosity are predicted to 
shorten the T1 value of the pyridine molecule. This is consistent with what is observed 
when ethanol is used as its viscosity is approximately double that of the other solvents, 
as shown in Table 25. Pyridine therefore demonstrates the lowest T1 values in ethanol, 
when tested under air, under vacuum and in the presence of active catalyst and H2. 
Table 25: T1 values calculated for the protons of pyridine (0.05 M) in the specified solvent 
samples under air, degassed and once activated with 1 (15 mol%) under 3 bars of H2 at 298 K 
Solvent  C6D6 THF-d8 CD2Cl2 Ethanol-d6 CD3OD 
Viscosity / cP At 25 °C 0.60 0.46 0.41 1.07 0.54 
T1 of Pyridine 
in air / s 
ortho 7.7 18.2 10.3 5.1 6.7 
meta 7.7 23.8 9.3 5.0 6.9 
para 7.6 24.4 9.4 5.6 7.4 
T1 of Pyridine 
in degassed 
solution / s 
ortho 74.5 25.4 47.0 22.9 13.3 
meta 58.7 62.1 42.0 18.1 26.2 
para 57.5 65.1 41.8 30.0 38.6 
T1 of Pyridine 
in solution with 
1 under 3 bars 
of H2 / s 
ortho 8.8 9.1 10.4 7.2 12.2 * 
meta 10.3 12.5 12.9 6.3 11.0 * 
para 11.5 12.6 13.8 8.3 13.5 * 
* Actually for 9 eq. of pyridine (0.07 M pyridine and 10 mol% 1) due to the lower solubility of 1 in 
methanol. For 11 eq. of pyridine, the T1 values for the o, m and p protons of pyridine were 13.1 s, 11.7 s 
and 14.7 s respectively. It is anticipated that the T1 values for pyridine in a sample containing 0.05 M 
pyridine and 15 mol% 1 would be lower again by ~ 1 s. 
Upon addition of 1 and H2 to the pyridine samples to form the active complex, 6, 
the T1 values for every sample dramatically decrease with respect to the degassed 
samples. This is due to the rate of pyridine exchange that occurs between the complex 
and free pyridine in solution, which relates to the lifetime of the active catalyst, and 
therefore this rate needs to be optimised to promote the most efficient polarisation 
transfer and thus produce the largest signal enhancements. 
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The fastest ligand exchange rates (see Section 3.2.4) in C6D6 and THF correlated 
to lower T1 values. In CD2Cl2, the ligand exchange rate, and thus T1 value, seems to be 
at an optimum. The T1 values for the methanol sample are longer than expected, 
however, this could be because the catalyst is the least soluble in methanol and 
deuteration of the pyridine ortho protons occurs over time, which hinders relaxation, 
thus lengthening T1.  
It is known that the effective T1 values decrease as the number of interactions 
with the catalyst increase and therefore at a higher concentration of pyridine, each 
pyridine molecule will have fewer interactions with the catalyst so the T1 values are 
anticipated to be higher. To test this, a sample containing 2.5 mol% 1 and 0.2 M 
pyridine in methanol was examined to compare the effect of the catalyst on T1 
relaxation. The corresponding T1 values of pyridine were found to be 23.0 s, 20.1 s and 
27.9 s for the ortho, meta and para protons respectively, which is an approximate 
doubling compared to the T1 values of the samples containing four times less pyridine. 
To gauge a further understanding of how the rate of pyridine ligand exchange 
affects the effective corresponding proton T1 values in CD2Cl2, T1 values for the free 
pyridine and two bound pyridine ligands were calculated at 263 K and 298 K, with the 
data given in Table 26. The values at 298 K, when pyridine exchange occurs at an 
observed rate of 3.46 ± 0.07 s−1, show that the free pyridine and the exchanging pyridine 
ligand have effective T1 values for their ortho protons of 10.4 s and 8.5 s respectively. 
On cooling to 263 K and thus completely inhibiting pyridine ligand exchange on the 
NMR timescale, the effective T1 values for the ortho protons of free pyridine are 16.3 s, 
whilst those for the pyridine ligand in the trans position to the hydride ligand reduce to 
2.3 s, commensurate with those for the pyridine bound trans to carbene at 298 K, which 
does not undergo exchange. This shows that when there is no interaction between 
pyridine and the catalyst, the T1 values are increased and when pyridine is permanently 
bound, the values decrease, hence longer time periods associated with the metal centre 
lead to assisted relaxation. Ligand exchange at 298 K leads to averaged T1 values thus 
the values depend on the ligand exchange rates and are affected by temperature. 
These T1 values have also been normalised by dividing through by the largest T1 
value of 16.3 s. At 263 K, the T1 values of free pyridine are approximately seven times 
larger than the T1 values for the non-exchanging pyridine sites. However, at 298 K, the 
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T1 values for free pyridine and the exchanging pyridine are similar, with the values for 
the non-exchanging pyridine being three times lower. 
Table 26: T1 values for the three proton sites of each of the three pyridine environments (free 
pyridine, pyridine trans to hydride and pyridine trans to carbene) within a CD2Cl2 solution of 
pyridine (0.05 M) once activated with 1 (15 mol%) under 3 bars of H2 at 298 K and at 263 K. At 
263 K the T1 value for the para proton signal of the pyridine ligand bound trans to a hydride 
ligand could not be determined due to signal overlap 
 
T1 of free pyridine in 
solution / s 
T1 of pyridine bound 
trans to hydride / s  
T1 of pyridine bound 
trans to carbene / s 
CD2Cl2 o m p o m p o m p 
At 298 K 10.4 12.9 13.8 8.5 11.4 12.8 2.8 3.4 4.9 
At 263 K 16.3 15.5 15.5 2.3 1.8 - 1.8 2.1 2.7 
Normalised 
at 298 K 
0.64 0.79 0.85 0.52 0.70 0.79 0.17 0.21 0.30 
Normalised 
at 263 K 
1 0.95 0.95 0.14 0.11 - 0.11 0.13 0.17 
 
A similar study was conducted using complex 2 with pyridine and H2 in C6D6, 
CD2Cl2 and CD3OD. The pyridine dissociation rates for the samples were measured at 
298 K along with the T1 values for the protons of the free and bound pyridine ligands.  
Here, again due to ligand exchange, the T1 values for the protons of free pyridine 
and the pyridine ligand bound trans to the hydride ligand are weighted average values 
that depend on the specific rate of exchange, as detailed in Table 27. This can be 
modelled but is beyond the scope of this work. Due to signal overlap of the ortho 
protons of both bound pyridine ligands in C6D6, the value of 2.98 s is also an average of 
the T1 values of both the exchanging and the non-exchanging pyridine ligand. The T1 
value for the non-exchanging pyridine ligand is predicted to be even shorter than the 
exchanging ligand. This is because it remains bound to the metal centre which speeds 
up its relaxation.  
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Table 27: Pyridine dissociation rates and T1 values for three samples of 16 mol% 2 and 0.05 M 
pyridine under 3 bars of H2 in C6D6, CD2Cl2 and CD3OD at 298 K 
Solvent 
Rate of py 
dissociation / s−1 
Lifetime / s T1 of free py / s 
T1 of bound 
ortho py / s 
   ortho meta para 
trans 
to H 
trans to 
carbene 
C6D6 24.8 ± 0.5 0.040 ± 0.001 8.38 8.93 9.72 2.98 
CD2Cl2 7.30 ± 0.03 0.137 ± 0.001 9.20 10.32 10.99 8.98 2.70 
CD3OD 1.35 ± 0.03 0.370 ± 0.007 5.57 6.88 7.93 4.00 1.96 
 
In 2016, Barskiy et al.91 described an analytical model for the SABRE process 
which considers the relaxation processes involved in SABRE. They report the average 
T1 value for the protons of free pyridine in solution as ~ 27.5 s which reduces to ~ 3.6 s 
on average for the protons of the pyridine ligands when they are bound to the iridium 
metal centre. This proton lifetime of the bound ligands was determined using the 
inversion recovery method, focusing on the pyridine ligand in the trans position to the 
carbene ligand, which does not undergo exchange.91 This is similar to the values given 
in Table 27 for complexes 8 and 15. Furthermore, strong coupling with the hydride 
protons, which occurs in the active SABRE complex, decreases the T1 value of the 
protons of pyridine,91 in-line with that seen here. 
Overall, interactions with the metal centre aid the relaxation of the pyridine 
substrates, as predicted based on previous descriptions using [Ir(COD)(IMes)Cl]. The 
effects, however, are also solvent dependent, with considerably different relaxation 
effects observed in the different solvents. It is important to note that all the T1 values 
measured here are larger than the time it takes to conduct the SABRE experiments 
described in Chapter 4 and therefore none of the substrates in the samples have 
undergone any substantial T1 relaxation before an enhanced spectrum is acquired. 
Therefore, these differences should not have any significant impact on the enhancement 
values obtained. 
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3.5. Conclusion 
This study has shown that the electronic effect of the substituent on the 
phenolate ring has a large influence on the conformation of the active catalyst formed in 
solution. Multiple isomers of each complex are present as first detailed in Figure 102 in 
Section 3.2.1, with the hydride and CH2 linker chemical shifts typically being indicative 
of the isomers present. The 1H NMR chemical shifts for the hydride ligands of A and A’ 
commonly appear at approximately δ −21 and −28 whilst for the hydride ligands of B 
and B’, they appear at about δ −22 and −25. As the substituent on the phenolate 
becomes more electron-donating, the favoured isomer changes from one form to another 
as shown in the summary in Table 28. The isomer labels, A and B refer to those given 
in Figure 119. 
Table 28: Summary of the active catalyst species formed in CD2Cl2 and CD3OD, along with the 
1H NMR chemical shifts of their hydride and CH2 linker signals 
Pre-
catalyst 
Isomer 
A or B 
Solvent 
Active 
catalyst 
HA 
chemical 
shift / δ 
HB 
chemical 
shift / δ 
CH2 linker 
chemical shifts 
/ δ 
1 A CD2Cl2 6 −21.36 −28.88 4.46 and 6.48 
3 A CD2Cl2 10A −21.95 −28.48 4.56 and 6.15 
3 B CD2Cl2 10B −22.56 −25.47 5.32 and 5.87 
4 A CD2Cl2 12A −22.08 −28.12 4.48 and 5.95 
4 B CD2Cl2 12B −22.55 −25.50 5.34 and 5.76 
2 B CD2Cl2 8 −22.55 −25.49 5.29 and 5.76 
1 A CD3OD 6 −21.62 −29.22 4.68 and 6.25 
3 A CD3OD 10A −21.66 −29.04 4.63 and 6.17 
4 A CD3OD 12A −21.72 −28.72 4.60 and 6.11 
4 C CD3OD 16 −22.29 −22.29 4.88 
2 C CD3OD 15 −22.33 −22.33 4.83 
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Figure 119: Summary of isomer forms and the interconversion processes that occur for the 
bidentate iridium carbene dihydride complexes in solution 
In CD2Cl2, two isomers of the active catalyst form due to ring-flip of the seven-
membered metallocycle. The Ir-O bond remains stable, despite the increase in electron 
density through the series, NO2 < COOMe < Cl < H, indicated by the decreasing 
Hammett parameters, σp−, 1.27 > 0.75 > 0.19 > 0.00. However, the electron density 
associated with the iridium metal centre, caused by varying the phenolate substituent, 
does affect the equilibrium position of the isomers. When the electron density on the 
metal centre is low, due to the presence of the strongly electron-withdrawing NO2 
group, isomer A dominates. However, as the substituent on the phenolate becomes more 
electron-donating, isomer B forms and then becomes the main species when the 
substituent is H, the most electron-donating. This is commensurate with the change in 
the chemical shift difference between the hydride signals, which is about δ 7 for isomer 
A but drops to about δ 3 for isomer B. Furthermore, the chemical shift difference 
between the inequivalent protons of the CH2 linker also decreases on flipping from A to 
B. For A, the difference is about δ 1.7 whereas for B this reduces to about δ 0.4. 
In methanol, where the Ir-O bond is retained, isomer A is the dominant form and 
B is not observed. This is the case for the most electron-withdrawing substituents, NO2 
and COOMe which have σp− values of 1.27 and 0.75 respectively. This reactivity is like 
that seen in CD2Cl2. Isomer B may not be observed due to too rapid exchange between 
the two isomers, even at 258 K, precluding signal resolution. However, in CD3OD, due 
to its ability to solvate the build-up of charge on the complexes as the electron density 
on the metal is increased, the Ir-O bond can cleave. Therefore, when the substituent on 
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the metal centre is Cl, with a σp− value of 0.19, some of species C forms with equivalent 
hydride ligands, and once the electron-donating H substituent is present, with a σp− 
value of 0.00, all the species formed is the Ir-O bond cleaved product C. 
When the substrate is changed to being chiral, it is predicted that A and A’ and 
B and B’ are no longer equivalent as the stereogenic centre will affect these isomers. 
This hypothesis is analysed further in Section 4.3.3, when the substrate, pyridine, is 
replaced with the chiral molecule, nicotine. A summary of these different complexes 
and their corresponding exchange processes is detailed in Figure 119. 
All the isomers detailed in Table 28 undergo substrate and H2 exchange with the 
corresponding ligand exchange rates for the samples in CD2Cl2, given in Table 29. The 
fastest overall ligand exchange processes are observed for complex 12A containing the 
Cl substituent, with a σp− value of 0.19, which lies between that of H and COOMe. 
Therefore, this slightly electron-withdrawing substituent imparts the optimum electronic 
properties for ligand exchange when the substrate is pyridine. This indicates that when 
the substituent in the para position to the phenolate is too electron-withdrawing, there is 
not enough electron density on the metal centre to enable rapid oxidative addition of 
hydrogen to the iridium centre. Furthermore, as the substituent becomes too electron-
donating, the metal centre cannot accommodate the extra electron density and thus this 
is also not favoured. Other potential effects on the system are detailed in Section 3.1. 
The following chapters will analyse the SABRE activity of these complexes to 
determine the effect of electron density on polarisation transfer efficiency.  
Table 29: Comparison of the ligand exchange rates and lifetimes of the dihydride complexes 6, 
10A, 12A and 8 in CD2Cl2 at 298 K 
Pre-
catalyst 
R 
group  
Hammett 
parameter 
/ σp− 
Active 
catalyst 
Rate of py 
loss / s−1 
Rate of H2 
loss from 
HB / s−1 
Rate of hydride 
interconversion 
(HB to HA) / s−1 
1 NO2 1.27 6 3.46 ± 0.07 0.51 ± 0.02 0.75 ± 0.02 
3 COOMe 0.75 10B 2.63 ± 0.21 1.21 ± 0.03 1.39 ± 0.07 
4 Cl 0.19 12A 4.15 ± 0.26 2.04 ± 0.07 1.81 ± 0.10 
2 H 0.00 8 3.74 ± 0.06 0.79 ± 0.01 1.57 ± 0.03 
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4. Exploiting neutral iridium carbene 
complexes in SABRE catalysis 
4.1. Introduction 
The field of SABRE catalysis has so far been limited to the use of symmetric 
monodentate carbene complexes which, when in their SABRE-active form, are present 
as charged species as discussed in Section 1.7. It has previously been stated in Section 
1.1.3, that polarisation transfer via the SABRE approach is only possible by breaking 
the symmetry of the p-H2, to unlock its polarising capabilities. This can be achieved by 
the formation of complexes with either chemically equivalent but magnetically 
inequivalent hydride ligands, or through complexes where the hydride ligands are both 
chemically and magnetically inequivalent.  
When parahydrogen oxidatively adds to a metal complex, it does so in a 
pairwise manner so that the hydride ligands remain spin-spin coupled. When the two 
created hydride ligands lie trans to two identical ligands, they remain chemically 
equivalent and both appear in the 1H NMR spectra at the same chemical shift. However, 
differing coupling networks are established within the complex, as depicted in Figure 
120, for an iridium dihydride bis-pyridine fragment, where the 4J-coupling value 
between the labelled pyridine proton, Hpy, and HA differs from that formed with HB. 
This is the basis of magnetic inequivalence. 
 
𝐽𝐻𝐴𝐻𝑝𝑦1 ≠  𝐽𝐻𝐴𝐻𝑝𝑦2 𝐽𝐻𝐵𝐻𝑝𝑦1 ≠  𝐽𝐻𝐵𝐻𝑝𝑦2  
Figure 120: Iridium dihydride bis-pyridine fragment showing magnetic inequivalence of the 
hydride ligands due to their different coupling values to the protons of the pyridine ligands 
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In 1987, Eisenschmid et al.222 studied the hydrogenation of some deuterated 
alkenes using p-H2 and a rhodium catalyst, [Rh3Cl3H2(CO)2((Ph2PCH2)2PPh)2]
+ under 
thermal conditions. For the starting alkene, CD2CD2, they showed that despite the two 
protons of the alkane product, CHD2CHD2, being chemically equivalent, they 
demonstrated signal enhancements due to their magnetic inequivalence caused by their 
differing couplings to the deuterium atoms present. This is shown in Figure 121. 
 
𝐽𝐻𝐴𝐷𝐵 ≠  𝐽𝐻𝐴𝐷𝐵′ 𝐽𝐻𝐵𝐷𝐴 ≠  𝐽𝐻𝐵𝐷𝐴′ 
Figure 121: Observation by Eisenschmid et al.222 showing the magnetic inequivalence of the p-
H2 derived protons due to their different couplings to the deuterium atoms of the 1,1,2,2-
tetradeuteroethane product 
Another study further demonstrated the need for inequivalence and the effect of 
coupling differences on the enhancements observed when using thermal PHIP 
experiments. In 1996, Duckett et al.223 analysed the reactivity of [Ru(H)2L2(CO)2] 
(where L = AsMe2Ph, PMe2Ph, PMe3) with p-H2 and showed that the two isomers of the 
complexes, the cis-cis-cis form and the trans-cis-cis form as shown in Figure 122, both 
exhibit enhanced hydride signals. Despite the trans-cis-cis isomer having both 
chemically and magnetically equivalent hydride ligands, it still demonstrated PHIP due 
to isomer exchange with the cis-cis-cis isomer, without loss of H2, as depicted in Figure 
122. When one CO ligand in the trans-cis-cis isomer of [Ru(H)2(PMe3)2(CO)2] was 
replaced with an equivalent 13C-labelled CO ligand, the symmetry of the complex was 
broken and significant enhancements of the p-H2 derived hydride ligands were 
observed. This was due to the hydride ligands becoming magnetically inequivalent due 
to the different coupling networks existing with the 13CO ligand. This thus proved an 
effective route to enable PHIP enhancements of the hydride ligands, just via isotopic 
perturbation of the coupling network. 
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Figure 122: Isomer interconversion between cis-cis-cis-[Ru(H)2L2(CO)2] and trans-cis-cis-
[Ru(H)2L2(CO)2]
223 and the formation of the 13CO-containing derivative with different couplings 
A more recent example of exploiting hydride inequivalence to enable 
observation of PHIP, compares two dihydride phosphine complexes where the p-H2 
symmetry is broken in two different ways.224 In [Ru(H)2(PPh3)3(CO)] the hydride 
ligands are chemically inequivalent, whereas in cis-[Ru(H)2(dppe)2] (where dppe = bis-
diphenylphosphinoethane) the hydride ligands are magnetically inequivalent. A time-
resolved NMR study of the photochemically initiated loss of H2 showed that this step 
occurs on the picosecond timescale with binding of p-H2 occurring on the microsecond 
timescale. Traditionally, p-H2 is represented by −½(2IxSx + 2IySy + 2IzSz), where 
½(2IxSx + 2IySy) is the zero quantum coherence term (ZQx) and ½(2IzSz) is the 
longitudinal two-spin-order term. Under thermal reactivity, p-H2 adds asynchronously, 
which causes the amplitude of the ZQx coherence to average to zero, leaving the 
observable transitions arising from the longitudinal two-spin-order term ½(2IzSz).
224 
This is explained in Section 1.4.3, in terms of the bulk magnetisation model, only 
populating the αβ/βα energy levels. Here, however, because the p-H2 reactivity in these 
experiments is initiated photochemically, by a laser which is synchronised with the 
NMR spectrometer, the ZQx coherence is created synchronously and is thus well-
defined. Because the laser is synchronised with the spectrometer, the delay time 
between the laser shot to initiate the reaction and the acquisition of the NMR spectra 
can be altered. This is termed a pump-probe experiment, where during the time delay, 
for chemically inequivalent hydride ligands, the ZQx state evolves coherently into ZQy 
and hence, using a 90 ° radio frequency probe NMR pulse, a signal can be observed, 
even though IzSz + ZQx itself is invisible. This is possible because the 90 ° pulse rotates 
the 2IzSz and ZQx into unobservable zero and double quantum terms respectively, and 
the ZQy term into an observable single quantum term.
224 This is in contrast to a 45 ° 
pulse which has to be used to analyse thermal reactivity due to the presence of the 2IzSz 
spin-order term. Photochemically, the evolution of ZQx into ZQy results in the enhanced 
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hydride NMR spectra of the complexes exhibiting oscillating amplitudes with different 
frequencies. For [Ru(H)2(PPh3)3(CO)], this oscillation frequency of 1101 ± 3 Hz, is 
equal to the frequency diﬀerence between the two chemically inequivalent hydride 
resonances. However, for cis-[Ru(H)2(dppe)2] this frequency of 83 ± 5 Hz is equal to 
the diﬀerence in spin-spin coupling between the hydride ligands and their coupling with 
the 31P nuclei highlighted in Figure 123, which is the origin of their magnetic 
inequivalence. 
 
Figure 123: Structures of [Ru(H)2(PPh3)3(CO)], showing its chemically inequivalent hydride 
ligands, and cis-[Ru(H)2(dppe)2], showing its magnetically inequivalent hydride ligands due to 
their different coupling values to the 31P nuclei highlighted in red 
Before the work described here was started all the examples in the literature of 
active catalysts for SABRE achieved the breakage in p-H2 symmetry by the creation of 
complexes in which the hydride ligands derived from p-H2 are made magnetically 
inequivalent. Very little knowledge of the effect of chemical and magnetic 
inequivalence was known with regard to SABRE-active catalysts. Since 2013, a few 
examples of polarisation transfer using catalysts with inequivalent hydride ligands have 
been published. In one specific case, where polarisation of 31P using [Ir(H)2(PPh3)3Cl] is 
achieved, the essential ligand exchange processes of the H2 and the PPh3 ligand lying 
trans to a hydride ligand, are facilitated at high temperatures in toluene. The chemical 
inequivalence arises from one hydride ligand being trans to a phosphorus and the other 
being trans to the chloride ligand.110  
In this work, the use of bidentate NHC complexes has enabled the production of 
dihydride species which undergo the necessary ligand exchange processes for SABRE 
as described in Section 3.3. In this chapter, the chemical and magnetic inequivalence of 
these hydride ligands is exploited to use the complexes as SABRE catalysts. Due to 
their neutral nature, their activity in a range of solvents using a range of substrates has 
also been examined.  
181 
 
4.2. Polarisation tests with pyridine 
In this work, full characterisation and ligand exchange studies have been 
completed using pyridine as the substrate. Pyridine is a six-membered heterocycle 
containing one nitrogen site. It is a suitable SABRE substrate because it can reversibly 
bind to iridium through its basic nitrogen and this facilitates exchange, whilst couplings 
to proton nuclei enable polarisation transfer. Its ability to be polarised via the SABRE 
approach has been well studied and it is commonly the first substrate tested, due to it 
being the initial model substrate for SABRE.2, 83, 87, 225 
  
Proton Position w.r.t. N 
HA / HE Ortho 
HB / HD Meta 
HC Para 
 
Figure 124: Pyridine showing labelling of protons and their positions within the heterocycle 
with respect to the nitrogen binding atom 
 
4.2.1. Studies using complex 1 
4.2.1.1. Initial tests 
Initial SABRE tests using complex 1 with pyridine and p-H2, gave a maximum 
enhancement of approximately 250-fold, for the ortho proton signal of free pyridine in 
solution. The enhanced 1H NMR spectra in Figure 125 was acquired after the addition 
of p-H2 to a Young’s NMR tube containing pre-activated catalyst and substrate. This 
tube was shaken in the low magnetic field outside of the NMR spectrometer before 
being inserted into the magnet for interrogation (see Experimental Section 8.3.1). Due 
to the study in Section 3.2.2 that showed faster ligand exchange rates occur in methanol 
at higher temperatures, a temperature of 60 °C was chosen. Previous studies using 
[Ir(COD)(IMes)Cl] show that the most efficient Polarisation Transfer Field (PTF) is 
approximately 6.5 x 10−3 T and thus this was used in the initial studies described here. 
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Figure 125: 1H NMR spectra of a sample containing 0.1 M pyridine and 5 mol% 1 in CD3OD 
under 3 bars of H2 after; (A) thermal equilibrium at high field; and (B) polarisation transfer 
from p-H2 at 6.5 x10
−3 T and 60 °C 
As well as observing signal enhancements of the protons of pyridine, analysis of 
the 13C NMR spectra under the polarisation conditions using p-H2 were completed, to 
determine where polarisation was transferred within the pyridine molecules. These tests 
led to polarised 13C NMR spectra being obtained after a single scan, as shown in Figure 
126, where enhanced signals for the three carbon environments of free pyridine are 
observed at δ 124, 137 and 149 for the meta, para and ortho carbon sites respectively. 
Here, as 13C is excited without decoupling, each 13CH environment is present as a 
doublet signal due to the J-coupling that exists between themselves and the polarised 
proton nuclei that they are coupled to. The signals arise from the creation of both Iz and 
IzSz states which have in phase and antiphase signals respectively. The antiphase 
character of the signals in Figure 126 is thus indicative of the IzSz state being the major 
term that is populated during SABRE. Therefore, when the 13C signal is decoupled from 
the attached proton the IzSz state is removed and hence the enhancement is decreased. 
The polarisation of heteronuclei can occur in two ways; either through indirect 
transfer (as here) when polarisation is transferred to coupled protons and then through to 
heteronuclei that couple to the polarised protons,2, 83, 99, 109 or via direct transfer to the 
heteronuclei which can occur when the coupling system is established directly between 
the hydride ligands and the heternuclei of a substrate at extremely low field.107-108, 116, 
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226-228 These tests show that the coupling network that exists within the pyridine 
molecules is sufficient for polarisation transfer to occur, once proton nuclei of the 
substrate molecules are polarised. This could prove important for studies where the 
polarisation can be captured and held on heternuclei, before unlocking the polarisation 
using specially devised NMR pulse programs. 
 
Figure 126: 13C NMR spectra of a sample containing 0.1 M pyridine and 5 mol% 1 in CD3OD 
after polarisation transfer at; (A) 60 °C and 6.5 x 10−3 T; (B) 60 °C and 2 x 10−3 T 
 
4.2.1.2. Effect of polarisation transfer field 
As has been shown for pyridine, the magnitude of polarisation transfer is 
affected considerably by the field at which the polarisation step occurs. This is due to 
having to establish the desired coupling network so that the chemical shift difference, 
between the hydride ligands and the nuclei on the substrate which are to be polarised, is 
approximately equal to the J-coupling between the hydride ligands, as discussed in 
Section 1.6.2 To determine the most effective PTF using 1 with pyridine and p-H2, the 
enhanced Zeeman amplitudes of each of the ortho, meta and para proton signals for 
pyridine were analysed using an automated flow system that is compatible with 
methanol. This involves a polariser cell where the solution is placed and then p-H2 is 
bubbled through the solution for a set time period before automatic transfer into the 
magnet.88 The magnetic field that the solution experiences can be varied linearly by 
changing the current in the polariser coil, which is then used to investigate the effect of 
the PTF and determine the optimum magnetic field (see Experimental Section 8.3.2). 
These tests show that using 1 with pyridine and p-H2, the maximum signal enhancement 
is gained at a PTF of 6.5 x 10−3 T (see Figure 127). Overall, the ortho protons are more 
A 
B 
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readily populated than the meta protons which are again more populated than the para 
protons of pyridine. This population trend may be due to the optimum coupling being 
established between the different proton environments and the hydride ligands.108 
Similar effects have also been seen for other catalyst systems and the magnetic field at 
which the phase change occurs can vary depending on the system studied.86 This study 
shows that in order to achieve the best polarisation levels, a field of 6.5 x 10−3 T needs 
to be employed. Furthermore, both the ortho and para signals appear in emission 
throughout the magnetic field range studied, but the meta proton signal exhibits a phase 
change from emission to absorption at approximately −2.5 x 10−3 T. The appearance of 
the meta signal has been seen for pyridine many times before and is likely due to the 
complex behaviour of the H-H coupling over the time of the experiment and is also 
dependent on whether the polarisation transfer occurs directly or indirectly.1 The 
imbalance in line intensities again suggests that Iz and IzSz type terms result, as 
described in Section 4.2.1.1 for the 13C signals. These different populated states can be 
probed using OPSY.  
 
Figure 127: 1H NMR spectra field plots of a sample containing 0.1 M pyridine and 5 mol% 1 in 
CD3OD after polarisation transfer from p-H2 at r.t. and varying PTF; (A) HA/E; (B) HC; (C) HB/D 
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4.2.1.3. OPSY NMR experiments 
The 1H NMR spectra shown in Sections 4.2.1.1 and 4.2.1.2 are acquired using a 
normal 1H NMR pulse sequence and therefore, as well as the polarised signals, weaker 
thermal signals are also observed. One 1H NMR spectroscopic method to eliminate the 
signals observed from thermal magnetisation is known as Only Parahydrogen 
Spectroscopy (OPSY). This approach involves specifically designed pulse sequences to 
study only those signals that are hyperpolarised and therefore created from the p-H2 
derived nuclei.229 Thermal signal is therefore not observed. OPSY works by using 
gradient pulses to enable coherence selection.229-230 Both double quantum OPSY 
sequences and zero quantum OPSY sequences can be exploited, to probe magnetisation 
shared between two spins. Because p-H2 is described by a spherically symmetric 
magnetic state, any NMR pulse applied to it results in the same magnetic state and 
therefore it is NMR silent. This is why its symmetry has to be broken, by converting it 
into two hydrides on a metal centre. 
𝑝𝐻2 = 2𝐼𝑥𝑆𝑥 + 2𝐼𝑦𝑆𝑦 + 2𝐼𝑧𝑆𝑧 
Under PHIP, the 2IxSx + 2IySy term (ZQx) averages to zero over the reaction as 
described in Section 4.1 and the 2IzSz term survives. The Z magnetisation has a 
coherence order of 0 whereas x and y magnetisations have coherence orders of 1. For an 
OPSY-dq NMR experiment, for example, upon the application of a 90x ° pulse to the 
2IzSz state, the magnetisation vectors are put into the transverse plane and become 2IySy. 
This double quantum coherence evolves further under the chemical shift operator and 
the effect can be dephased or rephased using a gradient pulse. In the case of the double 
quantum coherence, application of a second 90y ° pulse and a second gradient pulse 
with double the area of the first gradient is needed to produce a signal. Any single 
quantum coherences remain dephased and hence signals derived from the initial p-H2 
state are seen selectively. If the second gradient pulse is equal to zero, zero quantum 
coherence is selected and an OPSY-zq NMR experiment is completed. This pulse 
sequence is depicted graphically in Figure 128. The SABRE effect also creates 
longitudinal terms such as IzSz between coupled spins in the hyperpolarised targets. 
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Figure 128: The 1H OPSY NMR pulse sequence 
To remove the additional thermal signal, studies of a sample containing 0.1 M 
pyridine and 5 mol% 1 in CD3OD using an OPSY-dq NMR sequence with p-H2 were 
used to analyse the SABRE effect. OPSY-dq NMR spectra of 6 in CD3OD (see Figure 
129) show that the two hydride signals of 6 are derived from p-H2. This shows that 6 is 
the active SABRE catalyst as these hydride ligands transfer their polarisation to the 
pyridine substrates. Therefore, the pyridine ligands are also observed as they are 
coupled to the p-H2 derived hydride nuclei which creates similar IzSz type magnetisation 
between them. The 1H NMR spectra in Figure 129 were again acquired by adding p-H2 
to a Young’s NMR tube containing the sample of interest and shaking the sample in the 
low magnetic field outside the NMR spectrometer before interrogation. The spectra 
clearly show that at a higher temperature, the signal enhancement is greater, due to 
faster ligand exchange, as discussed in Section 3.2.2, hence greater polarisation build-up 
in free pyridine occurs. 
 
Figure 129: 1H OPSY-dq NMR spectra of a sample containing 0.1 M pyridine and 5 mol% 1 in 
CD3OD after polarisation transfer at; (A) 0 °C and 6.5 x 10
−3 T; (B) 60 °C and 6.5 x 10−3 T 
To improve the repeatability of the experiments, the automated flow system was 
used.88 Figure 130 shows 1H OPSY-dq NMR spectra obtained at different PTFs with the 
maximum enhancement at a PTF of 2.5 x 10−3 T. The PTF also affects the signal 
enhancement of 1H OPSY-zq NMR spectra, where the maximum enhancement is now 
A 
B 
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at a magnetic field of between 6.5 and 7.5 x 10−3 T. This means that at different PTFs, 
different magnetic states, including the higher order double quantum coherence, are 
optimally enhanced. Thus, analysing specific states provides an insight into the range of 
magnetic states that are created during the SABRE process.94, 96 These studies are 
beyond the scope of this work. 
 
Figure 130: 1H OPSY-dq NMR spectra of a sample containing 0.1 M pyridine and 5 mol% 1 in 
CD3OD after polarisation transfer at r.t. and; (A) 2.5 x 10
−3 T; (B) 0 x 10−4 T; (C) −2.5 x 10−3 
T; (D) −5 x 10−3 T; (E) −6.5 x 10−3 T; (F) −7.5 x 10−3 T; (G) −1 x 10−2 T; (H) −1.25 x 10−2 T; 
(I) −1.5 x 10−2 T 
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4.2.1.4. Proton signal enhancements as a function of 
temperature 
As for traditional catalysis, temperature can have a large effect on the 
enhancement levels due to ligand exchange rate variation, as detailed in Section 3.2.2. It 
was anticipated that at the higher temperatures studied, where ligand exchange is the 
most rapid, the signal enhancement values would also be higher. Thus shake-and-drop 
polarisation transfer experiments were conducted at temperatures ranging from ~ 273 K 
to ~ 333 K, which was the safest maximum temperature to test with the solvent 
methanol. The sample, containing 6, was heated in a water bath at each desired 
temperature for 1 minute, then p-H2 was introduced into the headspace of the sample 
and the sample was again brought back up to temperature for a further 10 seconds 
before being shaken at the desired field and acquiring a 1H NMR spectrum. The effect 
of temperature was tested at both the low magnetic field of 2 x 10−4 T (Figure 131) as 
well as at the optimum PTF of 6.5 x 10−3 T (Figure 132), to see whether the same effect 
was observed with the change in field.  
 
Figure 131: Pyridine proton enhancements as a function of temperature after polarisation 
transfer from p-H2 using 5 mol% 1 and 0.1 M pyridine at 2 x 10
−4 T 
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Figure 132: Pyridine proton enhancements as a function of temperature after polarisation 
transfer from p-H2 using 5 mol% 1 and 0.1 M pyridine at 6.5 x 10
−3 T 
Analysis of each proton environment for pyridine shows that upon increasing the 
temperature, the enhancement level also increases, at both magnetic fields, as 
anticipated. It was predicted that the exchange rates and thus enhancement levels would 
increase up to a maximum when the polarisation transfer would be at an optimum, 
which may not be achievable here, due to the boiling point of methanol being 64.7 °C. 
The exchange rates determine the lifetime of the active polarisation transfer catalyst 
species as discussed in Section 3.2.2. At higher temperatures, the rates would become 
too fast for efficient polarisation transfer as the active catalyst’s lifetime is significantly 
reduced and the coupling system’s lifetime is insufficient.87, 89, 93 
When the most efficient catalyst for SABRE to-date is used, in order to compare 
the trends with that observed for 6, the enhancement levels for pyridine when polarised 
using [Ir(H)2(IMes)(py)3]Cl, which forms from the pre-catalyst [Ir(COD)(IMes)Cl], are 
initially at a plateau and then decrease over the temperature range studied, at both 2 x 
10−4 T (Figure 133) and 6.5 x 10−3 T (Figure 134). This suggests that at below ambient 
temperature the exchange rates for efficient polarisation transfer are at an optimum and 
at higher temperatures they become too fast for efficient polarisation transfer to occur.93  
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Figure 133: Pyridine proton enhancements as a function of temperature after polarisation 
transfer from p-H2 using 5 mol% [Ir(COD)(IMes)Cl] and 0.1 M pyridine at 2 x 10
−4 T 
 
Figure 134: Pyridine proton enhancements as a function of temperature after polarisation 
transfer from p-H2 using 5 mol% [Ir(COD)(IMes)Cl] and 0.1 M pyridine at 6.5 x 10
−3 T 
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Figure 135: Temperature effects on normalised enhancements of the HA/E 
1H NMR resonance of 
pyridine after polarisation transfer using p-H2 at 2 x 10
−4 T in CD3OD (0.6 ml); each sample 
contains 5 mol% pre-catalyst ([Ir(COD)(IMes)Cl] or 1) and pyridine (0.1 M) 
 
Figure 136: Temperature effects on normalised enhancements of the HA/E 
1H NMR resonance of 
pyridine after polarisation transfer using p-H2 at 6.5 x 10
−3 T in CD3OD (0.6 ml); each sample 
contains 5 mol% pre-catalyst ([Ir(COD)(IMes)Cl] or 1) and pyridine (0.1 M) 
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To directly compare the general trend in pyridine enhancements when using 
[Ir(COD)(IMes)Cl] and 1 each data set must be normalised by dividing through by the 
largest enhancement factor gained when using each catalyst separately. This is shown in 
Figure 135 and Figure 136 and agrees with previous studies.93 These data show that 
although [Ir(COD)(IMes)Cl] is the best pre-catalyst so far, for newly developed pre-
catalysts, such as 1, optimisation of each variable is very important to gain the best 
performance. 
 
4.2.1.5. SABRE activity in different solvents 
As 6 remains neutral, it should demonstrate a wider solvent tolerance than 
current charged SABRE catalysts such as [Ir(H)2(IMes)(py)3]Cl, which is important 
when considering suitable substrates for SABRE, as not all can be used in the polar 
protic solvent methanol, for example those containing exchangeable protons. Thus, a 
large area of unexplored substrate possibilities exists, for example amines and alcohols. 
Testing of neutral 1, in a variety of solvents, with varying dielectric constants and 
viscosities was carried out to determine whether SABRE catalysis was restricted to the 
traditionally used solvent, methanol. SABRE studies using pyridine as the substrate 
were carried out in five different deuterated NMR solvents; C6D6, THF, CD2Cl2, 
C2D5OD and CD3OD. Complex 1 demonstrated improved solubility in polar aprotic and 
non-polar solvents such as DCM and benzene since it is not a charged species. 
Polarisation transfer to pyridine was also shown to be efficient. It was found that 
SABRE occurs in all the solvents that were studied and signal enhancements of the 
hydrides (see Figure 137) as well as the protons of pyridine were observed (see Table 
30). 
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Figure 137: The hydride region of each 1H NMR spectra when polarising pyridine using 1 in 
the specified solvents along with their dielectric constants, ε, and viscosities, η (cP), at 25 °C 
It was found that upon increasing dielectric constant of solvent, from benzene to 
methanol, the hydride trans to oxygen shifts slightly downfield and remains as a sharp 
signal. However, the hydride trans to pyridine appears much broader in all cases as it 
sits opposite to the exchanging pyridine ligand. The enhancements observed for the 
protons of pyridine are the mean average values from a set of four, along with the 
calculated standard error.231 In all the solvent systems studied, the active catalyst is 
formed but because of its slow production the level of SABRE enhancement observed 
in DCM, benzene and THF is initially lower than in methanol, which is typically used 
for SABRE. The solvent viscosity may also affect polarisation transfer due to relaxation 
effects (see Section 3.4) and in the lower viscosity solvents, more efficient mixing of 
the sample ensures better accessibility to fresh p-H2. This is particularly evident when 
comparing the alcohol samples which are both fully activated after 48 hours; the total 
signal enhancement of pyridine in methanol is more than double that of ethanol, which 
equates with a doubling in viscosity on changing from methanol to ethanol. 
ε = 2.3 
η = 0.60 
 
 
ε = 7.5 
η = 0.46 
 
 
ε = 9.1 
η = 0.41 
 
  
ε = 24.6 
η = 1.07 
 
 
ε = 32.6 
η = 0.54 
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Table 30: Pyridine 1H NMR signal enhancements for a series of 0.05 M pyridine and 15 mol% 1 
solutions at 298 K and 6.5 x 10−3 T with 3 bars of p-H2 after 48 hours and 24 days 
Solvent  C6D6 THF-d8 CD2Cl2 Ethanol-d6 CD3OD 
PHIP for 
hydride site 
after 48 hours 
trans 
to O 
317 ± 13 337 ± 88 231 ± 25 519 ± 84 * 350 ± 28 * 
Py 1H NMR 
enhancement 
after 48 hours 
/ fold 
ortho 116 ± 6 90 ± 8 138 ± 14 71 ± 5 182 ± 9 
meta 90 ± 4 54 ± 5 98 ± 17 26 ± 3 126 ± 9 
para 54 ± 3 49 ± 5 63 ± 7 30 ± 2 81 ± 4 
PHIP for 
hydride site 
after 24 days 
trans 
to O 
273 ± 14 243 ± 26 133 ± 24 1132 ± 257 * 15 ± 4 * 
Py 1H NMR 
enhancement 
after 24 days / 
fold 
ortho 488 ± 54 579 ± 24 316 ± 68 281 ± 29 27 ± 4 
meta 391 ± 53 402 ± 50 237 ± 80 135 ± 24 21 ± 4 
para 219 ± 28 262 ± 12 141 ± 33 141 ± 7 17 ± 2 
* The enhancement levels for the hydride ligand in ethanol and methanol are shown as signal-to-noise 
ratios due to the signal for the hydride ligand not being visible in the thermal spectra. For the other 
samples, the enhancement values are given based on the small thermal signal that was observed. 
After 24 days, the samples were retested (see Table 30) to see the effect of time 
on enhancement levels and determine the relative stability of the complex in different 
solvents. Although initially (after 48 hours) it appears the catalyst is a more efficient 
polarisation transfer catalyst in the polar solvent, methanol, over time its efficiency in 
non-polar solvents improves and no complex degradation is observed in DCM, benzene 
or THF. However, after 24 days the signal enhancements seen in methanol had severely 
dropped off. This relates to the 2H-labelling of the pyridine due to H-D exchange with 
the solvent and incorporation of deuterium into the ortho proton site of the pyridine; 50 
% deuteration of the ortho proton signal for pyridine was observed after 24 days. It 
could also be due to instability of the samples in methanol after longer time periods as 
the sample degrades. In comparison, when using ethanol, the 1H signal enhancements 
for pyridine had increased after 24 days, despite 40 % deuteration of the ortho proton 
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signal for pyridine in ethanol. This could be due to slower activation in ethanol than 
methanol and improved stability in ethanol. The enhancements for the non-polar 
solvents are now much larger than for the polar solvents. This relates to the slower 
activation of the catalyst in non-polar solvents and the fact that deuteration does not 
occur in benzene, DCM or THF. It could also be due to the solubility of the catalyst as 
the fact that it is neutral means it is more soluble in the less polar solvents. Slower 
activation is thought to occur because non-polar solvents such as benzene are either 
unable or only weakly able to be involved in the coordination sphere of the catalyst to 
aid activation. Other factors to consider are; the balance needed between time for 
activation and enhancement factor and the solubility of hydrogen in each different 
solvent. 
On closer inspection, polarisation is seen to be transferred to other proton nuclei 
within the active complex. Analysis of the enhanced 1H NMR spectra of a CD2Cl2 
sample containing 0.05 M pyridine and 15 mol% 1 at 298 K with 3 bars of p-H2 shows 
enhanced signals for the bound pyridine ligands, and resonances of the carbene 
backbone of 6. This is shown in Figure 138, with the minor enhanced signals labelled 
corresponding to the structure. This polarisation transfer to other proton resonances in 
the complex, and not just those of the bound pyridine lying in the trans position to the 
hydrides, is due to the magnetically inequivalent nature of the hydride ligands. These 
enhancements are very small due to the much less efficient coupling that is present 
between the hydrides and these protons, due to the larger distance between them. 
Similar enhanced signals for the complex are seen in both CD3OD and C6D6, although 
they exhibit very low intensities, in comparison to those for pyridine, particularly in the 
thermal 1H NMR spectra. This therefore precludes their quantification and the 
determination of the most effective solvent system for polarisation transfer to the 
protons of the carbene backbone. 
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Figure 138: Enhanced 1H NMR spectrum for a CD2Cl2 sample containing 0.05 M pyridine and 
15 mol% 1 at 298 K and 6.5 x 10−3 T with 3 bars of p-H2 demonstrating that polarisation is also 
transferred in a cis fashion to proton resonances of the bound pyridine ligands and the carbene 
backbone of 6 
The fact that polarisation is observed to transfer weakly across the Ir-O-C bond 
is important when considering potential substrate molecules. Molecules containing 
oxygen donor atoms which can bind to the iridium metal centre may be suitable 
substrates for the polarisation transfer process. They must be able to interact with the 
metal centre to enable the coupling network to establish as well as undergo reversible 
binding. The presence of the oxygen linker does not totally inhibit polarisation transfer.  
py2 
* 
* 
* 
* * 
 
* 
* 
py1 
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4.2.2. Studies using complex 2 
Using 2, polarisation transfer to pyridine occurred in all three solvent samples 
tested, as detailed in Table 31. Therefore, both complex 8, containing only one 
magnetisation-accepting pyridine ligand, and complex 15 containing two, act as 
efficient SABRE catalysts. However, these studies show that polarisation transfer is 
more effective in the less polar aprotic solvents where one of the ligand binding sites is 
blocked by the phenolate ligand, as overall these give the largest signal enhancements. 
Table 31: Pyridine proton enhancement values using 0.07 M pyridine with 10 mol% 2 in C6D6, 
CD2Cl2 and CD3OD under 3 bars of p-H2 after activation for 48 hours and 6 days at a 
polarisation transfer field of 6.5 x 10−3 T 
Solvent 
Starting material: active 
product ratio (activation time) 
Pyridine 1H NMR enhancement 
(fold) 
  ortho meta para 
C6D6 
42: 58 (48 hours) 796 ± 20 544 ± 35 371 ± 14 
0: 100 (6 days) 843 ± 27 600 ± 30 404 ± 13 
CD2Cl2 
26: 74 (48 hours) 754 ± 3 254 ± 14 472 ± 5 
0: 100 (6 days) 877 ± 32 337 ± 57 450 ± 22 
CD3OD 0: 100 (48 hours) 426 ± 5 47 ± 28 243 ± 3 
 
Retesting of the CD2Cl2 and C6D6 samples after 6 days, once no starting material 
remained, showed a slight increase in the average enhancement factors. These values 
are nearly double the values obtained when using complex 1, which links to the 
exchange rates being much faster (see Section 3.2.4). The enhancements in CD2Cl2 and 
C6D6 are much larger than those in CD3OD, despite the catalyst not being fully 
activated. In CD2Cl2 the enhancement factor for the para proton is nearly double that of 
the meta protons which is opposite to the effect in C6D6 where the meta protons are 
more strongly enhanced than the para proton. The enhancement seen for the meta 
protons in CD3OD is also much less than the same signals in CD2Cl2 and C6D6 due to it 
potentially having some antiphase character cancelling out the overall enhancement that 
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is observed. Overall, the enhancement factors of all samples are largest for the ortho 
protons of pyridine. These ortho protons are most strongly coupled to the p-H2 derived 
hydrides, although the meta and para protons also couple to the hydride ligands to 
receive polarisation. Furthermore, the different protons of pyridine couple together and 
can transfer polarisation between each other. However, the effect of T1 relaxation acts to 
reduce the level of polarisation, and this reduction is enhanced by interactions between 
the substrates and catalyst, as previously described in Section 3.4.91 
For the CD2Cl2 and C6D6 samples, the signals for all three of the proton 
environments of pyridine appear with a negative phase with respect to the thermal 
spectra. However, in CD3OD only the ortho and para signals appear with a negative 
phase and the meta proton signal appears positive. The appearance of the enhanced 
signals depends on the spin states that are populated, which is strongly affected by the 
magnetic field used for polarisation transfer and dependent on coupling within the 
system.91 Comparing these different samples indicates that the solvent in which 
polarisation transfer is conducted, can also affect the spin-order terms that are populated 
at the time of magnetisation transfer from p-H2 to substrate ligands. Thus, this is another 
factor that needs to be considered when optimising polarisation transfer to specific 
longitudinal spin states. 
To demonstrate catalyst activity at lower catalyst loadings, samples containing 
larger excesses of pyridine were tested with the enhancement results shown in Table 32. 
The observed enhancement values dramatically decrease due to the inhibition of p-H2 
exchange, relating to the fact that H2 dissociation occurs after pyridine dissociation as 
discussed in detail in Section 3.2.3. However, limited SABRE catalysis does still occur.  
Table 32: Pyridine proton enhancement values using 0.33 M pyridine with 2.3 mol% 2 in 
CD2Cl2 and CD3OD under 3 bars of p-H2 at 6.5 x 10
−3 T and 298 K 
 Pyridine 1H NMR SABRE enhancement (fold) 
Solvent ortho meta para 
CD2Cl2 32 ± 2 12 ± 3 15 ± 1 
CD3OH 8 ± 1 4 ± 1 5 ± 1 
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It is interesting to note that for the CD2Cl2 sample, as the amount of pyridine is 
increased, the Ir-O bond becomes unstable, and is cleaved, and the binding of an extra 
pyridine ligand is facilitated. This therefore leads to the formation of varying amounts 
of 15 as shown in the 1H NMR spectra in Figure 139. At greater excesses of pyridine, 
more of this product forms. As hydride ligands are strong σ-donors they exert a large 
trans effect and weaken the Ir-O bond. To reduce the amount of electron density on the 
iridium metal centre when the pyridine concentration is higher, it is therefore more 
favourable to bind a σ-donor pyridine ligand when compared to a σ-donor and π-donor 
alkoxide ligand, making trapping of the Ir-O bond cleaved form feasible. The higher 
concentration of pyridine also increases the potential to stabilise the charge build-up. 
This matches the behaviour when acid is added to 8, in that the Ir-O bond is broken, 
which may also indicate more generally, the reversible binding ability of the phenolate 
in solution. 
 
Figure 139: Three samples containing 2 in CD2Cl2 with increasing equivalents of pyridine 
showing the formation of 15 from 8; (A) 14 eq., (B) 42 eq. and (C) 72 eq. 
Because the catalyst forms the zwitterionic species in CD3OD, it was decided to 
test its activity in ethanol and in an ethanol: water mixture (30: 70) to see if it showed 
improved solubility and thus activity for biological applications. Despite having activity 
in pure deuterated ethanol, with 1H NMR signal enhancements for pyridine of 240 ± 23, 
40 ± 18 and 130 ± 12 for the ortho, meta and para protons respectively, catalyst 
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solubility was dramatically decreased when 70 % of the solvent from an activated 
ethanol sample was removed and replaced with D2O. The sample turned cloudy and 
although a broad enhanced hydride signal was visible at δ −22.46 for 15, polarisation 
transfer to pyridine was very poor. 
The effect of the PTF used for magnetisation transfer was also examined using a 
CD3OD sample. The appearance of the proton enhancement plots as a function of PTF 
depend on the JHH coupling between the hydride ligands and protons on the substrate 
ligands and the spin states which are then populated, as described in Section 1.6. The 
PTF affects the spin states that are populated as each spin state lies at a different energy, 
dependent on the applied field.91 Therefore, when the PTF is changed, spin state 
energies are changed and thus the levels of polarised enhanced signals are affected. This 
leads to the varied signal intensities seen in the plots in Figure 140.  
In this study, the ortho and para proton signals of pyridine are all in the same 
phase and show the same behaviour with the maximum signal enhancement occurring at 
a PTF of −7.0 x 10−3 T. This is similar to what has previously been reported for pyridine 
using [Ir(COD)(IMes)Cl].88, 93 The two profiles also show a slight increase in signal 
enhancement at zero magnetic field although this is significantly less than at −7.0 x 10−3 
T. In comparison, the signal for the meta protons of pyridine is considerably different 
and shows four phase changes. Again, the maximum enhancement is at −7.0 x 10−3 T in 
the same phase as for the ortho and para protons. A second maximum is observed again 
at zero field, this time with similar intensity to the previous maximum but with the 
opposite phase. These field effects are shown in Figure 140. 
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Figure 140: 1H NMR spectra field plots of a sample containing 0.1 M pyridine and 5 mol% 2 in 
CD3OD after polarisation transfer from parahydrogen at r.t. and varying PTFs from −140 x 
10−4 T to 20 x 10−4 T with the largest signals at a field of −70 x 10−4 T; (A) HA/E; (B) HC; (C) 
HB/D 
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4.2.3. Studies using complexes 3 and 4 
Using 3, CD2Cl2 is the most effective solvent for promoting magnetisation 
transfer from p-H2 to the protons of pyridine. The enhancements for the CD2Cl2 sample 
were measured when the solution contained 10A and 10B in a 37: 63 ratio. 
Table 33: SABRE enhancements for the protons of pyridine for samples containing 0.06 M 
pyridine and 10 mol% 3 under 3 bars of p-H2 at 6.5 x 10
−3 T 
Solvent Pyridine 1H NMR enhancement (fold) 
 ortho meta para 
C6D6 438 ± 53 264 ± 44 170 ± 25 
CD2Cl2 778 ± 65 370 ± 78 416 ± 37 
CD3OD 261 ± 24 152 ± 28 121 ± 12 
 
Using 4, CD2Cl2 is again the most effective solvent for promoting magnetisation 
transfer from p-H2 to the protons of pyridine. All three samples have multiple activated 
species present in solution that can all act as polarisation transfer catalysts. 
Table 34: SABRE enhancements for three activated samples of 4 under 3 bars of H2 at 6.5 x 
10−3 T; a CD2Cl2 sample containing 9 mol% 4 and 0.08 M pyridine, a C6D6 sample containing 7 
mol% 4 and 0.1 M pyridine and a CD3OH sample containing 5 mol% 4 and 0.16 M pyridine 
Solvent 
Starting material: active 
product ratio (activation time) 
Pyridine 1H NMR enhancement 
(fold) 
  ortho meta para 
C6D6 
68: 32 (24 hours) 574 ± 83 367 ± 96 227 ± 49 
29: 71(72 hours) 679 ± 54 407 ± 59 276 ± 27 
CD2Cl2 
42: 58 (24 hours) 680 ± 42 357 ± 49 359 ± 25 
8: 92 (72 hours) 1113 ± 137 586 ± 119 651 ± 78 
CD3OD 0: 100 (4 hours) 216 ± 28 28 ± 18 130 ± 18 
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4.3. Polarisation tests with other substrates  
4.3.1. Studies using complex 1 with nicotinamide 
4.3.1.1. Initial tests 
Nicotinamide (Figure 141) is a biologically relevant derivative of pyridine that 
also binds to the iridium centre of the polarisation transfer catalyst via its basic aromatic 
nitrogen site. The lone pair on the amide nitrogen atom is less available for binding to 
the iridium centre due to delocalisation into the carbonyl bond. Nicotinamide is a 
member of the vitamin B group of molecules and nicotinic acid is metabolised to form 
nicotinamide within the body.232-233 It is used by the body to form nicotinamide adenine 
dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) which 
are important coenzymes involved in many enzymatic oxidation and reduction 
reactions, such as glycolysis and the Krebs Cycle.232-233 Being able to demonstrate 
signal enhancement of biologically relevant substrates via SABRE is important for MRI 
applications. Being able to selectively polarise important drug molecules or precursors 
would be advantageous for imaging as patients would have to spend less time in the 
claustrophobic conditions of an MRI scanner and better resolution images could be 
obtained thereby enabling earlier diagnosis.112 
  
Proton label Chemical shift / δ 
HA 9.04 
HB 8.31 
HC 7.56 
HD 8.71 
 
Figure 141: Nicotinamide showing labelling of protons 
It has previously been shown that polarisation transfer to nicotinamide using the 
SABRE approach and the [Ir(COD)(IMes)Cl] pre-catalyst is effective and enables large 
signal enhancements to be observed. This substrate has been extensively studied using 
p-H2 with the automated flow system.
96 Since nicotinamide has proven itself as a 
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successful SABRE substrate it was thought that the neutral pre-catalyst, 1 should be 
tested for effectiveness at polarisation transfer. It was shown that at 6.5 x 10−3 T and 60 
°C substantial SABRE enhancement was observed (see Figure 142). 
 
Figure 142: 1H NMR spectra of a sample containing 0.1 M nicotinamide and 5 mol% 1 in 
CD3OD after; (A) thermal equilibrium at high field; and (B) polarisation transfer from p-H2 at 
6.5 x 10−3 T and 60 °C 
Analysis of pyridine had shown that at higher temperatures enhancements 
increased and this preliminary test shown in Figure 142 also seemed to demonstrate this 
therefore it was decided to repeatedly test the enhancements of nicotinamide at the 
higher temperature of 60 °C. Upon activation for 1 minute at 60 °C the enhancement 
levels for the four protons of nicotinamide were initially low (see Figure 143). 
However, when repeated, the levels increased so that the longer the overall time that 
was spent at elevated temperature, the larger the signal enhancement of the protons. 
This is also due to continued activation of the sample. 
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Figure 143: 1H NMR spectra of a sample containing 0.1 M nicotinamide and 5 mol% 1 in 
CD3OD at thermal equilibrium (A) and after polarisation transfer from p-H2 at 60 °C and 6.5 x 
10−3 T. Between each run (B-E) the sample was cooled to r.t. before the process was repeated 
Like with pyridine, enhanced 13C spectra were obtained with one scan after 
polarisation transfer at different fields and temperatures (see Figure 144). Again, the 
combination of a PTF of 6.5 x 10−3 T and a temperature of 60 °C gave the best signal 
enhancements of the carbon nuclei within nicotinamide and the 13C spectra show 
improved signal enhancement when compared to the 13C{1H} spectra, for reasons 
discussed in Section 4.2.1.1 (see Figure 145). The enhanced 13C NMR signals 
correspond to free nicotinamide in solution, with the largest signal apparent in both the 
13C and 13C{1H} spectra at approximately δ 125, corresponding to the meta carbon 
position (bonded to HC) within free nicotinamide. Therefore, the established coupling 
network at a magnetic field of 6.5 x 10−3 T, ensures that the most efficient polarisation 
transfer is to this carbon atom. 
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Figure 144: 13C NMR spectra of a sample containing 0.1 M nicotinamide and 5 mol% 1 in 
CD3OD after polarisation transfer from p-H2 at 60 °C and 2 x 10
−4 T (A) and 6.5 x 10−3 T (B) 
 
Figure 145: 13C{1H} NMR spectra of a sample containing 0.1 M nicotinamide and 5 mol% 1 in 
CD3OD after polarisation transfer from p-H2 at 60 °C and 2 x 10
−4 T (A) and 6.5 x 10−3 T (B) 
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4.3.1.2. Effect of polarisation transfer field  
It is known that changing the PTF affects the proton polarisation of each of the 
four sites of nicotinamide.96 Therefore using 1H NMR spectra the enhancement levels as 
the field is varied can be determined. For nicotinamide, all four proton sites are 
polarised, with the isolated HA site showing the greatest signal enhancement. HD shows 
the next largest enhancement, followed by HB. These three proton sites are in the ortho 
and para positions of the heterocycle with respect to the nitrogen site and all 
demonstrate signals in emission. The proton site HC, is meta with respect to the nitrogen 
in the ring and undergoes two phase changes from absorption to emission and back 
again between approximately −1.5 x 10−2 T and −1.25 x 10−2 T and at approximately −5 
x 10−3 T. Similar trends have previously been observed for nicotinamide when polarised 
using [Ir(COD)(IMes)Cl].96 
 
Figure 146: 1H NMR spectra field plots of a sample containing 0.1 M nicotinamide and 5 mol% 
1 in CD3OD after polarisation transfer from p-H2 at r.t. and varying PTF; (A) HA; (B) HD; (C) 
HB; (D) HC  
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4.3.1.3. OPSY NMR experiments 
Again, the use of the OPSY sequence enabled the most efficient PTF to be 
calculated for the zero quantum and double quantum magnetisation states. Initially, 
OPSY-dq tests were conducted on a sample after it had been warmed at 60 °C for 1 
minute, as this had proven most effective for pyridine (see Figure 147). This again 
showed that 6.5 x 10−3 T was a better PTF compared to 2 x 10−4 T. 
 
Figure 147: 1H OPSY-dq NMR spectra of a sample containing 0.1 M nicotinamide and 5 mol% 
1 in CD3OD after polarisation transfer from p-H2 at 60 °C and 2 x 10
−4 T (A) and 6.5 x 10−3 T 
(B) 
Using the flow probe a field plot could be produced to determine the effect that 
changing the field has on the signal enhancements. The largest signals, particularly for 
the two protons in the ortho position to the nitrogen atom, were observed at a PTF of 
between 6.5 x 10−3 T and 7.5 x 10−3 T for both OPSY-dq (Figure 148) and OPSY-zq 
which is consistent with what was observed for pyridine. A minor pair of enhanced 
hydride signals are also seen in these experiments which are proposed to correspond to 
a conformational isomer of the active catalyst species, due to ring-flip of the seven-
membered metallocycle as discussed previously in Sections 2.3 and 2.4. 
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Figure 148: 1H OPSY-dq NMR spectra of a sample containing 0.1 M nicotinamide and 5 mol% 
1 in CD3OD after polarisation transfer from p-H2 at r.t. and; (A) 2.5 x 10
−3 T; (B) 0 x 10−4 T; 
(C) −2.5 x 10−3 T; (D) −5 x 10−3 T; (E) −6.5 x 10−3 T; (F) −7.5 x 10−3 T; (G) −1 x 10−2 T; (H) 
−1.25 x 10−2 T; (I) −1.5 x 10−2 T  
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4.3.1.4. Proton signal enhancements as a function of 
temperature 
Despite the signal enhancements being much less for nicotinamide when 
compared to pyridine using 1 (see Section 4.2.1.4), the same increasing trend in 
enhancements is observed as the temperature is increased. This is true for the PTFs of 2 
x 10−4 T and 6.5 x 10−3 T (Figure 149). Again, when using [Ir(COD)(IMes)Cl], the 
signal enhancements at both magnetic fields reach a plateau at about room temperature 
(see Figure 150). As for 1 with pyridine, it is expected that the exchange rates would 
increase as the temperature increased and therefore at the higher temperatures the rates 
would be optimum for polarisation transfer. The maximum enhancement observed here 
for [Ir(COD)(IMes)Cl] corresponds to a temperature of ~ 30 °C, which is comparable to 
that seen for pyridine as the substrate (see Section 4.2.1.4). Therefore, it would be 
expected that the optimum exchange rates for polarisation transfer would be at this 
temperature. At higher temperatures, the rates become too fast so that the enhancements 
level off and as the temperature is increased further, the enhancements would eventually 
decrease. 
 
Figure 149: Nicotinamide proton enhancements as a function of temperature after polarisation 
transfer from p-H2 using 5 mol% 1 and 0.1 M pyridine at 6.5 x 10
−3 T 
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Figure 150: Nicotinamide proton enhancements as a function of temperature after polarisation 
transfer from p-H2 using 5 mol% Ir(COD)(IMes)Cl and 0.1 M pyridine at 6.5 x 10
−3 T 
 
Figure 151: Temperature effects on normalised enhancements of the HA 
1H NMR resonance of 
nicotinamide after polarisation transfer using p-H2 at 6.5 x 10
−3 T; one containing nicotinamide 
(0.1 M) and Ir(COD)(IMes)Cl (5 mol%) in CD3OD (0.6 ml) and one containing nicotinamide 
(0.1 M) and 1 (5 mol%) in CD3OD (0.6 ml). 
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4.3.2. Studies using complex 2 with 
nicotinaldehyde 
Another pyridine derivative that was investigated was nicotinaldehyde, with the 
structure shown in Figure 152, due to it being a liquid and having high solubility in 
C6D6, CD2Cl2 and CD3OD. Other pyridine derivatives such as nicotinamide proved to 
be insoluble in CD2Cl2 and C6D6 and so could not be investigated further. The signal 
enhancements for the protons of nicotinaldehyde in C6D6 and CD2Cl2 after 48 hours are 
given in Table 35. 
 
Figure 152: Nicotinaldehyde showing labelling of protons 
 
Table 35: Nicotinaldehyde proton enhancement values using 0.05 M nicotinaldehyde with 14 
mol% 2 in C6D6 and CD2Cl2 after activation for 48 hours and 5 days under 3 bars of H2 at 6.5 x 
10−3 T 
 
Starting 
material: 
Product ratio 
Nicotinaldehyde 1H NMR SABRE enhancement 
(fold) 
Solvent  H HA HB HC HD 
C6D6 ~ 54: 46 (48 h) 74 ± 11 226 ± 10 183 ± 14 105 ± 15 209 ± 10 
CD2Cl2 ~ 30: 70 (48 h) 100 ± 11 486 ± 36 400 ± 32 148 ± 34 396 ± 65 
C6D6 0: 100 (5 days) 75 ± 16 259 ± 17 209 ± 22 118 ± 22 244 ± 18 
CD2Cl2 0: 100 (5 days) 81 ± 10 372 ± 25 318 ± 26 140 ± 22 314 ± 28 
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Retesting of these samples after 5 days showed that all the starting material had 
reacted. However, a slight decrease in the average enhancement factors was observed 
when using CD2Cl2 as the solvent, although there was a slight increase when using 
C6D6, as detailed in Table 35. When analysing the spectra obtained from polarisation 
transfer studies, it was noted that in C6D6 and CD2Cl2 the major enhanced peaks are 
those corresponding to free nicotinaldehyde in solution as shown in Figure 153. 
 
Figure 153: 1H NMR spectra after shaking a 0.05 M nicotinaldehyde sample containing 14 
mol% 2 in CD2Cl2 (A) and C6D6 (B) with p-H2 at 6.5 x 10
−3 T 
The 1H NMR chemical shifts of the hydride ligands present in the CD2Cl2 and 
C6D6 samples containing nicotinaldehyde enables the identification of their 
corresponding structures. The chemical shifts are very similar to the equivalent 
complexes formed when the substrate used is pyridine and thus the SABRE-active 
complexes formed here are the nicotinaldehyde derivatives of complex 8. 
 In contrast, the CD3OD sample shows enhanced signals for free nicotinaldehyde 
as well as another species containing aromatic protons. This is because nicotinaldehyde 
is not stable in methanol, but instead reacts in solution to form a hemiacetal.  
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Figure 154: The structure and proton labels of the hemiacetal form of nicotinaldehyde 
Figure 154 shows the structure of the hemiacetal species with the 
nicotinaldehyde: hemiacetal ratio being 1: 3, in a CD3OD solution containing 0.05 M 
nicotinaldehyde. The enhanced 1H NMR spectrum of this sample is shown in Figure 
155, with the aromatic region of the spectrum expanded in Figure 156 along with 
labelled structures of nicotinaldehyde and its hemiacetal form. 
 
Figure 155: 1H NMR spectrum after shaking a 0.05 M nicotinaldehyde sample containing 14 
mol% 2 in CD3OD with p-H2 at 6.5 x 10
−3 T at 298 K 
 
Figure 156: Aromatic region of the 1H NMR spectra after shaking a 0.05 M nicotinaldehyde 
sample containing 14 mol% 2 in CD3OD with p-H2 at 6.5 x 10
−3 T at 298 K, with the labelled 
structures and their corresponding 1H NMR signals 
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Table 36: The proton enhancement values of nicotinaldehyde and its hemiacetal form, using a 
CD3OD solution of 0.05 M nicotinaldehyde with 14 mol% 2 after 48 hours and 5 days at 6.5 x 
10−3 T and 298 K 
Substrate 1H label Chemical shift / δ 1H NMR SABRE enhancement (fold) 
   After 48 h After 5 days 
Nicotin-
aldehyde 
H 10.13 7 ± 2 6 ± 1 
HA 9.07 52 ± 8 41 ± 5 
HB 8.33 67 ± 12 54 ± 6 
HC 7.66 2 ± 2 2 ± 2 
HD 8.82 57 ± 7 45 ± 5 
Hemi-
acetal 
form 
H’ 5.63 17 ± 4 12 ± 2 
HA’ 8.65 62 ± 7 49 ± 6 
HB’ 7.95 59 ± 10 41 ± 5 
HC’ 7.46 26 ± 7 22 ± 2 
HD’ 8.50 65 ± 6 63 ± 7 
 
The signal enhancements of each proton of both nicotinaldehyde and its 
hemiacetal form are given in Table 36. They show that the aldehyde proton of 
nicotinaldehyde, and the same proton in the hemiacetal form after nucleophilic addition 
of methanol, are both enhanced. This polarisation arises from the 4J-coupling to the 
aromatic protons on the pyridyl ring and thus demonstrates that longer range coupling 
and transfer across other atoms is possible. 
There are also multiple enhanced hydride signals observed in Figure 155, 
commensurate with several different SABRE-active catalysts present in solution. Since 
methanol can also act as a ligand in the SABRE process and receive polarisation (as 
observed in this study), many methanol-containing species are also present as depicted 
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in Figure 157. The wide variety of dihydride complexes present in solution explains the 
complicated hydride region of the 1H NMR spectra.  
 
Figure 157: Different SABRE-active complexes formed in CD3OD 
 
4.3.3. Studies using complex 2 with nicotine 
To look at a more biologically relevant molecule that still contains a pyridyl ring 
and exhibits good solubility in the desired solvents, (S)-nicotine was chosen. SABRE 
enhancements were analysed in C6D6, CD2Cl2 and CD3OD and were found to be more 
than ten times better in both C6D6 and CD2Cl2 when compared to CD3OD. 
 
Figure 158: Nicotine showing labelling of protons 
 
Table 37: 1H NMR signal enhancements of the aromatic protons of nicotine using 0.05 M 
nicotine with 14 mol% 2 in the specified solvents under 3 bars of p-H2 at 298 K and 6.5 x 10
−3 T 
 Nicotine 1H NMR SABRE enhancement (fold) 
Solvent HA HB HC HD 
C6D6 400 ± 54 315 ± 48 88 ± 30 338 ± 80 
CD2Cl2 419 ± 51 381 ± 48 146 ± 44 386 ± 55 
CD3OD 29 ± 4 28 ± 3 3 ± 3 31 ± 3 
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As expected, both samples in CD2Cl2 and C6D6 at 298 K showed two major 
PHIP enhanced hydride signals at δ −22.60 and −25.44 in CD2Cl2 and at δ −21.85 and 
−24.33 in C6D6. Several minor non-PHIP active hydrides were also visible. In CD3OD, 
the Ir-O bond is again broken, consistent with the reactivity observed using pyridine and 
nicotinaldehyde. However, two enhanced hydride signals are visible at δ −22.21 and 
−22.27 as shown in Figure 159.  
 
Figure 159: 1H NMR spectra after shaking a 0.05 M nicotine sample containing 14 mol% 2 in 
CD2Cl2 (A), C6D6 (B) and CD3OD (C) with p-H2 at 6.5 x 10
−3 T 
On closer inspection, for the sample in CD2Cl2, the thermal signal at δ −22.60 
appears as two overlapping doublets after multiple scans, which both show a coupling 
constant of 7.5 Hz (see Figure 160). These are equal to the coupling corresponding to 
the doublet hydride signal at δ −25.44. Upon cooling the sample to 240 K, both hydride 
signals now appear as two overlapping doublets with a common coupling constant of ~ 
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7.5 Hz (see Figure 160). For the C6D6 sample at 298 K, the two hydride signals also 
appear as overlapping doublets with common coupling constants of ~ 7.4 Hz. It is 
assumed that the same case exists here as for CD2Cl2 but the relatively high melting 
point of C6D6 prohibited lower temperature studies.  
 
Figure 160: 1H NMR spectra of the major hydride signals present in a solution of 8nicotine in 
CD2Cl2 at 298 K (A) and 240 K (B) 
The fact that all three samples contain double sets of hydride signals is 
consistent with two isomers of 8nicotine forming in solution. This is due to nicotine being 
chiral, which leads to the formation of two different species in each solution. This 
occurs when the nicotine ligand and oxygen ligand, that lie in the same plane as the 
hydride ligands, exchange positions due to nicotine exchange. This is discussed in detail 
in Section 3.2.1 for the substrate pyridine. The corresponding isomers are depicted in 
Figure 161. The aromatic regions of the 1H NMR spectra are also considerably 
complicated on cooling, as would be anticipated for solutions containing two very 
similar species in equilibrium. 
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Figure 161: The isomers of 8nicotine formed in CD2Cl2, C6D6 and CD3OD, depending on the 
orientation of the chiral nicotine ligands 
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4.4. Conclusion 
Due to the neutral nature of the bidentate iridium carbene complexes, and their 
ability to undergo both substrate and H2 exchange, efficient polarisation transfer 
catalysis is observed in a wide range of solvents when the complexes are reacted with 
substrate under p-H2. When using 6, pyridine and nicotinamide demonstrate good levels 
of hyperpolarisation, achieved via the SABRE approach, with polarisation of both 
proton and carbon nuclei being possible. Complex 6 remains neutral in solution due to 
retention of its iridium-oxygen bond, in both polar protic, aprotic and non-polar solvents 
such as methanol, dichloromethane and benzene. The higher solubility of the pre-
catalyst, 1, in dichloromethane and benzene aids its reactivity, when compared to that in 
methanol and ethanol. For THF, the total associated 1H NMR signal enhancements for 
the protons of pyridine show an increase of 1200-fold. Complexes 2, 3 and 4, once all 
activated with substrate and p-H2, also all undergo substrate and hydrogen exchange and 
thus act as efficient SABRE catalysts, with the highest signal enhancements using each 
catalyst typically being observed in CD2Cl2. The best signal enhancements of the 
protons of pyridine are shown for each pre-catalyst in Table 38. 
Table 38: Summary of the 1H NMR signal enhancements for the protons of pyridine for samples 
of each pre-catalyst in CD2Cl2 at 298 K and 6.5 x 10
−3 T 
Pre-
catalyst 
 
Hammett 
parameter 
Sample in 
CD2Cl2 
Pyridine 1H NMR SABRE 
enhancement (fold) 
 R σp−  ortho meta para 
1 NO2 1.27 
0.05 M py 
15 mol% 1 
316 ± 68 237 ± 80 141 ± 33 
2 H 0.00 
0.07 M py 
10 mol% 2 
877 ± 32 337 ± 57 450 ± 22 
3 COOMe 0.75 
0.06 M py 
10 mol% 3 
778 ± 65 370 ± 78 416 ± 37 
4 Cl 0.19 
0.08 M py 
9 mol% 4 
1113 ± 137 586 ± 119 651 ± 78 
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The polarisation transfer process depends on several factors, which have been 
investigated to optimise the catalytic system. The ligand exchange rates during the 
SABRE process are very important to ensure the desired coupling network is 
established to enable polarisation transfer. In the polar aprotic and non-polar solvents, 
the ligand exchange rates are increased as described in Section 3.2.4 and here this is 
shown to correspond to larger signal enhancements. However, these ligand exchange 
processes adversely affect the T1 relaxation of the protons of pyridine and therefore at 
low temperature, when exchange is inhibited, T1 values of free pyridine increase whilst 
those of bound pyridine ligands decrease. This exemplifies the important role the 
catalyst plays in accelerating the relaxation of the substrate ligands.  
Temperature also plays an important role in SABRE catalysis, with the level of 
signal enhancement being increased further through warming. The largest signal 
enhancements for both pyridine and nicotinamide were achieved at the highest 
temperature of ~ 330 K that could be safely studied. This is in stark contrast to the trend 
observed for [Ir(COD)(IMes)Cl], where its optimum operating temperature has been 
reported as 274 K.93 The magnetic field experienced by the sample at the point of 
catalytic magnetisation transfer is also particularly critical for SABRE. The most 
efficient Polarisation Transfer Field for both pyridine and nicotinamide, using the 
solvent methanol, was found to be ~ 6.5 x 10−3 T. The observations described here 
reflect a dramatic improvement in solvent tolerance of SABRE over that reported for 
the current best polarisation transfer catalysis precursor, [Ir(COD)(IMes)Cl]. 
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5. Optimisation of SABRE catalysis for a 
new ligand class 
5.1. Introduction 
Thus far, there are many examples in the literature demonstrating the 
hyperpolarisation of nitrogen-containing aromatic heterocycles, with pyridine being the 
model substrate as exemplified by the large number of publications detailing SABRE 
experiments.2, 79, 88, 93, 107-108, 225, 234-235 A significant amount of work has also been 
completed using pyridine derivatives such as nicotinamide.96, 236 One example uses 
nicotinic acid-modified oligopeptides237 with polarisation of the protons of the pyridyl 
unit acting as an NMR handle due to observation of enhanced signals. However, 
enhancements of the oligopeptides themselves are not observed. Some examples of 
heterocycles which demonstrate enhanced aromatic proton signals are shown in Figure 
162.81, 84, 94, 97, 113, 238 Studies using pyridine and other derivatives are exemplified in this 
work, in Chapter 4. 
 
Figure 162: Nitrogen-containing heterocycles (from left to right); isoxazole,81 3-amino-1,2,4-
triazine,113 quinolone,238 pyrazole,84 pyridazine,94 and pyrazinamide97 
However, only a few examples of polarisation transfer to different ligand classes 
exist. One such example99 demonstrates the feasibility of the SABRE process for 
polarising cyano-containing substrates such as acetonitrile, propionitrile and 
benzylnitrile, with an in-depth experimental and theoretical analysis completed using 
acetonitrile. Here, the atom which binds to the metal centre to aid polarisation transfer is 
still a nitrogen atom. This work shows the importance of establishing a coupling 
network between the p-H2 derived hydride ligands and protons of the substrate ligands, 
as when the CH3 group of acetonitrile was replaced with a CD3 group, no polarisation 
transfer was observed.99 
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In 2011, a study by Glöggler et al.239 detailed signal enhancements of amino 
acids and oligopeptides in CD3OD at very low magnetic field when Crabtree’s catalyst 
was used. Binding of the amino acids was postulated to occur in two ways as shown in 
Figure 163, to facilitate polarisation transfer. The amino acids described are glycine, 
histidine and phenylalanine along with the oligopeptides Glycine-Glycine and Proline-
Histidine-Leucine. 
 
Figure 163: Two proposed binding modes between amino acids and activated Crabtree’s 
catalyst that enable polarisation transfer when reacted with p-H2
239 
Another example by Moreno et al.240 describes the observation of enhanced 
signals for the solvent, methanol, in which SABRE transfer is conducted. The enhanced 
proton signal that is observed is due to residual CD3OH in the solution and they propose 
two mechanisms for its polarisation; either direct polarisation transfer via solvent 
binding (also noted previously84 and as occurs for the heterocyclic substrates) or via 
proton exchange in acidic medium. The proton exchange route to polarisation transfer is 
shown in Figure 164. 
 
Figure 164: Route to observing enhanced signals for the solvent OH peak occurring via proton 
exchange in acidic medium240 
Within the literature, the majority of hyperpolarisation experiments are 
conducted in deuterated protic solvents, with the most common being methanol. This 
therefore becomes a problem when any substrates that have exchangeable protons want 
to be exploited, as rapid H/D exchange with deuterated methanol occurs, inhibiting the 
SABRE process.84 If systems containing exchangeable protons also contain an aromatic 
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nitrogen atom, then binding and SABRE activity in methanol is still possible, as 
demonstrated for the substrates pyrazole84 and 4-aminopyridine.241 However, the amino 
protons are not observed and thus cannot be analysed directly. 
Amino groups are ubiquitous in nature. They are vital to life due to their 
presence in amino acids which make up peptides in all living things. Amino acids are 
also biochemical precursors to amine molecules and their degradation leads to the 
formation of amines. One example is the formation of serotonin from the amino acid 
tryptophan, via two enzymatic steps involving tryptophan hydroxylase and a 
carboxylase enzyme as shown in Figure 165.242 This leads to formation of the important 
neurotransmitter serotonin, which is commonly associated with a feeling of happiness 
and well-being. Other important neurotransmitters incorporating amine functionalities 
include norepinephrine, dopamine and histamine and these are also shown in Figure 
165. 
 
Figure 165: Biosynthesis of serotonin from tryptophan in the body242 and structures of some 
other amine-containing neurotransmitters; norepinephrine, dopamine and histamine 
Since amines are found throughout the body, particularly within the brain, 
amine-containing molecules are of huge pharmaceutical importance. This is because 
their biological activity can often be used to mimic or inhibit the action of the natural 
amines themselves or other species which can affect the natural amines. They can 
therefore serve as highly active and effective drugs to treat several illnesses. For 
example, drugs which act to increase the amount of serotonin are often targets for 
treatments for depression and anxiety, since serotonin is associated with positive moods. 
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One way to achieve this is to target the metabolic pathway that acts to decrease the 
availability of monoamine neurotransmitters. Many drug types have thus been 
developed as monoamine oxidase inhibitors (MAOI).243 These act to prevent the 
breakdown of monoamine neurotransmitters and thus increase their concentration 
within the body. They can therefore act as effective antidepressants. Some examples are 
shown in Figure 166. 
 
Figure 166: Examples of monoamine oxidase inhibitors containing amine groups; the amine is 
present as a hydrazine group in phenelzine and hydracarbazine, an amide group in 
moclobemide and a primary amine in (1S,2R)-(−)-tranylcypromine 
Another important type of widely used drug is anaesthetics. There are two main 
classes of local anaesthetics; ester-containing compounds and amide-containing 
compounds. A number of these also contain amine functionalities as shown by the two 
structures in Figure 167. These local anaesthetics work by binding to sodium channels 
to prevent the propagation of impulses along a nerve.244-245 
 
Figure 167: The structures of two local anaesthetics, tetracaine and prilocaine, both containing 
amine functionalities 
Amines also have many industrial applications. One important industrial 
reaction is the Haber-Bosch process; the direct formation of ammonia from hydrogen 
and nitrogen. High temperatures of between 400 and 500 °C and high pressures of up to 
250 bars are required, along with a heterogeneous metal catalyst.246 The catalyst is iron 
oxide-based, typically containing other metal oxides such as calcium, silicon and 
aluminium. The porosity of the material ensures a large surface area for the reaction to 
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occur and unreacted gases are recovered and reacted again to produce high yields of 
ammonia. The largest use of the ammonia produced in this process is as agricultural 
fertiliser to grow food crops, with other uses being as a household cleaner and as an 
important precursor for amine synthesis. 
There are also several other industrial areas which rely on amine molecules. 
Many synthetic dyes are based on the aniline motif247-249 and are thus needed in order to 
form azo dyes, which have intense colours due to their highly active chromophore 
regions. The structure of aniline yellow is shown in Figure 168, with the azo region 
highlighted. 
 
Figure 168: The structure of aniline yellow with the azo group highlighted in red 
Fatty amine compounds are also important as they are widely used in 
formulations such as in the healthcare industry in personal care products and as 
additives in the lubricants industry. They are typically synthesised from naturally 
derived fatty acids via reaction with ammonia to form fatty nitrile compounds, followed 
by hydrogenation of the nitrile to form the fatty amine derivatives. These molecules act 
as surfactants due to their hydrophilic amine head groups and hydrophobic hydrocarbon 
chains and can thus reduce friction and corrosion in engines and emulsify cosmetic 
formulations. 
This chapter focuses on a few amine molecules as substrates for the SABRE 
process. Some of the amine compounds employed are known neurotransmitters and are 
thus biologically compatible, which could prove important for MRI applications in the 
future. Complex 1 is used as the SABRE pre-catalyst due to its improved stability over 
the other bidentate carbene complex derivatives developed in this work. 
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5.2. Analysing polarisation transfer to amines 
This section includes an analysis of several amino-containing substrates, from 
the simplest amine, ammonia, to the biologically relevant tryptamine molecule and 
investigates their reactivity with complex 1 in CD2Cl2 under an atmosphere of H2. The 
substrate molecules, ammonia, benzylamine, phenethylamine and tryptamine, are 
shown to react with complex 1 in the presence of H2 to form several reactive complexes 
in solution, some of which undergo the relevant exchange processes that lead to 
observation of the SABRE effect in the proton resonances of the amine molecules. 
These tests reveal the formation of complex mixtures in solution, and a number of these 
species exhibit very broad signals due to the amine substrates being poor ligands and 
undergoing rapid ligand and proton exchange. These reasons thus precluded full 
characterisation of all the associated complexes and instead specific indicative 1H NMR 
signals for particular complexes were used to aid individual assignments. 
For a generic amine substrate, N, multiple different species exist as exemplified 
in Figure 169 and described for the specific amine substrates ammonia, benzylamine, 
phenethylamine and tryptamine respectively, in the following sections. The formation 
of these different species is substrate dependent and where possible, full characterisation 
of complexes containing specific substrates has been detailed in the following sections 
or given in the Experimental Sections 8.6.6 to 8.6.17. Otherwise, the complexes 
presented, are described based on similar species observed with different amine 
substrates and the hydride ligand signals are detailed. 
 
Figure 169: Summary of the different complexes formed when 1 is reacted with an amine 
substrate in the presence of H2 where A is the expected SABRE-active product as observed 
when pyridine is the substrate, B is a singlet hydride species which does not undergo PHIP and 
C is a dimer species seen at low concentrations of substrate 
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5.2.1. Ammonia 
In order to test the binding and polarisation transfer to the simplest amine, 
ammonia, enough gas to create a 0.1 M solution of ammonia was transferred, via a high 
vacuum line, into a CD2Cl2 solution containing 5 mol% 1. After addition of H2 and 
analysis with p-H2 at 298 K after 48 hours of activation, the effect of polarisation 
transfer was evident in the 1H NMR spectrum for free and bound NH3 as well as for 
several hydride ligands. However, the signals were not enhanced and all signals were 
broad. Two broad hydride resonances corresponding to the SABRE-active iridium 
complex, 6ammonia, were seen at δ −23.15 and −30.63 and the structure shown in Figure 
170 is proposed based on that observed when pyridine is the substrate, as discussed in 
Section 2.4.1. A set of four sharper coupled hydride signals at δ −26.00, −26.45, −30.62 
and −30.80 were also evident. These correspond to a dimeric species, 21ammonia, such as 
that depicted in Figure 170. However, their low concentration precluded full 
characterisation (see Section 5.2.3 for an in-depth discussion of the dimer present when 
the substrate is phenethylamine). To enable more accurate measurements and better 
control over the amount of amine used, liquid amines were then exploited. 
 
Figure 170: The SABRE-active monomer species, 6ammonia, and a postulated dimeric structure, 
21ammonia 
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5.2.2. Benzylamine 
Benzylamine was chosen as another simple amine. After activation of a CD2Cl2 
sample containing 6.5 mol% 1 and enough benzylamine (18 equivalents) to form a 0.08 
M solution, under 3 bars of H2 at 298 K, two main species are evident, in an 
approximate ratio of 45: 55. The first species contains a pair of very broad hydride 
signals at approximately δ −23 and −30. Upon the addition of p-H2 to this sample at 298 
K, these two signals demonstrate slight PHIP along with enhanced signals for the 
protons of benzylamine as shown in Figure 171. These signals arise from the SABRE-
active species, 6benzylamine, as shown in Figure 172 and as described for the substrate 
ammonia in Section 5.2.1. 
 
Figure 171: Single scan 1H NMR spectra at thermal equilibrium (A) and on the addition of p-H2 
at 6.5 x 10−3 T (B) showing the polarised hydride ligands and the SABRE-enhanced 
benzylamine signals 
H2 
CH2 
NH2 
CHAr 
HB 
HA 
H of 22 
4 x H of 21 
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Figure 172: SABRE-active species 6benzylamine and complex 22benzylamine containing only one 
hydride ligand, formed on reaction of benzylamine with 1 in CD2Cl2 under 3 bars of H2 
The second species contains a sharp singlet hydride signal at δ −28.60 which 
corresponds to a hydride ligand that lies trans to the phenolate arm. When examined 
with p-H2, this singlet hydride signal shows no enhancement, indicating no ligand 
exchange. The structure for this species is shown as 22benzylamine in Figure 172, with the 
full structure shown in Figure 173. Full characterisation data are given in the 
Experimental Section 8.6.7. The 1H NMR spectrum only shows four aromatic signals 
for the benzylamine ligand trans to the carbene ligand, consistent with C-H activation 
of the aromatic ring of benzylamine. Thus the coordination site labelled X in Figure 172 
is a carbon atom. This is also commensurate with that observed for tryptamine as 
discussed in detail in Section 5.2.4. Upon cooling this sample to 258 K, the hydride 
ligands that correspond to 6benzylamine are considerably sharper and slightly shifted to δ 
−22.88 and −30.50. The hydride signal at δ −28.60 for species 22benzylamine is not 
affected. 
 
Figure 173: Full structure of complex 22benzylamine (N1 signifies benzylamine) 
Four much sharper PHIP enhanced hydride signals are also observed in the 1H 
NMR spectrum at δ −26.45, −26.94, −30.30 and −30.63 when this sample is examined 
with p-H2 at 298 K (see Figure 171). These are like those observed with ammonia as 
described in Section 5.2.1. This species is labelled 21benzylamine in Figure 174. Thermally 
these signals are only observed after a considerable number of scans and thus the 
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enhanced signals for the hydride ligands of 21benzylamine when using p-H2 exemplify a 
major benefit of PHIP, in that previously unidentifiable minor species are seen.  
 
Figure 174: Iridium dimer 21benzylamine and the alkene-dihydride species 5, formed on reaction of 
benzylamine with 1 in CD2Cl2 under 3 bars of H2 
 
Figure 175: 1H COSY NMR spectrum showing coupling between the four hydride signals of 
21benzylamine 
On cooling to 258 K, the four sharp hydride signals still exchange with p-H2 and 
are shown to couple via a 1H COSY NMR spectrum (see Figure 175). The two 
resonances, at about δ −27, are both doublets of doublets; at δ −26.45 with coupling 
constants of 5.6 and 9.0 Hz and at δ −26.72 with coupling constants of 8.1 and 9.0 Hz. 
The two at about δ −31 are doublets; at δ −30.33 with a coupling constant of 8.1 Hz and 
at δ −30.66 with a coupling constant of 5.6 Hz. Hence the formation of a tetrahydride-
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containing species is confirmed, although further characterisation was again 
unachievable. A further species also becomes visible at 258 K, containing another pair 
of very broad hydride signals at δ −12.83 and −19.54 which corresponds to the alkene-
dihydride intermediate 5 that still contains COD. This is common in these complexes, as 
previously detailed in Section 2.4.1, and proton resonances for the bound alkene protons 
exist at δ 2.69 and 2.44. The H2 exchange at 298 K is too fast for this species to be 
observed, due to broadening of the signals into the baseline of the NMR spectrum as 
described previously in Section 2.4.2. However, after longer time periods it converts 
into the benzylamine-containing complexes with full hydrogenation of the COD. 
Upon cooling to 258 K the ratio of 6: 22: 21: 5 for this benzylamine-containing 
sample is approximately 51: 40: 3: 6 after 6 days of activation at room temperature 
under 3 bars of H2. Upon decreasing the amount of benzylamine in solution, the amount 
of 21benzylamine increases such that a sample containing approximately two equivalents of 
benzylamine (0.03 M solution of benzylamine and 33 mol% 1), at 263 K, contains a 
ratio of 6: 22: 21: 5 of about 38: 24: 32: 5 after 5 days of activation under 3 bars of H2. 
Characterisation of 21benzylamine is hindered by the overlapping of its corresponding 1H 
NMR peaks. 
Detailed in Table 39 are the corresponding SABRE 1H NMR signal 
enhancements for the proton sites of benzylamine. It is obvious that polarisation is 
transferred a long distance through the molecule and that this is more effective when 
less benzylamine is used, even though the proportion of 6benzylamine drops. 
Table 39: SABRE 1H NMR signal enhancements at 298 K and 6.5 x 10−3 T for the two samples 
containing 6.5 mol% 1 and 0.08 M benzylamine (~ 18 eq.) and 33 mol% 1 and 0.03 M 
benzylamine (~ 2 eq.) 
Proton signal of benzylamine 5 x CHAr CH2 NH2 
Thermal signal integral 5 2 2 
Enhanced signal for ~ 18 eq. of benzylamine  8 ± 1 9 ± 1 7 ± 1 
Enhanced signal for ~ 2 eq. of benzylamine  19 ± 1 4 ± 1 2 ± 1 
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5.2.3. Phenethylamine 
To see if the polarisation could be transferred further within a molecule, 
phenethylamine was tested, as compared to benzylamine, it has one more CH2 group 
between the amine and the aromatic ring. A CD2Cl2 sample containing approximately 
33 mol% 1 and enough phenethylamine for a 0.03 M solution was prepared and both the 
SABRE-active species, 6phenethylamine, and the dimer, 21phenethylamine, were formed. Both 
complexes demonstrated PHIP, with the corresponding 1H NMR signal intensity gains 
for the five aromatic protons and the two CH2 groups of phenethylamine being 24 ± 3, 
11 ± 1 and 13 ± 1-fold respectively, demonstrating therefore, a total signal increase for 
the protons of phenethylamine of approximately five times larger than the equivalent 
thermal signal. When the concentration of phenethylamine in solution was increased, 
such that the sample contained 5 mol% 1 and 0.1 M phenethylamine, the intensity gains 
decreased to approximately 3 ± 1 and 4 ± 1-fold for the two CH2 groups of 
phenethylamine. The enhancement of the NH2 group could not be quantified due to 
signal overlap, which led to the thermal signal corresponding to more than two protons. 
In this system, no singlet hydride signal was observed.  
Complex 6phenethylamine showed very broad hydride signals at δ −23.20 and 
−30.60 which sharpened on cooling to 263 K. At 263 K, the four hydride signals for 
21phenethylamine appear at δ −26.33, −26.71, −30.59 and −30.97. The two resonances at 
about δ −27 are again doublets of doublets; at δ −26.33 with coupling constants of 6.0 
and 8.8 Hz and at δ −26.71 with coupling constants of 8.0 and 8.8 Hz. The two at about 
δ −31 are doublets; at δ −30.59 with a coupling constant of 8.0 Hz and at δ −30.97 with 
a coupling constant of 6.0 Hz. The ratio 6: 21 was approximately 68: 32 at 263 K. 
Complex 21phenethylamine forms due to the low amount of amine present in solution and 
thus the complexes dimerise to stabilise the iridium metal centres. Therefore, when a 
sample containing only one equivalent of phenethylamine relative to pre-catalyst was 
prepared and activated under 3 bars of H2 for 4 days, species 21phenethylamine was the only 
major species present in solution. When the sample was shaken with p-H2 no 
enhancements were observed, showing that the route to PHIP enhancement of the 
hydride ligands of 21phenethylamine is via dimer cleavage, H2 exchange and subsequent 
dimer reformation, which can only be possible when more than one equivalent of 
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substrate is present in solution. Hence, alone, this complex is not responsible for the 
SABRE activity. 
Several tetrahydride iridium dimer species have been described in the literature 
that have similar structures to that proposed for 21phenethylamine. Three species are shown 
in Figure 176. Complexes A and B, described by Gruber et al. in 2013,250 form via 
addition of hydrogen and in the presence of acetonitrile or DCM respectively. Complex 
A has hydride ligand signals that appear at δ −17.77, −18.00, −20.04 and −20.24 in the 
1H NMR spectrum and on replacement of acetonitrile with DCM these shift to δ −16.15 
and −26.46, and demonstrate more fluxional behaviour due to the weakly binding DCM 
molecules and their exchange with the bulk solvent. The hydride region of the 1H NMR 
spectrum of complex A is shown in Figure 177, with the four terminal and bridging 
hydride ligands being inequivalent due to the orientation of the iso-propyl groups on the 
ligand. This is also commensurate with the complex being asymmetric. 
 
Figure 176: Three tetrahydride iridium dimer species described by Gruber et al.250 (A and B) 
and Bianchini et al.251 (C) 
 
Figure 177: The hydride region of the 1H NMR spectrum for complex A as detailed in Figure 
176 (Reprinted with permission from Gruber, S.; Neuburger, M.; Pfaltz, A. Organometallics 
2013, 32, 4702. Copyright © 2013 American Chemical Society)250 
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In the proposed structure of 21phenethylamine the inequivalent hydride signals arise 
due to the bent conformation and thus differing orientations of the seven-membered 
metallocyclic carbene ligand. This is equivalent to that observed for complex A shown 
in Figure 176 where the bidentate backbone and the fact that the two iso-propyl groups 
point downwards, lead to the hydride ligands becoming inequivalent as shown in the 1H 
NMR spectrum of the hydride region of complex A in Figure 177.250 
Complex C as shown in Figure 176, containing a tridentate phosphine ligand 
(triphos), was described by Bianchini et al.251 in 1993 and was found to form in the 
solid state via dimerisation of an [Ir(H)2(triphos)][BPh4] fragment. This fragment 
formed from ethene loss from [Ir(H)2(triphos)(C2H4)][BPh4]. The same ligand 
dissociation step from complex 6, [Ir(H)2(NHC-O)(amine)2], to form [Ir(H)2(NHC-
O)(amine)] (which is a necessary mechanistic step in the SABRE process) can be 
followed by dimerisation rather than ligand binding when low concentrations of ligand 
are present. This leads to the formation of the dimer complex, 21phenethylamine. The 
structure of 21phenethylamine is given in Figure 178 and its characterisation data are given 
in the Experimental Section 8.6.6. Multiple overlapping signals due to the very similar 
chemical shifts of the two bidentate carbene ligands and the multiple amine ligands, 
means that in some cases full characterisation is not possible. At 243 K, a minor isomer 
is also present with hydride ligand signals at δ −25.33 (dd, 2J(HH) = 6.1, 7.8 Hz), 
−26.03 (dd, 2J(HH) = 7.8, 7.8 Hz), −30.46 (d, 2J(HH) = 6.1 Hz) and −30.53 (d, 2J(HH) 
= 7.8 Hz). Its very low concentration precluded full characterisation. 
 
Figure 178: Line drawing of complex 21phenethylamine (N signifies phenethylamine) 
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5.2.4. Tryptamine 
To expand the range of amines that could be polarised, the biologically relevant 
minor neurotransmitter tryptamine was chosen. Upon activation of a CD2Cl2 sample 
containing approximately 12 mol% 1 and enough tryptamine for a 0.04 M solution with 
H2 at 298 K, one major species was formed in ~ 96 % yield with a minor species 
contributing the other ~ 4 %. The low solubility of tryptamine in CD2Cl2 meant higher 
concentrations of tryptamine could not be used. The minor species present in solution 
contained two inequivalent hydride ligands at δ −22.90 and −30.55 which were both 
broad at 298 K. Upon addition of p-H2, this species, 6tryptamine demonstrated SABRE 
and the two hydrides were evident as enhanced broad signals. Polarisation transfer was 
also seen to the NH2, two CH2 groups and some aromatic protons of the tryptamine 
ligand although the signals were not enhanced. A dimer species, 21tryptamine, is also 
evident, and seen only under PHIP conditions, with enhanced 1H NMR signals for the 
hydride ligands at δ −26.30, −26.85, −30.61 and −31.02. These structures are shown in 
Figure 179. 
 
Figure 179: The structure of tryptamine, the SABRE-active monomer species, 6tryptamine, and the 
dimeric structure, 21tryptamine formed on reaction of tryptamine with 1 in CD2Cl2 under H2 
However, the major species, 22tryptamine, containing one singlet hydride signal in 
the 1H NMR spectrum at δ −28.93, demonstrated no PHIP upon reaction with p-H2. The 
structure of 22tryptamine was confirmed by X-ray crystallography, in collaboration with 
Adrian Whitwood, Sam Hart and Rachel Bean in the XRD department at York. It is 
depicted in Figure 180 as an ORTEP plot, where the sixth ligand in the octahedral 
complex was identified as a carbon atom, due to C-H activation of the five-membered 
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ring of one of the tryptamine ligands (C27 in Figure 180) to form a six-membered 
metallocycle. The primary amine of each tryptamine ligand also binds to the iridium 
metal centre. A crystal suitable for X-ray diffraction was grown via the slow diffusion 
of toluene into a concentrated DCM solution of the complex. It crystallised in the R-3 
space group, yielding unit cell parameters for a, b and c of 48.3824(6), 48.3824(6) and 
10.78400(10) Å respectively and for α, β and γ of 90, 90 and 120 ° respectively. Key 
data for bond lengths and angles are shown in Table 40. The geometry around the 
iridium centre is distorted octahedral with the corresponding bond angles all being close 
to 90 °. 
 
 
Figure 180: ORTEP plot of 22tryptamine, showing the C-H activated metallocycle, with H atoms 
(apart from NH, NH2 and hydride ligand) omitted for clarity and the thermal ellipsoids set at a 
50 % probability level 
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Table 40: Selected bond lengths and angles for the crystal structure of 22tryptamine as shown in 
Figure 180 
Atoms Length / Å  Atoms Angle / ˚ 
Ir-O 2.235(2)  C(carbene)-Ir-O 97.69(10) 
Ir-C(carbene) 1.985(3)  C(carbene)-Ir-C27 93.36(12) 
Ir-C27 2.018(3)  C(carbene)-Ir-N5 177.15(11) 
Ir-N5 2.136(3)  C(carbene)-Ir-N6 92.88(10) 
Ir-N6 2.200(2)  O-Ir-C27 95.36(11) 
   O-Ir-N5 79.74(10) 
   O-Ir-N6 81.70(9) 
   N5-Ir-N6 85.55(10) 
   C27-Ir-N5 88.12(11) 
   C27-Ir-N6 173.40(11) 
 
5.2.5. Summary 
Overall, these complexes, where weakly binding ligands have been used as 
substrates, demonstrate instability and degradation. This is potentially due to the very 
weak interactions not providing enough electron density to stabilise the iridium catalysts 
and intermediates. To aid stabilisation a neutral, strongly coordinating ligand could be 
added, such as triphenylphosphine. Previous work utilising Crabtree’s catalyst has 
shown that incorporation of an NHC, as well as the existing phosphine ligand, has 
enabled the production of more stable, catalytically active complexes.252-254 Combining 
both a phosphine and an NHC has also been exploited previously for SABRE catalysts 
as reported by Fekete et al. in 2013.86 
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5.3. Exploiting PPh3 to aid complex stabilisation 
5.3.1. Addition of PPh3 to samples containing 
pyridine 
To try and stabilise these amine-containing iridium carbene dihydride 
complexes, triphenylphosphine was chosen to be added as an extra ligand to samples 
using 1. It was thought that the PPh3 would bind trans to the carbene (as similar SABRE 
catalysts have been made previously)86 thus creating only one site for substrate binding, 
therefore aiding stabilisation. Initially it was decided to add PPh3 to complex 6pyridine in 
CD2Cl2 as the chemistry of this species has been well studied (see Section 2.4.1).
255 On 
addition of PPh3 a new species formed immediately and NMR spectroscopy confirmed 
that it contained the bidentate carbene, two hydride ligands, one pyridine ligand and one 
PPh3 ligand. However, this was not the expected complex as the PPh3 coordinated trans 
to a hydride ligand by replacing the labile pyridine ligand, thus blocking the pyridine 
exchange site required for SABRE, to form 23pyridine as shown in Figure 181. Therefore, 
due to this pyridine dissociation pathway no longer being available, no PHIP was 
observed thermally with p-H2. This species is therefore the kinetic product as it is most 
easily and rapidly formed as the pyridine ligand is labile so can simply be replaced. At 
298 K, the two hydride ligands, which share a common 2J(HH) coupling constant of 4.8 
Hz, appear at δ −8.50, with a trans 2J(HP) coupling constant of 162.8 Hz, and at δ 
−27.32 with a cis 2J(HP) coupling constant of 10.8 Hz. This product formed due to the 
pyridine ligand trans to the hydride ligand being labile and the other pyridine ligand 
trans to the carbene being strongly bound.  
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Figure 181: ORTEP plot of 23pyridine with solvent and H atoms omitted for clarity and the 
thermal ellipsoids set at a 50 % probability level 
The crystal structure of 23pyridine is also shown in Figure 181 as an ORTEP plot 
and was determined in collaboration with Adrian Whitwood, Sam Hart and Rachel Bean 
in the XRD department at York. A single crystal, suitable for X-ray diffraction was 
grown via the slow diffusion of toluene into a concentrated solution of the complex in 
DCM. It crystallised into the P212121 space group, yielding unit cell parameters for a, b 
and c of 13.63451(11), 16.69609(15) and 21.33132(16) Å respectively and for α, β and 
γ of 90, 90 and 90 ° respectively. Key data for bond lengths and angles are shown in 
Table 41. The geometry around the iridium centre is distorted octahedral with the 
corresponding bond angles all being close to 90 °. Full NMR characterisation data for 
23pyridine are given in the Experimental Section 8.6.9. 
Table 41: Selected bond lengths and angles for the crystal structure of 23pyridine as shown in 
Figure 181 
Atoms Length / Å  Atoms Angle / ˚ 
Ir-O 2.218(3)  C(carbene)-Ir-O 95.22(12) 
Ir-C(carbene) 1.978(3)  O-Ir-P 102.64(8) 
Ir-P 2.3491(9)  O-Ir-N 84.92(11) 
Ir-N 2.138(3)  C(carbene)-Ir-P 96.17(10) 
   C(carbene)-Ir-N 173.39(13) 
   P-Ir-N 90.24(8) 
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To determine whether the PPh3 would always bind trans to a hydride, a CD2Cl2 
sample of 1 with pyridine was remade, adding the PPh3 to 1 and pyridine in CD2Cl2 and 
then activating under an atmosphere of H2. This time, the reaction took several days to 
go to completion at room temperature and the species that formed was thus the more 
stable thermodynamic product, 24pyridine, as shown in Figure 182. The PPh3 ligand is 
now trans to the carbene which reduces steric interactions, and the pyridine ligand is 
trans to a hydride ligand. The two hydride ligands now undergo exchange with H2 
thermally so demonstrate PHIP and SABRE when in the presence of p-H2 and appear as 
very broad singlets at δ −21.73 and −28.93 at 298 K. On cooling to 273 K the hydride 
signals broaden into the baseline due to the exchange no longer being fast enough to be 
averaged and resolved in the 1H NMR experiment. Upon heating to 303 K, they now 
appear as two broad doublets due to a common cis 2J(HP) coupling constant of 18.4 Hz 
with the 2J(HH) coupling not being visible due to the much more rapid H2 exchange. 
The bis-phosphine complex, 25, is also formed when excess phosphine is added. This 
complex does not demonstrate PHIP as the SABRE pyridine dissociation mechanism 
cannot occur. Upon the addition of further phosphine, all of 24pyridine converted into 25 
(see Figure 182). The hydride signals for 25, which share a common 2J(HH) coupling 
constant of 4.7 Hz, appear in the 1H NMR spectrum at δ −9.6 and at δ −27.9 (which also 
has two 2J(PHcis) coupling constants of 13.4 Hz). The signal at δ −9.6 also demonstrates 
a 2J(PHcis) coupling constant of 22.9 Hz, and a much larger 
2J(PH) coupling constant of 
138.6 Hz, indicative of it also lying in a trans position to a PPh3 ligand. 
Photochemical PHIP of 25 was also investigated, however, no p-H2 exchange 
was observed. The complex absorbs very weakly at 355 nm, the wavelength of the laser 
used, as the charge-transfer bands that can exist for these types of species and can be 
excited photochemically come at much higher energy.166-167 Characterisation data for 
24pyridine and 25 are included in the Experimental Sections 8.6.10 and 8.6.11 
respectively. Only partial characterisation data were obtained for 24pyridine, due to it 
undergoing rapid exchange and thus exhibiting some broad signals, for example for the 
CH2 linker protons. 
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Figure 182: Formation of complex 24pyridine and 25, with excess PPh3 in solution 
 
 
Figure 183: ORTEP plot of 25 with solvent and H atoms omitted for clarity and the thermal 
ellipsoids set at a 50 % probability level 
The crystal structure of 25 is shown in Figure 183 as an ORTEP plot and was 
determined in collaboration with Adrian Whitwood, Sam Hart and Rachel Bean in the 
XRD department at York. A single crystal, suitable for X-ray diffraction, was grown 
from a concentrated solution of 25 in DCM. It crystallised into the P21 space group, 
yielding unit cell parameters for a, b and c of 13.01715(19), 15.90413(14) and 
13.68980(17) Å respectively and for α, β and γ of 90, 113.2175(16) and 90 ° 
respectively. The residual electron density was 1 e Å−3 indicating a clean single crystal. 
Key data for bond lengths and angles are shown in Table 42. It is very like 23pyridine, 
with the geometry around the iridium centre again being distorted octahedral and the 
corresponding bond angles all being close to 90 °. 
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Table 42: Selected bond lengths and angles for the crystal structure of 25 as shown in Figure 
183 
Atoms Length / Å  Atoms Angle / ˚ 
Ir-O 2.226(2)  C(carbene)-Ir-O 94.95(9) 
Ir-C(carbene) 2.033(3)  O-Ir-P1 99.95(5) 
Ir-P1 2.3527(7)  O-Ir-P2 82.19(5) 
Ir-P2 2.3076(7)  C(carbene)-Ir-P1 99.01(7) 
   C(carbene)-Ir-P2 157.90(7) 
   P1-Ir-P2 103.07(2) 
 
As combining all the ligands with the pre-catalyst before adding H2 led to the 
formation of a SABRE-active species, it was decided to explore this route. The addition 
of phosphine could potentially stabilise complexes where the substrate to be polarised is 
a very weakly binding ligand, as the five-coordinate intermediate where a substrate has 
dissociated would be more stable than a potential four-coordinate species (see Figure 
184). 
 
Figure 184: Potential intermediates formed when using weakly coordinating substrate ligands 
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5.3.2. Benzylamine 
As benzylamine had been shown to polarise weakly when it was the only ligand 
present in solution (see Section 5.2.2) it was decided to test the hypothesis of involving 
PPh3 to stabilise the complexes formed in solution to see if enhancements could be 
increased. The use of PPh3 could help prevent formation of the inactive singlet hydride 
species 22benzylamine as discussed in Section 5.2.2. A CD2Cl2 sample containing 1, PPh3 
and benzylamine was activated under an atmosphere of H2. At 298 K, three major 
hydride species were present in a ratio of 1: 2: 1 for the structures of 23benzylamine: 
24benzylamine: 25 as shown in Figure 185, each containing two different hydride ligand 
environments. For two of these species, both hydride ligands gave very broad signals 
and subsequent cooling and warming enabled the signals to become more resolved. 
These three species are summarised in Figure 185. 
 
Figure 185: The three major species identified in the hydride region present at 298 K for a 
sample containing 1, PPh3 and benzylamine under 3 bars of H2 with hydride characterisation 
data detailed at the specified temperatures 
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The only species out of these three that undergoes exchange with hydrogen in 
solution is 24benzylamine, where the benzylamine has bound trans to a hydride ligand. 
This enables the incorporation of p-H2 into the complex and thus enables polarisation 
transfer to occur. This is exhibited in the enhanced spectra for the protons of the 
substrate benzylamine, where the NH2, CH2 and some aromatic protons are polarised 
due to SABRE (see Figure 186). Despite only half of the sample being a SABRE-active 
catalyst, the CH2 group and five aromatic protons of benzylamine show signal 
enhancements of 88 ± 1 and 72 ± 2-fold respectively. These are considerably larger than 
the enhancements observed for the sample without phosphine as detailed in Section 
5.2.2. An enhanced signal for the NH2 protons was observed, however, it was difficult 
to quantify due to the peak being very broad and overlapping with other signals within 
the 1H NMR spectrum. The hydride ligand signals are also significantly enhanced. 
 
Figure 186: Thermal 1H NMR spectrum for benzylamine (A) and hyperpolarised spectrum (B) 
at 6.5 x 10−3 T showing enhanced signals for the hydride ligands as well as for the amine, CH2 
and aromatic protons of benzylamine 
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5.3.3. Phenethylamine 
To test with phenethylamine, a sample containing approximately 15 mol% 1, 
phenethylamine (for a 0.025 M solution) and PPh3 (for a 0.006 M solution) in CD2Cl2 
was prepared. This reaction was not as clean as with benzylamine although similar 
major species were formed as well as some other minor impurities. Complex 
23phenethylamine formed, with a 31P signal at δ 11.1, which proved to be SABRE-inactive 
and its active isomer, complex 24phenethylamine also formed, with a 31P signal at δ 22.4. 
Due to only approximately one equivalent of phosphine in the sample, no formation of 
25 was observed. Instead, at 298 K, two very broad singlet hydride signals were visible 
at δ −23.13 and −30.49 which sharpened considerably on cooling to 250 K. These were 
shown to undergo PHIP and very broad enhanced signals were observed at 298 K due to 
the bis-phenethylamine complex, 6phenethylamine. This species is also expected to be 
SABRE-active as for the pyridine derivative studied in detail in Section 2.4.1.  
At 298 K, the ratio of isomers 23: 24: 6 was observed to be 22: 41: 37 and the 
corresponding 1H NMR signal enhancements for the five aromatic protons, the two CH2 
groups and the NH2 group were 23 ± 1, 14 ± 1, 15 ± 1 and 16 ± 1-fold respectively. This 
represents a great improvement in the polarising capabilities of these catalysts when the 
solution contains a phosphine ligand capable of stabilising the complexes. On cooling to 
250 K these three complexes now only constitute approximately 72 % of the total 
hydride-containing species in a 20: 20: 32 ratio respectively, with the other 28 % made 
up of minor species that are broadened into the baseline at 298 K. On increasing the 
concentration of PPh3, the PHIP inactive complex 25 also forms as expected and as 
described in Section 5.3.1. A summary of these complexes is given in Figure 187, along 
with details of the hydride chemical shifts and couplings. 
Over a longer time period, crystals formed which were found to correspond to 2-
(phenyl)ethylammonium chloride via XRD, which is already a known structure.256 This 
shows that over time, deactivation and degradation of the sample occurs because the 
chloride salt is not able to be polarised. This also shows that the CD2Cl2 solvent is not 
innocent in these systems. 
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Figure 187: Major species present in an activated CD2Cl2 sample containing 1, phenethylamine 
and PPh3 under 3 bars of H2 with hydride characterisation data detailed at the specified 
temperatures 
 
 
 
248 
 
5.3.4. Tryptamine 
After one day of activation of 1 with tryptamine and PPh3, under H2 in CD2Cl2, 
four species were evident in the hydride region of the spectrum. These included the C-H 
activated singlet hydride species, 22tryptamine, and inactive SABRE species, 23tryptamine, 
as well as the SABRE-active species, 24tryptamine, now exhibiting enhanced hydride 
signals as doublets of doublets due to cis-phosphorus coupling as the substrate trans to 
the carbene is now a PPh3 ligand. Complex 25 also forms as seen with other samples. 
The two hydride signals for 23tryptamine are very broad at 298 K which suggests 
fluxionality. The ratio of the four species 22: 23: 24: 25 was 25: 24: 44: 7. 
 
Figure 188: Major species present in an activated CD2Cl2 sample containing 1, tryptamine and 
PPh3 under 3 bars of H2 
After being left under an atmosphere of H2 for a further 24 hours, only three 
species remained in the hydride region of the spectrum. The signals for 25 had 
disappeared and the ratios of the remaining three species had changed so that 22: 23: 24 
was now 28: 24: 48. This suggests that the phosphine is not as strongly bound as 
anticipated but can be replaced by an amine ligand. Despite only 48 % of the sample 
being attributed to the SABRE-active species 24tryptamine, polarisation transfer was still 
evident throughout the tryptamine molecule as not only was the broad NH2 peak 
enhanced, but the signals for the two CH2 groups were increased by 9 ± 1 and 8 ± 1-fold 
respectively. The aromatic proton signals were also enhanced, with the total signal 
intensity approximately three times that of the thermal equilibrium signal. This shows 
that polarisation can be transferred through multiple bonds via J-coupling. These signals 
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were less enhanced compared to the benzylamine sample and the corresponding hydride 
signals were visibly larger. Also, the normal H2 signal was large, suggesting rapid 
exchange and thus conversion of the p-H2. This could explain why polarisation transfer 
was not so effective, if the p-H2 was consumed without transferring its polarisation. 
 
Figure 189: Enhanced 1H NMR spectrum for tryptamine using 1 with PPh3 and p-H2 at 6.5 x 
10−3 T showing significantly enhanced signals for the hydride ligands. A large H2 signal is also 
observed, consistent with rapid consumption of p-H2, and only minimal polarisation of the 
tryptamine substrate 
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5.4. Use of other phosphines 
Due to the fact that multiple products form on addition of PPh3, it was decided 
to use different phosphine ligands to alter the steric and electronic properties of the 
complexes, related to the Tolman steric and electronic parameters as detailed in Section 
1.2.30, 257 Initially PCy3 was chosen, as the much bulkier ligand could inhibit binding of 
multiple phosphine ligands to the iridium metal centre. Phenethylamine was chosen as 
the amine to use due to it not forming the singlet hydride species, 22, and therefore it 
providing the cleanest sample. 
Table 43: Tolman Cone Angles and Electronic Parameters for five different phosphines 
Phosphine 
Steric effects: 
Cone Angle / ° 
Phosphine 
Electronic effects: 
TEP / χ 
PPh3 145 PPh3 12.9 
PPh2Cy  153 PBz3 10.5 
PiPr3 160 PPh2Cy 8.7 
PBz3 165 PiPr3 3.0 
PCy3 170 PCy3 0.3 
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5.4.1. PCy3 
First studies using PCy3 as the phosphine ligand gave several different species in 
solution. When enough PCy3 to make a 0.05 M solution was included in a sample 
containing 14 mol% 1 and phenethylamine (0.04 M solution) in CD2Cl2 activated under 
H2, two isomers, like those observed previously, were present in solution, corresponding 
to 26PCy3 and 27PCy3 as shown in Figure 190. After 60 hours, complex 26PCy3 had 
rearranged to form 27PCy3 which presumably relieves the steric pressures that are 
present in 26PCy3, due to the large steric bulk of the PCy3 ligand interacting 
unfavourably with the large steric bulk of the bidentate carbene ligand. This shows 
conversion from the kinetic product to the thermodynamic product. Characterisation 
data for 26PCy3 and 27PCy3 are given in the Experimental Sections 8.6.12 and 8.6.13 
respectively. Multiple overlapping signals for the phenethylamine and PCy3 ligands 
precluded their full characterisation. At 298 K, the hydride signals for the desired 
SABRE-active species, 27PCy3, appear at δ −23.90 for HA and −30.97 for HB, and are 
very broad, suggesting very rapid exchange. Therefore, the SABRE activity of this 
catalyst is very poor. The hydride signals for 26PCy3 are present at δ −10.59 (with a large 
trans HP coupling constant of 155.2 Hz) and −29.54. When analysing the 1H NMR 
signal enhancements the effect of polarisation transfer is visible in the CH2 groups and 
the aromatic protons show almost twice the signal when compared to the thermal 
spectrum. However, there is also a very broad signal for hydrogen in the enhanced 
spectra, again commensurate with very rapid p-H2 exchange. On cooling to 263 K the 
hydride ligand signals for 27PCy3 sharpen and a 31P signal is observed at δ 17.2.  
 
Figure 190: Labelled structures of complexes 26PCy3 and 27PCy3 where N is phenethylamine 
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Figure 191: Broad hydride signals of 27PCy3 at 298 K in CD2Cl2 
Another hydride signal was also present in the 1H NMR spectrum of the solution 
as a triplet at δ −11.23 with a cis-phosphorus coupling constant of 12.1 Hz and a 31P 
signal at δ 31.7 at 263 K. This hydride species exhibits no signals for the carbene 
backbone, shows no coupling to any species other than PCy3 and also forms in the 
absence of phenethylamine. Due to this hydride signal demonstrating cis-phosphorus 
coupling and being a triplet, two PCy3 ligands must lie trans to one another to relieve 
steric crowding, which is also commensurate with their bulky size. This species is 
consistent with substitution of the carbene backbone that must occur due to the very 
bulky ligands not having enough space in the coordination sphere of the iridium metal 
centre. Similar observations have been described by Mann et al.258 for the iridium penta-
hydride complex [Ir(H)5(PEt2Ph)2] where a singlet hydride was observed at δ −11 with a 
cis-phosphorus coupling constant of 12 Hz. The corresponding 31P NMR spectrum with 
the ethyl groups decoupled, gave a sextet signal, consistent with coupling to five 
hydride ligands. These penta-hydride complexes have commonly been prepared from 
corresponding COD bis-phosphine complexes259 and have also been used to form multi-
hydride-containing iridium complexes.260-264 The structure of complex 28PCy3 and its 
hydride and phosphorus signals at 263 K are shown in Figure 192 (see Experimental 
Section 8.6.14 for full characterisation data). The ratio of 27: 28 was 95: 5 at 263 K for 
the sample containing 14 mol% 1, phenethylamine (0.04 M solution) and PCy3 (0.05 M 
solution). 
 
 
 
27PCy3 
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Figure 192: The structure of 28PCy3 and its corresponding 
1H and 31P NMR spectra at 263 K, 
showing the hydride signal (A) and phosphorus signal (B) with the sextet splitting due to the five 
hydride ligands (cyclohexyl decoupled) 
To confirm the identity and reactivity of 28PCy3, tetrafluoroboric acid diethyl 
ether complex was added to the CD2Cl2 NMR sample of 28PCy3 along with acetonitrile. 
An immediate colour change was observed from dark orange to light yellow and 
subsequent NMR analysis confirmed the disappearance of the hydride signal at δ 
−11.23. The reaction between [Ir(H)5(PCy3)2], tetrafluoroboric acid and acetonitrile is 
shown in Figure 193. An equivalent reaction using acetone was described by Xu et al. in 
1996.204 
 
Figure 193: Reaction between [Ir(H)5(PCy3)2], 28PCy3, and HBF4 in the presence of acetonitrile 
to form [Ir(H)2(MeCN)2(PCy3)2][BF4] 
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A triplet hydride signal at δ −22.17 with a  cis-phosphorus coupling constant of 
15.5 Hz is now observed with the corresponding 31P signal at δ 22.6 at 263 K as shown 
in Figure 194, with the structure of [Ir(H)2(MeCN)2(PCy3)2][BF4] shown above the 
spectra. Full characterisation data are included in Table 44 and Experimental Section 
8.6.15. 
 
 
Figure 194: The structure of [Ir(H)2(MeCN)2(PCy3)2][BF4] and its corresponding 
1H and 31P 
NMR spectra at 263 K, showing the hydride signal (A) and phosphorus signal (B) with the 
triplet splitting due to the two hydride ligands (cyclohexyl decoupled) 
 
Table 44: NMR characterisation data at 263 K for [Ir(H)2(MeCN)2(PCy3)2][BF4] 
 [Ir(H)2(MeCN)2(PCy3)2][BF4] 
Ligand 1H / δ 13C / δ 
MeCN 2.42 (s, 6H) 3.7, 120.2 
PCy3 1.97-1.87 (m, 54H), 1.50-1.40 (m, 12H) 34.5, 29.5, 27.6, 26.6 (31P 22.6) 
H −22.17 (t, 2J(HPcis) = 15.5 Hz)  
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Similar iridium solvent-containing complexes have previously been synthesised 
containing the solvent ligands acetonitrile, acetone, tetrahydrofuran, water as well as a 
number of small alcohol ligands.69 The synthetic routes employed, commonly involve 
the direct formation of the solvent-containing complexes from the [Ir(COD)(PR3)2] 
precursors via reaction in the desired solvent under an atmosphere of hydrogen. 
However, one study by Gruet et al.260 in 2003 used the same synthetic route as shown in 
Figure 193 in order to produce the acetone-containing derivative, 
[Ir(H)2(OCMe2)2(PCy3)2][BF4] via protonation of [Ir(H)5(PCy3)2].  
The absence of the carbene ligand was further supported by the formation of 
crystals of the imidazolium tetrafluoroborate salt, as shown in Figure 195 and confirmed 
by X-ray crystallography in collaboration with Adrian Whitwood, Sam Hart and Rachel 
Bean in the XRD department at York. It crystallised into the R-3 space group, with unit 
cell parameters for a, b and c of 25.8153(3), 25.8153(3) and 15.33067(18) Å 
respectively and for α, β and γ of 90, 90 and 120 ° respectively. The bond angle, N1-C4-
C5, is 113.27(11) °, which is larger than that of 109.8(5) ° observed for complex 1 (see 
Section 2.3). This is because of the absence of ring strain in the salt. 
 
Figure 195: ORTEP plot of the imidazolium tetrafluoroborate salt with the BF4 and H atoms 
omitted for clarity and the thermal ellipsoids set at a 50 % probability level 
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5.4.2. PiPr3 
When changing the phosphine to PiPr3, the reactivity observed is like that of 
PCy3. Here, at 298 K the SABRE-active catalyst, 27PiPr3, has broad signals at δ −23.56 
for HA and −30.94 for HB (see Figure 196). The triplet hydride species 28PiPr3 has a 
signal at δ −11.32 with a cis-phosphorus coupling constant of 12.3 Hz and a 31P signal 
at δ 44.9. PiPr3 is less bulky than PCy3 and therefore a bis-phosphine dihydride complex 
29PiPr3 also forms which is observed to have a molecular cation signal at m/z 851.49 by 
LIFDI mass spectrometry. At 298 K, the hydride signals for 29PiPr3 (see Figure 196) 
appear at δ −12.86, with a cis-phosphorus coupling constant of 23.3 Hz, and at δ −31.49 
with a cis-phosphorus coupling constant of 15.4 Hz, with two 31P signals at δ 23.6 and 
37.8 with a 2J(PPtrans) coupling constant of 337 Hz. On cooling to 263 K the hydride 
signals for the SABRE-active catalyst 27PiPr3 sharpen and the 31P signal appears at δ 
27.0. The ratio of 27: 28: 29 is approximately 14: 12: 74 at 243 K and thus due to its 
low concentration, full characterisation of 27PiPr3 was not feasible. Characterisation data 
for the structures in Figure 197 are given in the Experimental Sections 8.6.13 and 
8.6.16. 
 
Figure 196: Hydride signals of 27PiPr3, 28PiPr3 and 29PiPr3 at 298 K in CD2Cl2 
 
Figure 197: Labelled structures of 27PiPr3 and 29PiPr3 formed when P
iPr3 is used 
27PiPr3 
28PiPr3 
29PiPr3 
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The SABRE analysis of this sample, containing 14 mol% 1, phenethylamine 
(0.04 M solution) and enough PiPr3 for a 0.05 M solution, showed that catalyst 27PiPr3 is 
much more effective at transferring polarisation when compared to the PCy3 derivative. 
The signal enhancements for the five aromatic protons and the two CH2 groups are 53 ± 
1, 13 ± 2 and 17 ± 3-fold respectively, demonstrating significant improvement 
compared to a sample containing no phosphine. The ratio of 27: 28: 29 as shown in 
Figure 196, is 59: 3: 38 but after 8 days the ratio had changed to 91: 6: 3, due to 
dissociation of one phosphine ligand due to steric crowding, and the subsequent binding 
of an amine ligand. 
 
5.4.3. PBz3 
Using PBz3 the selectivity is reduced so that the speciation is more like that of 
PPh3. Now, at 298 K the desired SABRE-active catalyst, 27PBz3 has hydride signals at δ 
−22.82 and −29.93, both with cis-phosphorus coupling constants of 19.3 Hz, and a 31P 
signal at δ 0.1. However, the inactive isomer, 26PBz3 also forms in low concentration, 
which precludes full characterisation, with hydride signals at δ −8.68, with a large 
trans-phosphorus coupling constant of 182.8 Hz, and at δ −28.16 with a 31P signal at δ 
−8.9. The bis-phosphine complex, 30PBz3 also forms, with hydride signals at δ −10.67, 
with cis and trans-phosphorus coupling constants of 25.9 and 153.0 Hz respectively, 
and δ −28.65, with two cis-phosphorus coupling constants of 12.0 Hz each. In complex 
30PBz3, the phosphine ligands are cis to one another as PBz3 is considerably less bulky 
than PCy3 or P
iPr3. This also means that the degradation hydride product 28, caused by 
too much steric bulk does not form. The structures of 26PBz3, 27PBz3 and 30PBz3 are 
shown in Figure 198 with the corresponding NMR characterisation data for 27PBz3 and 
30PBz3 given in the Experimental Sections 8.6.13 and 8.6.17 respectively. The hydride 
region of the 1H NMR spectrum at 298 K is shown in Figure 199, where the ratio of 26: 
27: 30 is equal to 11: 75: 14. 
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Figure 198: Labelled structures of 26PBz3, 27PBz3 and 30PBz3 formed when 1 is reacted with 
phenethylamine in the presence of PBz3 and H2 
The SABRE analysis of this sample, containing 11 mol% 1, phenethylamine 
(0.04 M solution) and enough PBz3 for a 0.05 M solution, showed that catalyst 27PBz3 is 
again effective at transferring polarisation when compared to both the PCy3 and P
iPr3 
derivatives. The signal enhancements for the five aromatic protons could not be easily 
quantified due to overlap with the benzyl groups of the phosphine ligand but those 
corresponding to the CH2 groups are 74 ± 11 and 70 ± 9-fold enhanced respectively, 
again demonstrating significant improvement compared to a sample containing no 
phosphine. 
 
Figure 199: Hydride signals of 26PBz3, 27PBz3 and 30PBz3 at 298 K in CD2Cl2 
 
27PBz3 
30PBz3 
26PBz3 
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5.4.4. PPh2Cy 
When the phosphine used is PPh2Cy the speciation is like that of PBz3. This is 
because at 298 K it forms the desired SABRE species, 27PPh2Cy, with two broad hydride 
signals at δ −22.32 and −30.68 with the corresponding 31P signal at δ 23.5. The inactive 
isomer 26PPh2Cy also forms in low concentration which precludes full characterisation, 
again with broad hydride signals appearing at δ −9.60, with a large trans phosphorus 
coupling constant of 162.8 Hz, and at δ −28.67. For this complex, the 31P signal is 
present at δ 14.7. The signals for the bis-phosphine complex, 30PPh2Cy are the sharpest, 
consistent with it not undergoing exchange, and they are present at δ −10.20, with cis 
and trans-phosphorus coupling constants of 18.5 and 135.7 Hz respectively, and at δ 
−29.21, with two cis-phosphorus coupling constants of 13.0 Hz each. Again, NMR 
characterisation data for 27PPh2Cy and 30PPh2Cy are given in the Experimental Sections 
8.6.13 and 8.6.17 respectively. 
 
Figure 200: Labelled structures of 26PPh2Cy, 27PPh2Cy and 30PPh2Cy 
 
Figure 201: Hydride signals of 26PPh2Cy, 27PPh2Cy and 30PPh2Cy at 298 K in CD2Cl2  
 
30PPh2Cy 
27PPh2Cy 
26PPh2Cy 
* 
* 
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The SABRE analysis of this sample, containing 11 mol% 1, phenethylamine 
(0.04 M solution) and enough PPh2Cy for a 0.05 M solution, showed that catalyst 
27PPh2Cy is effective at transferring polarisation when compared to the PCy3 and P
iPr3 
derivatives. The signal enhancements for the five aromatic protons could not be easily 
quantified due to overlap with the benzyl groups of the phosphine ligand but those 
corresponding to the CH2 groups are 59 ± 3 and 48 ± 3 respectively, demonstrating 
improvement compared to a sample containing no phosphine. The ratio of 26: 27: 30 as 
shown in Figure 201 is 9: 62: 29 at 298 K. 
 
5.4.5. Summary 
Overall, the SABRE-active species, 27 is the most favourable complex when 
only the necessary amount of phosphine is present in solution. When excess phosphine 
is present, the formation of bis-phosphine species, 29 and 30, which undergo no ligand 
exchange is favoured due to the stronger Ir-P bond in comparison to the Ir-N bond 
formed with the amine ligands. The trans-phosphine ligand arrangement in 29 is 
favoured for the bulkier phosphine ligands when compared to the cis arrangement in 30, 
where the phosphine ligands have lower Tolman cone angles. Complexes 26 are the 
least stable amino-phosphine-containing isomers, due to the steric crowding caused by 
the bidentate carbene ligand being in a cis position to the phosphine ligand. To relieve 
the unfavourable steric effects, rearrangement to form 27 is possible, as seen for the 
PCy3 containing complex. This is consistent with 26 being the minor isomer in solution. 
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5.5. Conclusion 
In this chapter, the stable bidentate iridium carbene complex, 1, has been 
exploited in the polar aprotic solvent dichloromethane to demonstrate SABRE of 
previously unexplored amine ligands as substrates. Using ammonia, benzylamine, 
phenethylamine and tryptamine, SABRE catalysts 6 form, equivalent to when pyridine 
is the substrate. However, several other complexes form which inhibit SABRE, as they 
do not undergo ligand exchange. The dimer species 21 shows that hydride ligands 
bridge iridium metal centres at low substrate concentrations and the formation of the 
singlet hydride complexes 22 indicate that the amine substrates easily undergo C-H 
activation. 
To prevent formation of the SABRE-inactive complexes, the addition of 
phosphine was investigated to stabilise the species. The addition of PPh3 to a pyridine 
sample of 1 in CD2Cl2 under H2 leads to two isomers, the formation of which is 
dependent on the order of addition. The SABRE-inactive species 23 forms when PPh3 is 
added to a pre-activated sample of 6, thus to form the desired SABRE species, 
phosphine must be added before the addition of H2. In this case, with pyridine, species 
24 forms along with the bis-phosphine complex, which forms on addition of excess 
phosphine. However, when the same procedure was followed using the desired amine 
substrates, mixtures of 6, 23, 24 and 25 formed. 
As both steric and electronic parameters of different phosphine ligands can 
greatly affect reactivity, the different phosphine co-ligands PCy3, P
iPr3, PBz3 and 
PPh2Cy were tested. However, no selectivity was observed and the clean production of 
a sample containing only a SABRE-active complex was not achieved. The trend in 
speciation follows the electronic effects of the phosphines, rather than their steric 
effects; the complexes formed in the presence of PiPr3 match those with PCy3 and 
likewise PBz3 and PPh3 show similar reactivity. Both isomers 26 and 27 formed as well 
as bis-phosphine containing species. The unexpected formation of the penta-hydride 
complex 28 shows that very electron-donating phosphine ligands can stabilise the 
iridium metal centre in high oxidation state (Ir(V)). 
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6. Kinetic studies on the hydrogenation 
activity of a series of neutral iridium 
carbene catalysts 
6.1. Introduction 
NMR spectroscopy is a very versatile technique that is particularly useful for 
analysing mixtures due to its ability to distinguish different nuclei according to their 
chemical environment. This means that many different reactions can be analysed using 
NMR spectroscopy as long as signals for the starting material and product do not 
overlap. Thus, quantitative data can be extracted from sequential NMR spectra to gain 
information about reaction kinetics. 
One such reaction pathway that can be followed using NMR spectroscopy 
involves the study of enzyme kinetics. For example, Eicher et al.265 used 31P NMR 
spectroscopy to analyse the change in concentration of a complex mixture containing 
two enzymes from E. coli, phosphoglucose isomerase and phosphofructokinase, in order 
to quantify the concentrations of the nucleotide phosphates, ATP and ADP. They chose 
to use 31P NMR to analyse the phosphates, due to its high natural abundance and 
gyromagnetic ratio.  
A number of experiments aimed at students have also been developed using 
NMR to follow the progress of an enzyme reaction with an organic starting material.266-
268 In 2015, Her et al.267 described a simple experiment, aimed at undergraduate 
students, for analysing the enzyme-catalysed hydrolysis of sucrose to glucose, using 
quantitative NMR, enabling the observation of a decrease in sucrose corresponding to 
an increase in the concentration of glucose.267 Knowing the initial concentration of 
substrate, the Michaelis-Menten equation could be used to determine the Michaelis 
constant, KM and the maximum rate, Vmax for the hydrolysis reaction. The NMR spectra 
acquired throughout the time course of the reaction are shown in Figure 202. 
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Figure 202: The NMR spectra acquired at different time intervals during the enzyme-catalysed 
hydrolysis of sucrose (S, δ 5.41) to form the product α-glucose (Pα, δ 5.22) and the slow 
conversion of α-glucose to β-glucose (Pβ, δ 4.64) (Reprinted with permission from Her, C.; 
Alonzo, A. P.; Vang, J. Y.; Torres, E.; Krishnan, V. V. J. Chem. Educ. 2015, 92, 1943. 
Copyright © 2015 American Chemical Society)267 
The importance of chemical shift differences between starting material and 
product when using NMR analysis has been demonstrated clearly by Butler et al.269 
when they used ionic liquids as reaction media to study the reaction of benzonitrile 
oxide with ethyl trans-cinnamate as shown in Figure 203.  
 
Figure 203: Reaction of benzonitrile oxide with ethyl trans-cinnamate completed in the ionic 
liquid 1-butyl-3-methylimidazol-3-ium bis(trifluoromethanesulfonyl)imide, with the starred 
protons indicating those used to monitor the progress of the reaction269 
The 1H NMR signals for the labelled protons of interest in the starting material 
and two products shown in Figure 203 fall in the chemical shift region between δ 4.40 
and 6.60. The signals for the ionic liquid used, 1-butyl-3-methylimidazol-3-ium 
bis(trifluoromethanesulfonyl)imide, do not appear in the same region, hence the reaction 
could easily be monitored using 1H NMR spectroscopy.269 
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Another useful reaction that can easily be followed using 1H NMR is 
hydrogenation. Hydrogenation using a transition metal catalyst with hydrogen is a direct 
route used to reduce multiple bonds within organic substrates. This can be used to create 
saturated compounds or, with careful control, enables the production of partially 
hydrogenated species. This catalysis is commonly conducted using either homogeneous 
or heterogeneous catalysts. Kinetic studies of these reactions enable the determination 
of hydrogenation rates, which are calculated by fitting to a kinetic model which follows 
a set mechanism and therefore identification of intermediates in the reaction pathway is 
not possible. These studies traditionally monitor the rate of increase in the product 
concentration or consumption of starting material, using analytical methods such as 
NMR, IR etc. 
One example is the heterogeneous hydrogenation of citral, the unsaturated 
aldehyde-containing substrate shown in Figure 204, which forms a number of reduced 
species as revealed in Figure 204.270-271 The use of a Pt/SiO2 catalyst under an 
atmosphere of hydrogen enables the hydrogenation of both the carbon-carbon double 
bonds and the aldehyde C=O bond of citral. However, the selectivity can be tuned by 
changing the temperature of the reaction. At 298 K, limited selectivity is observed, 
although the most dominant species are the partially saturated aldehyde and alcohol 
species shown on the left side of Figure 204. In contrast, when the temperature is 
increased to 423 K, aldehyde hydrogenation is favoured over carbon-carbon double 
bond hydrogenation as shown on the right side of Figure 204. 
 
Figure 204: Selectivity observed on hydrogenation of citral in hexane using Pt/SiO2 with 20 atm 
of H2, at 298 K to form the partially saturated aldehyde, citronellal, or the partially saturated 
alcohol, citronellol. At high temperature very little carbon-carbon double bond hydrogenation 
is observed which leads to the unsaturated alcohols geraniol and nerol270 
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For this reaction, the growth in product concentration over time, coupled with 
the decrease in the concentration of citral starting material at 423 K is shown in Figure 
205. This speciation was followed using gas chromatography. 
 
Figure 205: Reaction of citral in hexane with 20 atm of H2 over a heterogeneous Pt/SiO2 
catalyst at 423 K showing the selectivity for the production of the alcohol (UALC) over the 
partially saturated species (PSALD and PSALC) as shown in Figure 204 (Reprinted from Singh, 
U. K.; Albert Vannice, M. Journal of Catalysis 2000, 191, 165, Copyright © 2000, with 
permission from Elsevier)270 
A number of transition metal complexes can be used to catalyse the 
homogeneous hydrogenation of multiple bonds. One iridium-based complex, 
[Ir(COD)(PCy3)(py)][PF6], known as Crabtree’s catalyst, has proven very active for the 
hydrogenation of a wide range of unsaturated species, both sterically unhindered and 
hindered. The importance of dihydride-dialkene complexes and their role in 
homogeneous hydrogenation reactions has also been investigated by Crabtree et al. Low 
temperature studies of the reaction of H2 with [Ir(COD)(PCy3)(py)][PF6] have 
demonstrated the formation of [Ir(H)2(COD)(PCy3)(py)][PF6] with hydride ligand 
signals at δ −12.7 and −18.0 consistent with lying trans to COD and pyridine 
respectively.157 On warming to room temperature, these signals disappear. This 
dihydride-dialkene complex was also shown not to form without excess COD in 
solution. This is consistent with its ability to easily hydrogenate COD to COA and thus 
without refreshing the supply of COD ligand, the dihydride-dialkene species cannot be 
observed.157 Using this complex in hydrogenation reactions, the fastest kinetics were 
observed for the least hindered alkene substrates but hydrogenation rates of the most 
sterically hindered alkenes were shown to be considerably faster than for the least 
hindered alkenes when using Wilkinson’s catalyst, [RhCl(PPh3)3]. These data are 
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summarised in Table 45, with the rates detailed as Turnover Frequencies (TOF) for the 
number of moles of substrate reduced per mole of catalyst per hour. 
Table 45: Hydrogenation rates in moles of substrate reduced per mole of catalyst per hour for 
four different alkenes using Crabtree’s iridium catalyst and Wilkinson’s rhodium catalyst44 
 
Substrate and hydrogenation rates  
/ mol substrate reduced (mol of catalyst)−1 h−1 
Catalyst Hexene Cyclohexene 
1-Methyl-
cyclohexene 
2,3-Dimethyl-
but-2-ene 
[Ir(COD)(PCy3)(py)][PF6] 6400 4500 3800 4000 
[RhCl(PPh3)3] 60 70 - 0 
 
Since the prediction of the PHIP phenomenon in 1986 by Bowers and 
Weitekamp20 and its subsequent observation a year later,77 there has been a large 
increase in its use to study reaction mechanisms and intermediates. A number of 
examples now exist, where the kinetics of a parahydrogenation reaction have been 
monitored.272-276 In 1992, Chinn and Eisenberg272 described a quantitative method for 
analysing PHIP behaviour and using it to determine reaction rates. They termed this 
method Rates Of Catalytic Hydrogenation Estimated Spectroscopically Through 
Enhanced Resonances (ROCHESTER). When p-H2 adds pairwise across a multiple 
bond, such as the double bond in ethyl (Z)-α-acetamidocinnamate using the catalyst 
[Rh(NBD)(chiraphos)][BF4],
272 observation of the enhanced p-H2 derived signals is 
possible using a small angle (30-45 °) detection pulse.272, 274 The enhanced signals can 
then be analysed over time, with a set of spectra being acquired every few seconds 
demonstrating a decaying signal, dependent on both the p-H2 consumption and the 
effect of the system relaxing back to equilibrium. Calculation of reaction rates has been 
achieved using an excess of substrate meaning the hydrogenation follows pseudo-first 
order kinetics, with the decrease fitted to an exponential decay curve. This technique 
has also been examined further by Hübler et al.274 Another method is also described by 
Hübler et al. and named Dynamic PASADENA Spectroscopy (DYPAS). For this 
method, the reactions were studied using an NMR sequence involving p-H2 addition 
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followed by a variable delay before acquisition. Varying the delay time enabled 
observation of the decreasing signal for both free and bound hydrogenated substrate as 
shown in Figure 206. Similar observations have been made by Wildschütz et al.275 
during their study of the asymmetric hydrogenation of β-dehydroamino acids. 
 
Figure 206: Intensities of enhanced signals for bound ethylbenzene (squares) and free 
ethylbenzene (triangles) formed from the hydrogenation of styrene using 
[Rh(dppb)(COD)][BF4] and the DYPAS NMR method (Reprinted with permission from Hubler, 
P.; Giernoth, R.; Kummerle, G.; Bargon, J. J. Am. Chem. Soc. 1999, 121, 5311. Copyright © 
1999 American Chemical Society)274 
More recently, 1H OPSY NMR experiments have been used to analyse a 
hydrogenation reaction276 without the need for re-addition of p-H2 or a system having 
returned to thermal equilibrium. Consecutive 1H OPSY NMR experiments were used 
during this study, by Tang et al.276 due to the ability of OPSY NMR to destroy any 
magnetisation before recording each successive spectra. Thus, reactions can be followed 
until all the p-H2 is consumed. Repeating the introduction of fresh p-H2 into the solution 
enables repeat studies to be made, to see how the reaction changes over time. This is 
shown in Figure 207, where at the start of the reaction when fresh p-H2 has been 
bubbled through or shaken into the solution, the enhanced signals show the largest 
intensity. As the reaction progresses and the p-H2 is used up, the amount of 
hydrogenation occurring during each successive experiment decreases until no signal 
remains after 200 s. Upon reintroduction of p-H2 into the solution, this trend is then 
repeated as shown in Figure 207. 
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Figure 207: The decrease in 1H OPSY NMR signal intensity observed during the hydrogenation 
of ethyl propiolate to ethyl acrylate using [Rh(COD)(DIOP)][BF4] as the catalyst. The 
hydrogenation was conducted in D2O in the presence of SDS (sodium dodecyl sulfate) and 
consecutive 1H OPSY NMR spectra were recorded until the enhanced signal intensity decreased 
to zero (Reproduced from Tang, J. A.; Gruppi, F.; Fleysher, R.; Sodickson, D. K.; Canary, J. 
W.; Jerschow, A. Chem. Commun. 2011, 47, 958 with permission of The Royal Society of 
Chemistry http://dx.doi.org/10.1039/C0CC03421E)276 
The work in this chapter uses a similar approach to Tang et al.276 with analysis 
of the parahydrogenation of phenylacetylene completed using 1H OPSY NMR 
experiments. Kinetic analysis is completed, following the decay of the enhanced signals 
and the rates of hydrogenation of phenylacetylene are analysed, comparing Crabtree’s 
catalyst with the neutral bidentate iridium carbene complexes developed in this work. 
The observed rates of hydrogenation as a function of time can then be used, along with 
the corresponding hydrogen concentrations in solution, to determine the order of the 
reactions with respect to the hydrogen concentrations in solution. This provides an 
insight into the mechanism and any intermediates present during the hydrogenation 
reactions. 
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6.2. Monitoring the parahydrogenation of 
phenylacetylene  
In this section, the hydrogenation activity of the iridium(I) carbene phenolate 
complexes developed in Chapter 2 is detailed. Their ability to act as hydrogenation 
catalysts is investigated using phenylacetylene as the substrate. This simple alkyne was 
chosen as the substrate to study as this eliminated the potential further complication that 
could arise from hydrogenation of a di-substituted starting material, which could form 
both cis and trans isomers. Phenylacetylene can first be hydrogenated to styrene and 
then further hydrogenated to form ethyl benzene as shown in Figure 208. When using p-
H2, cis-trans isomerisation of styrene is possible, however, after relaxation, both 
isomers are equivalent.  
 
Figure 208: The hydrogenation of phenylacetylene to form styrene and then ethylbenzene 
This section details the kinetic studies carried out by analysing 1H OPSY NMR 
spectra and following the progress of each reaction. The neutral bidentate carbene 
complexes developed previously, 1, 2, 3 and 4 are compared to the reactivity of 
Crabtree’s catalyst, under the same conditions, with the kinetic analysis following the 
consumption of parahydrogen. Combining the experimentally observed rate constants 
with the calculated hydrogen concentrations, the use of Letort’s method of a double 
logarithmic plot of the hydrogen concentration vs the hydrogenation rate at each time 
has enabled the reaction order of hydrogen with respect to time, nt to be estimated for 
each catalyst. 
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6.2.1. The use of 1H OPSY NMR spectroscopy to 
study reaction kinetics 
To compare the hydrogenation potential and efficiency of the newly-developed 
neutral bidentate carbene catalysts used for SABRE, CD2Cl2 samples were prepared 
containing 2.0 mol% catalyst and phenylacetylene as the compound to be hydrogenated 
(120 mM solutions of phenylacetylene). The catalysts tested were Crabtree’s catalyst, 
[Ir(COD)(PCy3)(py)][PF6], and the bidentate phenolate derivatives, 1, 2, 3 and 4. The 
use of 1H OPSY NMR spectra enables the analysis of protons that are specifically 
derived from parahydrogen. With OPSY NMR, upon incorporation of parahydrogen 
into a hydrogenated substrate, the observed signals are initially significantly enhanced. 
However, over time, the p-H2 in solution is used up during the reaction. This means that 
the initially enhanced signal decreases in intensity so that upon repeated acquisition of 
spectra, less and less enhancement is seen, until no observable signal remains in the 
OPSY spectrum. The rate of proton signal decay can be used to determine the rate of 
hydrogen consumption and thus give an indication of the relative hydrogenation rates 
for the individual catalysts. The higher the value, the faster the hydrogenation reaction 
and the more active the catalyst. The OPSY sequence works by destroying the entire 
signal that is present before selecting only the magnetic states that are p-H2 derived as 
described in Section 4.2.1. Therefore, each OPSY spectrum corresponds to the amount 
of hydrogenation that has occurred in the timeframe of the experiment. 
After addition of p-H2 to a sample of catalyst and phenylacetylene in CD2Cl2, 
the sample was shaken in the Earth’s field for ten seconds before being dropped into the 
NMR spectrometer for examination. One spectrum was recorded immediately after 
transfer to the magnet and a specific time delay was set between recording subsequent 
spectra. For faster reactions, the time delay chosen was shorter to allow collection of 
more data points before all the p-H2 had been consumed. The decay was fitted to follow 
pseudo-first order kinetics as the phenylacetylene was in excess during the reaction, 
such that the change in concentration of phenylacetylene was essentially negligible. 
However, this assumption becomes less correct as the reaction progresses. Hydrogen is 
the limiting reagent, so using the isolation method for analysis, the calculated rate 
constant is kobs. Once the signal had completely decayed the sample was removed from 
the spectrometer and reshaken for another ten seconds to redissolve fresh parahydrogen 
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from the headspace of the NMR tube. Due to the consumption of p-H2, the 
concentration within the NMR tube is lower for the second shake in comparison to the 
first shake. However, in CD2Cl2, the solubility of 1.01 bars of H2, at 298 K, is reported 
to be 1.51 ± 0.06 mM, and at the pressures used here, the pressure-concentration 
relationship is linear, so that at 3 bars, the concentration increases to 4.49 ± 0.18 mM.277 
In comparison to the concentration of phenylacetylene, which is 120 mM, the 
concentration of H2 is considerably lower and therefore this confirms that it is the 
limiting reagent. The amount of H2 that this 3 bars of pressure supplies into the 1.8 mL 
headspace of a Young’s NMR tube, is about 218 μmol, calculated using the ideal gas 
law, PV = nRT, where P is pressure (Pa), V is volume (m3), n is the number of moles, R 
is the ideal gas constant (8.314 J K−1 mol−1), and T is temperature (K). Thus, in 0.6 mL 
of sample, about 2.7 μmol of H2 is soluble and used up during the first shake, meaning 
that for the second shake, the amount of H2 remaining is 215.3 μmol and the amount of 
phenylacetylene remaining is 117.3 μmol. As these changes in concentration of both 
hydrogen and phenylacetylene are negligible, they cannot be the reason for the differing 
rates of hydrogen consumption and therefore any changes that are observed must be due 
to changes in reaction species and activity in solution. 
After the second shake, the sample was again transferred into the magnet and 
more OPSY spectra were collected. The kinetic model used is shown below, where the 
concentration of alkene at time zero is at a maximum, which then decays according to 
the observed pseudo-rate constant, kobs, as the p-H2 is consumed. 
[𝑎𝑙𝑘𝑒𝑛𝑒]𝑡 = [𝑎𝑙𝑘𝑒𝑛𝑒]0𝑒
−𝑘𝑜𝑏𝑠𝑡 
From these decay data, the amount of styrene produced over time can be 
calculated by cumulatively summing the enhanced signal intensities to gain a growth 
curve. These plots can also be used to calculate rate constants, as is the case for 
traditional kinetics measurements, when a growth in product concentration as a function 
of time is observed.  
Using the kobs values obtained from either method of kinetic analysis, the 
concentration of hydrogen in solution at each time point can also be calculated 
according to the model shown below, where the concentration of H2 is at a maximum at 
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time zero. The rate of hydrogen consumption is the same as the rate of styrene 
production as hydrogen is the limiting reactant in solution. 
[𝐻2] = [𝐻2]0𝑒
−𝑘𝑜𝑏𝑠𝑡 
Using the calculated values for kobs and their corresponding values for the 
concentration of hydrogen, the order of reaction can be calculated. This is achieved 
according to the formulae shown below, where ν is the rate of reaction, k is the rate 
constant, c is the concentration of hydrogen and n is the corresponding reaction order. 
𝜈 = 𝑘𝑐𝑛 
𝑙𝑜𝑔10𝜈 =  𝑙𝑜𝑔10𝑘 + 𝑛𝑙𝑜𝑔10𝑐 
A double-logarithmic plot of log10ν against log10c gives a straight-line gradient 
which is equal to the order of the reaction. There are two methods of measuring and 
achieving this plot. The first involves measuring the reaction rates of a single reaction as 
the time progresses and the reactant concentration changes. This has been described as 
Letort’s method of determining a reaction order with respect to time, nt, and is possible 
here because the OPSY NMR method probes the rates of reaction as a function of time. 
A second method involves measuring initial reaction rates at different initial 
concentrations, which Letort referred to as the order with respect to concentration, nc. 
 
6.2.2. Hydrogenation of phenylacetylene using 
Crabtree’s catalyst 
For Crabtree’s catalyst, the first shake gave an observed experimental rate 
constant for hydrogen decay of (10.5 ± 1.2) x 10−2 s−1 and (10.4 ± 1.0) x 10−2 s−1 for the 
two largest hydrogenated signals for styrene whilst the second shake proved slower, at 
(3.24 ± 0.09) x 10−2 s−1 and (3.14 ± 0.09) x 10−2 s−1 for the same two signals (Figure 
209). This is consistent with deactivation of the catalyst during the hydrogenation 
reactions which therefore slows down the hydrogenation rates.44 Furthermore, 
degradation visibly occurs over time as the solution darkens from yellow to brown and a 
precipitate forms. An enhanced signal for the proton of styrene at δ 5.81 is also 
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observed during these experiments, despite this proton not originating from p-H2, due to 
cross polarisation.222 
 
Figure 209: The decay of parahydrogen derived signals upon hydrogenation of phenylacetylene 
to styrene using Crabtree’s catalyst, [Ir(COD)(PCy3)(py)][PF6] 
During these measurements, a very small proton signal for H2 is visible in the 
first few OPSY NMR spectra, which shows that the process is efficient as the p-H2 that 
binds to the catalyst goes on to hydrogenate the substrate rather than dissociate without 
reacting. Hyperpolarised signals for COE were also visible in the OPSY NMR spectra, 
showing that activation of the catalyst requires the hydrogenation of the COD ligand 
and subsequent dissociation of the resulting COE. Thermal spectra recorded after each 
run show the absence of signals for H2 or HD, indicating that all the H2 in solution had 
been consumed to form the major product styrene (~ 90 %), along with a small amount 
of ethyl benzene, COE and some minor hydride-containing species (< 2 %). From these 
hydrogen decay data, the relative concentration of styrene has been calculated over time 
(Figure 210). For the first shake the rates were calculated as (10.3 ± 1.1) x 10−2 s−1 and 
(10.2 ± 1.1) x 10−2 s−1 for the two largest hydrogenated signals for styrene and for the 
second one they are (3.03 ± 0.03) x 10−2 s−1 and (2.98 ± 0.03) x 10−2 s−1 respectively. 
They therefore match those calculated from the p-H2 decay graphs, as expected.  
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Figure 210: Relative concentration of styrene produced from summing the integrals of styrene 
after each OPSY spectrum using Crabtree’s catalyst 
Using Letort’s method of a double logarithmic plot, the order of the reaction 
with respect to time, nt, using Crabtree’s catalyst was determined. Shake one gave an 
order of 1.10 ± 0.06 whereas for shake two the order decreased to 0.96 ± 0.02, as shown 
in Figure 211. This suggests that initially about 10 % of the iridium centres have two 
molecules of hydrogen bound, but as the reaction progresses this decreases as there is a 
change in mechanism or speciation over time. This is consistent with deactivation of the 
catalyst due to the formation of iridium dimers as reported by Crabtree.44 It could also 
be due to the fact that initial activation of Crabtree’s catalyst requires two hydrogen 
molecules to fully hydrogenate the COD ligand and therefore the active species for 
hydrogenation, where COD is no longer present, is different to the starting complex. 
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Figure 211: Letort’s logarithmic graphs to determine reaction order with respect to time for 
shake one (A) and shake two (B) showing the decrease in order using Crabtree’s catalyst 
A repeat of this experiment using Crabtree’s catalyst, with an identically made 
sample produced comparable results as shown in Table 46, showing that in the first 
shake, the reaction order with respect to time for the concentration of H2 is more than 1. 
Table 46: Rate and order values for two identically produced samples of Crabtree’s catalyst 
used for the hydrogenation of phenylacetylene 
Sample Shake 
1H NMR 
signal / δ 
Initial rates / 
10−2 s−1 
Cumulative rates 
/ 10−2 s−1 
Order, nt 
A 1 
6.79 
5.29 
(10.5 ± 1.2) 
(10.4 ± 1.0) 
(10.3 ± 1.1) 
(10.2 ± 1.1) 
1.10 ± 0.06 
1.06 ± 0.09 
A 2 
6.79 
5.29 
(3.24 ± 0.09) 
(3.14 ± 0.09) 
(3.03 ± 0.03) 
(2.98 ± 0.03) 
0.96 ± 0.02 
0.97 ± 0.02 
B 1 
6.79 
5.29 
(9.94 ± 0.61) 
(9.91 ± 0.62) 
(9.11 ± 1.68) 
(8.65 ± 0.56) 
1.14 ± 0.08 
1.22 ± 0.08 
B 2 
6.79 
5.29 
(2.76 ± 0.10)  
(2.77 ± 0.10) 
(2.54 ± 0.05) 
(2.55 ± 0.05) 
0.96 ± 0.02 
0.96 ± 0.02 
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6.2.3. Hydrogenation of phenylacetylene using the 
neutral bidentate carbene complexes 
In contrast to observations using Crabtree’s catalyst, for 1 there is no change in 
the rates between the first and second shake ((2.93 ± 0.61) x 10−2 s−1 and (2.96 ± 0.63) x 
10−2 s−1 for the two largest hydrogenated signals for styrene for the first shake and (2.95 
± 0.73) x 10−2 s−1 and (3.00 ± 0.67) x 10−2 s−1 for the same signals for the second shake, 
see Figure 212). This suggests that degradation of the catalyst either does not occur or 
happens over a much longer time period than studied. This is consistent with no 
precipitation of degraded catalyst over longer time periods. Instead the catalyst may be 
resistant to forming the cluster type species that Crabtree’s catalyst is reported to 
form.44  
 
Figure 212: The decay of parahydrogen derived signals upon hydrogenation of phenylacetylene 
to styrene using 1 
This catalyst is, however, less efficient than Crabtree’s catalyst as a larger signal 
for H2 is observed at the start of the 
1H OPSY NMR experiments, albeit not enough to 
significantly hinder hydrogenation or affect kinetic modelling. Therefore, a small signal 
for hydrogen is observable in the thermal spectra recorded after each run, indicating that 
all the hydrogen in solution is not consumed during the reaction. During these reactions, 
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no enhanced signals for COE were observed and the proton spectrum recorded after the 
OPSY NMR runs indicates no hydrogenation of COD has occurred. An example system 
has been described previously, when, on the timescale of phenylacetylene 
hydrogenation, no hydrogenation of the diene of the catalyst occurs. Esteruelas et al. 
have studied phenylacetylene hydrogenation using [Rh(NBD)(PPh3)2][BF4] where NBD 
is 2,5-norbornadiene278 or [Ir(COD)(η2-iPr2PCH2CH2OMe)] where COD is 1,5-
cyclooctadiene and have found the COD ligand to be stable.279 The stability of COD to 
hydrogenation in the complex [Ir(H)2(COD)(dppm)][BF4] at room temperature has also 
been studied280 and no decomposition has been observed, suggesting these diene 
complexes can form important stable intermediates in hydrogenation reactions. 
On analysing the relative increase in styrene concentration over time (see Figure 
213), the same values were again obtained for each shake; (2.95 ± 0.06) x 10−2 s−1 and 
(3.05 ± 0.07) x 10−2 s−1 for the two largest hydrogenated signals for styrene for the first 
shake and (2.78 ± 0.10) x 10−2 s−1 and (2.93 ± 0.06) x 10−2 s−1 for the second. The 
simulated data does not quite fit the experimental data due to the fact that the 
mechanism involves numerous steps and full hydrogenation does not occur. 
Furthermore, error is introduced in the analysis approach, as a minor amount of H2 
binds and falls off, without hydrogenation occurring. 
 
Figure 213: Relative concentration of styrene produced from summing the integrals of styrene 
after each OPSY spectrum using 1 
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Figure 214: Letort’s logarithmic graphs to determine reaction order with respect to time for 
shake one (A) and shake two (B) showing the constant order using 1 
When Letort’s method was used to calculate the reaction order, the values for 
both shakes were close to 1 (1.02 ± 0.03 for shake one and 0.96 ± 0.05 for shake two, 
see Figure 214). The initial reaction order of 1 suggests that only one molecule of p-H2 
binds to the catalyst and that activation is very rapid, in contrast to when Crabtree’s 
catalyst is used (see Section 6.4 for further discussion on the mechanism). The fact that 
the order of 1 is maintained for the second shake indicates again that only one molecule 
of p-H2 binds to each catalyst centre during hydrogenation. 
Upon moving to 3, the rates recorded using the OPSY NMR analysis technique 
are slightly faster than for 1, at (3.98 ± 0.41) x 10−2 s−1 and (4.02 ± 0.45) x 10−2 s−1 for 
the two largest hydrogenated signals for styrene for the first shake and (4.23 ± 0.34) x 
10−2 s−1 and (4.17 ± 0.43) x 10−2 s−1 for the same signals for the second shake. They 
follow the same trend as for 1, indicating that the reaction mechanism and speciation 
does not change over the time course of the reaction. On analysing the relative increase 
in styrene concentration over time, the same values were again obtained for each shake, 
however, they were lower values than those obtained from the original data and are less 
accurate due to the extra data manipulation; (2.24 ± 0.11) x 10−2 s−1 and (2.26 ± 0.11) x 
10−2 s−1 for the two largest hydrogenated signals for styrene for the first shake and (2.35 
± 0.14) x 10−2 s−1 and (2.36 ± 0.13) x 10−2 s−1 for the second. The order of the reactions 
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again both correspond to approximately 1 (1.02 ± 0.05 for shake one and 1.01 ± 0.04 for 
shake two). There is a small signal for hydrogen in the first OPSY NMR spectra of each 
shake, once more indicating a small amount of ineffective hydrogen addition, although 
minimum effect on the simulated data is observed. 
On changing to catalyst 4, hydrogenation of phenylacetylene occurs with the 
observed rates corresponding to (3.29 ± 0.54) x 10−2 s−1 and (3.10 ± 0.19) x 10−2 s−1 for 
shake one and (3.77 ± 0.42) x 10−2 s−1 and (4.01 ± 0.33) x 10−2 s−1 for shake two. When 
using the cumulative summing approach, the model does not fit the data accurately, 
particularly towards the end of each measurement. The rate values are now much lower, 
at (2.37 ± 0.15) x 10−2 s−1 and (2.59 ± 0.15) x 10−2 s−1 for shake one and (1.79 ± 0.32) x 
10−2 s−1 and (2.20 ± 0.33) x 10−2 s−1 for shake two. Hydrogen is now highly visible in 
the 1H OPSY NMR spectra and the thermal spectra recorded after the 
parahydrogenation reaction has occurred. This is due to hydrogen exchanging with the 
complex but not being transferred to the phenylacetylene and therefore the hydrogen is 
not the limiting factor because it is not used up in solution during each shake. This 
allows hydrogenation using normal hydrogen to occur and therefore the rate 
measurements become less accurate. This is reflected in the numbers for the orders of 
reaction which are approximately equal at 1.29 ± 0.11 for shake one and 1.31 ± 0.13 for 
shake two. Because there is now excess hydrogen in solution, multiple hydrogen ligands 
have the potential to bind to the catalyst and change the reaction mechanism. 
When the even less stable complex 2 is used, the reactivity is now very different 
to that observed for 1 and more like that of 4. Here, a very substantial hydrogen peak is 
seen in the OPSY NMR spectra, which leads to a dramatic reduction in the 
hydrogenation capabilities of the catalyst. Thus, comparable hydrogen decay rates could 
not be calculated. This rapid consumption of p-H2, without hydrogenation, is consistent 
with that observed on addition of hydrogen alone, to the catalyst and is also 
commensurate with the observation of a large thermal signal for hydrogen after the 
hydrogenation reaction. Here, the limiting step is no longer the hydrogenation process. 
Table 47 gives a summary of the observed hydrogenation rates and reaction orders 
calculated using Crabree’s catalyst, 1, 3 and 4. The initial OPSY spectra for 
phenylacetylene hydrogenation using Crabtree’s catalyst, 1 and 2 are shown for 
comparison in Figure 215, with a significant H2 signal being observable when using 2. 
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Table 47: Average values for the hydrogenation rates of phenylacetylene to styrene using the 
enhanced signal decay data and the cumulatively summed data, along with the orders of 
reaction determined from the rate data based on the enhanced signal decay. The four catalysts 
detailed are Crabtree’s catalyst and complexes 1, 3 and 4 
Catalyst Crabtree’s 1 3 4 
Shake one 10.5 ± 1.1 2.95 ± 0.62 4.00 ± 0.43 3.20 ± 0.37 
Shake two 3.19 ± 0.09 2.98 ± 0.70 4.20 ± 0.39 3.89 ± 0.38 
Cumulative one 10.3 ± 1.1 3.00 ± 0.07 2.25 ± 0.11 2.48 ± 0.15 
Cumulative two 3.01 ± 0.03 2.86 ± 0.08 2.36 ± 0.14 2.00 ± 0.33 
Order one 1.10 ± 0.06 1.02 ± 0.03 1.02 ± 0.05 1.29 ± 0.11 
Order two 0.96 ± 0.02 0.96 ± 0.05 1.01 ± 0.04 1.31 ± 0.13 
 
Figure 215: 1H OPSY-dq spectra of the hydrogenation of phenylacetylene using Crabtree’s 
catalyst (A), complex 1 (B) and complex 2 (C) showing the large signal for H2 at ~ δ 4.6 in (C) 
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6.3. Monitoring the parahydrogenation of 
styrene 
To gain an insight into the mechanism of hydrogenation, two CD2Cl2 samples 
both containing 2.0 mol% catalyst and enough styrene to produce 120 mM solutions 
were studied using the 1H OPSY NMR method. Here, both catalysts, 
[Ir(COD)(PCy3)(py)][PF6] and 1, were able to hydrogenate styrene to ethyl benzene; 
however, rates could not be determined for the two samples. This is because when using 
Crabtree’s catalyst, the reaction occurred too rapidly, such that the majority of the p-H2 
had been consumed in the first 1H OPSY NMR spectrum and this corresponded to an 
approximate conversion of 30 % from styrene to ethyl benzene, when comparing the 
resulting 1H NMR spectrum with the spectrum prior to p-H2 addition. No signals for 
excess H2, HD or hydride species were present. Small enhanced signals were also 
visible in the 1H OPSY NMR spectra for styrene itself, due to non-hydrogenative 
polarisation transfer to styrene. This may be from a SABRE-like effect due to coupling 
between the hydrides and styrene protons, although this only occurs at a low magnetic 
field and is therefore only visible in the first few scans. However, the observation of 
enhanced styrene may also be due to the alkyl-alkene equilibrium that is possible.281 
Partial hydrogenation of the styrene could occur to form the alkyl product which, 
without reductive elimination, could reform the η2-alkene. Coupling between the p-H2 
derived proton (highlighted in Figure 216) and the original styrene protons could then 
be the route to polarisation transfer and observation of enhanced styrene signals. 
Another route may be via reversible p-H2 addition and moving of the p-H2 atoms into 
the styrene molecule. For Crabtree’s catalyst, only a minimal signal for COE is 
observed in the initial 1H OPSY NMR spectrum, with the signal-to-noise being poorer 
than for the spectra of phenylacetylene hydrogenation. 
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Figure 216: Reversible equilibration between the η2-alkene and alkyl form showing coupling 
that could lead to polarisation transfer described by Andriollo et al. for an osmium phosphine 
complex281 
For 1 the rates were much slower and after the first set of 1H OPSY NMR 
measurements less than 5 % of the starting material had been hydrogenated to form 
ethyl benzene. In this sample, a large 1H OPSY NMR signal was observed for H2 as 
well as for styrene, meaning that oxidative addition and reductive elimination occurs 
without hydrogenation, but with polarisation transfer occurring to the alkene protons of 
styrene, such that they appear enhanced. This is demonstrated in Figure 217. Again for 
1, no hydrogenation of COD is observed. A comparison between the 1H NMR spectrum 
recorded before p-H2 addition and one recorded after parahydrogenation, shows a large 
signal for excess H2 in solution.  
 
Figure 217: Hydrogenated signals for ethyl benzene using Crabtree’s catalyst (A) and using 1 
(B) also showing a large H2 signal and enhanced styrene signals 
H2 
Ethyl benzene 
Styrene 
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6.4. Elucidating the hydrogenation mechanisms 
Selectivity in hydrogenation reactions of triple bonds, to form either partially 
hydrogenated double bonds or fully hydrogenated saturated systems is a challenge. The 
over-hydrogenation of phenylacetylene to form ethylbenzene is commonly observed for 
the types of homogeneous catalysts used, with ethylbenzene being produced on a much 
slower timescale than styrene.278-279, 282 The 1H OPSY NMR spectra shown in Figure 
218 clearly show the differences between using Crabtree’s catalyst, where 
hydrogenation of the COD ligand and subsequent catalyst decomposition and 
deactivation occurs, and using 1 where no COD hydrogenation is evident and the 
catalyst remains stable. 
 
Figure 218: Initial 1H OPSY-dq spectra for phenylacetylene hydrogenation using Crabtree’s 
catalyst (A), showing signals for COE and hydride species (inset) and using complex 1 (B) with 
no signals corresponding to hydrogenation of COD or hydride species (inset) 
 
COE 
Ethyl benzene 
Ethyl benzene 
Hydride signals 
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When starting from styrene, hydrogenation to ethylbenzene has also been shown 
to occur. The fact that hydrogenation of styrene occurs, means that two possible 
mechanisms to produce ethyl benzene are possible when the starting material is 
phenylacetylene; either direct addition of two equivalents of H2 to phenylacetylene 
without dissociation from the metal centre, or dissociation of styrene, followed by re-
association and then a second hydrogenation step. However, because only very limited 
amounts of ethylbenzene are formed from phenylacetylene, particularly when using 1, it 
suggests that most of the phenylacetylene must be hydrogenated to styrene, before the 
hydrogenation of styrene to ethylbenzene occurs. 
When considering the mechanistic pathways of hydrogenation using Crabtree’s 
catalyst and 1, the relaxation of the p-H2 derived hydride ligands is very important. If 
the relaxation rate of the p-H2 derived nuclei is fast relative to the pairwise transfer of 
the hydrides to an unsaturated bond, then the spin states will have returned to 
equilibrium before an enhanced NMR spectrum can be acquired. This typically occurs if 
p-H2 adds to a metal complex before an unsaturated substrate. However, if the 
relaxation is slow, as occurs when p-H2 binds to a metal complex after another ligand, 
then enhanced spectra are observed, as the p-H2 derived nuclei can rapidly add across a 
multiple bond.77, 222, 283 
When the catalyst is Crabtree’s, the diene (COD) is easily hydrogenated and 
therefore the ligands that must bind to the metal centre must be alkyne or alkene 
substrates or solvent. As the substrates are hydrogenated, no ligands remain to stabilise 
the metal centre so decomposition occurs. A postulated mechanism, where the COD 
ligand is first hydrogenated, and the metal binds a substrate ligand and a solvent ligand, 
before the addition of fresh p-H2 to enable parahydrogenation, is shown in Figure 219. 
In this case, phenylacetylene can be fully hydrogenated to ethylbenzene either directly 
or in multiple steps. During the reactions shown in Figure 219, using Crabtree’s 
catalyst, relaxation effects should not cause a problem. This is because the mechanism 
proceeds via alkyne binding followed by oxidative addition of the hydrogen.68 Rapid 
transfer to the alkyne follows, which limits the time available for relaxation of the 
hydrides when bound to the iridium metal centre and therefore this does not need to be 
factored in. 
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Figure 219: Possible mechanistic routes for hydrogenation to form ethyl benzene from 
phenylacetylene using Crabtree’s catalyst 
In comparison, a different route has been described in the literature for the 
hydrogenation catalyst, [Ir(COD)(iPr2PCH2CH2OMe)][BF4], containing a diene and 
bidentate ligand, where the diene is hydrogenation resistant.279 Studies using 
[Ir(COD)(iPr2PCH2CH2OMe)][BF4], as depicted in Figure 220, where the oxygen donor 
is a methoxy group, have shown the hydrido-alkynyl-dialkene complex A is the main 
species in solution. This is confirmed in the 1H NMR spectrum by the presence of a 
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hydride ligand signal at δ −23.24. The equivalent alkynyl complex is not observed when 
1 is used and instead the dihydride-dialkene complex 5 is visible, with a structure like 
that shown for B. This complex is not seen when [Ir(COD)(iPr2PCH2CH2OMe)][BF4] is 
used, but is proposed as an important intermediate. As no vacant site is available in 
complex 5 or in B, the mechanism suggested by Esteruelas et al.279 for hydrogenation 
using [Ir(COD)(iPr2PCH2CH2OMe)][BF4], describes dissociation of the OMe group of 
the bidentate ligand in B, followed by coordination of the phenylacetylene to form C, 
and subsequent transfer of the hydride lying in a cis position to the alkyne. This 
produces the trans-hydrido-alkenyl complex shown in D. Hydrogen must then react 
with D to enable the reductive elimination of styrene.279 For this reaction, relaxation 
may have an important effect because when the dihydrogen addition occurs first, there 
is more time for relaxation of the hydride ligands when bound to the iridium metal 
centre before addition across the triple bond of the alkyne. In the case of complex 1, 
dissociation of the phenolate oxygen has not been shown to occur under any previous 
reaction conditions. Instead, a vacant site for phenylacetylene binding may be created 
via dissociation and rebinding of one side of the COD ligand as the COD ligand has 
previously been shown to be labile. 
 
Figure 220: The proposed mechanistic pathway for the hydrogenation of phenylacetylene to 
form styrene using [Ir(COD)(iPr2PCH2CH2OMe)][BF4] as described by Esteruelas et al.
279 
Although the dihydride-dialkene complex 5 is observed in small quantities 
during hydrogenation reactions when using 1, the fact that significantly enhanced 
signals of the hydrogenation products are observed in the 1H NMR spectra when 
complex 1 is used means that rapid relaxation effects are not in operation. Therefore, the 
pathway of hydrogen addition after ligand addition is most likely. However, as 
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hydrogenation of the COD ligand is not observed in the 1H OPSY NMR spectra during 
the reactions, it is anticipated that only a very small proportion of the complex is rapidly 
converted to the active hydrogenation catalyst via intermediate 5. The high amount of 
hydrogenation indicates that this small amount of complex is very active for 
hydrogenation of phenylacetylene. This is also commensurate with the slow reaction of 
complex 1 with pyridine and hydrogen when forming the SABRE active species as 
described in Section 2.4.1. This mechanism also suggests that double hydrogenation of 
phenylacetylene to ethylbenzene without elimination from the metal centre does not 
occur. The major points to consider are that; 
1. no hydrogenation of the bound COD ligand is visible on the NMR timescale 
during the reaction  
2. H2 is observed in the 1H OPSY NMR spectra due to rapid H2 oxidative addition 
and reductive elimination without hydrogenation 
3. the only observable hydride signals, at δ −11.0 and − 21.5, are very small and 
correspond to the dihydride complex, 5, as has previously been shown when 
only H2 is added to complex 1 in CD2Cl2 
4. the slow production of only small amounts of ethylbenzene is seen, due to 
formation of styrene having to occur first 
Overall, for these iridium carbene complexes, H2 binds reversibly and this can 
transfer reversibly into the alkyne, phenylacetylene, to form the alkene, styrene. Once a 
second hydrogenation step has occurred to form ethylbenzene, the alkane, the 
hydrogenation is no longer reversible. When looking at the mechanism using the neutral 
bidentate iridium carbene complexes, the electron density on the metal centre has a 
large effect on the stability and reactivity of the complexes. As the electron-donating 
ability of the complexes is increased, through the series from NO2 < COOMe < Cl < H, 
the electron density on the metal increases. This leads to faster reversible binding of H2 
and subsequently a poorer ability to transfer H2 into the alkyne to form the alkene. 
Therefore complex 1 is the most efficient hydrogenation catalyst out of the series, due 
to its greater ability to transfer the hydrogen. 
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6.5. Conclusion 
In this chapter, a new method to analyse reaction kinetics and gain information 
about the order of reaction has been developed. The use of 1H OPSY NMR experiments 
has facilitated the study of the parahydrogenation of phenylacetylene to styrene and 
ethyl benzene. The reactions followed the decrease in enhanced signal corresponding to 
the p-H2 derived protons of styrene, commensurate with the consumption of p-H2. The 
reactivities of complexes 1, 2, 3 and 4 were investigated and compared to the reactivity 
of Crabtree’s catalyst, [Ir(COD)(PCy3)(py)][PF6]. It was found that the neutral bidentate 
carbene derivatives act very differently to Crabtree’s catalyst, with only hydrogenation 
of the phenylacetylene occurring and no hydrogenation of the COD ligand being 
observed as for hydrogenation using Crabtree’s catalyst. When using the neutral 
bidentate carbene derivatives, the only minor hydride-containing products were those 
that are equivalent to complex 5 as discussed in Section 2.4.1, formed when hydrogen is 
added to 1. No other stable hydride species were formed, in contrast to when Crabtree’s 
catalyst was employed for hydrogenation. Furthermore, large signals for H2 in solution 
were observed when complexes 2, 3 and 4 were used, consistent with rapid oxidative 
addition and reductive elimination of p-H2 without productive hydrogenation of the 
substrate occurring. This was not the case when Crabtree’s catalyst was employed, thus 
demonstrating that it is far more efficient at hydrogenation compared to the neutral 
bidentate carbene derivatives. 
The rates of parahydrogen consumption, equivalent to the rates of substrate 
formation, were used to gain information about the orders of reaction with respect to 
hydrogen. It was found that for Crabtree’s catalyst the initial hydrogenation rates were 
approximately three times faster than the rates when using 1, but over time the rates 
using Crabtree’s catalyst decreased to be approximately equal to those of 1. In addition, 
when using Crabtree’s catalyst ~ 1.15 molecules of H2 were needed for initial 
hydrogenation, but over time, due to changes in speciation, active catalyst form and 
degradation, this reduced to ~ 1 molecule. When using 1, both the hydrogenation rates 
and reaction order stayed the same, with no catalyst degradation being observed and 
consistently only one molecule of hydrogen being bound to the catalyst at once. 
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7. Conclusions and future studies 
The goal of this work was to synthesise neutral bidentate iridium carbene 
complexes and investigate their ability to transfer polarisation from parahydrogen to 
suitable substrates. The focus of this project was to use these complexes to improve the 
sensitivity of solution NMR. Several neutral pre-catalyst derivatives have been 
synthesised which contain a carbene ligand with a pendent phenolate group. The 
complexes incorporate a variety of electron-withdrawing substituents within the carbene 
backbone and they have proven to be efficient SABRE catalysts for a variety of 
different substrates in a range of different polarity solvents. Their potential to act as 
hydrogenation catalysts has also been investigated. 
 
7.1. Development of neutral bidentate iridium 
carbene complexes 
In Chapter 2, four new bidentate iridium carbene complexes have been 
developed with the structure shown in Figure 221. Overall, the four substituents H, Cl, 
COOMe and NO2 have increasing Hammett σp− values, of 0.00, 0.19, 0.75 and 1.27 
respectively and thus their electron-withdrawing capabilities increase through the series. 
 
Figure 221: Structure of the neutral bidentate iridium carbene complexes with the described R 
group in the para position to the phenolate group 
Multi-step synthetic procedures have been developed to synthesise these 
derivatives, with the simplest route being for 1, due to the commercial availability of the 
benzyl bromide starting material. The other three complexes required multiple steps 
before the benzyl bromide could be reacted with mesityl imidazole to form the 
necessary imidazolium bromide salt precursor to the carbene ligand as shown in Figure 
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222. The iridium complexes were formed from the silver carbene complexes via 
transmetallation with [Ir(COD)Cl]2. 
 
Figure 222: Main synthetic steps required to form the bidentate iridium carbene derivatives 
Complexes 1, 3, and 4 exhibit fluxional behaviour in solution with their 
corresponding NMR spectra demonstrating temperature dependence. At 298 K, the 1H 
NMR signals for the CH2 linker protons and the COD CH protons are broadened into 
the baseline of the spectra. The signals for the CH3 and CH aromatic protons of the 
mesityl ring are also broadened at 298 K, commensurate with rapid rotation around the 
C-N bond. On cooling, all the signals for 1, 3 and 4 resolve. Complex 2, however, does 
not exhibit this fluxional behaviour on the NMR timescale at 298 K and all its 1H NMR 
signals are therefore resolved. Crystal structures of 1 and 3 have also been determined 
by XRD and show that the complexes adopt distorted square planar configurations, with 
their corresponding bond angles all being close to 90 °. 
In CD2Cl2, in the presence of H2, each complex undergoes the rapid and 
reversible addition of H2 to form two very minor dialkene-dihydride isomers as shown 
in Figure 223. No reactivity with pyridine alone is observed for these complexes in 
CD2Cl2. However, in the presence of both pyridine and hydrogen, the COD ligand is 
slowly hydrogenated to COE and COA and bis-pyridyl dihydride complexes form as 
shown in Figure 223. Several singlet hydride species, as depicted in square brackets in 
Figure 223, thought to form during COD hydrogenation, are also present during these 
reactions, and they disappear over time.  
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Figure 223: Formation of the dialkene-dihydride complexes, upon addition of H2 and 
subsequent formation of the bis-pyridyl dihydride complexes in the presence of pyridine and H2, 
via singlet hydride intermediates. The isomer structures are also shown due to ring-flip of the 
seven-membered metallocycle 
Due to ring-flip of the seven-membered metallocycle in the carbene backbone, 
and the potential for pyridine to bind to either side of the metallocycle, multiple isomers 
are present in solution as depicted in Figure 224. The relative equilibrium position is 
dependent on the electron-withdrawing capability of the substituent on the phenolate 
ring as detailed in Section 3.5. When the substrate is pyridine, A and A’ are equivalent 
and B and B’ are equivalent, as pyridine is not chiral. However, when chirality is 
introduced in the form of a chiral substrate, these are no longer equivalent and therefore 
1H NMR signals for the isomers are visible as discussed in Section 4.3.3 for the 
substrate nicotine. 
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Figure 224: Summary of the isomer forms present for the bidentate iridium carbene dihydride 
complexes in solution and the intermediate that occurs on pyridine dissociation showing the 
electron-donating ability of the phenolate 
In CD3OD, the reactivity of 1 and 3 are very similar to when the solvent is 
CD2Cl2. However, for complex 4, the Ir-O bond becomes unstable in CD3OD and a tris-
pyridyl dihydride species forms alongside the bis-pyridyl dihydride species. When the 
substituent is H in 2, which is even less electron-withdrawing, the activation pathway 
proceeded via initial iridium-oxygen bond cleavage to form a square planar iridium 
complex with the COD, carbene and pyridine ligands as depicted in Figure 225. 
Addition of hydrogen to this formed the alkene-dihydride complex with subsequent 
COD hydrogenation leading to the tris-pyridyl dihydride species (see Figure 225).  
 
Figure 225: Reaction of 2 with pyridine, in CD3OD, to form 13 and subsequent H2 addition to 
form dihydride complex 14 before COD hydrogenation leads to complex 15, with Ir-O bond 
dissociation 
A summary of the different complexes formed in both CD2Cl2 and CD3OD is 
given in Table 48, along with the 1H NMR chemical shifts of the hydride ligands which 
are indicative of the isomer formed. The decreasing stability of the iridium-oxygen 
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bond, leading to its cleavage, indicates that the iridium centre cannot accommodate the 
extra electron density which arises from the phenolate bond. At higher electron 
densities, such as when the substituent on the phenolate is H, the oxygen ligand has a 
higher capability for σ- and π-donation as depicted in Figure 224. Therefore, it is 
preferential for the iridium-oxygen bond to break and a pyridine ligand to bind, so that 
the electron donation is lowered. 
Table 48: Summary of the major SABRE-active products formed when the four pre-catalysts 1, 
2, 3 and 4 are reacted with pyridine and hydrogen in methanol and dichloromethane 
Pre-
catalyst 
Major product(s) formed with 
pyridine and H2 in CD3OD 
Major product(s) formed with 
pyridine and H2 in CD2Cl2 
1 
 
Hydrides δ −21 and −29 
 
Hydrides δ −21 and −29 
3 
 
Hydrides δ −21 and −29 
 
Hydrides δ −21 
and −29 
 
Hydrides δ −22 
and −25 
4  
Hydrides δ −21 
and −29 
 
Hydrides δ −22 
 
Hydrides δ −21 
and −29 
 
Hydrides δ −22 
and −25 
2 
 
Hydrides δ −22 
 
Hydrides δ −22 and −25 
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These complexes are yellow/orange in solution and all four of them exhibit 
charge-transfer bands in the visible region of the spectra, consistent with their respective 
colours. For 1, an intraligand band at 406 nm with a molar absorption coefficient of 
21060 dm3 mol−1 cm−1 masks the metal d-to-p-orbital transitions which are visible for 
the other complexes at approximately 380, 430 and 490 nm, with molar absorption 
coefficients of between approximately 300 and 3000 dm3 mol−1 cm−1. The IR spectra of 
the complexes show stretching frequencies at approximately 1970 cm−1 and 2060 cm−1 
for the two CO ligands, one trans to the phenoxide and one trans to the carbene, 
indicating the σ-donating properties of the carbene and phenolate ligands. 
In this work, the formation of the CO complexes was used to determine the 
significance of the π-donation to the iridium metal centre from the phenolate ligand. 
This gave an indication of the electron-donating capabilities of the differing 
substituents. However, these CO complexes could also be used as SABRE pre-catalysts, 
depending on the ease at which the CO ligands could be substituted for substrate and 
hydride ligands. They could also have the potential to be used as CO-releasing 
molecules (CORMs) for medicinal purposes.284 
All the pyridine dihydride-containing complexes undergo both pyridine and H2 
exchange at 298 K, which enables the incorporation of fresh parahydrogen and new 
substrate into the complex. Therefore, they can act as SABRE catalysts. An analysis of 
the resultant exchange rates calculated using 1H EXSY NMR experiments show that the 
rates increase as a function of temperature and are on the order of seconds. In CD3OD, 
hydrogen-deuterium exchange also occurs between the complexes and deuterium from 
the solvent, thus affecting the hydrogenation potential of the catalysts. Furthermore, the 
pyridine exchange rates are independent of the concentration of pyridine whereas the 
hydrogen exchange rates depend on the pyridine concentration. Thus, the first step in 
the reaction pathway is the dissociation of pyridine, followed by the binding of fresh 
hydrogen, subsequent loss of the former hydrogen molecule and rebinding of pyridine. 
Thus, the analysis of the pyridine ligand exchange rates is more representative than the 
hydrogen ligand exchange rates, due to analysis of a single step in the pathway rather 
than multiple steps. 
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Due to the presence of the chelating ligand and ring-flipping of the seven-
membered metallocycle, as previously described for the formation of different isomers, 
a hydride interconversion process also occurs, which depends on what side of the 
phenolate the pyridine ligand rebinds. Another hydride interconversion process is also 
possible due to the formation of a dihydrogen complex, which is low-lying in energy 
and allows rotation of the bound η2-H2 ligand. These processes are shown in Figure 226. 
 
Figure 226: Hydride interconversion due to pyridine addition to differing faces of the bidentate 
ligand and the route to hydride interconversion via the formation of a dihydrogen intermediate 
The solvent has also been shown to have a strong effect on the ligand exchange 
rates, as shown in a study when complex 6 was the active catalyst. The pyridine 
dissociation rates were shown to increase as the solvent polarity decreased, consistent 
with the inability of non-polar solvents to stabilise the 16-electron intermediate formed 
upon pyridine loss.  
Further studies using 6 have been completed to determine the effect of ligand 
exchange on the T1 relaxation of the protons of pyridine. At 298 K, when ligand 
exchange occurs, the T1 values for the exchanging pyridine ligand are average values for 
the ligand free in solution and when bound to the metal centre. When the ligand is 
permanently bound to the metal centre, as for the pyridine ligand in the trans position to 
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the carbene ligand, its T1 values are dramatically decreased due to assisted relaxation. 
This exchange effect has been exemplified using 6 in CD2Cl2 by cooling a sample from 
298 K to 263 K to inhibit exchange, with the results detailed in Table 49. Any 
interaction between the substrate and catalyst promotes relaxation and thus during 
SABRE this decreases the lifetime of the hyperpolarised state. 
Table 49: T1 values for the three proton sites of each of the three pyridine environments (free 
pyridine, pyridine trans to hydride and pyridine trans to carbene) within a CD2Cl2 solution of 
pyridine (0.05 M) once activated with 1 (15 mol%)  under 3 bars of H2 at 298 K and 263 K. The 
T1 value for the para proton signal of the pyridine ligand bound trans to a hydride ligand could 
not be determined due to signal overlap 
 
T1 of free pyridine in 
solution / s 
T1 of pyridine bound 
trans to hydride / s  
T1 of pyridine bound 
trans to carbene / s 
CD2Cl2 o m p o m p o m p 
At 298 K 10.4 12.9 13.8 8.5 11.4 12.8 2.8 3.4 4.9 
At 263 K 16.3 15.5 15.5 2.3 1.8 - 1.8 2.1 2.7 
 
To extend this study, derivatives of these complexes could be synthesised 
containing cyclooctene (COE) instead of COD.285-286 This may lead to decreased 
reaction times as the hydrogenation of COE should be faster than the hydrogenation of 
COD. Furthermore, the COE ligands will also be more labile due to the absence of the 
chelate effect. The SABRE activity of the iridium COE complex, [IrCl(COE)2]2, has 
recently been demonstrated by Iali et al., where it has been shown to undergo 
hydrogenation of one COE ligand, upon reaction with pyridine and hydrogen, to form 
the equivalent hydride species, [IrCl(H)2(COE)(py)2].
285 This negates the need for the 
incorporation of an NHC into the complex. 
Further investigations into altering other parts of the bidentate carbene could 
also help to improve the reactivity of these species. Firstly, the substituents on the 
mesityl ring could be changed to see what effect the electronic properties of this ring 
have on the iridium metal centre. This study has been done to some extent, with the 
development of the series of symmetric NHC derivatives, ItBu, ICy and IPr, although 
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these modifications mainly contribute to larger steric changes.87, 93 Their structures and 
corresponding Tolman Electronic Parameters, which are based on the average CO 
stretching frequencies of the complexes [Ir(NHC)(CO)2Cl], are shown in Figure 227.
87, 
172 
 
Figure 227: Structures and corresponding Tolman Electronic Parameters of three NHC 
derivatives 
Secondly, changing the imidazole core may also prove to give enhanced activity 
for these complexes. In relation to the SABRE process, some studies have been done 
using SIMes and SIPr which involve modification of the rigidity of the imidazole ring, 
by making it a saturated system. In comparison to the unsaturated imidazole ring 
derivatives, IMes and IPr, these saturated systems are slightly less electron-donating and 
lead to faster ligand exchanges rates and consequently lower signal enhancements.93 
However, overall these electronic effects are very weak and again the major effects 
result from the steric properties of the NHC ligands. 
Other examples involve adding extra substituents to the imidazole ring, for 
example chlorine substituents.172 Viciano et al.287 have created 
bis(dichloroimidazolylidene) ligands, as shown in Figure 228 and in comparison to the 
non-chlorinated versions, they donate less electron density via σ-donation which leads 
to higher activity for the hydrosilylation of terminal acetylenes (see Figure 228). More 
complex systems have also been developed with aromatic rings and extra heteroatoms 
included in the imidazole ring system, in order to tune the properties of different 
systems.288 
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Figure 228: Bis(dichloroimidazolylidene) iridium complex developed by Viciano et al. for 
hydrosilylation of terminal acetylenes287 
Thirdly, the oxygen linker could be changed to a softer nitrogen or sulfur donor 
atom. Several examples have been described in the literature.289-292 One method of 
making complexes such as these, is via oxidative addition of an N-H bond, for example 
to an iridium pincer complex as shown in Figure 229 to form an anilide hydride 
species.290 However, they easily undergo reductive elimination to form stable iridium(I) 
complexes. In relation to sulfur donor atoms, Herberhold et al.292 have described several 
thiol-containing species with half-sandwich iridium cores. However, these thiol ligands 
can react with multiple metal centres to form dimers, as they act as very good bridging 
ligands.291 This would be undesirable for SABRE as detailed for a dimer complex in 
Section 5.2.3. 
 
Figure 229: Formation of an anilide hydride iridium complex290 
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7.2. SABRE reactivity of neutral bidentate 
iridium carbene complexes 
In order to determine how effective the catalysts are at polarisation transfer, 
SABRE studies using the neutral bidentate iridium carbene complexes have been 
completed in a range of different solvents. For the active catalysts which only contain 
two pyridine ligands, for example, all the complexes in CD2Cl2, the hydride ligands are 
both magnetically and chemically inequivalent due to one lying trans to a nitrogen-
donor substrate ligand and the other lying trans to the phenolate oxygen ligand. 
However, when the iridium-oxygen bond is cleaved, the hydride ligands are now 
chemically equivalent but magnetically inequivalent. When used with parahydrogen, 
significant signal enhancements of these hydride ligands are observed, alongside large 
signals for the protons of the substrate molecules. Most testing was completed using 
pyridine as the substrate as this is a model substrate for SABRE. Due to the neutral 
nature of the catalysts, good hyperpolarisation activity is observed in several solvents, 
with the most effective solvents being polar aprotic or non-polar. OPSY NMR 
experiments have been exploited as they enable the observation of only signals that are 
derived from the hyperpolarised state, thus eliminating any thermal signals. 
When using 1, polarisation transfer to the proton sites of pyridine is observed as 
well as to the carbon atoms, with the greatest signal enhancements being observed at a 
polarisation transfer field of −6.5 x 10−3 T and a temperature of 60 °C. The proton 
signal enhancements were found to increase as a function of temperature, commensurate 
with the increase in ligand exchange rates as detailed in Section 3.2.2. When comparing 
this SABRE activity to that seen when [Ir(COD)(IMes)Cl] is used, the same polarisation 
transfer field produces the largest enhancements although the temperature dependence 
does not follow the same trend. For [Ir(COD)IMes)Cl], the proton signal enhancements 
of pyridine decrease at higher temperatures, as the exchange rates become too fast for 
optimal transfer due to the amount of time for coupling to establish being too short. 
Polarisation transfer to nicotinamide follows similar trends to those seen for pyridine.  
When analysing the effect of solvent on the enhancement values and ligand 
exchange rates, the highest enhancements were observed for pyridine in benzene, 
tetrahydrofuran and dichloromethane which equates to the most rapid pyridine 
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dissociation rates. Due to the neutral nature of the catalyst it also benefits from 
improved solubility in these solvents, which aids the SABRE process. When using the 
less stable complex 2, the greatest enhancement values were obtained in 
dichloromethane with a total pyridine 1H NMR enhancement of 1500-fold being 
possible, as described in Chapter 4. Polarisation transfer to nicotinaldehyde and nicotine 
(see Figure 230) were also investigated with dichloromethane again proving to be the 
most effective solvent for carrying out SABRE experiments. For nicotinaldehyde a total 
1H NMR enhancement of 1100-fold was achieved and for nicotine this proved to be 
1300-fold for the four aromatic protons. When nicotinaldehyde was used in methanol, 
its hemiacetal form (see Figure 230) was also present in solution due to nucleophilic 
attack of the methanol solvent onto the carbonyl group of the aldehyde. This species 
also demonstrated enhanced signals. Complex 3 also gives the largest signal 
enhancements in dichloromethane where a total pyridine 1H NMR enhancement of 
1600-fold was observed. The chlorine-substituted complex 4 proved to be the most 
efficient polarisation transfer catalyst, with a total pyridine 1H NMR signal 
enhancement of 2300-fold again being achieved in dichloromethane. 
 
Figure 230: Structures of nicotinaldehyde, its hemiacetal form, and nicotine 
Due to nicotine being a chiral substrate, it led to the production of both isomers 
B and B’, as shown in Figure 224, with the hydride ligands at about δ −22 and −25 
exhibiting only very small differences in chemical shift in the corresponding 1H NMR 
spectra. This confirms that four isomers are possible and they are dependent on the 
orientation of the seven-membered metallocycle as well as the face of the carbene 
ligand at which the substrate rebinds and the chirality of the substrate. 
The substrates typically used for SABRE studies are N-heterocycles. However, 
in Chapter 5, the SABRE approach has been expanded to use amine molecules as 
substrates. The use of a neutral pre-catalyst, 1, in an aprotic solvent, dichloromethane, 
ensures no H/D exchange can occur and therefore this has enabled the polarisation 
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transfer from parahydrogen to several amine substrates including ammonia, 
benzylamine, tryptamine and phenethylamine as shown in Figure 231. 
 
Figure 231: Structures of ammonia, benzylamine, phenethylamine and tryptamine 
SABRE tests using the polarisation transfer pre-catalyst 1 in dichloromethane in 
the presence of the desired amine substrate and hydrogen have led to minimal 
polarisation transfer being observed. Several inactive complexes have also been 
observed to form, with an inactive dimer species, 21, being common when low 
concentrations of substrate are used. The dimer complex forms to stabilise the iridium 
metal centres and its structure is shown in Figure 232. A singlet hydride species also 
forms (see Figure 232 for the structure of the complex formed with the substrate 
tryptamine), which is due to C-H activation of the aromatic ring of the amine substrates.  
 
Figure 232: Inactive complexes formed using 1 under H2 with amine substrates in CD2Cl2 
To prevent formation of 21, phosphine ligands have been added to samples used 
for SABRE in order to act as stabilising ligands and improve the SABRE activity. The 
order of ligand addition was shown to be important. This is because the ligand in the 
trans position to the carbene is not labile, and thus when phosphine is added to the pre-
activated sample, the exchanging substrate ligand trans to the hydride ligand is replaced 
by a phosphine ligand, rendering the catalyst inactive. When the phosphine is added 
before activation with hydrogen, the active SABRE isomer with the phosphine lying 
trans to the carbene is favoured and subsequently proves to exhibit good SABRE 
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activity for the amine substrates tested. It is less favourable for the phosphine ligand to 
bind trans to the hydride ligand compared to the carbene, due to the stronger σ-donating 
capability of the hydride. The different complexes formed are shown in Figure 233, 
when PPh3 is the phosphine that is used.  
 
Figure 233: Isomers 23 and 24 and the bis-phosphine complex 25 
To investigate how the steric and electronic properties of the phosphine ligands 
affects the formation of the different complexes, several phosphine ligands have been 
investigated. As well as PPh3, the phosphine ligands used were PCy3, PBz3, P
iPr3 and 
PPh2Cy. Their cone angles vary from 145 ° for PPh3 to 170 ° for PCy3, with the 
electronic effects varying from 12.9 for PPh3 to 0.3 for PCy3 with PCy3 being the most 
electron-donating. For all these phosphine ligands, the same set of complexes as shown 
in Figure 233 are formed. A different bis-phosphine isomer complex forms when the 
bulkiest phosphine ligands are used. This is because the ligands are too bulky to sit in a 
cis position and instead the trans-phosphine complex forms as shown in Figure 234. 
Furthermore, with the bulky phosphine ligands PCy3 and P
iPr3, decomposition of the 
bidentate NHC ligand occurs due to the iridium metal centre not being able to 
accommodate the high steric bulk. Instead a penta-hydride complex, 28, is formed as 
shown in Figure 234. 
 
Figure 234: Trans-phosphine isomer, 29, and [Ir(H)5(PCy3)2], 28 
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To improve the activity and selectivity of these amine polarisation studies, an 
extension of this work would involve tethering the phosphine ligand into the position 
trans to the carbene. This could prevent the formation of multiple isomers and may also 
prevent multi-addition of the phosphine ligand. A potential synthetic route is shown in 
Figure 235, with the [IrCl(COE)2]2 dimer being used in the final step to form the desired 
SABRE pre-catalyst. 
 
Figure 235: Potential synthetic route to form a tridentate iridium carbene complex containing a 
bound phenolate and phosphine ligand 
The activation of this tridentate iridium complex with substrate and hydrogen 
would be predicted to form the desired SABRE-active catalyst as shown in Figure 236. 
The length of the alkyl linker to the phosphine complex can be modified to optimise the 
tridentate binding for the trans-phosphine-carbene arrangement. 
 
Figure 236: Formation of [Ir(H)2(P-NHC-O)(py)] from [Ir(COE)(P-NHC-O)] 
A further extension of this work would be to test the effect on reaction species 
formed, when using arsine ligands instead of phosphine ligands. However, with arsine 
ligands being more electron-donating than the corresponding phosphine derivatives, the 
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product formed with an arsine ligand in the trans position to the carbene may be 
considerably more unstable. 
As discussed previously in Section 1.9, one area where the use of the SABRE 
technique is of particular interest, is in MRI diagnostics for medical applications. Since 
these complexes have very good solubility and activity in non-polar solvents, a phase 
extraction technique could be used. In this case, the polarisation transfer could occur in 
the organic phase before extraction of the hyperpolarised agent into the aqueous phase 
prior to injection into a patient. This would require the substrate molecule (contrast 
agent in MRI) to be soluble in both the aqueous and organic phases. This technique has 
been reported by Reineri et al.293 although the process involves hydrogenation of a 
suitable precursor with p-H2 and subsequent hydrolysis with water in order for it to 
cross from the organic to the aqueous phase. This is shown in Figure 237, with an 
estimated 18.3 % polarisation of the 13C atom of 1-13C-2,3-d2-succinic acid, based on 
the experiment being conducted with 98 % enriched p-H2. 
 
Figure 237: Demonstration of phase-extraction used to remove the polarisation transfer 
catalyst from hyperpolarised substrate, suitable for MRI studies293 
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7.3. Hydrogenation activity of neutral bidentate 
iridium carbene complexes 
As iridium complexes have been described to act as efficient hydrogenation 
catalysts, Chapter 6 explores hydrogenation reactions and uses the developed neutral 
catalysts to study the hydrogenation of multiple bonds. The use of 1H OPSY NMR 
experiments has facilitated the study of the parahydrogenation of the triple bond of 
phenylacetylene to form styrene and ethyl benzene as shown in Figure 238.  
 
Figure 238: The hydrogenation of phenylacetylene to form styrene and ethyl benzene 
The initial OPSY NMR spectrum recorded after addition of p-H2 to a sample 
typically shows large enhanced signals for the protons of styrene (with minor enhanced 
signals present for ethyl benzene) that are p-H2-derived. A typical spectrum is shown in 
Figure 239 for the hydrogenation of phenylacetylene using Crabtree’s catalyst.  
 
Figure 239: 1H OPSY NMR spectrum after p-H2 addition to a sample containing 2.0 mol% 
Crabtree’s catalyst and 120 mM phenylacetylene in CD2Cl2, showing the enhanced signals for 
styrene, ethyl benzene, COE and hydride species   
As time passes, a decrease in the intensity of the signals occurs in subsequent 
spectra. This leads to an exponential decay being observed, corresponding to the 
consumption of p-H2. A cumulative summing approach can then be used to demonstrate 
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the growth in product concentration over time, as typically observed for kinetic studies. 
To continue this study, Letort’s method of double logarithmic plots of the concentration 
of H2 and the kobs values has enabled the orders of reaction with respect to time to be 
calculated. Examples of these three plots are given in Figure 240 for the hydrogenation 
of phenylacetylene using 1.  
 
Figure 240: A decay curve corresponding to the observed rate of p-H2 consumption for the 
hydrogenation of phenylacetylene using 1, the growth curve corresponding to the production of 
styrene over time and the double logarithmic plot enabling the determination of the reaction 
order with respect to time  
The reactivities of complexes 1, 2, 3 and 4 have been investigated and compared 
to the reactivity of Crabtree’s catalyst, [Ir(COD)(PCy3)(py)][PF6]. During 
hydrogenation of phenylacetylene using Crabtree’s catalyst, hydrogenation of the 
phenylacetylene to both styrene and ethyl benzene occurred. Several enhanced hydride 
signals were also seen along with enhanced signals corresponding to COE due to 
hydrogenation of the COD ligand of Crabtree’s catalyst. Only a very small signal for H2 
was observed in the OPSY spectra, demonstrating that Crabtree’s catalyst is very 
efficient at conducting hydrogenation of phenylacetylene. 
In comparison, when 1, 2, 3 and 4 were used, no hydrogenation of the COD 
ligand occurred, suggesting a different hydrogenation mechanism. When using the 
neutral bidentate carbene derivatives, the only minor hydride-containing products were 
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those that are equivalent to complex 5 as discussed in Section 2.4.1, formed when 
hydrogen is added to 1. Furthermore, large signals for H2 in solution were observed 
when complexes 2, 3 and 4 were used. This shows that these complexes rapidly add 
hydrogen but only carry out limited hydrogenation of the triple bond of 
phenylacetylene. Overall, the initial hydrogenation of phenylacetylene using Crabtree’s 
catalyst was approximately three times faster than when using 1, but over time the rates 
using Crabtree’s catalyst decreased to be approximately equal to those of 1, consistent 
with deactivation of Crabtree’s catalyst. The order of reaction using Crabtree’s catalyst 
also changed from ~ 1.15 when first reacted with p-H2, to ~ 1 after the initial reaction 
had occurred. This is consistent with changes in speciation, active catalyst form and 
degradation. When using the neutral complexes, both the hydrogenation rates and 
reaction order stayed the same between successive shakes. No catalyst degradation was 
observed and consistently only one molecule of H2 was calculated to be bound to the 
catalyst at once. 
These studies have shown that the hydrogenation mechanisms between the 
different catalysts vary considerably. For Crabtree’s catalyst, the COD ligand must be 
hydrogenated and replaced with alkyne or solvent ligands before H2 binds to form the 
active dihydride species that can then hydrogenate phenylacetylene. However, for the 
neutral catalysts developed during this work, the COD ligand remains intact and a 
dihydride species forms first before rearrangement occurs to enable phenylacetylene to 
bind and be hydrogenated. Only a very minor amount of the catalyst may form the 
active hydrogenation species. 
To extend this study, the hydrogenation of other species containing multiple 
bonds could be tested to determine the potential range of compounds that may be able to 
be hydrogenated. However, with the mechanism involving the addition of H2 before the 
addition of substrate, and no COD hydrogenation, the hydrogenation of substrates that 
have a large steric bulk may be limited as the iridium metal centre may become 
inaccessible if the binding of larger ligands is required. Further studies to determine the 
route of phenylacetylene addition to the dihydrido-dialkene complex would prove 
useful in elucidating the full mechanistic pathway. 
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7.4. Summary 
During this work, the aims originally set out in Section 1.10 have been met as 
several neutral bidentate iridium carbene complexes have been synthesised and 
developed as efficient polarisation transfer catalysts for the SABRE approach. The 
activity of these complexes has been optimised in several ways, for example by 
changing the solvent used for polarisation transfer, optimising the magnetic field at the 
point of magnetisation transfer and seeing the effect of temperature on the signal 
enhancement of substrates. These catalysts have also been used as hydrogenation 
catalysts and their reaction mechanisms for both SABRE and hydrogenation have been 
studied in-depth. 
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8. Experimental 
8.1. Calculations 
8.1.1. Method for calculating standard errors 
Standard errors are calculated using the Jackknife method, eliminating each 
value from a set of values, in turn and then recalculating the parameters. The standard 
deviations are then calculated for each set of values and from this the standard error is 
calculated using the equations below.231  
Standard Deviation 
𝑠 =  √
∑(𝑥 − ?̅?)2
(𝑛 − 1)
 
where: 𝑠 = standard deviation 
 𝑥 = measured values 
 ?̅? = sample mean 
 𝑛 = sample size 
Standard Error 
𝑆𝑡 𝑒𝑟𝑟𝑜𝑟 =  
𝑠(𝑛 − 1)
√𝑛
 
where: 𝑠 = standard deviation 
 𝑛 = sample size 
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8.1.2. Arrhenius and Eyring-Polanyi equations 
used to calculate activation parameters 
All the activation parameters are calculated from data that uses two times the 
value for the experimental rate constant because at the transition state the reaction has 
an equal probability of continuing forward to the products or going back to the 
reactants. The Arrhenius and Eyring-Polanyi equations used, are shown below. 
Arrhenius equation: 
𝑘 = 𝐴𝑒−𝐸𝑎/𝑅𝑇 
 
ln(𝑘) =  −
𝐸𝑎
𝑅
(
1
𝑇
) + ln (𝐴) 
Eyring-Polanyi equation: 
𝑘 =
𝑘𝐵𝑇
ℎ
𝑒−∆𝐺
ǂ/𝑅𝑇 
 
ln (
𝑘
𝑇
) =  
−∆𝐻ǂ
𝑅
(
1
𝑇
) + ln (
𝑘𝐵
ℎ
) +  
∆𝑆ǂ
𝑅
 
where:  
𝑘 = rate constant / s−1 
𝐸𝑎 = Activation energy / J mol
−1 
𝑇 = temperature / K 
𝑅 = Gas constant / 8.314 J K−1 mol−1 
𝐴 = Pre-exponential factor 
 
where:  
𝑘 = rate constant / s−1 
𝑇 = temperature / K 
𝑅 = Gas constant / 8.314 J K−1 mol−1 
∆𝐻ǂ = enthalpy of activation / J mol−1 
∆𝑆ǂ = entropy of activation / J K−1 
ℎ = Planck’s constant / 6.626 x 10−34 kg m2 s−1 
𝑘𝐵 = Boltzmann constant / 1.38 x 10
−23 J K−1 
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8.2. Modelling ligand exchange 
8.2.1. Modelling pyridine ligand exchange in 
complexes of [Ir(H)2(R-NHC-O)(py)2]  
In these [Ir(H)2(R-NHC-O)(py)2] complexes, there is only one pyridine ligand 
that can exchange with free pyridine in the bulk solution and therefore a simple model 
can be used. This pyridine dissociation step is the first step that occurs within the 
mechanism of ligand exchange for SABRE and therefore can be easily modelled using 
the experimental data. The 16-electron intermediate C is very reactive so is likely to be 
trapped rapidly by other potential ligands in solution so itself will be in very low 
concentration. The concentration of pyridine is also much higher than the concentration 
of the iridium species so it is unlikely that the same pyridine ligand will rebind to the 
iridium centre, however, if this back reaction is not allowed within the model, then the 
quality of the data fit is reduced. 
 
[𝐴]𝑡 = [𝐴]0 − 𝑘𝑑[𝐴]𝑡 + 𝑘𝑎[𝐵][𝐶]𝑡 
[𝐵]𝑡 = [𝐵]0 + 𝑘𝑑[𝐴]𝑡 − 𝑘𝑎[𝐵][𝐶]𝑡 
[𝐶]𝑡 = [𝐶]0 + 𝑘𝑑[𝐴]𝑡 − 𝑘𝑎[𝐵][𝐶]𝑡 
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8.2.2. Modelling pyridine ligand exchange in 
complexes of [Ir(H)2(R-NHC-O−)(py)3]+  
In these [Ir(H)2(R-NHC-O
−)(py)3]
+ complexes, there are two pyridine ligands 
that are both trans to hydride ligands that have the potential to exchange with the same 
probability as each other. Here, the model is more complicated because there are now 
two steps that can lead to dissociation of the two starting pyridine ligands. The rate of 
pyridine loss for the second step will be half that of the first as there is now only one 
pyridine ligand that can dissociate, compared to two in the starting complex, where each 
has the same probability of dissociating. 
 
[𝐴]𝑡 = [𝐴]0 − 𝑘𝑑1[𝐴]𝑡 + 𝑘𝑎1[𝐵][𝐶]𝑡 
[𝐵]𝑡 = [𝐵]0 + 𝑘𝑑1[𝐴]𝑡 − 𝑘𝑎1[𝐵][𝐶]𝑡 − 𝑘𝑎1
2
[𝐵]𝑡 
[𝐶]𝑡 = [𝐶]0 + 𝑘𝑑1[𝐴]𝑡 − 𝑘𝑎1[𝐵][𝐶]𝑡 − 𝑘𝑑1
2
[𝐶]𝑡 + 𝑘𝑎1
2
[𝐷][𝐸]𝑡 + 𝑘𝑎1
2
[𝐵][𝐸]𝑡 
[𝐷]𝑡 = [𝐷]0 + 𝑘𝑑1
2
[𝐶]𝑡 − 𝑘𝑎1
2
[𝐷][𝐸]𝑡 
[𝐸]𝑡 = [𝐸]0 + 𝑘𝑑1
2
[𝐶]𝑡 − 𝑘𝑎1
2
[𝐷][𝐸]𝑡 
Species C can be reformed by the association of pyridine ligand D with very 
reactive species E and therefore, because D is essentially the same as B, species C can 
also be reformed from the association of pyridine ligand B with species E. The 
concentrations of the species containing bound pyridine ligands, A and C can be 
summed and those containing free pyridine, B and D can be summed and the pyridine 
dissociation rate can then be modelled using the intermediates. By allowing all the back 
reactions to occur in the model, the data can fit the model most effectively, despite any 
values for back reactions being insignificant.  
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8.2.3. Modelling H2 ligand exchange in complexes 
of [Ir(H)2(R-NHC-O)(py)2]  
For SABRE to be efficient, the hydride ligands must be lost and then re-added in 
a pairwise fashion to the iridium centre. In these [Ir(H)2(R-NHC-O)(py)2] complexes, 
the hydride ligands are inequivalent, so as well as undergoing H2 loss, they also undergo 
a hydride interchange process which also has to be modelled. The interchange process 
between the hydride ligands of complexes A and B will occur at the same rate, kint. The 
two hydride ligands can interchange and hydrogen loss can occur from both complexes 
with either arrangement of hydride ligands, at the same rate, kd. Intermediate D is so 
reactive that it is likely to be immediately trapped by another ligand and so will have 
very low concentration in solution. 
 
[𝐴]𝑡 = [𝐴]0 − 𝑘𝑖𝑛𝑡[𝐴]𝑡 + 𝑘𝑖𝑛𝑡[𝐵]𝑡 − 𝑘𝑑[𝐴]𝑡 + 𝑘𝑎[𝐶][𝐷]𝑡 
[𝐵]𝑡 = [𝐵]0 − 𝑘𝑖𝑛𝑡[𝐵]𝑡 + 𝑘𝑖𝑛𝑡[𝐴]𝑡 − 𝑘𝑑[𝐵]𝑡 + 𝑘𝑎[𝐶][𝐷]𝑡 
[𝐶]𝑡 = [𝐶]0 + 𝑘𝑑[𝐴]𝑡 + 𝑘𝑑[𝐵]𝑡 − 2𝑘𝑎[𝐶][𝐷]𝑡 
[𝐷]𝑡 = [𝐷]0 + 𝑘𝑑[𝐴]𝑡 + 𝑘𝑑[𝐵]𝑡 − 2𝑘𝑎[𝐶][𝐷]𝑡 
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8.2.4. Modelling H2 ligand exchange in complexes 
of [Ir(H)2(R-NHC-O−)(py)3]+  
Here, in these [Ir(H)2(R-NHC-O
−)(py)3]
+ complexes, the two hydride ligands are 
equivalent and so the model is like the model for a single pyridine loss process. The two 
hydride ligands are lost in a pairwise process to form dihydrogen. It is this that is 
analysed from the experimental data. The concentration of intermediate C, formed from 
H2 loss would be very low as it is very unstable so would not be present in solution in 
the described form, thus its concentration is effectively negligible. Also, the probability 
of the same H2 molecule that has dissociated, rebinding to the same iridium centre is 
very small, however, without allowing this back reaction to be modelled, the data fitting 
is not as concordant. 
 
[𝐴]𝑡 = [𝐴]0 − 𝑘𝑑[𝐴]𝑡 + 𝑘𝑎[𝐵][𝐶]𝑡 
[𝐵]𝑡 = [𝐵]0 + 𝑘𝑑[𝐴]𝑡 − 𝑘𝑎[𝐵][𝐶]𝑡 
[𝐶]𝑡 = [𝐶]0 + 𝑘𝑑[𝐴]𝑡 − 𝑘𝑎[𝐵][𝐶]𝑡 
For the step of dihydride loss to form dihydrogen, the actual mechanism 
involves many steps before dihydrogen loss occurs and therefore what is observed is a 
value that encompasses all these steps. However, they cannot all be modelled because 
there are a number of very short-lived intermediates that are not observed and one 
particular, very important intermediate for the SABRE process, which is the 
intermediate before the dihydrogen loss step, poses a number of problems. This is 
because the dihydrogen-dihydride intermediate, [Ir(H)2(H2)(R-NHC-O)(py)], which is 
how fresh p-H2 is introduced into the complexes, can be viewed as a very short-lived 
species containing four fluxional hydride ligands, each with very short relaxation times. 
The concentration of this is thus expected to be very low at any one moment in time and 
modelling from this species, which is not observed, is problematic. Instead, the species 
that are observed are the initial dihydride complex which then undergoes several 
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reaction steps before it loses hydrogen, which is what is observed as the ‘product’ in the 
1H NMR spectrum. It is known that the rate of pyridine loss is the limiting factor 
affecting the process, as this is the first step in the SABRE mechanism. A way to 
increase the concentration of the important dihydrogen-dihydride intermediate in 
solution would be to increase the hydrogen pressure as this would increase the 
concentration of H2 in solution. However, as this intermediate is not stable and is very 
fluxional the potential observed signals would be very broad and thus would not be 
useful for analysing via NMR. 
 
8.3. Polarisation methods for NMR experiments 
Polarisation transfer experiments were conducted in either a Young’s NMR 
tube2 (Method A) or by using an automated polariser88, 96 (Method B). 
 
8.3.1. Method A2 
For polarisation transfer experiments, using the shake-and-drop method, a 
Young’s NMR tube containing a solution of the relevant iridium catalyst, analyte and 
solvent (0.6 mL), formed the sample. This sample was degassed prior to the 
introduction of parahydrogen at a pressure of 3 bars. For the temperature studies in 
Sections 4.2.1 and 4.3.1, the sample was placed in a water bath of known temperature 
for 1 minute before shaking in the desired magnetic field (using the fringe field of the 
magnet) for 10 seconds before being rapidly transported to the magnet for interrogation 
by NMR spectroscopy. 
 
8.3.2. Method B88 
Samples polarised using the polariser were achieved as follows. The polarisation 
chamber was charged with the relevant iridium catalyst, analyte to be polarised and 
CD3OD (3 mL). Parahydrogen was introduced to the solution via six inlet tubes at a 
pressure of 3 bars for 10 seconds. This solution was then transferred into the Bruker 
Avance III series 400 MHz spectrometer equipped with a TXO flow probe head (flow 
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cell volume = 200 μl) for interrogation by NMR using helium as a flow gas. A single 
transient was recorded for the nucleus of interest. Once interrogated, the solution was 
returned to the polarising chamber and this process repeated as required. A coil 
surrounded the reaction chamber such that a magnetic field could be generated in the z 
direction. This coil was designed to produce static DC fields in the range of −150 to 150 
x 10−4 T. For field profiling five 1H NMR spectra were collected at each point to ensure 
reproducibility. 
 
8.3.3. Calculation of 1H NMR enhancement factors 
To calculate the enhancements observed for each of the 1H NMR signals, the 
following formula was used: 
𝐸 =
𝑆𝑝𝑜𝑙
𝑆𝑢𝑛𝑝𝑜𝑙
 
E = enhancement 
Spol = signal intensity of polarised sample 
Sunpol = signal intensity of unpolarised (reference) sample 
Experimentally, the reference NMR spectra were acquired with the same sample 
that was used for the hyperpolarised measurement after it had fully relaxed (typically 5-
10 minutes at high magnetic field). Reference and polarised spectra were collected 
using identical acquisition parameters, particularly the receiver gain. The raw integrals 
of the relevant resonances in the polarised and unpolarised spectra were used to 
determine the enhancement levels. These 1H NMR enhancement factors are field 
dependent, as detailed in Sections 4.2.1 and 4.3.1, and it is common practice to report 
these enhancement factors. However, a more unified measure is % polarisation.  
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8.4. General information 
All experimental procedures were performed under an atmosphere of dinitrogen, 
using standard Schlenk line techniques or an MBraun Unilab glovebox, unless 
otherwise stated. General solvents for synthetic chemistry were dried using an 
Innovative Technology anhydrous solvent engineering system or were distilled from an 
appropriate drying agent under N2 as necessary. Parahydrogen was prepared by cooling 
hydrogen gas over charcoal in a copper block at 30 K. 
 
8.4.1. NMR 
NMR measurements were made on a Bruker Avance III series 400 MHz NMR 
spectrometer (1H at 400.13 MHz, 13C at 100.62 MHz, 31P at 162.0 MHz) and a 500 
MHz NMR spectrometer (1H at 500.13 MHz, 13C at 125.77 MHz, 15N at 50.7 MHz, 31P 
at 202.5 MHz). NMR samples were made up in Young’s tap equipped 5 mm NMR 
tubes. The deuterated solvents (methanol-d4, methanol-d3, CDCl3, C6D6, CD2Cl2, THF-
d8) were obtained from Sigma-Aldrich and Cambridge Isotope Laboratories (ethanol-d6) 
and used as supplied. Multiplicities are given as s (singlet), d (doublet), t (triplet), m 
(multiplet), br (broad) and ps (pseudo). 
 
8.4.2. X-ray Crystallography 
Samples for single crystal X-ray analysis were typically grown by either slow 
diffusion of hexane or toluene into a DCM solution or by slow evaporation from a 
concentrated DCM solution of the sample. Suitable crystals were selected in 
collaboration with Adrian Whitwood, Sam Hart and Rachel Bean in the XRD 
department at York and crystallography data was collected on a SuperNova, single 
source at offset, Eos diffractometer. The crystals were kept at 110.05(10) K during data 
collection. Using Olex2,294 the structures were solved with the ShelXS295 structure 
solution program using Direct Methods and refined with the ShelXL295 refinement 
package using Least Squares minimisation. The structures were visualised using 
Mercury software. 
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8.4.3. UV-vis and IR 
UV-visible absorption spectra were recorded on a Thermo Scientific Evolution 
Array UV-vis spectrophotometer (190-1100 nm) and processed using VISIONcollect 
software whereby background absorption spectra were subtracted from the sample 
spectra. IR spectra were recorded using a Bruker Tensor 37 FT-IR with a micro 
diamond ATR Probe (MIR). 
 
8.4.4. Mass Spectrometry 
Several mass spectrometers were used, with either the hard electrospray 
ionisation (ESI) technique or the softer liquid introduction field desorption ionisation 
(LIFDI) technique. For routine analysis, particularly during synthesis, a Bruker amaZon 
SL ESI LC/MSn Ion Trap MS system coupled to a DIONEX HPLC system (with an 
APCI II source for LC coupling and a UV detector) was used. A Bruker micrOTOF 
(time-of-flight) instrument was also used. To prevent fragmentation, LIFDI was used 
with a Waters GCT Premier TOF spectrometer in order to gain information about 
larger, unstable metal complexes. 
 
8.4.5. Elemental Analysis 
A Sartorius SE2 analytical balance, able to accurately weigh 0.1 μg, was used to 
prepare samples for elemental analysis. Repeat data for each sample were collected on 
an Exeter Analytical CE-440 elemental analyser, which is calibrated against acetanilide 
standards. The amounts of carbon (C), hydrogen (H), and nitrogen (N) are reported as 
mean percentages.  
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8.5. Precursor synthesis 
In this section, the synthetic procedures used to form 1-(2,4,6-trimethylphenyl)-
1H-imidazole and [Ir(COD)Cl]2 are detailed. These two compounds are the starting 
materials that are needed to make all the different imidazolium salt derivatives and the 
subsequent iridium carbene complexes. 
 
8.5.1. 1-(2,4,6-trimethylphenyl)-1H-imidazole125 
 
Glacial acetic acid (10 mL), aqueous formaldehyde (3 mL, 37 wt %, 40 mmol, 1 eq.) 
and aqueous glyoxal (4.6 mL, 40 wt %, 40 mmol, 1 eq.) were added to a round-bottom 
flask and heated at 70 °C. A solution of glacial acetic acid (10 mL), ammonium acetate 
(3.08 g, 40 mmol, 1 eq., in 2 mL water) and mesitylamine (5.6 mL, 40 mmol, 1 eq.) was 
added dropwise over a period of 30 min before the solution was left for 18 h. The 
reaction mixture was cooled to room temperature and was added dropwise to a stirred 
solution of sodium hydrogen carbonate (29.4 g in 300 mL water). The product formed a 
precipitate which was filtered off and washed with water before being allowed to air 
dry. The brown solid was recrystallised from ethyl acetate and was isolated via vacuum 
filtration (4.36 g, 59 %); 1H NMR [CDCl3, 400 MHz, 298 K] δ 7.44 (s, 1H, CHimidazole), 
7.24 (s, 1H, CHimidazole), 6.98 (s, 2H, 2 x CHmesityl), 6.90 (s, 1H, CHimidazole), 2.35 (s, 3H, 
CH3), 2.00 (s, 6H, 2 x CH3); 
13C{1H} NMR [CDCl3] δ 138.8, 137.5, 135.4, 133.4, 
129.5, 129.0, 120.1, 21.0 (CH3), 17.3 (2 x CH3); MS [ESI] m/z 187.0 (M+H)
+ 
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8.5.2. [Ir(COD)Cl]2146 
 
IrCl3.3H2O (1 g, 2.84 mmol), propan-2-ol (17 mL) and water (8.5 mL) were added to a 
round-bottom flask and nitrogen was bubbled through the solution for 2 h. COD (3.5 
mL) was added and the solution was bubbled through with nitrogen for a further 15 min 
before the flask was fitted with a condenser and the solution was heated at 90 °C for 3 h 
under a nitrogen atmosphere. A red precipitate formed as the solution cooled and then 
the propan-2-ol was removed under reduced pressure. The resulting precipitate was 
filtered, washed with ice cold methanol and dried under vacuum (592 mg, 62 %); 1H 
NMR [CDCl3, 400 MHz, 298 K] δ 4.26 (s br, 8H, 8 x CH), 2.28 (m br, 8H, 8 x CH), 
1.55 (m br, 8H, 8 x CH); 13C{1H} NMR [CDCl3] δ 62.1, 31.8 
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8.6. NO2 carbene synthesis 
8.6.1. 3-(2-hydroxy-5-nitrobenzyl)-1-(2,4,6-
trimethylphenyl) imidazolium bromide125 
 
1-(2,4,6-trimethylphenyl)-1H-imidazole (0.61 g, 3.3 mmol, 1 eq.) and 2-hydroxy-5-
nitrobenzyl bromide (0.76 g, 3.3 mmol, 1 eq.) were dissolved in toluene (8 mL). The 
resulting mixture was refluxed for 18 h and then the solution was cooled to room 
temperature. The precipitate was collected via vacuum filtration and was washed with 
diethyl ether (1.25 g, 91 %); 1H NMR [DMSO, 400 MHz, 298 K] δ 11.81 (s, 1H, OH), 
9.55 (s, 1H, CHimidazole), 8.39 (d, 1H, 
4J(HH) = 2.6 Hz, CHAr), 8.22 (dd, 1H, 
4J(HH) = 
2.6 Hz, 3J(HH) = 9.0 Hz, CHAr), 8.05 (s, 1H, CHimidazole), 7.94 (s, 1H, CHimidazole), 7.15 
(s, 2H, 2 x CHmesityl), 7.09 (d, 1H, 
3J(HH) = 9.0 Hz, CHAr), 5.53 (s, 2H, CH2), 2.33 (s, 
3H, CH3), 2.01 (s, 6H, 2 x CH3);
 13C{1H} NMR [DMSO] δ 163.3 (CAr), 141.2 (CAr), 
140.3 (CAr), 139.1 (CHimidazole), 135.2 (CAr), 132.0 (CAr), 130.1 (2 x CHmesityl), 128.1 
(CHAr), 127.9 (CHAr), 125.0 (CHimidazole), 124.1 (CHimidazole), 122.2 (CAr), 116.7 (CHAr), 
49.2 (CH2), 21.5 (CH3), 17.7 (2 x CH3); MS [ESI] m/z 338.1 (M−Br)+; IR (cm−1): νOH 
1339, νCO 1279 
A crystal suitable for X-ray diffraction was grown in the presence of HBF4 as 
described in Section 5.4.1 with the ORTEP plot for the imidazolium tetrafluoroborate 
salt shown in Figure 241. 
 
Figure 241: ORTEP plot of the imidazolium tetrafluoroborate salt with the BF4 and H atoms 
omitted for clarity and the thermal ellipsoids set at a 50 % probability level 
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Table 50: Crystal data for the structural refinement of 3-(2-hydroxy-5-nitrobenzyl)-1-(2,4,6-
trimethylphenyl) imidazolium tetrafluoroborate 
Identification code  sbd1706 
Empirical formula and weight C19H20BF4N3O3  425.19 
Temperature / K  110.05(10) 
Crystal system and space group trigonal R-3 
Unit cell dimensions a / Å = 25.8153(3)   
b / Å = 25.8153(3)  
c / Å = 15.33067(18) 
α / ° = 90  
β / ° = 90 
γ / ° = 120 
Volume / Å3  8848.0(2) 
Z  18 
Density (calculated) / ρcalc / g cm−3 1.436 
Absorption coefficient / μ / mm−1  1.055 
F(000) 3960.0 
Crystal size / mm3  0.257 × 0.207 × 0.158 
Radiation  CuKα (λ = 1.54184) 
2Θ range for data collection/°  6.992 to 142.124 
Index ranges  −31 ≤ h ≤ 31, −30 ≤ k ≤ 29, −18 ≤ l ≤ 17 
Reflections collected  14441 
Independent reflections  3775 [Rint = 0.0161, Rsigma = 0.0114] 
Data / restraints / parameters  3775 / 0 / 316 
Goodness-of-fit on F2  1.023 
Final R indexes [I ≥ 2σ (I)] R1 = 0.0397, wR2 = 0.1046 
Final R indexes [all data]  R1 = 0.0421, wR2 = 0.1070 
Largest diff. peak / hole / e Å−3  0.33 / −0.22 
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8.6.2. Silver(I) 3-(2-methylene-4-nitrophenolate)-
1-(2,4,6-trimethylphenyl)imidazolylidene125 
 
3-(2-hydroxy-5-nitrobenzyl)-1-(2,4,6-trimethylphenyl) imidazolium bromide (500 mg, 
1.2 mmol, 1 eq.), silver(I) oxide (569.4 mg, 2.5 mmol, 2 eq.) and 4 Å molecular sieves 
(1.12 g) were added to a round-bottom flask under a nitrogen atmosphere. Dried THF 
(8.5 mL) and toluene (8.5 mL) were added to the flask and the reaction mixture was 
stirred at reflux for 3 h. Once cooled to room temperature, the mixture was diluted with 
dichloromethane (80 mL), filtered through a pad of Celite and washed through with 
dichloromethane (2 x 5 mL). The solvent was removed under reduced pressure to 
produce a yellow solid (0.45 g, 85%); 1H NMR [CDCl3, 400 MHz, 298 K] δ 8.16 (s br, 
1H, CHAr), 7.78 (s br, 1H, CHAr), 7.38 (s br, 1H, CHAr), 7.01 (s br, 2H, 2 x CHmesityl), 
6.99 (s br, 1H, CHAr), 5.84 (s br, 1H, CHAr), 5.27 (s br, 2H, CH2), 2.42 (s, 3H, CH3), 
1.96 (s br, 6H, 2 x CH3); 
13C{1H} NMR [CDCl3] δ 174.7, 139.6, 137.2, 135.2, 134.5, 
129.2 (2 x CHmesityl), 127.2 (CHAr), 126.8 (CHAr), 124.4, 122.2, 121.9 (CHAr), 121.5 
(CHAr), 50.3 (CH2), 21.4 (CH3), 17.9 (2 x CH3); MS [ESI] m/z 783 (Ag dimer, 
protonated phenol groups) 
Only partial 13C{1H} NMR data could be obtained due to very broad and 
overlapping NMR signals.  
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8.6.3. Iridium(I) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-
trimethylphenyl)imidazolylidene) 
(cyclooctadiene), 1146 
 
Silver(I) 3-(2-methylene-4-nitrophenolate)-1-(2,4,6-trimethylphenyl)imidazolylidene 
(170 mg, 0.38 mmol, 2 eq.) and [Ir(COD)Cl]2 (129 mg, 0.19 mmol, 1 eq.) were added to 
a Schlenk flask under N2. Dry THF (12 mL) was added and the reaction mixture was 
stirred overnight at room temperature. The mixture was diluted with DCM, filtered 
through Celite, purified by column chromatography (silica, DCM: acetone 80: 20) and 
evaporated to dryness to produce an orange/brown powder (0.23 g, 96 %); 1H NMR 
[CD2Cl2, 500 MHz, 298 K] δ 8.17 (d, 1H, 4J(HH) = 3.0 Hz, CHAr), 7.96 (dd, 1H, 
4J(HH) = 3.0 Hz, 3J(HH) = 9.3 Hz, CHAr), 7.14 (d, 1H, 
3J(HH) = 1.9 Hz, CHimidazole), 
7.03 (s br, 2H, 2 x CHmesityl), 6.72 (d, 1H, 
3J(HH) = 1.9 Hz, CHimidazole), 6.60 (s br, 1H, 
CH2 linker), 6.57 (d, 1H, 
3J(HH) = 9.3 Hz, CHAr), 4.79 (s br, 1H, CH2 linker), 4.40 (s 
br, 2H, 2 x CHCOD), 3.30 (s br, 1H, CHCOD), 2.45 (s br, 1H, CHCOD), 2.39 (s, 3H, CH3), 
2.09 (s br, 4H, CH2(COD)), 2.03 (s br, 6H, 2 x CH3), 1.58 (s br, 4H, CH2(COD));
 1H NMR 
[CD2Cl2, 500 MHz, 253 K] δ 8.18 (d, 1H, 4J(HH) = 3.0 Hz, CHAr), 7.96 (dd, 1H, 
4J(HH) = 3.0 Hz, 3J(HH) = 9.2 Hz), 7.14 (d, 1H, 3J(HH) = 1.9 Hz, CHimidazole), 7.06 (s, 
1H, CHmesityl), 6.96 (s, 1H, CHmesityl), 6.72 (d, 1H, 
3J(HH) = 1.9 Hz, CHimidazole), 6.60 (d, 
1H, 2J(HH) = 14.0 Hz, CH2 linker), 6.55 (d, 1H, 
3J(HH) = 9.2 Hz, CHAr), 4.79 (d, 1H, 
2J(HH) = 14.0 Hz, CH2 linker), 4.42 (m, 1H, CHCOD), 4.26 (m, 1H, CHCOD), 3.27 (m, 
1H, CHCOD), 2.41 (m, 1H, CHCOD), 2.36 (s, 3H, CH3), 2.20-2.00 (m, 4H, 2 x CH2(COD)), 
2.07 (s, 3H, CH3), 1.96 (s, 3H, CH3), 1.68-1.53 (m, 4H, 2 x CH2(COD)); 
13C{1H} NMR 
[CD2Cl2, 253 K] δ 175.7 (C-OIr), 175.1 (C-Ir), 139.0 (CAr), 136.1 (CAr), 135.5 (CAr), 
134.4 (CAr), 134.0 (CAr), 129.1 (CHAr), 128.4 (CHAr), 127.0 (CHAr), 126.3 (CHAr), 123.4 
(CHimidazole), 123.2 (CAr), 121.5 (CHAr), 119.6 (CHimidazole), 84.7 (CH), 84.6 (CH), 51.2 
(CH2), 49.7 (CH), 48.3 (CH), 34.5 (CH2), 33.8 (CH2), 28.9 (CH2), 28.4 (CH2), 21.0 
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(CH3), 18.7 (CH3), 17.6 (CH3); MS [ESI] m/z 638.19 (M+H)
+. Anal. Calcd for 
C27H30N3O3Ir (Mr = 636.77): C, 50.93; H, 4.75; N, 6.60. Found: C, 50.64; H, 4.52; N, 
6.14.  
 
Figure 242: ORTEP plot of 1 with H atoms omitted for clarity and the thermal ellipsoids set at 
a 50 % probability level 
 
Table 51: Crystal data for the structural refinement of 1 
Identification code  sbd1402 
Empirical formula and weight C27H30IrN3O3  644.77 
Temperature / K  110.05(10)  
Crystal system and space group monoclinic  P21/n  
Unit cell dimensions a / Å = 8.7533(3)   
b / Å = 19.4098(11)  
c / Å = 13.9131(4) 
α / ° = 90  
β / ° = 90.472(3) 
γ / ° = 90 
Volume / Å3  2363.77(17)  
Z  4  
Density (calculated) / ρcalc / g cm−3 1.812  
Absorption coefficient / μ / mm−1  5.918  
F(000) 1269.0  
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Crystal size / mm3  0.1894 × 0.1261 × 0.0302  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.86 to 59.996  
Index ranges  −7 ≤ h ≤ 12, −23 ≤ k ≤ 27, −19 ≤ l ≤ 19  
Reflections collected  12799  
Independent reflections  6892 [Rint = 0.0326, Rsigma = 0.0509]  
Data / restraints / parameters  6892 / 0 / 321 
Goodness-of-fit on F2  1.143  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0345, wR2 = 0.0675 
Final R indexes [all data]  R1 = 0.0415, wR2 = 0.0701  
Largest diff. peak / hole / e Å−3  1.81 / −1.39  
 
UV-vis absorption data for complex 1 at six different concentrations are given in 
Table 52 with the corresponding absorption spectra shown in Figure 243. 
Table 52: Concentration and absorbance values for six samples of 1 in DCM at different 
concentrations 
Sample Concentration / μmol dm−3 Absorbance 
A 60.4 1.05 
B 48.3 0.84 
C 29.0 0.52 
D 23.2 0.42 
E 16.2 0.30 
F 6.5 0.13 
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Figure 243: Visible region of the absorption spectra for 1 in DCM at different concentrations as 
listed in Table 52 
The calibration graph in Figure 244 was used to gain the molar absorption 
coefficient for the absorption band of 1 as described in Section 2.6.1. 
 
Figure 244: Calibration graph used to calculate the molar absorption coefficient for the 
absorption band of 1 at 406 nm using the data in Table 52 
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8.6.4. Iridium(III) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(dihydride)(pyridine)2, 6A 
 
To a Young’s NMR tube was added 1 (10 mg, 16 μmol, 1 eq.), pyridine (3.8 μL, 47 
μmol, 3 eq.) and CD2Cl2 (0.6 mL). The solution was then degassed three times on a high 
vacuum line using a freeze-thaw procedure with liquid N2, before the addition of 3 bars 
of H2. The mixture was then left to react at r.t. for 3 days; 
1H NMR [CD2Cl2, 400 MHz, 
233 K] δ 8.92 (m, 2H, 2 x CHpy ortho), 8.17 (d, 1H, 4J(HH) = 2.8 Hz, CHAr), 8.13 (m, 2H, 
2 x CHpy ortho), 8.04 (dd, 1H, 
3J(HH) = 9.0 Hz, 4J(HH) = 2.8 Hz, CHAr), 7.66 (m, 1H, 
CHpy para), 7.60 (m, 1H, CHpy para), 7.19 (d, 1H, 
3J(HH) = 1.5 Hz, CHimidazole), 7.11 (m, 
2H, 2 x CHpy meta), 7.01 (s, 1H, CHmesityl), 6.92 (m, 2H, 2 x CHpy meta), 6.69 (d, 1H, 
3J(HH) = 9.0 Hz, CHAr), 6.61 (d, 1H, 
3J(HH) = 1.5 Hz, CHimidazole), 6.48 (d, 1H, 
2J(HH) 
= 13.6 Hz, CH2 linker), 6.46 (s, 1H, CHmesityl), 4.46 (d, 1H, 
2J(HH) = 13.6 Hz, CH2 
linker), 2.31 (s, 3H, CH3), 2.16 (s, 3H, CH3), 0.93 (s, 3H, CH3), −21.36 (d, 1H, 2J(HH) 
= 8.9 Hz), −28.88 (d, 1H, 2J(HH) = 8.9 Hz); 13C{1H} NMR [CD2Cl2] δ 177.7 (C-O), 
175.5 (C-Ir), 154.6 (2 x CHpy ortho), 152.8 (2 x CHpy ortho), 137.9 (CAr), 137.0 (CAr), 136.5 
(CAr), 136.0 (CAr), 135.8 (CHpy para), 135.5 (CHpy para), 132.2 (CAr), 128.7 (CHmestiyl), 
128.1 (CHmestiyl), 127.2 (CHAr), 126.9 (CHAr), 124.8 (CAr), 124.7 (2 x CHpy meta), 124.5 
(2 x CHpy meta), 122.2 (CHAr), 120.5 (CHimidazole), 120.0 (CHimidazole), 51.7 (CH2), 25.3 
(CH3), 21.0 (CH3), 16.6 (CH3); 
15N NMR [CD2Cl2] δ 192.5, 190.9 
The 13C{1H} spectrum showed large peaks for COD, COE and COA but the 
active catalyst signals were not visible, even after multiple scans, due to sample 
dilution. The carbene carbon and other quaternary carbon signals were identified using 
an HMBC pulse sequence exploiting the long-range coupling, with the coupling 
constant optimised at 6 Hz. 
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8.6.5. Iridium(I) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-
trimethylphenyl)imidazolylidene) 
(dicarbonyl), 17 
 
Iridium(I) (3-(2-methylene-4-nitrophenolate)-1-(2,4,6-trimethylphenyl)imidazolylidene) 
(cyclooctadiene) (20 mg, 0.0314 mmol, 1eq.) was dissolved in DCM (2 mL) and the 
mixture was stirred at r.t. whilst CO was bubbled through for 2 min. Stirring under an 
atmosphere of CO was continued for 10 min before the solution was purged with N2 and 
the solvent was removed. The residue was triturated with hexane to afford a yellow 
solid (12 mg, 67 %); 1H NMR [CD2Cl2, 400 MHz, 298 K] δ 8.20 (d, 1H, 4J(HH) = 3.0 
Hz, CHAr), 8.04 (dd, 1H, 
4J(HH) = 3.0 Hz, 3J(HH) = 9.2 Hz, CHAr), 7.28 (d, 1H, 
3J(HH) 
= 1.9 Hz, CHimidazole), 7.06 (s, 2H, 2 x CHmesityl), 6.93 (d, 1H, 
3J(HH) = 1.9 Hz, 
CHimidazole), 6.74 (d, 1H, 
3J(HH) = 9.2 Hz, CHAr), 5.43 (s br, 2H, CH2), 2.40 (s, 3H, 
CH3), 2.01 (s, 6H, 2 x CH3); 
13C{1H} NMR [CD2Cl2] δ 181.9 (C=O), 173.3 (C=O), 
173.0 (C-Ir), 151.3 (C-O), 139.9 (CAr), 136.2 (CAr), 135.2 (2 x CAr), 134.7 (CAr), 129.1 
(2 x CHmesityl), 126.3 (CHAr), 126.2 (CHAr), 123.5 (CAr), 123.4 (CHimidazole), 121.9 
(CHAr), 121.0 (CHimidazole), 50.6 (CH2), 20.9 (CH3), 17.8 (2 x CH3); MS [ESI] m/z 586.1 
(M+H)+; IR νCO (cm−1): 2065.5, 1971.9 
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8.6.6. Iridium carbene phenethylamine dimer, 
21phenethylamine 
 
To a Young’s NMR tube was added 1 (5 mg, 8 μmol, 1 eq.), phenethylamine (1 μL, 8 
μmol, 1 eq.) and CD2Cl2 (0.6 mL). The solution was then degassed three times on a high 
vacuum line using a freeze-thaw procedure with liquid N2, before the addition of 3 bars 
of H2. The mixture was then left to react at r.t. for 3 days; 
1H NMR [CD2Cl2, 400 MHz, 
243 K] δ 8.16 (d, 1H, 4J(HH) = 2.6 Hz, CHAr), 8.15 (d, 1H, 4J(HH) = 2.6 Hz, CHAr), 
8.05 (dd, 1H, 4J(HH) = 2.6 Hz, 3J(HH) = 9.2 Hz, CHAr), 8.00 (dd, 1H, 
4J(HH) = 2.6 Hz, 
3J(HH) = 9.2 Hz, CHAr), 7.36-7.2 (m, 5H, 5 x CHAr), 7.20 (d, 1H, 
3J(HH) = 2.2 Hz, 
CHimidazole), 7.05-6.94 (m, 5H, 5 x CHAr), 7.04 (d, 1H, 
3J(HH) = 1.7 Hz, CHimidazole),7.00 
(s, 1H, CHmesityl), 6.96 (s, 1H, CHmesityl), 6.86 (d, 1H, 
2J(HH) = 14.2 Hz, CH2), 6.86 (s, 
1H, CHmesityl), 6.70 (d, 1H, 
3J(HH) = 2.2 Hz, CHimidazole), 6.60 (d, 1H, 
3J(HH) = 9.2 Hz, 
CHAr), 6.53 (d, 1H, 
3J(HH) = 1.7 Hz, CHimidazole), 6.34 (d, 1H, 
3J(HH) = 9.2 Hz, CHAr), 
6.25 (d, 1H, 2J(HH) = 13.7 Hz, CH2), 4.19 (d, 1H, 
2J(HH) = 14.2 Hz, CH2), 4.16 (d, 1H, 
2J(HH) = 13.7 Hz, CH2), 2.35-2.28 (m br, 4H, CHalkyl), 2.31 (s, 3H, CH3), 2.27 (s, 3H, 
CH3), 2.16-2.08 (m br, 4H, CHalkyl), 1.83 (s, 3H, CH3), 1.76 (s, 3H, CH3), 1.68 (s, 3H, 
CH3), 1.53 (s, 3H, CH3), −26.30 (dd, 1H, 2J(HH) = 6.1 Hz, 2J(HH) = 8.1 Hz, Ht), 
−26.54 (dd, 1H, 2J(HH) = 8.1 Hz, 2J(HH) = 8.1 Hz, Ht’), −30.59 (d, 1H, 2J(HH) = 8.1 
Hz, Hb), −30.97 (d, 1H, 2J(HH) = 6.1 Hz, Hb’); 13C{1H} NMR [CD2Cl2] δ 177.6 (CAr), 
176.9 (CAr), 156.3 (C-Ir), 150.8 (C-Ir), 139.0 (Cmesityl), 138.5 (Cmesityl), 138.5 (Cmesityl), 
137.4 (Cmesityl), 136.5 (Cmesityl), 135.9 (Cmesityl), 135.3 (Cmesityl), 134.1 (CAr), 133.0 
(Cmesityl), 132.5 (CAr), 129.8 (CHmesityl), 129.2 (CHAr), 129.0 (CHmesityl), 128.8 (CHAr), 
128.4 (CHmesityl), 128.4 (CHAr), 128.3 (CHAr), 128.2 (CHmesityl), 128.0 (CHAr), 126.8 
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(CHAr), 126.7 (CHAr), 121.4 (CHAr), 121.4 (CHimidazole), 121.3 (CHAr), 121.0 
(CHimidazole), 119.7 (CHimidazole), 119.3 (CHimidazole), 51.6 (CH2), 50.9 (CH2), 19.3 (CH3), 
18.3 (CH3), 18.0 (CH3), 17.6 (CH3) 
In some places this characterisation data is incomplete due to multiple 
overlapping signals for the very similar chemical shifts of the two bidentate carbene 
ligands and the multiple amine ligands. 
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8.6.7. Iridium(III) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(hydride)(benzylamine)(C-
H activated benzylamine), 22benzylamine 
 
To a Young’s NMR tube was added 1 (5 mg, 8 μmol, 1 eq.), benzylamine (1.7 μL, 16 
μmol, 2 eq.) and CD2Cl2 (0.6 mL). The solution was then degassed three times on a high 
vacuum line using a freeze-thaw procedure with liquid N2, before the addition of 3 bars 
of H2. The mixture was then left to react at r.t. for 3 days; 
1H NMR [CD2Cl2, 400 MHz, 
298 K] δ 8.15 (d, 1H, 4J(HH) = 2.9 Hz, CHAr), 7.95 (dd, 1H, 4J(HH) = 2.9 Hz, 3J(HH) = 
8.8 Hz, CHAr), 7.40-7.34 (m, 4H, 4 x CHAr), 7.33 (d, 1H, 
3J(HH) = 2.1 Hz, CHimidazole), 
7.06 (m, 1H, CHAr), 7.02 (s, 1H, CHmesityl), 6.90 (s, 1H, CHmesityl), 6.90 (m, 1H, CHAr), 
6.85 (d, 1H, 3J(HH) = 2.1 Hz, CHimidazole), 6.80-6.70 (m, 3H, CHAr), 6.54 (d, 1H, 
3J(HH) 
= 8.8 Hz, CHAr), 5.63 (d, 1H, 
2J(HH) = 13.8 Hz, CH2 linker), 4.41 (d, 1H, 
2J(HH) = 
13.8 Hz, CH2 linker), 4.34 (ddd, 1H, 
2J(HH) = 13.9 Hz, 3J(HH) = 5.5 Hz, 3J(HH) = 5.5 
Hz, CH2), 3.96 (ddd, 1H, 
2J(HH) = 13.9 Hz, 3J(HH) = 6.5 Hz, 3J(HH) = 6.5 Hz, CH2), 
3.89 (s br, 1H, NH2), 3.64 (ddd, 1H, 
2J(HH) = 13.3 Hz, 3J(HH) = 9.8 Hz, 3J(HH) = 4.1 
Hz, CH2), 3.46 (ddd, 1H, 
2J(HH) = 13.3 Hz, 2J(HH) = 9.5 Hz, 3J(HH) = 6.2 Hz, CH2), 
3.39 (s br, 1H, NH2), 2.70 (t br, 1H, 
3J(HH) = 9.8 Hz, NH2), 2.35 (s, 3H, CH3), 2.33 (s 
br, 1H, NH2), 2.02 (s, 3H, CH3), 1.74 (s, 3H, CH3), −28.50 (s, 1H); 13C{1H} NMR 
[CD2Cl2] δ 177.6 (C-Ir), 157.7 (C-O), 138.6 (CAr), 137.3 (CAr), 136.6 (CHAr), 136.3 
(CAr), 133.5 (CAr), 133.4 (CAr), 129.4 (CHAr), 129.3 (CHmesityl), 129.0 (CHAr), 128.9 
(CHAr), 128.4 (CHmesityl), 127.9 (CHAr), 127.6 (CHAr), 127.4 (CHAr), 126.4 (CHAr), 
125.5 (CAr), 124.8 (CHAr), 122.0 (CHAr), 121.5 (CHimidazole), 121.0 (CHAr), 120.7 
(CHimidazole), 120.0 (CHAr), 119.6 (CAr), 53.2 (CH2), 50.8 (CH2), 50.4 (CH2), 20.7 (CH3), 
18.7 (CH3), 17.4 (CH3)  
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8.6.8. Iridium(III) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(hydride)(tryptamine)(C-H 
activated tryptamine), 22tryptamine 
 
To a Young’s NMR tube was added 1 (5 mg, 8 μmol, 1 eq.), tryptamine (2.5 mg, 16 
μmol, 2 eq.) and CD2Cl2 (0.6 mL). The solution was then degassed three times on a high 
vacuum line using a freeze-thaw procedure with liquid N2, before the addition of 3 bars 
of H2. The mixture was then left to react at r.t. for 3 days; 
1H NMR [CD2Cl2, 400 MHz, 
298 K] δ 8.02 (d, 1H, 4J(HH) = 3.1 Hz, CHAr), 7.86 (dd, 1H, 4J(HH) = 3.1 Hz, 3J(HH) = 
9.0 Hz, CHAr), 7.47 (d, 1H,
 3J(HH) = 7.6 Hz, CHAr), 7.38 (d, 1H,
 3J(HH) = 7.6 Hz, 
CHAr), 7.31 (d, 1H, 
3J(HH) = 1.6 Hz, CHimidazole), 7.27 (t, 1H,
 3J(HH) = 7.6 Hz, CHAr), 
7.17 (t, 1H, 3J(HH) = 7.6 Hz, CHAr), 7.15 (d, 1H,
 3J(HH) = 7.6 Hz, CHAr), 7.03 (d, 1H,
 
3J(HH) = 7.6 Hz, CHAr), 7.00 (s, 1H, CHAr), 6.98 (s, 1H, CHmesityl), 6.94 (s, 1H, CHAr), 
6.87 (d, 1H, 3J(HH) = 1.6 Hz, CHimidazole), 6.83 (t, 1H,
 3J(HH) = 7.6 Hz, CHAr), 6.78 (s, 
1H, CHmesityl), 6.70 (t, 1H,
 3J(HH) = 7.6 Hz, CHAr), 6.22 (d, 1H, 
3J(HH) = 9.0 Hz, 
CHAr), 5.27 (d, 1H, 
2J(HH) = 13.8 Hz, CH2 linker), 4.19 (d, 1H, 
2J(HH) = 13.8 Hz, CH2 
linker), 3.42 (s, 2H, NH2), 3.24 (m, 1H, CH2), 3.01 (m, 1H, CH2), 2.93 (m, 1H, CH2), 
2.83 (m, 1H, CH2), 2.71 (m, 1H, CH2), 2.67 (m, 1H, CH2), 2.56 (m, 1H, CH2), 2.41 (m, 
1H, CH2), 2.30 (s, 3H, CH3), 2.15 (s, 3H, CH3), 1.67 (s, 3H, CH3), −28.94 (s, 1H); 
13C{1H} NMR [CD2Cl2] δ 177.1 (C-O), 155.5 (C-Ir), 138.8 (CAr), 138.3 (CAr), 136.6 
(CAr), 136.5 (CAr), 136.5 (CAr), 133.5 (CAr), 133.3 (C-NO2), 129.7 (CHAr), 129.7 (CAr), 
129.5 (CHAr), 128.5 (CHAr), 127.7 (CHAr), 127.4 (CHAr), 126.5 (CHAr), 126.5 (CAr), 
124.6 (CAr), 122.6 (CHAr), 122.5 (CHAr), 121.7 (CHAr), 121.5 (CHAr), 120.9 (CHAr), 
119.7 (CAr), 117.0 (CHAr), 115.9 (CHAr), 113.3 (CHAr), 111.6 (CHAr), 110.9 (CHAr), 
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108.7 (CAr), 107.6 (CHAr), 50.5 (CH2), 45.5 (CH2), 43.4 (CH2), 28.7 (CH2), 25.8 (CH2), 
20.8 (CH3), 19.0 (CH3), 17.3 (CH3) 
 
Figure 245: ORTEP plot of 22tryptamine, with H atoms (apart from the NH, NH2 and hydride 
ligand) omitted for clarity and the thermal ellipsoids set at a 50 % probability level 
 
Table 53: Crystal data for the structural refinement of 22tryptamine 
Identification code  sbd1630  
Empirical formula and weight C39H42IrN7O3  848.99  
Temperature / K  110.05(10)  
Crystal system and space group trigonal  R-3  
Unit cell dimensions a / Å = 48.3824(6) 
b / Å = 48.3824(6) 
c / Å = 10.78400(10) 
α / ° = 90  
β / ° = 90 
γ / ° = 120 
Volume / Å3  21861.8(6)  
Z  18  
Density (calculated) / ρcalc / g cm−3 1.161  
Absorption coefficient / μ / mm−1  5.603  
F(000) 7668.0  
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Crystal size / mm3  0.348 × 0.061 × 0.044  
Radiation CuKα (λ = 1.54184)  
2Θ range for data collection/°  7.308 to 134.142  
Index ranges  −57 ≤ h ≤ 43, −47 ≤ k ≤ 57, −12 ≤ l ≤ 12  
Reflections collected  43702  
Independent reflections  8684 [Rint = 0.0419, Rsigma = 0.0247]  
Data / restraints / parameters  8684 / 1 / 460  
Goodness-of-fit on F2  1.022  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0285, wR2 = 0.0729  
Final R indexes [all data]  R1 = 0.0309, wR2 = 0.0743  
Largest diff. peak / hole / e Å−3  0.90 / −0.66  
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8.6.9. Iridium(III) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(dihydride)(pyridine) 
(triphenylphosphine), 23pyridine 
 
To a Young’s NMR tube was added 1 (2 mg, 3.2 μmol, 1 eq.), pyridine (0.8 μL, 9.4 
μmol, 3 eq.) and CD2Cl2 (0.6 mL). The solution was then degassed three times on a high 
vacuum line using a freeze-thaw procedure with liquid N2, before the addition of 3 bars 
of H2. The mixture was then left to react at r.t. for 3 days. Once reacted to form 6, PPh3 
(0.8 mg, 3.2 μmol, 1 eq.) was added to the NMR tube and the mixture was degassed 
three times again before 3 bars of H2 were added; 
1H NMR [CD2Cl2, 400 MHz, 263 K] 
δ 8.74 (m, 2H, 2 x CHpy ortho), 8.00 (s br, 1H, CHAr), 7.38 (m, 1H, CHpy para), 7.36 (m br, 
1H, CHAr), 7.31-7.06 (m, 15H, 15 x CHAr), 7.02 (d, 1H, 
3J(HH) = 1.6 Hz, CHimidazole), 
6.92 (s, 1H, CHmesityl), 6.89 (s, 1H, CHmesityl), 6.78 (m, 2H, 2 x CHpy meta), 6.75 (d, 1H, 
3J(HH) = 1.6 Hz, CHimidazole), 6.68 (d, 1H, 
3J(HH) = 9.7 Hz, CHAr), 4.72 (d, 1H, 
2J(HH) 
= 14.0 Hz, CH2 linker), 3.68 (d, 1H, 
2J(HH) = 14.0 Hz, CH2 linker), 2.38 (s, 3H, CH3), 
1.82 (s, 3H, CH3), 1.39 (s, 3H, CH3), −8.47 (dd, 1H, 2J(HH) = 5.0 Hz, 2J(HPtrans) = 
163.2 Hz), −27.31 (dd, 1H, 2J(HH) = 5.0 Hz, 2J(HPcis) = 10.6 Hz); 13C{1H} NMR 
[CD2Cl2] δ 181.7 (C-OIr), 155.8 (2 x CHpy ortho), 150.2 (C-Ir), 138.1 (CAr), 138.0 (CAr), 
136.9 (CAr), 135.3 (CHpy para), 134.9 (CAr), 134.4 (3 x CAr), 134.0 (3 x CHAr), 133.8 (6 x 
CHAr), 133.0 (CAr), 128.8 (CHmesityl), 128.7 (CHmesityl), 128.1 (6 x CHAr), 127.0 (CHAr), 
125.6 (CAr), 124.0 (2 x CHpy meta), 123.8 (CHAr), 121.0 (CHimidazole), 120.9 (CHimidazole), 
119.7 (CHAr), 48.9 (CH2), 21.0 (CH3), 19.0 (CH3), 18.2 (CH3); 
31P{1H} NMR [CD2Cl2] 
13.6 (s) 
For this complex, the 13C{1H} data were collected via indirect HMQC methods 
and as such the 31P-13C couplings were not observed. 
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Figure 246: ORTEP plot of 23pyridine, with solvent and H atoms omitted for clarity and the 
thermal ellipsoids set at a 50 % probability level 
 
Table 54: Crystal data for the structural refinement of 23pyridine 
Identification code  sbd1631  
Empirical formula and weight C56H56IrN4O3P  1056.21  
Temperature / K  110.05(10)  
Crystal system and space group orthorhombic  P212121 
Unit cell dimensions a / Å = 13.63451(11)    
b / Å = 16.69609(15)   
c / Å = 21.33132(16) 
α / ° = 90  
β / ° = 90 
γ / ° = 90 
Volume / Å3  4855.93(7)  
Z  4  
Density (calculated) / ρcalc / g cm−3 1.445  
Absorption coefficient / μ / mm−1  2.831  
F(000) 2144.0  
Crystal size / mm3  0.146 × 0.131 × 0.102  
Radiation MoKα (λ = 0.71073)  
2Θ range for data collection/°  6.732 to 60.16  
338 
 
Index ranges  −19 ≤ h ≤ 19, −23 ≤ k ≤ 22, −11 ≤ l ≤ 30  
Reflections collected  39802  
Independent reflections  14222 [Rint = 0.0262, Rsigma = 0.0302]  
Data / restraints / parameters  14222 / 180 / 625  
Goodness-of-fit on F2  1.065  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0236, wR2 = 0.0517  
Final R indexes [all data]  R1 = 0.0272, wR2 = 0.0536  
Largest diff. peak / hole / e Å−3  0.88 / −0.70  
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8.6.10. Iridium(III) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(dihydride)(pyridine) 
(triphenylphosphine), 24pyridine 
 
To a Young’s NMR tube was added 1 (2 mg, 3.2 μmol, 1 eq.), pyridine (0.8 μL, 9.4 
μmol, 3 eq.), PPh3 (0.8 mg, 3.2 μmol, 1 eq.) and CD2Cl2 (0.6 mL). The solution was 
then degassed three times on a high vacuum line using a freeze-thaw procedure with 
liquid N2, before the addition of 3 bars of H2. The mixture was then left to react at r.t. 
for 3 days; 1H NMR [CD2Cl2, 400 MHz, 298 K] δ 8.16 (d, 1H, 4J(HH) = 3.2 Hz, CHAr), 
7.93 (dd, 1H, 4J(HH) = 3.2 Hz, 3J(HH) = 9.3 Hz, CHAr), 7.88 (m, 2H, 2 x CHpy ortho), 
7.64 (m, 3H, 3 x CHAr), 7.46 (m, 6H, 6 x CHAr), 7.36 (m, 1H, CHpy para), 7.29 (s br, 
CHimidazole), 7.27-7.18 (m, 6H, 6 x CHAr), 7.04 (s, 1H, CHmesityl), 6.77 (s br, CHimidazole), 
6.57 (m, 2H, 2 x CHpy meta), 6.52 (s, 1H, CHmesityl), 6.33 (d, 1H, 
3J(HH) = 9.3 Hz, CHAr), 
2.33 (s br, 3H, CH3), 2.19 (s br, 3H, CH3), 1.19 (s v. br, 3H, CH3), −21.73 (s br), −28.93 
(s br); 13C{1H} NMR [CD2Cl2] δ 177.9 (C-OIr), 138.0 (CAr), 137.3 (CAr), 136.3 (CAr), 
134.2 (6 x CHAr), 133.9 (6 x CHAr), 132.3 (CAr), 128.9 (CHmesityl), 128.3 (CHmesityl), 
127.8 (4 x CHAr), 126.7 (CHAr), 124.5 (CAr), 124.0 (2 x CHpy), 123.7 (CHpy), 121.7 
(CHAr), 120.9 (CHimidazole), 120.6 (CHimidazole), 20.7 (CH3), 18.6 (CH3); 
31P{1H} NMR 
[CD2Cl2] 22.4 (s) 
For this complex, the 13C{1H} data were collected via indirect HMQC methods 
and as such the 31P-13C couplings were not observed. Full characterisation data are not 
available due to the complex undergoing rapid exchange and therefore exhibiting signal 
broadening. 
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8.6.11. Iridium(III) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(dihydride)(PPh3)2, 25 
 
To a CD2Cl2 sample of 24 (3.2 μmol, 1 eq.) in a Young’s NMR tube was added PPh3 
(1.6 mg, 6.4 μmol, 2 eq.). The solution was then degassed three times on a high vacuum 
line using a freeze-thaw procedure with liquid N2, before the addition of 3 bars of H2; 
1H NMR [CD2Cl2, 400 MHz, 298 K] δ 7.96 (d, 1H, 4J(HH) = 3.2 Hz, CHAr), 7.79 (dd, 
1H, 4J(HH) = 3.2 Hz, 3J(HH) = 9.0 Hz, CHAr), 7.28-7.18 (m, 12H, 12 x CHAr), 7.17 (d, 
1H, 3J(HH) = 1.6 Hz, CHimidazole), 7.10-7.02 (m, 18H, 18 x CHAr), 6.99 (s, 1H, CHmesityl), 
6.96 (s, 1H, CHmesityl), 6.86 (d, 1H, 
3J(HH) = 1.6 Hz, CHimidazole), 5.72 (d, 1H, 
3J(HH) = 
9.0 Hz, CHAr), 5.38 (d, 1H, 
2J(HH) = 13.5 Hz, CH2 linker), 3.92 (d, 1H, 
2J(HH) = 13.5 
Hz, CH2 linker), 2.43 (s, 3H, CH3), 1.82 (s, 3H, CH3), 1.34 (s, 3H, CH3), −9.6 (ddd, 1H, 
2J(HH) = 4.7 Hz, 2J(HPcis) = 22.9 Hz,
 2J(HPtrans) = 138.6 Hz), −27.9 (ddd, 1H, 2J(HH) = 
4.7 Hz, 2J(HPcis) = 13.4 Hz, 
2J(HPcis) = 13.4 Hz); 
13C{1H} NMR [CD2Cl2] δ 180.0 (C-
OIr), 165.6 (C-Ir), 138.5 (CAr), 137.9 (CAr), 136.1 (CAr), 135.0 (CAr), 134.3 (CAr), 133.8 
(CAr), 132.6 (CAr), 129.1 (CHAr and CHmesityl), 128.7 (2 x CHAr), 128.6 (2 x CHAr), 128.2 
(CHmesityl), 127.6 (2 x CHAr), 127.2 (2 x CHAr), 126.8 (2 x CHAr), 126.3 (CHAr), 125.5 
(CAr), 121.8 (CHimidazole), 121.3 (CHAr), 120.8 (CHimidazole), 50.1 (CH2), 20.9 (CH3), 18.6 
(CH3), 17.3 (CH3); 
31P{1H} NMR [CD2Cl2, 400 MHz, 298 K] 15.2 (s), 4.5 (s); MS 
[LIFDI] m/z 1055.36 (M+.) 
For this complex, the 13C{1H} data were collected via indirect HMQC methods 
and as such the 31P-13C couplings were not observed. The 31P{1H} data were also 
collected using indirect methods, hence the 31P-31P coupling data are not presented. 
 
341 
 
 
Figure 247: ORTEP plot of 25, with solvent and H atoms omitted for clarity and the thermal 
ellipsoids set at a 50 % probability level 
 
Table 55: Crystal data for the structural refinement of 25 
Identification code  sbd1514 
Empirical formula and weight C57H52Cl4IrN3O3P2 1222.96 
Temperature / K  110.05(10)  
Crystal system and space group monoclinic    P21 
Unit cell dimensions a / Å = 13.01715(19)    
b / Å = 15.90413(14)   
c / Å = 13.68980(17) 
α / ° = 90  
β / ° = 113.2175(16) 
γ / ° = 90 
Volume / Å3  2604.63(6) 
Z  2 
Density (calculated) / ρcalc / g cm−3 1.559 
Absorption coefficient / μ / mm−1  2.878 
F(000) 1228.0 
Crystal size / mm3  0.2972 × 0.1132 × 0.0988 
Radiation MoKα (λ = 0.71070) 
2Θ range for data collection/°  6.78 to 63.86 
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Index ranges  −19 ≤ h ≤ 18, −23 ≤ k ≤ 23, −19 ≤ l ≤ 19  
Reflections collected  32785 
Independent reflections  15727 [Rint = 0.0272, Rsigma = 0.0405] 
Data / restraints / parameters  15727 / 1 / 644 
Goodness-of-fit on F2  1.053 
Final R indexes [I ≥ 2σ (I)] R1 = 0.0245, wR2 = 0.0528 
Final R indexes [all data]  R1 = 0.0291, wR2 = 0.0551 
Largest diff. peak / hole / e Å−3  1.06 / −0.75 
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8.6.12. Iridium(III) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(PCy3)(phenethylamine) 
(dihydride), 26PCy3 
 
To a Young’s NMR tube was added 1 (7 mg, 11 μmol, 1 eq.), phenethylamine (1.4 μL, 
11 μmol, 1 eq.), PCy3 (3.1 mg, 11 μmol, 1 eq.) and CD2Cl2 (0.6 mL). The solution was 
then degassed three times on a high vacuum line using a freeze-thaw procedure with 
liquid N2, before the addition of 3 bars of H2. The mixture was then left to react at r.t. 
for 3 days; 1H NMR [CD2Cl2, 400 MHz, 243 K] δ 8.12 (d, 1H, 4J(HH) = 2.7 Hz, CHAr), 
7.97 (dd, 1H, 4J(HH) = 3.0 Hz, 3J(HH) = 9.1 Hz, CHAr), 7.29-7.22 (m, 3H, 3 x CHAr), 
7.19 (m, 2H, 2 x CHAr), 7.07 (d, 1H, 
3J(HH) = 1.9 Hz, CHimidazole), 6.94 (s, 1H, 
CHmesityl), 6.91 (s, 1H, CHmesityl), 6.67 (d, 1H, 
3J(HH) = 1.9 Hz, CHimidazole), 6.45 (d, 1H, 
3J(HH) = 9.1 Hz, CHAr), 5.79 (d, 1H, 
2J(HH) = 13.2 Hz, CH2 linker), 4.32 (d, 1H, 
2J(HH) = 13.2 Hz, CH2 linker), 3.30 (m, 1H, CH2), 2.98 (m, 1H, CH2), 2.74 (m, 1H, 
CH2), 2.33 (s, 3H, CH3), 2.27 (m, 1H, CH2), 2.03 (s, 3H, CH3), 2.00 (m, 12H, CH2), 
1.74 (m, 12H, CH2), 1.73 (s, 3H, CH3), 1.51 (m, 6H, CH2), −10.59 (dd, 1H, 2J(HH) = 
4.7 Hz, 2J(HPtrans) = 155.2 Hz), −29.54 (dd, 1H, 2J(HH) = 4.7 Hz, 2J(HPcis) = 10.8 Hz); 
13C{1H} NMR [CD2Cl2] δ 180.8 (C-O), 154.5 (C-Ir), 138.6 (CAr), 137.5 (CAr), 136.7 
(CAr), 134.8 (CAr), 132.3 (CAr), 129.2 (CHAr), 129.0 (CHmesityl), 128.4 (CHAr), 128.4 
(CHmesityl), 128.2 (CHAr), 127.7 (CHAr), 126.8 (CHAr), 126.7 (CHAr), 124.9 (CAr), 120.8 
(CHimidazole), 120.0 (CHAr), 119.8 (CHimidazole), 56.1 (CH2), 50.0 (CH2), 39.4 (CH2), 29.1 
(CH2), 21.0 (CH3), 19.4 (CH3), 18.9 (CH3) 
For this complex, the 13C{1H} data were collected via indirect HMQC methods 
and as such the 31P-13C couplings were not observed. Multiple overlapping signals for 
the phenethylamine and PCy3 ligands precluded their full characterisation. Since 26PCy3 
is formed in low concentration and it converts into 27PCy3 over the course of hours, no 
31P signal could be identified.  
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8.6.13. Iridium(III) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(PR3)(phenethylamine) 
(dihydride), 27 
 
To a Young’s NMR tube was added 1 (7 mg, 11 μmol, 1 eq.), phenethylamine (1.4 μL, 
11 μmol, 1 eq.), PR3 (PCy3, PiPr3, PBz3 or PPh2Cy, 11 μmol, 1 eq.) and CD2Cl2 (0.6 
mL). The solution was then degassed three times on a high vacuum line using a freeze-
thaw procedure with liquid N2, before the addition of 3 bars of H2. The mixture was 
then left to react at r.t. for 3 days.  
For these species, the 13C{1H} data were collected via indirect HMQC methods 
and as such the 31P-13C couplings were not observed. Furthermore, partial NMR data are 
given in some cases, where multiple overlapping signals for a mixture of complexes in 
solution precluded full spectroscopic data determination.  
27PCy3: 1H NMR [CD2Cl2, 400 MHz, 243 K] δ 8.12 (s br, 1H, CHAr), 7.92 (dd, 1H, 
4J(HH) = 3.1 Hz, 3J(HH) = 9.3 Hz, CHAr), 7.36 (s, 1H, CHmesityl), 7.29 (s br, 1H, 
CHimidazole), 7.06-6.97 (m, 5H, 5 x CHAr), 7.05 (s, 1H, CHmesityl), 6.89 (s br, 1H, 
CHimidazole), 6.29 (d, 1H, 
2J(HH) = 13.2 Hz, CH2 linker), 6.24 (d, 1H, 
3J(HH) = 9.3 Hz, 
CHAr), 4.38 (d, 1H, 
2J(HH) = 13.2 Hz, CH2 linker), 2.39 (s, 3H, CH3), 2.34 (m, 2H, 
CH2), 2.15 (s, 3H, CH3), 2.12 (m, 12H, CH2), 2.09 (m, 2H, CH2), 2.00 (s, 3H, CH3), 
1.85 (m, 12H, CH2), 1.61 (m, 6H, CH2), 1.09 (m, 3H, CH), −23.51 (dd, 1H, 2J(HH) = 
7.5 Hz, 2J(HPcis) = 18.0 Hz), −30.66 (dd, 1H, 2J(HH) = 7.5 Hz, 2J(HPcis) = 18.0 Hz); 
13C{1H} NMR [CD2Cl2] δ 178.7 (C-O), 174.9 (C-Ir), 138.9 (CAr), 137.7 (CAr), 136.8 
(CAr), 134.3 (CAr), 131.1 (CAr), 129.4 (CHmesityl), 129.4 (CHAr), 128.8 (CHAr), 128.3 
(CHAr), 128.0 (CHmesityl), 127.8 (CHAr), 126.7 (CHAr), 126.7 (CHAr), 124.8 (CAr), 121.7 
(CHAr), 120.6 (CHimidazole), 120.3 (CHimidazole), 51.4 (CH2), 34.5 (CH2), 27.7 (CH2), 21.0 
(CH3), 19.4 (CH3), 18.7 (CH2), 17.7 (CH3);
 31P{1H} NMR [CD2Cl2, 263 K] 17.2 (s) 
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27PiPr3: 1H NMR [CD2Cl2, 400 MHz, 243 K] δ 8.11 (d, 1H, 4J(HH) = 3.1 Hz, CHAr), 
7.91 (dd, 1H, 4J(HH) = 3.1 Hz, 3J(HH) = 9.3 Hz, CHAr), 7.37-7.22 (m, 5H, 5 x CHAr), 
7.04 (s br, 1H, CHimidazole), 7.03 (s, 1H, CHmesityl), 6.91 (s, 1H, CHmesityl), 6.85 (s br, 1H, 
CHimidazole), 6.48 (d, 1H, 
2J(HH) = 13.8 Hz, CH2 linker), 6.25 (d, 1H 
3J(HH) = 9.3 Hz, 
CHAr), 4.36 (d, 1H, 
2J(HH) = 13.8 Hz, CH2 linker), 2.39 (s, 3H, CH3), 2.17 (m, 2H, 
CH2), 2.16 (s, 3H, CH3), 2.15 (m, 3H, 3 x CH), 2.00 (s, 3H, CH3), 1.50 (m, 2H, CH2), 
0.94 (dd, 18H, 3J(HH) = 7.1 Hz, 2J(HPcis) = 12.0 Hz, 6 x CH3), −23.25 (dd, 1H, 2J(HH) 
= 8.1 Hz, 2J(HPcis) = 19.0 Hz), −30.78 (dd, 1H, 2J(HH) = 8.1 Hz, 2J(HPcis) = 17.5 Hz); 
31P{1H} NMR [CD2Cl2, 243 K] 26.1 (s) 
27PBz3: 1H NMR [CD2Cl2, 400 MHz, 243 K] δ 8.11 (d, 1H, 4J(HH) = 2.8 Hz, CHAr), 
7.93 (dd, 1H, 4J(HH) = 2.8 Hz, 3J = 9.2 Hz, CHAr), 7.29 (m, 3H, 3 x CHAr), 7.24 (m, 
6H, 6 x CHAr), 7.14 (m, 6H, 6 x CHAr), 7.10 (m, 1H, CHAr), 7.07 (m, 2H, 2 x CHAr), 
7.01 (s, 1H, CHmesityl), 6.90 (s, 1H, CHmesityl), 6.75 (m, 2H, 2 x CHAr), 6.43 (d, 1H, 
3J(HH) = 9.2 Hz, CHAr), 5.18 (d, 1H, 
2J(HH) = 13.5 Hz, CH2 linker), 3.94 (d, 1H, 
2J(HH) = 13.5 Hz, CH2 linker), 3.24 (dd, 3H, 
2J(PH) = 8.7 Hz, 2J(HH) = 13.0 Hz, CH2), 
3.04 (m, 1H, CH2), 2.92 (m, 1H, CH2), 2.89 (dd, 3H, 
2J(PH) = 7.0 Hz, 2J(HH) = 13.0 
Hz, CH2), 2.83 (m, 1H, CH2), 2.73 (m, 1H, CH2), 2.30 (s, 3H, CH3), 2.01 (s, 3H, CH3), 
1.83 (s, 3H, CH3), −22.64 (s br, 1H), −29.85 (s br, 1H); 13C{1H} NMR [CD2Cl2] δ 179.2 
(C-O), 138.6 (CAr), 138.4 (CAr), 133.7 (CAr), 133.4 (CAr), 131.6 (CAr), 130.5 (CHAr), 
130.4 (CHAr), 129.5 (CHmesityl), 128.7 (CHAr), 128.3 (CHmesityl), 128.3 (CHAr), 128.0 
(CHAr), 127.8 (CHAr), 126.5 (CHAr), 125.9 (CHAr), 124.0 (CAr), 121.6 (CHAr), 120.9 
(CHAr), 120.9 (CAr), 50.7 (CH2), 43.9 (CH2), 40.2 (CH2), 35.7 (CH2), 20.7 (CH3), 18.6 
(CH3), 17.5 (CH3);
 31P{1H} NMR [CD2Cl2, 298 K] 0.1 (s) 
27PPh2Cy: 1H NMR [CD2Cl2, 400 MHz, 303 K] δ 8.15 (d, 1H, 4J(HH) = 3.0 Hz, CHAr), 
7.90 (dd, 1H, 4J(HH) = 3.0 Hz, 3J(HH) = 9.3 Hz, CHAr), 7.90 (m, 1H, CHAr), 7.80 (m, 
2H, CHAr), 7.20 (m, 2H, 2 x CHAr), 6.98 (s, 1H, CHmesityl), 6.96 (m, 2H, 2 x CHAr), 6.86 
(s, 1H, CHmesityl), 6.31 (d, 1H, 
3J(HH) = 9.3 Hz, CHAr), 6.05 (s br, 1H, CH2 linker), 4.64 
(s br, 1H, CH2 linker), 2.11 (s, 3H, CH3), 2.27 (s, 3H, CH3), 1.86 (s, 3H, CH3), −22.32 
(s br, 1H), −30.68 (s br, 1H); 13C{1H} NMR [CD2Cl2] δ 178.8 (C-O), 138.3 (CAr), 137.3 
(CAr), 136.8 (CAr), 133.8 (CAr), 132.4 (CAr), 129.1 (CHmesityl), 128.1 (CHmesityl), 127.4 
(CHAr), 126.5 (CHAr), 124.8 (CAr), 121.3 (CHAr), 20.2 (CH3), 18.7 (CH3), 17.5 (CH3);
 
31P{1H} NMR [CD2Cl2, 298 K] 23.5 (s)  
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8.6.14. [Ir(H)5(PCy3)2], 28PCy3 
 
To a Young’s NMR tube was added 1 (7 mg, 11 μmol, 1 eq.), PCy3 (6.2 mg, 22 μmol, 2 
eq.) and CD2Cl2 (0.6 mL). The solution was then degassed three times on a high 
vacuum line using a freeze-thaw procedure with liquid N2, before the addition of 3 bars 
of H2. The mixture was then left to react at r.t. for 3 days; 
1H NMR [CD2Cl2, 400 MHz, 
263 K] δ 2.00-1.00 (br m, 66H, PCy3 ligands), −11.23 (t, 5H, 2J(HPcis) = 12.1 Hz); 
31P{1H} NMR [CD2Cl2] 31.7 (s) 
Due to the presence of the degraded carbene ligand and excess unreacted 
phosphine in solution, the NMR spectra did not show the clean formation of 28PCy3. 
Multiple overlapping signals in the alkyl region of the 1H and 13C NMR spectra 
precluded full determination of the specific proton and carbon resonances assigned to 
the cyclohexyl groups. 
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8.6.15. [Ir(H)2(MeCN)2(PCy3)2][BF4] 
 
To a CD2Cl2 solution of 28PCy3 (11 μmol, 1 eq.) in a Young’s NMR tube was added 
tetrafluoroboric acid diethyl ether complex (1.8 μL, 11 μmol, 1 eq.) and acetonitrile (1 
μL, 22 μmol, 2 eq.). The solution was then degassed three times on a high vacuum line 
using a freeze-thaw procedure with liquid N2, before the addition of 3 bars of H2; 
1H 
NMR [CD2Cl2, 400 MHz, 263 K] δ 2.42 (s, 6H, 2 x MeCN), 1.97-1.87 (m, 54H, PCy3), 
1.50-1.40 (m, 12H, PCy3), −22.17 (t, 2H, 2J(HPcis) = 15.5 Hz); 13C{1H} NMR [CD2Cl2] 
120.2 (2 x CN), 34.5 (CHalkyl), 29.5 (CHalkyl), 27.6 (CHalkyl), 26.6 (CHalkyl), 3.7 (2 x 
CH3); 
31P{1H} NMR 22.6 (s) 
For this complex, the 13C{1H} data were collected via indirect HMQC methods 
and as such the 31P-13C couplings were not observed.  
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8.6.16. Iridium(III) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(PiPr3)2(dihydride), 29 
 
To a Young’s NMR tube was added 1 (7 mg, 11 μmol, 1 eq.), phenethylamine (1.4 μL, 
11 μmol, 1 eq.), PiPr3 (4.2 μL, 22 μmol, 2 eq.) and CD2Cl2 (0.6 mL). The solution was 
then degassed three times on a high vacuum line using a freeze-thaw procedure with 
liquid N2, before the addition of 3 bars of H2. The mixture was then left to react at r.t. 
for 3 days; 1H NMR [CD2Cl2, 400 MHz, 243 K] δ 8.15 (d, 1H, 4J(HH) = 3.2 Hz, CHAr), 
7.89 (dd, 1H, 4J(HH) = 3.2 Hz, 3J(HH) = 9.5 Hz, CHAr), 7.28 (d, 1H, 
3J(HH) = 1.9 Hz, 
CHimidazole), 6.90 (s, 1H, CHmesityl), 6.87 (s, 1H, CHmesityl), 6.86 (d, 1H, 
3J(HH) = 1.9 Hz, 
CHimidazole), 6.24 (d, 1H, 
3J(HH) = 9.5 Hz, CHAr), 5.96 (d, 1H, 
2J(HH) = 13.3 Hz, CH2 
linker), 4.35 (d, 1H, 2J(HH) = 13.3 Hz, CH2 linker), 2.27 (s, 3H, CH3), 2.20 (s, 3H, 
CH3), 2.17 (m, 3H, 3 x CH), 1.89 (s, 3H, CH3), 1.51 (m, 3H, 3 x CH), 1.24 (m, 18H, 6 x 
CH3), 1.16 (m, 18H, 6 x CH3), −12.73 (ddd, 1H, 2J(HH) = 5.6 Hz, 2J(HPcis) = 20.5 Hz, 
2J(HPcis) = 25.9 Hz), −31.40 (ddd, 1H, 2J(HH) = 5.6 Hz, 2J(HPcis) = 15.1 Hz, 2J(HPcis) = 
15.1 Hz); 13C{1H} NMR [CD2Cl2] δ 180.5 (C-O), 177.1 (C-Ir), 138.3 (CAr), 137.3 (CAr), 
136.6 (CAr), 134.9 (CAr), 131.3 (CAr), 129.0 (CHmesityl), 128.4 (CHmesityl), 128.0 (CHAr), 
126.8 (CHAr), 124.4 (CAr), 124.0 (CHimidazole), 121.0 (CHimidazole), 120.3 (CHAr), 51.4 
(CH2), 25.9 (3 x CH), 25.3 (3 x CH), 21.8 (CH3), 20.6 (CH3), 19.7 (6 x CH3), 18.4 
(CH3), 16.2 (6 x CH3); 
31P NMR [CD2Cl2] 37.6 (ddd, 
2J(PPtrans) = 329 Hz, 
2J(PHcis) = 
18.0 Hz, 2J(PHcis) = 11.5 Hz), 22.0 (ddd, 
2J(PPtrans) = 329 Hz, 
2J(PHcis) = 23.1 Hz, 
2J(PHcis) = 12.3 Hz); MS [LIFDI] m/z 851.49 (M
+.) 
For this complex, the 13C{1H} data were collected via indirect HMQC methods 
and as such the 31P-13C couplings were not observed. Due to excess PiPr3 in solution, as 
well as the presence of phenethylamine, multiple overlapping signals in the alkyl region 
of the 1H NMR spectrum precluded determination of the 1H-31P couplings.  
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8.6.17. Iridium(III) (3-(2-methylene-4-
nitrophenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(PR3)2(dihydride), 30 
 
To a Young’s NMR tube was added 1 (7 mg, 11 μmol, 1 eq.), phenethylamine (1.4 μL, 
11 μmol, 1 eq.), PR3 (PBz3 or PPh2Cy, 22 μmol, 2 eq.) and CD2Cl2 (0.6 mL). The 
solution was then degassed three times on a high vacuum line using a freeze-thaw 
procedure with liquid N2, before the addition of 3 bars of H2. The mixture was then left 
to react at r.t. for 3 days. 
30PBz3: 1H NMR [CD2Cl2, 400 MHz, 263 K] δ 8.14 (d, 1H, 4J(HH) = 2.8 Hz, CHAr), 
7.97 (dd, 1H, 4J(HH) = 2.8 Hz, 3J(HH) = 9.3 Hz, CHAr), 7.32 (s br, 1H, CHimidazole), 7.32 
(m, 3H, 3 x CHAr), 7.24 (s, 1H, CHmesityl), 7.24 (m, 3H, 3 x CHAr), 7.19 (m, 6H, 6 x 
CHAr), 7.18 (m, 6H, 6 x CHAr), 6.91 (m, 6H, 6 x CHAr), 6.89 (s br, 1H, CHimidazole), 6.78 
(s, 1H, CHmesityl), 6.78 (m, 6H, 6 x CHAr), 6.60 (d, 1H, 
3J(HH) = 9.3 Hz, CHAr), 5.61 (d, 
1H, 2J(HH) = 13.3 Hz, CH2 linker), 4.26 (d, 1H, 
2J(HH) = 13.3 Hz, CH2 linker), 3.02 
(dd, 3H, 2J(PH) = 6.8 Hz, 2J(HH) = 13.0 Hz, CH2), 2.88 (dd, 3H, 
2J(PH) = 8.5 Hz, 
2J(HH) = 14.3 Hz, CH2), 2.81 (dd, 3H, 
2J(PH) = 6.6 Hz, 2J(HH) = 13.0 Hz, CH2), 2.66 
(d br, 3H, 2J(HH) = 14.3 Hz, CH2), 2.28 (s, 3H, CH3), 2.07 (s, 3H, CH3), 1.73 (s, 3H, 
CH3), −10.61 (ddd, 1H, 2J(HH) = 4.9 Hz, 2J(HPcis) = 25.6 Hz, 2J(HPtrans) = 153.4 Hz), 
−28.63 (ddd, 1H, 2J(HH) = 4.9 Hz, 2J(HPcis) = 13.6 Hz, 2J(HPcis) = 13.6 Hz); 13C{1H} 
NMR [CD2Cl2] δ 178.3 (C-O), 167.8 (C-Ir), 138.3 (CAr), 138.2 (CAr), 136.3 (CAr), 134.3 
(CAr), 132.0 (CAr), 131.0 (CHAr), 130.4 (CHAr), 129.5 (CHAr), 129.0 (CHAr), 128.9 
(CHmesityl), 128.2 (CHmesityl), 127.6 (CHAr), 126.9 (CHAr), 126.3 (CAr), 125.9 (CHAr), 
124.2 (CAr), 122.0 (CHimidazole), 122.0 (CHAr), 121.9 (CHAr), 120.9 (CAr), 120.9 
(CHimidazole), 50.8 (CH2), 36.9 (CH2), 32.6 (CH2), 20.8 (CH3), 19.4 (CH3), 19.0 (CH3); 
31P NMR [CD2Cl2] δ 4.0 (ddd, 2J(PHcis) = 13.6 Hz, 2J(PHcis) = 13.6 Hz, 2J(PPcis) = 15.1 
Hz), −15.8 (ddd, 2J(PHcis) = 25.6 Hz, 2J(PPcis) = 15.1 Hz, 2J(PHtrans) = 153.4 Hz) 
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30PPh2Cy: 1H NMR [CD2Cl2, 400 MHz, 303 K] δ 8.09 (d, 1H, 4J(HH) = 2.8 Hz, CHAr), 
7.68 (dd, 1H, 4J(HH) = 3.2 Hz, 3J(HH) = 9.3 Hz, CHAr), 7.49 (m, 4H, 4 x CHAr), 7.32 
(m, 2H, 2 x CHAr), 7.32 (m, 2H, 2 x CHAr), 7.31 (m, 2H, 2 x CHAr), 7.28 (s br, 1H, 
CHimidazole), 7.24 (m, 4H, 4 x CHAr), 7.15 (m, 2H, 2 x CHAr), 7.05 (m, 2H, 2 x CHAr), 
6.98 (m, 2H, 2 x CHAr), 6.95 (s, 1H, CHmesityl), 6.91 (s, 1H, CHmesityl), 6.89 (s br, 1H, 
CHimidazole), 5.86 (d, 1H, 
2J(HH) = 13.5 Hz, CH2 linker), 5.37 (d, 1H, 
3J(HH) = 9.3 Hz, 
CHAr), 4.37 (d, 1H, 
2J(HH) = 13.5 Hz, CH2 linker), 2.39 (m, 2H, CH2), 2.37 (s, 3H, 
CH3), 2.27 (m, 2H, CH2), 2.11 (m, 4H, CH2), 2.03 (m, 4H, CH2), 1.98 (s, 3H, CH3), 
1.86 (m, 4H, CH2), 1.80 (m, 4H, CH2), 1.32 (s, 3H, CH3), −10.23 (ddd, 1H, 2J(HH) = 
4.2 Hz, 2J(HPcis) = 18.4 Hz, 
2J(HPtrans) = 135.7 Hz), −29.20 (ddd, 1H, 2J(HH) = 4.2 Hz, 
2J(HPcis) = 12.9 Hz, 
2J(HPcis) = 12.9 Hz); 
13C{1H} NMR [CD2Cl2] δ 181.4 (C-O), 166.0 
(C-Ir), 138.3 (CAr), 137.9 (CAr), 136.7 (CAr), 134.8 (CHAr), 134.7 (CAr), 133.9 (CHAr), 
133.6 (CHAr), 133.4 (CHAr), 132.5 (CAr), 129.2 (CHmesityl), 128.7 (CHAr), 128.3 
(CHmesityl), 128.1 (CAr), 127.4 (CHAr), 127.2 (CAr), 126.7 (CHAr), 126.2 (CHAr), 125.8 
(CAr), 121.9 (CHimidazole), 121.0 (CHimidazole), 120.8 (CHAr), 50.6 (CH2), 20.8 (CH3), 19.4 
(CH3), 16.5 (CH3);
 31P{1H} NMR [CD2Cl2] δ 19.6 (s br), 8.6 (s br) 
For these species, the 13C{1H} data were collected via indirect HMQC methods 
and as such the 31P-13C couplings were not observed. Furthermore, partial NMR data are 
given in some cases, where multiple overlapping signals for a mixture of complexes in 
solution precluded full spectroscopic data determination. 
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8.7. H carbene synthesis 
8.7.1. 2-benzyloxybenzaldehyde 
 
To a solution of 2-hydroxybenzaldehyde (4.36 mL, 41 mmol, 1 eq.) in dry acetone (50 
mL) under nitrogen, was added K2CO3 (7.36 g, 53 mmol, 1.3 eq.) followed by benzyl 
bromide (6.32 mL, 53 mmol, 1.3 eq.) and the mixture was stirred at reflux for 2 h. The 
acetone was removed, water and ethyl acetate were added and the mixture was extracted 
with ethyl acetate, dried over MgSO4, filtered and concentrated. The product was 
purified by column chromatography (silica, hexane: ethyl acetate, 9: 1) to afford a pale 
yellow oil (7.78 g, 90 %); 1H NMR [CDCl3, 500 MHz, 298 K] δ 10.60 (s, 1H, CHO), 
7.89 (dd, 1H, 3J(HH) = 7.6 Hz, 4J(HH) = 1.7 Hz, CHAr), 7.56 (dt, 1H, 
3J(HH) = 7.6 Hz, 
4J(HH) = 1.7 Hz, CHAr), 7.49-7.36 (m, 5H, 5 x CHAr), 7.09 (s, 1H, CHAr), 7.08 (s, 1H, 
CHAr), 5.23 (s, 2H, CH2); 
13C{1H} NMR [CDCl3] 190.2 (C=O), 161.5 (CArO), 136.5 
(CAr), 136.3 (CHAr), 129.2 (2 x CHAr), 128.9 (CHAr), 128.7 (CHAr), 127.7 (2 x CHAr), 
125.7 (CAr), 121.5 (CHAr), 113.5 (CHAr), 70.9 (CH2); MS [ESI] m/z 235.07 (M+Na)
+ 
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8.7.2. 2-benzyloxybenzyl alcohol148 
 
To a solution of 2-benzyloxybenzaldehyde (2 g, 9.42 mmol, 1 eq.) in MeOH (30 mL) at 
0 °C was added NaBH4 (713 mg, 18.8 mmol, 2 eq.) portionwise over 10 min. After the 
evolution of gas was complete, the mixture was warmed to room temperature and 
stirred for 30 min. The solvent was removed and water and ethyl acetate were added. 
The mixture was extracted with ethyl acetate, dried over MgSO4, filtered and 
concentrated to afford a pale yellow oil (2.00 g, 99 %); 1H NMR [CDCl3, 500 MHz, 298 
K] δ 7.48-7.39 (m, 4H, 4 x CHAr), 7.39-7.30 (m, 2H, 2 x CHAr), 7.30-7.26 (m, 1H, 
CHAr), 7.02-6.95 (m, 2H, 2 x CHAr), 5.15 (s, 2H, CH2), 4.77 (d, 2H, 
3J(HH) = 6.4 Hz, 
CH2OH), 2.30 (t, 1H, 
3J(HH) = 6.4 Hz, OH); 13C{1H} NMR [CDCl3] 157.1 (CArO), 
137.2 (CAr), 129.9 (CAr), 129.4 (CHAr), 129.3 (CHAr), 129.2 (2 x CHAr), 128.6 (CHAr), 
127.8 (2 x CHAr), 121.5 (CHAr), 112.1 (CHAr), 70.5 (CH2O), 62.7 (CH2OH); MS [ESI] 
m/z 237.09 (M+Na)+ 
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8.7.3. 2-benzyloxybenzyl bromide 
 
To a solution of 2-benzyloxy benzyl alcohol (1.4 g, 6.53 mmol, 1 eq.) in DCM (20 mL) 
under N2 at ~ 5 °C was added PBr3 (1.24 mL, 13.1 mmol, 2 eq.) and the mixture was 
stirred at room temperature for 2 h. Cold water was added whilst stirring before the 
mixture was extracted with ethyl acetate. The organic layers were washed with water, 
then brine then dried over MgSO4, filtered and concentrated to afford the product (1.3 g, 
72 %); 1H NMR [CDCl3, 400 MHz, 298 K] δ 7.53 (ps d, 2H, 3J(HH) = 7.3 Hz, 2 x 
CHAr), 7.43 (ps t, 2H, 
3J(HH) = 7.3 Hz, 2 x CHAr), 7.40-7.35 (m, 2H, 2 x CHAr), 7.32-
7.27 (m, 1H, CHAr), 6.99-6.94 (m, 2H, 2 x CHAr), 5.19 (s, 2H, CH2), 4.65 (s, 2H, 
CH2Br); 
13C{1H} NMR [CDCl3] 156.6 (CArO), 136.9 (CAr), 131.0 (CHAr), 130.2 (CHAr), 
128.6 (2 x CHAr), 128.0 (CHAr), 127.2 (2 x CHAr), 126.5 (CAr), 121.0 (CHAr), 112.4 
(CHAr), 70.1 (CH2O), 29.2 (CH2Br) 
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8.7.4. 3-(2-benzyloxy benzyl)-1-(2,4,6-
trimethylphenyl) imidazolium bromide 
 
2-benzyloxy benzyl bromide (1.3 g, 4.69 mmol, 1 eq.) and 1-(2,4,6-trimethylphenyl)-
1H-imidazole (0.87 g, 4.69 mmol, 1 eq.) were dissolved in toluene (20 mL) and heated 
at reflux for 2 h. The solution was cooled to room temperature and the resulting 
precipitate was filtered, washed with diethyl ether and air dried to afford a cream solid 
(1.5 g, 70 %); 1H NMR [DMSO, 400 MHz, 298 K] δ 9.37 (t, 1H, 4J(HH) = 1.7 Hz, 
CHimidazole), 7.92 (t, 1H, 
4J(HH) = 1.7 Hz, CHimidazole), 7.89 (t, 1H, 
4J(HH) = 1.7 Hz, 
CHimidazole), 7.44-7.39 (m, 3H, 3 x CHAr), 7.39-7.36 (m, 1H, CHAr), 7.36-7.32 (m, 2H, 2 
x CHAr), 7.32-7.30 (m, 1H, CHAr), 7.17 (d, 1H, 
3J(HH) = 8.2 Hz, CHAr), 7.05 (t, 1H, 
3J(HH) = 7.4 Hz, CHAr), 5.52 (s, 2H, CH2), 5.20 (s, 2H, CH2), 2.32 (s, 3H, CH3), 1.92 
(s, 6H, 2 x CH3); 
13C{1H} NMR [DMSO] 156.7 (CArO), 140.8 (CAr), 138.1 (CAr), 137.1 
(CHimidazole), 134.7 (2 x CAr), 131.5 (CAr), 131.4 (CHAr), 130.9 (CHAr), 129.7 (2 x 
CHmesityl), 128.9 (2 x CHAr), 128.4 (CHAr), 127.7 (2 x CHAr), 124.5 (CHimidazole), 123.7 
(CHimidazole), 122.6 (CAr), 121.5 (CHAr), 113.1 (CHAr), 69.8 (CH2O), 49.3 (CH2), 21.1 
(CH3), 17.2 (2 x CH3); MS [ESI] m/z 383.2 (M−Br)+ 
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8.7.5. 3-(2-hydroxy benzyl)-1-(2,4,6-
trimethylphenyl) imidazolium bromide 
 
To a Parr reactor was added 3-(2-benzyloxy benzyl)-1-(2,4,6-trimethylphenyl) 
imidazolium bromide (800 mg, 1.73 mmol, 1 eq.), palladium hydroxide on carbon (80 
mg, 10 % by weight) and methanol (15 mL) and the mixture was stirred at 35 °C under 
5 bars of H2 for 20 h. Starting material was still present by LCMS so the solution was 
stirred again under 5 bars of H2 at 45 °C for 6 h. Upon completion of the reaction by 
LCMS, the mixture was filtered through Celite, washed with DCM and concentrated to 
afford a yellow solid (644 mg, 100 %); 1H NMR [DMSO, 400 MHz, 298 K] δ 9.48 (s, 
1H, CHimidazole), 7.91 (s, 1H, CHimidazole), 7.87 (s, 1H, CHimidazole), 7.35 (dd, 1H, 
4J(HH) = 
1.2 Hz, 3J(HH) = 7.6 Hz, CHAr), 7.25 (dt, 1H, 
4J(HH) = 1.2 Hz, 3J(HH) = 7.6 Hz, 
CHAr), 7.14 (s, 2H, CHmesityl), 6.93-6.85 (m, 2H, 2 x CHAr), 5.42 (s, 2H, CH2), 2.33 (s, 
3H, CH3), 2.00 (s, 6H, 2 x CH3); 
13C{1H} NMR [DMSO] 156.5 (CArO), 140.7 (CAr), 
138.4 (CAr), 138.2 (CHimidazole), 134.8 (2 x CAr), 131.0 (CHAr), 130.8 (CHAr), 129.6 (2 x 
CHmesityl), 124.3 (CHimidazole), 123.5 (CHimidazole), 120.9 (CAr), 119.6 (CHAr), 115.9 
(CHAr), 49.4 (CH2), 21.0 (CH3), 17.3 (2 x CH3); MS [ESI] m/z 293.1 (M−Br)+ 
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8.7.6. Silver(I) 3-(2-methylenephenolate)-1-(2,4,6-
trimethylphenyl)imidazolylidene  
 
To a flask containing 3-(2-hydroxy benzyl)-1-(2,4,6-trimethylphenyl) imidazolium 
bromide (177 mg, 0.474 mmol, 1 eq.), silver(I) oxide (61 mg, 0.261 mmol, 0.55 eq.) and 
molecular sieves 4 Å (400 mg), under a nitrogen atmosphere in the dark, was added 
DCM (10 mL) and the solution was stirred at room temperature for 16 h. The mixture 
was filtered through Celite, washed with DCM and the solvent was removed under 
reduced pressure to afford a pale pink oil (120 mg, 63 %); 1H NMR [CDCl3, 500 MHz, 
298 K] all signals broad, δ 7.16 (s, 1H, CHAr), 7.10 (s, 1H, CHAr), 7.03 (s, 1H, CHAr), 
7.00 (s, 1H, CHAr), 6.82 (s, 2H, 2 x CHAr), 6.75 (s, 1H, CHAr), 6.56 (s, 1H, CHAr), 5.41 
(s, 2H, CH2), 2.38 (s, 3H, CH3), 1.68 (s, 6H, 2 x CH3); Partial 
13C{1H} NMR [CDCl3] δ 
130.0 (CHAr), 128.9 (2 x CHAr), 121.4 (CHAr), 121.3 (CHAr), 121.2 (CHAr), 119.6 
(CHAr), 114.9 (CHAr), 52.0 (CH2), 21.1 (CH3), 17.5 (2 x CH3); MS [ESI] m/z 693 (Ag 
dimer, protonated phenol groups) 
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8.7.7. Iridium(I) (3-(2-methylenephenolate)-1-
(2,4,6-trimethylphenyl)imidazolylidene) 
(cyclooctadiene), 2 
 
To a Schlenk flask was added [Ir(COD)Cl]2 (67 mg, 0.10 mmol, 0.5 eq.) and Ag(H-
NHC-O) (80 mg, 0.20 mmol, 1 eq.) and once under an atmosphere of N2, dry DCM (5 
mL) and dry THF (1 mL) were added. The reaction was stirred in the dark at r.t. for 4 h. 
The mixture was filtered over Celite, washed with DCM and the solvent was removed 
under reduced pressure. The product was washed through a silica plug with DCM: 
acetone 9: 1 and the solvent was removed under reduced pressure (repeated three times) 
to afford an orange solid (50 mg, 42 %). The product was stored in a glovebox. 1H NMR 
[CD2Cl2, 500 MHz, 294 K] δ 7.34 (dd, 1H, 3J(HH) = 7.5 Hz, 4J(HH) = 1.6 Hz, CHAr), 
7.30 (ddd, 1H, 3J(HH) = 7.7 Hz, 3J(HH) = 7.6 Hz, 4J(HH) = 1.6 Hz, CHAr), 7.04 (s, 1H, 
CHmesityl), 6.96 (ddd, 1H, 
3J(HH) = 7.5 Hz, 3J(HH) = 7.6 Hz, 4J(HH) = 1.2 Hz, CHAr), 
6.94 (s, 1H, CHmesityl), 6.93 (dd, 1H, 
3J(HH) = 7.7 Hz, 4J(HH) = 1.2 Hz, CHAr), 6.84 (d, 
1H, 3J(HH) = 2.0 Hz, CHimidazole), 6.76 (d, 1H, 
3J(HH) = 2.0 Hz, CHimidazole), 6.55 (d, 
1H, 2J(HH) = 14.9 Hz, CH2), 5.15 (d, 1H, 
2J(HH) = 14.9 Hz, CH2), 4.39 (m, 2H, 2 x 
CHCOD), 3.22 (m, 1H, CHCOD), 2.78 (m, 1H, CHCOD), 2.36 (s, 3H, CH3), 2.27 (s, 3H, 
CH3), 2.17 (m, 1H, CH2(COD)), 2.06 (m, 1H, CH2(COD)), 1.94 (s, 3H, CH3), 1.81 (m, 1H, 
CH2(COD)), 1.59 (m, 2H, CH2(COD)), 1.48 (m, 1H, CH2(COD)), 1.39 (m, 1H, CH2(COD)), 1.19 
(m, 1H1.48 (m, 1H, CH2(COD)); 
13C{1H} NMR [CD2Cl2] δ 179.4 (C-Ir), 155.8 (C-O), 
138.6 (CAr), 136.5 (CAr), 135.6 (CAr), 134.3 (CAr), 131.5 (CHAr), 130.3 (CHAr), 129.2 
(CHmesityl), 128.1 (CHmesityl), 123.2 (CHimidazole), 121.1 (CAr), 120.1 (CHAr), 119.7 
(CHimidazole), 117.6 (CHAr), 83.6 (CHCOD), 83.4 (CHCOD), 53.1 (CHCOD), 51.6 (CHCOD), 
51.3 (CH2), 34.8 (CH2(COD)), 29.8 (CH2(COD)), 28.6 (CH2(COD)), 28.4 (CH2(COD)), 20.6 
(CH3), 19.1 (CH3), 17.5 (CH3); MS [ESI] m/z 591.2 (M+H)
+ 
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1H NMR [CD3OD, 500 MHz, 243 K] δ 7.38 (d, 1H, 3J(HH) = 2.0 Hz, CHimidazole), 7.37 
(dd, 1H, 3J(HH) = 8.0 Hz, 4J(HH) = 1.4 Hz, CHAr), 7.30 (ddd, 1H, 
3J(HH) = 8.0 Hz, 
3J(HH) = 8.0 Hz, 4J(HH) = 1.7 Hz, CHAr), 7.13 (s, 1H, CHmesityl), 7.08 (d, 1H, 
3J(HH) = 
2.0 Hz, CHimidazole), 7.06 (s, 1H, CHmesityl), 6.92 (d br, 
3J(HH) = 8.0 Hz, 1H, CHAr), 6.91 
(d br, 3J(HH) = 8.0 Hz, 1H, CHAr), 6.26 (d, 1H, 
2J(HH) = 15.0 Hz, CH2), 5.30 (d, 1H, 
2J(HH) = 15.0 Hz, CH2), 4.39 (m, 1H, CHCOD), 4.28 (m, 1H, CHCOD), 3.20 (m, 1H, 
CHCOD), 2.86 (m, 1H, CHCOD), 2.43 (s, 3H, CH3), 2.35 (s, 3H, CH3), 2.11 (m, 1H, 
CH2(COD)), 2.03 (m, 1H, CH2(COD)), 1.98 (s, 3H, CH3), 1.78 (m, 1H, CH2(COD)), 1.55 (m, 
2H, 2 x CH2(COD)), 1.46 (m, 1H, CH2(COD)), 1.37 (m, 1H, CH2(COD)), 1.24 (m, 1H, 
CH2(COD)); 
13C{1H} NMR [CD3OD] δ 178.4 (C-Ir), 155.6 (C-O), 138.6 (CAr), 136.1 
(CAr), 129.9 (CHAr), 129.8 (CAr), 129.1 (CHAr), 128.9 (CAr), 128.0 (CAr), 127.9 
(CHmesityl), 128.9 (CHmesityl), 123.1 (CHimidazole), 119.0 (CHAr), 121.6 (CHimidazole), 114.6 
(CHAr), 81.9 (CHCOD), 81.3 (CHCOD), 52.6 (CHCOD), 51.3 (CHCOD), 49.7 (CH2), 33.8 
(CH2(COD)), 32.3 (CH2(COD)), 28.9 (CH2(COD)), 28.4 (CH2(COD)), 19.9 (CH3), 18.6 (CH3), 
16.9 (CH3) 
 
UV-vis absorption data for complex 2 at six different concentrations are given in 
Table 56 with the corresponding absorption spectra shown in Figure 248. 
Table 56: Concentration and absorbance values for six samples of 2 in DCM at different 
concentrations 
 Concentration / μmol dm−3 Absorbance 
Sample  At 373 nm At 425 nm At 490 nm 
A 676 0.70 0.91 0.18 
B 338 0.35 0.45 0.09 
C 270 0.29 0.37 0.08 
D 216 0.24 0.30 0.07 
E 173 0.19 0.24 0.05 
F 138 0.15 0.20 0.04 
359 
 
 
Figure 248: Visible region of the absorption spectra for 2 in DCM at different concentrations as 
listed in Table 56 
The calibration graph in Figure 249 was used to gain the molar absorption 
coefficients for the absorption bands of 2 as described in Section 2.6.1. 
 
Figure 249: Calibration graph used to calculate the molar absorption coefficients for the three 
absorption bands of 2 in DCM at 373, 425 and 490 nm using the data in Table 56 
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8.7.8. Iridium(III) (3-(2-methylenephenolate)-1-
(2,4,6-trimethylphenyl)imidazolylidene) 
(dihydride)(pyridine)2, 8 
 
To a Young’s NMR tube was added 2 (10 mg, 17 μmol, 1 eq.), pyridine (3.8 μL, 47 
μmol, 2.8 eq.) and CD2Cl2 or C6D6 (0.6 mL). The solution was then degassed three 
times on a high vacuum line using a freeze-thaw procedure with liquid N2, before the 
addition of 3 bars of H2. The mixture was then left to react at r.t. for 1 day; 
1H NMR 
[CD2Cl2, 400 MHz, 298 K] δ 8.81 (m, 2H, 2 x CHpy ortho), 8.75 (m, 2H, 2 x CHpy ortho), 
7.65 (m, 1H, CHpy para), 7.58 (m, 1H, CHpy para), 7.24 (ddd, 1H, 
3J(HH) = 7.8 Hz, 3J(HH) 
= 7.8 Hz, 4J(HH) = 1.8 Hz, CHAr), 7.18 (dd, 1H, 
3J(HH) = 7.8 Hz, 4J(HH) = 1.8 Hz, 
CHAr), 7.02 (m, 2H, 2 x CHpy meta), 6.99 (m, 2H, 2 x CHpy meta), 6.93 (s, 1H, CHmesityl), 
6.89 (dd br, 1H, 3J(HH) = 7.8 Hz, 3J(HH) = 7.8 Hz, CHAr), 6.87 (dd, 1H, 
3J(HH) = 7.8 
Hz, 4J(HH) = 1.2 Hz, CHAr), 6.62 (d, 1H, 
3J(HH) = 2.2 Hz, CHimidazole), 6.58 (d, 1H, 
3J(HH) = 2.2 Hz, CHimidazole), 6.49 (s, 1H, CHmesityl), 5.76 (d, 1H, 
2J(HH) = 14.5 Hz, 
CH2 linker), 5.29 (d, 1H, 
2J(HH) = 14.5 Hz, CH2 linker), 2.23 (s, 3H, CH3), 2.17 (s, 3H, 
CH3), 1.80 (s, 3H, CH3), −22.55 (d, 1H, 2J(HH) = 8.2 Hz), −25.49 (d, 1H, 2J(HH) = 8.2 
Hz); 13C{1H} NMR [CD2Cl2] δ 156.5 (C-O), 155.7 (2 x CHpy ortho), 138.1 (CAr), 137.6 
(CAr), 135.9 (CAr), 135.0 (CHpy para), 135.0 (CAr), 131.4 (CHAr), 129.7 (CHAr), 128.6 
(CHmestiyl), 128.0 (CHmestiyl), 124.5 (2 x CHpy meta), 124.3 (2 x CHpy meta), 123.3 (CAr), 
120.8 (CHimidazole), 119.4 (CHAr), 119.1 (CHimidazole), 118.0 (CHAr), 52.5 (CH2), 20.6 
(CH3), 18.2 (CH3), 17.8 (CH3) 
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1H NMR [C6D6, 400 MHz, 298 K] δ 9.04 (m, 2H, 2 x CHpy ortho), 9.04 (m, 2H, 2 x CHpy 
ortho), 7.21 (dd, 1H, 
3J(HH) = 7.2 Hz, 4J(HH) = 1.1 Hz, CHAr), 7.12 (dt, 1H, 
3J(HH) = 
7.2 Hz, 4J(HH) = 1.6 Hz, CHAr), 6.90 (dd, 1H, 
3J(HH) = 7.2 Hz, 4J(HH) = 1.6 Hz, 
CHAr), 6.75 (dt, 1H, 
3J(HH) = 7.2 Hz, 4J(HH) = 1.1 Hz, CHAr), 6.73 (s, 1H, CHmesityl), 
6.68 (m, 1H, CHpy para), 6.57 (m, 1H, CHpy para), 6.48 (d, 1H, 
3J(HH) = 2.2 Hz, 
CHimidazole), 6.33 (d, 1H, 
2J(HH) = 14.6 Hz, CH2 linker), 6.26 (m, 2H, 2 x CHpy meta), 
6.18 (s, 1H, CHmesityl), 6.14 (m, 2H, 2 x CHpy meta), 6.01 (d, 1H, 
3J(HH) = 2.2 Hz, 
CHimidazole), 5.70 (d, 1H, 
2J(HH) = 14.6 Hz, CH2 linker), 2.44 (s, 3H, CH3), 1.98 (s, 3H, 
CH3), 1.78 (s, 3H, CH3), −21.91 (d, 1H, 2J(HH) = 7.7 Hz), −24.50 (d, 1H, 2J(HH) = 7.7 
Hz); 13C{1H} NMR [C6D6] δ 157.7 (C-O), 155.9 (2 x CHpy ortho), 155.3 (C-Ir), 154.5 (2 
x CHpy ortho), 138.5 (CAr), 136.9 (CAr), 136.2 (CAr), 135.4 (CAr), 133.9 (CHpy para), 131.3 
(CHAr), 129.7 (CHAr), 128.6 (CHmestiyl), 127.9 (CHmestiyl), 123.7 (CAr), 123.6 (2 x CHpy 
meta), 123.6 (2 x CHpy meta), 119.9 (CHimidazole), 119.3 (CHimidazole), 119.1 (CHAr), 118.9 
(CHAr), 53.4 (CH2), 20.4 (CH3), 18.6 (CH3), 18.0 (CH3) 
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8.7.9. Iridium(I) (3-(2-methylenephenoxide)-1-
(2,4,6-trimethylphenyl)imidazolylidene) 
(cyclooctadiene)(pyridine), 13 
 
To a Young’s NMR tube was added 2 (10 mg, 17 μmol, 1 eq.), pyridine (3.8 μL, 47 
μmol, 2.8 eq.) and CD3OD (0.6 mL). The solution was then degassed three times on a 
high vacuum line using a freeze-thaw procedure with a dry ice/acetone bath; 1H NMR 
[CD3OD, 400 MHz, 243 K] δ 7.97 (m, 2H, 2 x CHpy ortho), 7.83 (m, 1H, CHpy para), 7.34 
(m, 2H, 2 x CHpy meta), 7.32 (s br, 1H, CHimidazole), 7.31 (dd br, 
3J(HH) = 7.0 Hz, 3J(HH) 
= 7.0 Hz, 1H, CHAr), 7.16 (d br, 
3J(HH) = 7.0 Hz, 1H, CHAr), 7.22 (s br, 1H, CHmesityl), 
7.12 (s br, 1H, CHimidazole), 6.83 (s br, 1H, CHmesityl), 6.93 (d br, 
3J(HH) = 7.0 Hz, 1H, 
CHAr), 6.89 (dd br, 
3J(HH) = 7.0 Hz, 3J(HH) = 7.0 Hz, 1H, CHAr), 6.40 (d, 1H, 
2J(HH) 
= 14.6 Hz, CH2), 5.64 (d, 1H, 
2J(HH) = 14.6 Hz, CH2), 4.02 (m, 1H, CHCOD), 3.86 (m, 
1H, CHCOD), 3.78 (m, 1H, CHCOD), 3.27 (m, 1H, CHCOD), 2.48 (m, 1H, CH2(COD)), 2.41 
(s, 3H, CH3), 2.31 (s, 3H, CH3), 2.36 (m, 1H, CH2(COD)), 2.20 (m, 1H, CH2(COD)), 2.09 
(m, 1H, CH2(COD)), 1.98 (m, 2H, 2 x CH2(COD)), 1.67 (m, 1H, CH2(COD)), 1.57 (m, 1H, 
CH2(COD)), 0.88 (s, 3H, CH3); 
13C{1H} NMR [CD3OD] δ 177.0 (C-Ir), 155.8 (C-O), 
151.1 (2 x CHpy ortho), 139.4 (CAr), 137.8 (CHpy para), 136.6 (CAr), 134.9 (CAr), 134.8 
(CAr), 129.7 (CHAr), 129.5 (CHAr), 129.0 (CHmesityl), 128.7 (CHmesityl), 125.9 (2 x CHpy 
meta), 123.9 (CHimidazole), 123.0 (CAr), 122.6 (CHimidazole), 119.3 (CHAr), 114.7 (CHAr), 
83.5 (CHCOD), 80.3 (CHCOD), 65.4 (CHCOD), 62.9 (CHCOD), 50.7 (CH2), 33.8 (CH2(COD)), 
31.2 (CH2(COD)), 30.3 (CH2(COD)), 27.3 (CH2(COD)), 19.9 (CH3), 17.0 (CH3), 15.2 (CH3); 
15N NMR [CD3OD] 248 
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8.7.10. Iridium(III) (3-(2-methylenephenoxide)-1-
(2,4,6-trimethylphenyl)imidazolylidene) 
(cyclooctadiene)(dihydride)(pyridine), 14 
 
To a degassed CD3OD solution of 13 (17 μmol, 1 eq.) in a dry ice/acetone bath at −78 
°C was added 3 bars of H2 and the mixture was analysed immediately at low 
temperature; 1H NMR [CD3OD, 400 MHz, 243 K] δ 8.99 (m, 2H, 2 x CHpy ortho), 7.89 
(m, 1H, CHpy para), 7.37 (m, 2H, 2 x CHpy meta), 7.22 (s br, 1H, CHimidazole), 7.17 (s br, 
1H, CHimidazole), 7.13 (s br, 2H, 2 x CHmesityl), 7.11 (dd br, 
3J(HH) = 7.5 Hz, 3J(HH) = 
8.0 Hz, 1H, CHAr), 6.73 (d br, 
3J(HH) = 8.0 Hz, 1H, CHAr), 6.70 (dd br, 
3J(HH) = 7.5 
Hz, 3J(HH) = 7.5 Hz, 1H, CHAr), 6.50 (d br, 
3J(HH) = 7.5 Hz, 1H, CHAr), 5.00 (d, 1H, 
2J(HH) = 15.2 Hz, CH2), 4.89 (m, 1H, CHCOD), 4.77 (m, 1H, CHCOD), 4.71 (m, 1H, 
CHCOD), 4.70 (d, 1H, 
2J(HH) = 15.2 Hz, CH2), 4.00 (m, 1H, CHCOD), 2.60 (m, 2H, 2 x 
CH2(COD)), 2.50 (m, 1H, CH2(COD)), 2.38 (s, 3H, CH3), 2.37 (m, 1H, CH2(COD)), 2.08 (s, 
3H, CH3), 2.07 (s, 3H, CH3), 1.97 (m, 1H, CH2(COD)), 1.94 (m, 2H, 2 x CH2(COD)), 1.80 
(m, 1H, CH2(COD)), −12.34 (s, 1H), −17.50 (d, 1H, 2J(NH) = 16.8 Hz); 13C{1H} NMR 
[CD3OD] δ 177.1 (C-Ir), 157.7 (2 x CHpy ortho), 154.7 (C-O), 139.1 (CAr), 138.1 (CAr), 
137.6 (CHpy para), 135.1 (CAr), 134.6 (CAr), 129.0 (CHmesityl), 128.9 (CHmesityl), 128.8 
(CAr), 127.2 (CHAr), 125.7 (2 x CHpy meta), 123.8 (CHAr), 123.7 (CHimidazole), 122.9 
(CHimidazole), 118.9 (CHAr), 114.2 (CHAr), 91.5 (CHCOD), 90.5 (CHCOD), 80.1 (CHCOD), 
79.0 (CHCOD), 49.6 (CH2), 36.0 (CH2(COD)), 31.0 (CH2(COD)), 30.1 (CH2(COD)), 25.3 
(CH2(COD)), 19.8 (CH3), 16.8 (CH3), 16.7 (CH3); 
15N NMR [CD3OD] 227 
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8.7.11. Iridium(III) (3-(2-methylenephenoxide)-1-
(2,4,6-trimethylphenyl)imidazolylidene) 
(dihydride)(pyridine)3, 15 
 
Upon warming a solution of 14 in CD3OD under 3 bars of H2 at r.t., the formation of 15 
was observed; 1H NMR [CD3OD, 400 MHz, 298 K] δ 8.41 (m, 4H, 4 x CHpy ortho), 8.23 
(m, 2H, 2 x CHpy ortho), 7.87 (m, 1H, CHpy para), 7.82 (m, 2H, 2 x CHpy para), 7.22 (m, 4H, 
4 x CHpy meta), 7.15 (s, 1H, CHimidazole), 7.11 (m, 2H, 2 x CHpy meta), 7.07 (dd br, 
3J(HH) 
= 7.3 Hz, 3J(HH) = 7.3 Hz, 1H, CHAr), 6.96 (s, 1H, CHimidazole), 6.80 (d br, 
3J(HH) = 7.3 
Hz, 1H, CHAr), 6.75 (dd br, 
3J(HH) = 7.3 Hz, 3J(HH) = 7.3 Hz, 1H, CHAr), 6.71 (s, 2H, 
2 x CHmesityl), 6.70 (d br, 
3J(HH) = 7.3 Hz, 1H, CHAr), 4.83 (s, 2H, CH2), 2.07 (s, 6H, 2 
x CH3), 2.24 (s, 3H, CH3), −22.33 (s, 2H); 13C{1H} NMR [CD3OD] δ 179.0 (C-Ir), 
155.5 (2 x CHpy ortho), 154.4 (C-O), 153.8 (4 x CHpy ortho), 138.4 (CAr), 137.7 (CAr), 136.5 
(2 x CHpy para), 136.4 (CHpy para), 135.2 (2 x CAr), 128.6 (2 x CHmesityl), 128.2 (CHAr), 
127.7 (CHAr), 125.8 (4 x CHpy meta), 125.5 (2 x CHpy meta), 123.4 (CAr), 122.3 
(CHimidazole), 121.4 (CHimidazole), 118.9 (CHAr), 114.3 (CHAr), 48.3 (CH2), 19.6 (CH3), 
17.4 (2 x CH3); 
15N NMR [CD3OD] 258 (py1), 240 (py2) 
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8.7.12. Iridium(I) (3-(2-methylenephenolate)-1-
(2,4,6-trimethylphenyl)imidazolylidene) 
(dicarbonyl), 18 
 
Iridium(I) (3-(2-methylenephenolate)-1-(2,4,6-trimethylphenyl)imidazolylidene) 
(cyclooctadiene) (20 mg, 0.0338 mmol, 1eq.) was dissolved in DCM (2 mL) and the 
mixture was stirred at r.t. whilst CO was bubbled through for 2 min. Stirring under an 
atmosphere of CO was continued for 10 min before the solution was purged with N2 and 
the solvent was removed. The residue was triturated with hexane to afford a beige solid 
(14 mg, 78 %); 1H NMR [CD2Cl2, 500 MHz, 298 K] δ 7.45 (ps dd, 1H, 3J(HH) = 7.5 
Hz, 4J(HH) = 1.7 Hz, CHAr), 7.35 (ps dt, 1H, 
3J(HH) = 7.9 Hz, 3J(HH) = 1.7 Hz, CHAr), 
7.16 (d, 1H, 3J(HH) = 1.9 Hz, CHimidazole), 7.06 (s, 2H, 2 x CHmesityl), 7.03 (ps dt, 1H, 
3J(HH) = 7.6 Hz, 4J(HH) = 1.3 Hz, CHAr), 6.98 (d, 1H, 
3J(HH) = 1.9 Hz, CHimidazole), 
6.96 (ps dd, 1H, 3J(HH) = 8.1 Hz, 4J(HH) = 0.8 Hz, CHAr), 5.69 (s br, 2H, CH2), 2.41 (s, 
3H, CH3), 2.11 (s, 6H, 2 x CH3); 
13C{1H} NMR [CD2Cl2] δ 181.0 (C=O), 174.4 (C-Ir), 
167.7 (C=O), 154.8 (C-O), 139.7 (CAr), 135.1 (2 x CAr), 131.4 (CHAr), 130.6 (CHAr), 
129.1 (2 x CHmesityl), 123.5 (CHimidazole),121.7 (CHimidazole), 121.3 (CAr), 120.9 (CHAr), 
116.8 (CHAr), 50.7 (CH2), 20.9 (CH3), 17.9 (2 x CH3); MS [ESI] m/z 541.1 (M+H)
+; IR 
νCO (cm−1): 2058.3, 1974.3 
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8.8. COOMe carbene synthesis 
8.8.1. Methyl 4-benzyloxy-3-formyl benzoate 
 
To a solution of methyl 3-formyl-4-hydroxy benzoate (400 mg, 2.22 mmol, 1 eq.) in 
MeCN (10 mL) under N2 was added K2CO3 (399 mg, 2.89 mmol, 1.3 eq.) followed by 
benzyl bromide (0.34 mL, 2.89 mmol, 1.3 eq.) and the mixture was heated at 82 °C for 
2 h. Water and ethyl acetate were added and the mixture was extracted with ethyl 
acetate. The organic layers were dried over MgSO4, filtered and concentrated. The 
product was purified by column chromatography (silica, hexane: ethyl acetate, 8: 2) to 
afford a white solid (512 mg, 85 %); 1H NMR [CDCl3, 400 MHz, 298 K] δ 10.57 (s, 
1H, CHO), 8.56 (d, 1H, 4J(HH) = 2.0 Hz, CHAr), 8.25 (dd, 1H, 
4J(HH) = 2.0 Hz, 3J(HH) 
= 8.6 Hz, CHAr), 7.52-7.38 (m, 5H, 5 x CHAr), 7.14 (d, 1H, 
3J(HH) = 8.6 Hz, CHAr), 
5.30 (s, 2H, CH2), 3.94 (s, 3H, CH3); 
13C{1H} NMR [CDCl3] 188.9 (HC=O), 166.0 
(C=O), 163.9 (CArO), 137.1 (CHAr), 135.3 (CAr), 130.6 (CHAr), 128.9 (2 x CHAr), 128.6 
(CHAr), 127.4 (2 x CHAr), 124.8 (CAr), 123.2 (CAr), 112.9 (CHAr), 70.9 (CH2), 52.2 
(CH3); MS [ESI] m/z 293.08 (M+Na)
+ 
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8.8.2. Methyl 4-benzyloxy-3-hydroxymethyl 
benzoate  
 
To a solution of methyl 4-benzyloxy-3-formyl benzoate (500 mg, 1.85 mmol, 1 eq.) in 
MeOH (20 mL) was added NaBH4 (210 mg, 5.55 mmol, 3 eq.) and the mixture was 
stirred at r.t. for 1.5 h. Water was added and the mixture was extracted with DCM. 
Organic layers were dried over MgSO4, filtered and concentrated to afford a colourless 
oil (466 mg, 92 %); 1H NMR [CDCl3, 400 MHz, 298 K] δ 8.06 (d, 1H, 4J(HH) = 2.0 
Hz, CHAr), 8.02 (dd, 1H, 
4J(HH) = 2.0 Hz, 3J(HH) = 8.7 Hz, CHAr), 7.47-7.36 (m, 5H, 5 
x CHAr), 7.01 (d, 1H, 
3J(HH) = 8.7 Hz, CHAr), 5.21 (s, 2H, CH2), 4.80 (d, 2H, 
3J(HH) = 
6.5 Hz, CH2OH), 3.93 (s, 3H, CH3), 2.23 (t, 1H, 
3J(HH) = 6.5 Hz, OH); 13C{1H} NMR 
[CDCl3] 166.8 (C=O), 160.1 (CArO), 136.0 (CAr), 131.2 (CHAr), 130.2 (CHAr), 129.5 
(CAr), 128.8 (2 x CHAr), 128.4 (CHAr), 127.4 (2 x CHAr), 122.8 (CAr), 111.1 (CHAr), 70.3 
(CH2), 61.6 (CH2OH), 52.0 (CH3); MS [ESI] m/z 295.09 (M+Na)
+ 
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8.8.3. Methyl 4-benzyloxy-3-bromomethyl 
benzoate 
 
To a solution of methyl 4-benzyloxy-3-hydroxymethyl benzoate (2 g, 7.34 mmol, 1 eq.) 
in DCM under N2 was added PBr3 (0.91 mL, 11 mmol, 1.3 eq.) and the mixture was 
stirred at r.t. for 1.5 h. Water was added slowly whilst stirring and the mixture was 
extracted with ethyl acetate. The organic layers were washed with brine, dried over 
MgSO4, filtered and concentrated. The product was purified by column chromatography 
(silica, hexane: ethyl acetate, 7: 3) to afford a white solid (1.57 g, 64 %); 1H NMR 
[CDCl3, 400 MHz, 298 K] δ 8.09 (d, 1H, 4J(HH) = 2.1 Hz, CHAr), 8.01 (dd, 1H, 4J(HH) 
= 2.1 Hz, 3J(HH) = 8.7 Hz, CHAr), 7.54-7.50 (m, 2H, 2 x CHAr), 7.47-7.36 (m, 3H, 3 x 
CHAr), 6.99 (d, 1H, 
3J(HH) = 8.7 Hz, CHAr), 5.26 (s, 2H, CH2), 4.63 (s, 2H, CH2), 3.92 
(s, 3H, CH3); 
13C{1H} NMR [CDCl3] 166.4 (C=O), 160.1 (CArO), 136.0 (CAr), 132.5 
(CHAr), 132.2 (CHAr), 128.7 (2 x CHAr), 128.2 (CHAr), 127.2 (2 x CHAr), 126.5 (CAr), 
122.8 (CAr), 111.7 (CHAr), 70.4 (CH2), 52.1 (CH3), 28.2 (CH2); MS [ESI] m/z 357.01 
(M+Na)+  
369 
 
8.8.4. 3-(methyl 4-benzyloxy-3-benzyl benzoate)-1-
(2,4,6-trimethylphenyl) imidazolium 
bromide 
 
Methyl 4-benzyloxy-3-bromomethyl benzoate (260 mg, 0.776 mmol, 1 eq.) and 1-
(2,4,6-trimethylphenyl)-1H-imidazole (144 mg, 0.776 mmol, 1 eq.) were dissolved in 
toluene (10 mL) and heated at 70 °C for 20 h. The solution was cooled to r.t. and diethyl 
ether was added. The white precipitate was filtered and the filtrate was concentrated, 
triturated with diethyl ether and refiltered to afford more white solid (336 mg, 94 %); 1H 
NMR [DMSO, 400 MHz, 298 K] δ 9.40 (s br, 1H, CHimidazole), 8.05 (dd, 1H, 4J(HH) = 
2.1 Hz, 3J(HH) = 8.6 Hz, CHAr), 8.02 (t, 1H, 
4J(HH) = 1.7 Hz, CHimidazole), 7.95 (d, 1H, 
4J(HH) = 2.1 Hz, CHAr), 7.93 (t, 1H, 
4J(HH) = 1.7 Hz, CHimidazole), 7.44-7.42 (m, 2H, 2 
x CHAr), 7.40-7.33 (m, 3H, 3 x CHAr), 7.33 (d, 1H, 
3J(HH) = 8.6 Hz, CHAr), 7.14 (s, 2H, 
2 x CHmesityl), 5.61 (s, 2H, CH2), 5.31 (s, 2H, CH2), 3.84 (s, 3H, OCH3), 2.33 (s, 3H, 
CH3), 1.95 (s, 6H, 2 x CH3); 
13C{1H} NMR [DMSO] 166.1 (C=O), 160.5 (CArO), 140.8 
(CAr), 138.3 (CHimidazole), 136.4 (CAr), 134.7 (2 x CAr), 132.9 (CHAr), 131.7 (CAr), 131.6 
(CHAr), 129.7 (2 x CHmesityl), 129.0 (2 x CHAr), 128.7 (CHAr), 127.9 (2 x CHAr), 124.5 
(CHimidazole), 124.0 (CHimidazole), 123.2 (CAr), 122.6 (CAr), 113.1 (CHAr), 70.4 (CH2), 52.5 
(OCH3), 49.0 (CH2), 21.1 (CH3), 17.2 (2 x CH3); MS [ESI] m/z 441.3 (M−Br)+ 
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8.8.5. 3-(methyl 3-benzyl-4-hydroxy benzoate)-1-
(2,4,6-trimethylphenyl) imidazolium 
bromide 
 
To a Parr reactor was added 3-(methyl 4-benzyloxy-3-benzyl benzoate)-1-(2,4,6-
trimethylphenyl) imidazolium bromide (200 mg, 0.384 mmol, 1 eq.), palladium 
hydroxide on carbon (24 mg, 12 % by weight) and methanol (10 mL) and the mixture 
was heated at 45 °C under 5 bars of H2 for 18 h. The mixture was filtered over Celite, 
washed with methanol and concentrated to afford a pale brown solid (165 mg, 100 %); 
1H NMR [DMSO, 400 MHz, 298 K] δ 9.51 (t br, 1H, 4J(HH) = 1.7 Hz, CHimidazole), 7.99 
(t, 1H, 4J(HH) = 1.7 Hz, CHimidazole), 7.94 (d, 1H, 
4J(HH) = 2.2 Hz, CHAr), 7.90 (t, 1H, 
4J(HH) = 1.7 Hz, CHimidazole), 7.86 (dd, 1H, 
4J(HH) = 2.2 Hz, 3J(HH) = 8.6 Hz, CHAr), 
7.14 (s, 2H, 2 x CHmesityl), 6.94 (d, 1H, 
3J(HH) = 8.6 Hz, CHAr), 5.46 (s, 2H, CH2), 3.80 
(s, 3H, OCH3), 2.33 (s, 3H, CH3), 2.00 (s, 6H, 2 x CH3); 
13C{1H} NMR [DMSO] 166.3 
(C=O), 161.6 (CArO), 140.8 (CAr), 138.6 (CHimidazole), 134.8 (2 x CAr), 132.3 (CHAr), 
132.3 (CHAr), 131.7 (CAr), 129.7 (2 x CHmesityl), 124.4 (CHimidazole), 123.8 (CHimidazole), 
121.4 (CAr), 115.9 (CHAr), 52.5 (OCH3), 49.2 (CH2), 21.1 (CH3), 17.3 (2 x CH3); MS 
[ESI] m/z 351.3 (M−Br)+ 
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8.8.6. Iridium(I) (3-(methyl 3-benzyl-4-hydroxy 
benzoate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(cyclooctadiene), 3 
 
To a Schlenk flask containing 3-(methyl 3-benzyl-4-hydroxy benzoate)-1-(2,4,6-
trimethylphenyl) imidazolium bromide (150 mg, 0.348 mmol, 1 eq), silver(I) oxide (161 
mg, 0.696 mmol, 2 eq) and molecular sieves 4 Å (600 mg) under an atmosphere of N2 
in the dark, was added DCM (10 mL) and the mixture was stirred at r.t. for 3 h. To this 
was then added [Ir(COD)Cl]2 (117 mg, 0.174 mmol, 0.5 eq) and the mixture was stirred 
at r.t. for a further 1 h. The mixture was then filtered over Celite and silica, washed with 
DCM: acetone, 4: 1 and concentrated under reduced pressure to afford an orange solid 
(178 mg, 79 %); 1H NMR [CD2Cl2, 400 MHz, 243 K] δ 7.87 (d, 1H, 4J(HH) = 2.2 Hz, 
CHAr), 7.68 (dd, 1H, 
3J(HH) = 8.8 Hz, 4J(HH) = 2.2 Hz, CHAr), 7.12 (d, 1H, 
3J(HH) = 
1.8 Hz, CHimidazole), 7.04 (s br, 1H, CHmesityl), 6.95 (s br, 1H, CHmesityl), 6.69 (s br, 1H, 
3J(HH) = 1.8 Hz, CHimidazole), 6.55 (d, 1H, 
3J(HH) = 8.8 Hz, CHAr), 6.53 (d br, 1H, 
2J(HH) = 13.6 Hz, CH2 linker), 4.75 (d br, 1H, 
2J(HH) = 13.6 Hz, CH2 linker), 4.34 (br 
m, 1H, CHCOD), 4.28 (br m, 1H, CHCOD), 3.80 (s, 3H, OCH3), 3.17 (br m, 1H, CHCOD), 
2.36 (s br, 4H, CH3, CHCOD), 2.18-2.10 (m, 3H, CH2(COD)), 2.05 (s, 3H, CH3), 1.96 (s br, 
4H, CH3, CH2(COD)),  1.59-1.35 (s br, 4H, 2 x CH2(COD)); 
13C{1H} NMR [CD2Cl2] δ 
174.8 (C-Ir), 173.3 (C-OIr), 167.4 (OC=O), 139.0 (CAr), 136.2 (CAr), 135.7 (CAr), 134.4 
(CAr), 131.9 (CHAr), 131.4 (CHAr), 129.1 (CHmesityl), 128.3 (CHmesityl), 123.9 (CAr), 123.3 
(CHimidazole), 121.2 (CHAr), 119.6 (CHimidazole), 114.2 (CAr), 84.5 (CH), 84.0 (CH), 51.6 
(OCH3), 51.4 (CH2), 48.5 (CH), 47.4 (CH), 34.4 (CH2), 33.4 (CH2), 29.0 (CH2), 28.3 
(CH2), 21.0 (CH3), 18.7 (CH3), 17.7 (CH3); MS [ESI] m/z 649.2 (M
+.) 
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Figure 250: ORTEP plot of 3 with H atoms omitted for clarity and the thermal ellipsoids set at 
a 50 % probability level 
 
Table 57: Crystal data for the structural refinement of 3 
Identification code  sbd1626  
Empirical formula and weight C29H33IrN2O3  649.77 
Temperature / K  110.05(10)  
Crystal system and space group triclinic  P-1 
Unit cell dimensions a / Å = 13.7657(5)  
b / Å = 14.4796(6)  
c / Å = 14.5701(6) 
α / ° = 61.959(4)  
β / ° = 87.209(3) 
γ / ° = 80.925(3) 
Volume / Å3  2530.06(19)  
Z  4  
Density (calculated) / ρcalc / g cm−3 1.706  
Absorption coefficient / μ / mm−1  10.480  
F(000) 1288.0  
Crystal size / mm3  0.106 × 0.078 × 0.059  
Radiation CuKα (λ = 1.54184)  
2Θ range for data collection/°  6.876 to 142.366  
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Index ranges  −16 ≤ h ≤ 13, −17 ≤ k ≤ 17, −17 ≤ l ≤ 17  
Reflections collected  36840  
Independent reflections  9696 [Rint = 0.0424, Rsigma = 0.0322]  
Data / restraints / parameters  9696 / 0 / 639  
Goodness-of-fit on F2  1.046  
Final R indexes [I ≥ 2σ (I)] R1 = 0.0310, wR2 = 0.0790  
Final R indexes [all data]  R1 = 0.0349, wR2 = 0.0822  
Largest diff. peak / hole / e Å−3  1.13 / −1.18 
 
UV-vis absorption data for complex 3 at eight different concentrations are given 
in Table 58 with the corresponding absorption spectra shown in Figure 251. 
Table 58: Concentration and absorbance values for eight samples of 3 in DCM at different 
concentrations 
 Concentration / μmol dm−3 Absorbance 
Sample  At 380 nm At 432 nm At 491 nm 
A 385 1.31 0.62 0.21 
B 308 1.06 0.50 0.17 
C 215 0.75 0.36 0.13 
D 172 0.62 0.31 0.12 
E 154 0.55 0.27 0.11 
F 103 0.40 0.20 0.09 
G 77 0.30 0.16 0.08 
H 41 0.19 0.11 0.06 
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Figure 251: Visible region of the absorption spectra for 3 in DCM at different concentrations as 
listed in Table 58 
The calibration graph in Figure 252 was used to gain the molar absorption 
coefficients for the absorption bands of 3 as described in Section 2.6.1. 
 
Figure 252: Calibration graph used to calculate the molar absorption coefficients for the three 
absorption bands of 3 at 380, 432 and 491 nm using the data in Table 58 
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8.8.7. Iridium(III) (3-(methyl 3-benzyl-4-hydroxy 
benzoate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(dihydride)(pyridine)2, 10A 
and 10B 
 
To a Young’s NMR tube was added 3 (10 mg, 15 μmol, 1 eq.), pyridine (3.8 μL, 47 
μmol, 3 eq.) and CD2Cl2 or CD3OD (0.6 mL). The solution was then degassed three 
times on a high vacuum line using a freeze-thaw procedure with either liquid N2 (for 
CD2Cl2) or a dry ice/acetone bath (for CD3OD), before the addition of 3 bars of H2. The 
mixture was then left to react at r.t. for 2 days. 
10A: 1H NMR [CD2Cl2, 400 MHz, 303 K] δ 9.02 (m, 2H, 2 x CHpy ortho), 8.41 (m, 2H, 2 
x CHpy ortho), 7.85 (d, 1H, 
4J(HH) = 2.7 Hz, CHAr), 7.77 (dd, 1H, 
4J(HH) = 2.7 Hz, 
3J(HH) = 8.6 Hz, CHAr), 7.64 (m, 1H, CHpy para), 7.31 (m, 1H, CHpy para), 7.15 (d, 1H, 
3J(HH) = 2.1 Hz, CHimidazole), 7.09 (m, 2H, 2 x CHpy meta), 7.00 (s br, 1H, CHmesityl), 6.96 
(m, 2H, 2 x CHpy meta), 6.73 (d, 1H, 
3J(HH) = 8.6 Hz, CHAr), 6.60 (d, 1H, 
3J(HH) = 2.1 
Hz, CHimidazole), 6.59 (s br, 1H, CHmesityl), 6.15 (d br, 1H, 
2J(HH) = 13.1 Hz, CH2 linker), 
4.56 (d br, 1H, 2J(HH) = 13.1 Hz, CH2 linker), 3.83 (s, 3H, CH3), 2.34 (s br, 3H, CH3), 
2.12 (s br, 3H, CH3), 2.02 (s br, 3H, CH3), −21.95 (d, 1H, 2J(HH) = 8.3 Hz), −28.48 (d, 
1H, 2J(HH) = 8.3 Hz); 13C{1H} NMR [CD2Cl2] δ 175.2 (C-O), 167.6 (C=O), 156.2 (C-
Ir), 154.7 (2 x CHpy ortho), 153.9 (2 x CHpy ortho), 138.7 (CAr), 137.5 (CAr), 136.7 (CAr), 
135.2 (CHpy para), 134.4 (CHpy para), 132.4 (CHAr), 131.5 (CHAr), 128.8 (CAr), 128.5 
(CHmesityl), 127.8 (CHmesityl), 125.0 (CAr), 124.2 (2 x CHpy meta), 122.9 (2 x CHpy meta), 
121.7 (CHAr), 120.0 (CHimidazole), 119.8 (CHimidazole), 111.9 (CAr), 51.9 (CH2), 50.7 
(CH3), 20.7 (CH3), 18.9 (CH3), 17.9 (CH3) 
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10A: 1H NMR [CD3OD, 400 MHz, 298 K] δ 8.90 (m, 2H, 2 x CHpy ortho), 8.23 (m, 2H, 2 
x CHpy ortho), 7.94 (d, 1H, 
4J(HH) = 2.3 Hz, CHAr), 7.77 (dd, 1H, 
4J(HH) = 2.3 Hz, 
3J(HH) = 8.6 Hz, CHAr), 7.75 (m, 1H, CHpy para), 7.69 (m, 1H, CHpy para), 7.39 (d, 1H, 
3J(HH) = 2.0 Hz, CHimidazole), 7.15 (m, 2H, 2 x CHpy meta), 7.01 (m, 2H, 2 x CHpy meta), 
6.98 (s br, 1H, CHmesityl), 6.80 (d, 1H, 
3J(HH) = 8.6 Hz, CHAr), 6.72 (d, 1H, 
3J(HH) = 
2.0 Hz, CHimidazole), 6.51 (s br, 1H, CHmesityl), 6.17 (d br, 1H, 
2J(HH) = 12.6 Hz, CH2 
linker), 4.63 (d br, 1H, 2J(HH) = 12.6 Hz, CH2 linker), 3.85 (s, 3H, CH3), 2.29 (s br, 3H, 
CH3), 2.11 (s br, 3H, CH3), 1.09 (s br, 3H, CH3), −21.66 (s br, 1H), −29.04 (s br, 1H); 
13C{1H} NMR [CD3OD] δ 174.7 (C-O), 168.5 (C=O), 154.7 (C-Ir), 154.5 (2 x CHpy 
ortho), 153.7 (2 x CHpy ortho), 137.5 (CAr), 137.5 (CAr), 136.2 (CAr), 135.6 (CHpy para), 
135.5 (CHpy para), 135.4 (CAr), 132.2 (CHAr), 131.2 (CHAr), 128.4 (CHmesityl), 127.8 
(CHmesityl), 126.5 (CAr), 124.4 (2 x CHpy meta), 124.2 (2 x CHpy meta), 122.1 (CHAr), 120.3 
(CHimidazole), 120.0 (CHimidazole), 113.4 (CAr), 50.5 (CH2), 50.3 (CH3), 19.6 (CH3), 17.9 
(CH3), 15.7 (CH3) 
10B: 1H NMR [CD2Cl2, 400 MHz, 303 K] δ 8.84 (m, 2H, 2 x CHpy ortho), 8.77 (m, 2H, 2 
x CHpy ortho), 7.94 (dd, 1H, 
4J(HH) = 2.2 Hz, 3J(HH) = 8.2 Hz, CHAr), 7.91 (d, 1H, 
4J(HH) = 2.2 Hz, CHAr), 7.69 (m, 1H, CHpy para), 7.60 (m, 1H, CHpy para), 7.06 (m, 2H, 2 
x CHpy meta), 7.01 (m, 2H, 2 x CHpy meta), 6.96 (s, 1H, CHmesityl), 6.94 (d, 1H, 
3J(HH) = 
8.2 Hz, CHAr), 6.64 (d, 1H, 
3J(HH) = 2.2 Hz, CHimidazole), 6.61 (d, 1H, 
3J(HH) = 2.2 Hz, 
CHimidazole), 6.54 (s, 1H, CHmesityl), 5.87 (d, 1H, 
2J(HH) = 14.5 Hz, CH2 linker), 5.32 (d, 
1H, 2J(HH) = 14.5 Hz, CH2 linker), 3.90 (s, 3H, CH3), 2.26 (s, 3H, CH3), 2.19 (s, 3H, 
CH3), 1.83 (s, 3H, CH3), −22.56 (d, 1H, 2J(HH) = 8.0 Hz), −25.47 (d, 1H, 2J(HH) = 8.0 
Hz); 13C{1H} NMR [CD2Cl2] δ 166.4 (C=O), 160.9 (C-O), 155.7 (2 x CHpy ortho), 155.2 
(C-Ir), 154.2 (2 x CHpy ortho), 138.2 (CAr), 137.7 (CAr), 136.1 (CAr), 135.3 (CHpy para), 
135.1 (CAr), 135.1 (CHpy para), 133.4 (CHAr), 132.7 (CAr), 131.7 (CHAr), 128.6 
(CHmesityl), 128.3 (CHmesityl), 124.7 (2 x CHpy meta), 124.4 (2 x CHpy meta), 123.4 (CAr), 
123.0 (CHimidazole), 119.4 (CHimidazole), 118.0 (CHAr), 52.2 (CH2), 51.6 (CH3), 20.4 
(CH3), 18.3 (CH3), 17.7 (CH3) 
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8.8.8. Iridium(I) (3-(methyl 3-benzyl-4-hydroxy 
benzoate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(dicarbonyl), 20 
 
Iridium(I) (3-(methyl 3-benzyl-4-hydroxy benzoate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(cyclooctadiene) (20 mg, 0.0308 mmol, 1eq.) was dissolved in DCM (2 
mL) and the mixture was stirred at r.t. whilst CO was bubbled through for 2 min. 
Stirring under an atmosphere of CO was continued for 10 min before the solution was 
purged with N2 and the solvent was removed. The residue was triturated with hexane to 
afford a yellow solid (12 mg, 67 %); 1H NMR [CD2Cl2, 400 MHz, 298 K] δ 7.92 (d, 1H, 
4J(HH) = 2.2 Hz, CHAr), 7.79 (dd, 1H, 
4J(HH) = 2.2 Hz, 3J(HH) = 8.7 Hz, CHAr), 7.25 
(d, 1H, 3J(HH) = 1.7 Hz, CHimidazole), 7.04 (s, 2H, 2 x CHmesityl), 6.89 (d, 1H, 
3J(HH) = 
1.7 Hz, CHimidazole), 6.72 (d, 1H, 
3J(HH) = 8.7 Hz, CHAr), 5.39 (s br, 2H, CH2), 3.84 (s, 
3H, OCH3), 2.39 (s, 3H, CH3), 2.00 (s, 6H, 2 x CH3); 
13C{1H} NMR [CD2Cl2] δ 182.1 
(C=O), 173.1 (C-Ir), 170.7 (OCAr), 168.9 (C=O), 167.0 (OC=O), 139.7 (CAr), 135.3 (2 x 
CAr), 135.0 (CAr), 131.7 (CHAr), 131.5 (CHAr), 129.1 (2 x CHmesityl), 123.9 (CAr), 123.3 
(CHimidazole), 121.6 (CHAr), 120.9 (CHimidazole), 116.7 (CAr), 51.3 (OCH3), 50.9 (CH2), 
20.9 (CH3), 17.9 (2 x CH3); MS [ESI] m/z 599.1 (M+H)
+; IR νCO (cm−1): 2050.2, 1964.0 
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8.9. Cl carbene synthesis 
8.9.1. 4-hydroxy-4-(2-benzyloxy-5-chlorophenyl)-
2-butanone 
 
To a solution of 5-chlorosalicylaldehyde (1 g, 6.39 mmol, 1 eq.) in dry acetone (20 mL) 
under N2 was added K2CO3 (1.15 g, 8.30 mmol, 1.3 eq.) followed by benzyl bromide 
(0.99 mL, 8.30 mmol, 1.3 eq.) and the mixture was heated at 40 °C for 64 h. The 
solution was cooled to r.t. and the solvent was evaporated. Saturated aqueous NaHCO3 
was added and the mixture was extracted with ethyl acetate. The organic layers were 
dried over MgSO4, filtered and concentrated. The product was purified by column 
chromatography (silica, hexane: ethyl acetate, 9: 1 to 4: 6) to afford a white solid (1.60 
g, 82 %); 1H NMR [CDCl3, 400 MHz, 298 K] δ 7.51 (d, 1H, 4J(HH) = 2.7 Hz, CHAr), 
7.44-7.33 (m, 5H, 5 x CHAr), 7.20 (dd, 1H, 
4J(HH) = 2.7 Hz, 3J(HH) = 8.7 Hz, CHAr), 
6.86 (d, 1H, 3J(HH) = 8.7 Hz, CHAr), 5.45 (ddd, 1H, 
3J(HH) = 2.6 Hz, 3J(HH) = 3.9 Hz, 
3J(HH) = 9.5 Hz, CHOH), 5.10 (s, 2H, CH2), 3.48 (d, 1H, 
3J(HH) = 3.9 Hz, OH), 2.98 
(dd, 1H, 3J(HH) = 2.6 Hz, 2J(HH) = 17.6 Hz, CH2), 2.71 (dd, 1H, 
3J(HH) = 9.5 Hz, 
2J(HH) = 17.6 Hz, CH2), 2.16 (s, 3H, CH3); 
13C{1H} NMR [CDCl3] 209.4 (C=O), 153.2 
(CAr), 136.4 (CAr), 133.2 (CAr), 128.8 (2 x CHAr), 128.2 (CHAr), 127.9 (CHAr), 127.2 (2 
x CHAr), 126.7 (CHAr), 126.5 (CAr), 112.9 (CHAr), 70.5 (OCH2), 65.0 (CHOH), 50.0 
(CH2C=O), 30.7 (CH3); MS [ESI] m/z 327.1 (M+Na)
+; IR νCO (cm−1): 1699.0 
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8.9.2. 2-benzyloxy-5-chloro benzaldehyde 
 
To a dry DMF (5 mL) solution of 5-chloro-2-hydroxybenzaldehyde (200 mg, 1.28 
mmol, 1 eq.) under N2, was added K2CO3 (230 mg, 1.66 mmol, 1.3 eq.) and benzyl 
bromide (0.2 mL, 1.66 mmol, 1.3 eq.). The solution was stirred at 60 °C for 18 h, before 
being cooled to r.t. Then water and diethyl ether were added. The ether layers were 
dried over MgSO4, filtered and concentrated to afford a white solid (293 mg, 93 %); 
1H 
NMR [CDCl3, 400 MHz, 298 K] δ 10.50 (s, 1H, CHO), 7.83 (d, 1H, 4J(HH) = 2.7 Hz, 
CHAr), 7.49 (dd, 1H, 
4J(HH) = 2.7 Hz, 3J(HH) = 8.8 Hz, CHAr), 7.46-7.37 (m, 5H, 5 x 
CHAr), 7.03 (d, 1H, 
3J(HH) = 8.8 Hz, CHAr), 5.21 (s, 2H, CH2); 
13C{1H} NMR [CDCl3] 
188.4 (C=O), 159.5 (CArO), 135.6 (CAr), 135.4 (CHAr), 128.8 (2 x CHAr), 128.5 (CHAr), 
128.1 (CHAr), 127.4 (2 x CHAr), 126.8 (CAr), 126.1 (CAr), 114.8 (CHAr), 71.0 (CH2); MS 
[ESI] m/z 269.03 (M+Na)+ 
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8.9.3. 2-benzyloxy-5-chloro benzyl alcohol 
 
To a stirred solution of 2-benzyloxy-5-chloro benzaldehyde (293 mg, 1.19 mmol, 1 eq.) 
in MeOH (25 mL) was added NaBH4 (90 mg, 2.38 mmol, 2 eq.) slowly. The mixture 
was stirred at r.t. for 3 h before the solvent was removed and water was added. The 
residue was extracted with ethyl acetate and the organic layers were dried over MgSO4, 
filtered and concentrated to afford a colourless oil (262 mg, 89 %); 1H NMR [CDCl3, 
400 MHz, 298 K] δ 7.44-7.36 (m, 5H, 5 x CHAr), 7.35 (d, 1H, 4J(HH) = 2.7 Hz, CHAr), 
7.23 (dd, 1H, 4J(HH) = 2.7 Hz, 3J(HH) = 8.6 Hz, CHAr), 6.89 (d, 1H, 
3J(HH) = 8.6 Hz, 
CHAr), 5.12 (s, 2H, CH2), 4.73 (d br, 2H, 
3J(HH) = 4.7 Hz, CH2OH), 2.21 (t br, 1H, 
3J(HH) = 4.7 Hz, OH); 13C{1H} NMR [CDCl3] 154.9 (CArO), 136.3 (CAr), 131.3 (CAr), 
128.8 (2 x CHAr), 128.5 (CHAr), 128.3 (2 x CHAr), 127.4 (2 x CHAr), 126.0 (CAr), 112.8 
(CHAr), 70.4 (CH2), 61.4 (CH2OH); MS [ESI] m/z 271.05 (M+Na)
+ 
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8.9.4. 2-benzyloxy-5-chloro benzaldehyde 
dimethyl acetal 
 
To a solution of 2-benzyloxy-5-chloro benzaldehyde (1.40 g, 5.68 mmol, 1 eq.) in 
MeOH (50 mL) was added NaBH4 (430 mg, 11.4 mmol, 2 eq.) slowly. The mixture was 
stirred at r.t. for 2 h. The solvent was removed and water was added. The mixture was 
extracted with ethyl acetate and the organic layers were dried over MgSO4, filtered and 
concentrated to afford a white solid (1.43 g, 86 %); 1H NMR [CDCl3, 400 MHz, 298 K] 
δ 7.55 (d, 1H, 4J(HH) = 2.7 Hz, CHAr), 7.46-7.34 (m, 5H, 5 x CHAr), 7.24 (dd, 1H, 
4J(HH) = 2.7 Hz, 3J(HH) = 8.8 Hz, CHAr), 6.88 (d, 1H, 
3J(HH) = 8.8 Hz, CHAr), 5.69 (s, 
1H, CH), 5.13 (s, 2H, CH2O), 3.39 (s, 6H, 2 x CH3); 
13C{1H} NMR [CDCl3] 154.7 
(CArO), 136.7 (CAr), 129.3 (CHAr), 128.6 (2 x CHAr), 128.5 (CAr), 128.0 (CHAr), 127.6 
(CHAr), 127.1 (2 x CHAr), 125.9 (CAr), 113.6 (CHAr), 98.7 (CH), 70.5 (CH2), 53.9 (2 x 
CH3) 
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8.9.5. 2-benzyloxy-5-chloro benzaldehyde 
 
To a solution of 2-benzyloxy-5-chloro benzaldehyde dimethyl acetal (1.43 g, 4.88 
mmol, 1 eq.) in toluene (50 mL) was added paratoluenesulfonic acid (90 mg, 10 mol%) 
and the mixture was stirred at r.t. for 18 h. Saturated aqueous NaHCO3 was added and 
the mixture was extracted with ethyl acetate. The organic layers were dried over 
MgSO4, filtered and concentrated. The resulting residue was triturated with hexane and 
filtered to afford a white solid (675 mg, 56 %): 1H NMR [CDCl3, 400 MHz, 298 K] δ 
10.50 (s, 1H, CHO), 7.83 (d, 1H, 4J(HH) = 2.7 Hz, CHAr), 7.49 (dd, 1H, 
4J(HH) = 2.7 
Hz, 3J(HH) = 8.8 Hz, CHAr), 7.46-7.37 (m, 5H, 5 x CHAr), 7.03 (d, 1H, 
3J(HH) = 8.8 
Hz, CHAr), 5.21 (s, 2H, CH2); 
13C{1H} NMR [CDCl3] 188.4 (C=O), 159.5 (CArO), 
135.6 (CAr), 135.4 (CHAr), 128.8 (2 x CHAr), 128.5 (CHAr), 128.1 (CHAr), 127.4 (2 x 
CHAr), 126.8 (CAr), 126.1 (CAr), 114.8 (CHAr), 71.0 (CH2); MS [ESI] m/z 269.03 
(M+Na)+ 
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8.9.6. 2-benzyloxy-5-chloro benzyl alcohol 
 
To a solution of 2-benzyloxy-5-chloro benzaldehyde (600 mg, 2.43 mmol, 1 eq.) in 
THF (10 mL) was added NaBH4 (184 mg, 4.86 mmol, 2 eq.) and the solution was 
stirred at room temperature for 1 h. Water and ethyl acetate were added and the organic 
layers were washed with brine, dried over MgSO4, filtered and concentrated to afford a 
colourless oil (600 mg, 99 %); 1H NMR [CDCl3, 400 MHz, 298 K] δ 7.44-7.36 (m, 5H, 
5 x CHAr), 7.35 (d, 1H, 
4J(HH) = 2.7 Hz, CHAr), 7.23 (dd, 1H, 
4J(HH) = 2.7 Hz, 3J(HH) 
= 8.6 Hz, CHAr), 6.89 (d, 1H, 
3J(HH) = 8.6 Hz, CHAr), 5.12 (s, 2H, CH2), 4.73 (d br, 2H, 
3J(HH) = 4.7 Hz, CH2OH), 2.21 (t br, 1H, 
3J(HH) = 4.7 Hz, OH); 13C{1H} NMR 
[CDCl3] 154.9 (CArO), 136.3 (CAr), 131.3 (CAr), 128.8 (2 x CHAr), 128.5 (CHAr), 128.3 
(2 x CHAr), 127.4 (2 x CHAr), 126.0 (CAr), 112.8 (CHAr), 70.4 (CH2), 61.4 (CH2OH); 
MS [ESI] m/z 271.05 (M+Na)+ 
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8.9.7. 2-benzyloxy-5-chloro benzyl bromide 
 
To a solution of 2-benzyloxy-5-chloro benzyl alcohol (262 mg, 1.05 mmol, 1 eq.) in 
DCM (5 mL) under N2 at ~ 5 °C was added PBr3 (0.2 mL, 2.11 mmol, 2 eq.). The 
mixture was stirred at r.t. for 2 h. Cold water was added and the mixture was extracted 
with ethyl acetate. The organic layers were dried over MgSO4, filtered, concentrated 
and purified by column chromatography (silica, hexane: ethyl acetate, 8: 2) to afford a 
white solid (214 mg, 65 %); 1H NMR [CDCl3, 500 MHz, 298 K] δ 7.49-7.45 (m, 2H, 2 
x CHAr), 7.43-7.38 (m, 2H, 2 x CHAr), 7.37-7.32 (m, 1H, CHAr), 7.34 (d, 1H, 
4J(HH) = 
2.9 Hz, CHAr), 7.21 (dd, 1H, 
4J(HH) = 2.9 Hz, 3J(HH) = 8.6 Hz, CHAr), 6.85 (d, 1H, 
3J(HH) = 8.6 Hz, CHAr), 5.14 (s, 2H, CH2), 4.53 (s, 2H, CH2Br); 
13C{1H} NMR 
[CDCl3] 155.1 (CArO), 136.4 (CAr), 130.7 (CHAr), 129.7 (CHAr), 128.7 (2 x CHAr), 128.2 
(CAr), 128.1 (CHAr), 127.2 (2 x CHAr), 125.7 (CAr), 113.6 (CHAr), 70.5 (CH2O), 27.8 
(CH2Br) 
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8.9.8. 3-(2-benzyloxy-5-chloro benzyl)-1-(2,4,6-
trimethylphenyl) imidazolium bromide 
 
2-benzyloxy-5-chloro benzyl bromide (214 mg, 0.69 mmol, 1 eq.) and 1-(2,4,6-
trimethylphenyl)-1H-imidazole (128 mg, 0.69 mmol, 1 eq.) were dissolved in toluene (5 
mL) and heated at 70 °C for 16 h. The solution was cooled to room temperature and the 
white precipitate was filtered. The filtrate was concentrated and the resulting residue 
was triturated with diethyl ether. The white precipitate that formed was filtered, washed 
with diethyl ether and air dried to afford a white solid (288 mg, 84 %); 1H NMR 
[DMSO, 400 MHz, 298 K] δ 9.38 (ps t, 1H, 4J(HH) = 1.5 Hz, CHimidazole), 8.00 (ps t, 
1H, 4J(HH) = 1.8 Hz, CHimidazole), 7.91 (ps t, 1H, 
4J(HH) = 1.8 Hz, CHimidazole), 7.52-
7.46 (m, 2H, 2 x CHAr), 7.42-7.30 (m, 5H, 5 x CHAr), 7.20 (d, 1H, 
3J(HH) = 8.8 Hz, 
CHAr), 7.12 (s, 2H, 2 x CHmesityl), 5.51 (s, 2H, CH2), 5.21 (s, 2H, CH2), 2.32 (s, 3H, 
CH3), 1.92 (s, 6H, 2 x CH3); 
13C{1H} NMR [DMSO] 155.6 (CAr), 140.7 (CAr), 138.2 
(CHimidazole), 136.8 (CAr), 134.7 (2 x CAr), 131.6 (CAr), 130.7 (CHAr), 130.8 (CHAr), 
129.7 (2 x CHmesityl), 129.0 (2 x CHAr), 128.3 (CHAr), 127.8 (2 x CHAr), 124.4 
(CHimidazole), 123.7 (CHimidazole), 123.6 (CAr), 114.7 (CHAr), 70.1 (CH2), 48.7 (CH2), 21.1 
(CH3), 17.3 (2 x CH3); MS [ESI] m/z 417.3 (M−Br)+ 
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8.9.9. 2-(tert-butyldimethylsilyloxy)-5-chloro 
benzaldehyde 
 
To a solution of 5-chloro-2-hydroxybenzaldehyde (1.5 g, 9.58 mmol, 1 eq.) in DCM (20 
mL) was added triethylamine (2.0 mL, 14.4 mmol, 1.5 eq.) followed by TBDMSCl 
(2.17 g, 14.4 mmol, 1.5 eq.) and the mixture was stirred at r.t. for 20 h. Water was 
added and the mixture was extracted with DCM. The organic layers were washed with 
brine, dried over MgSO4, filtered and concentrated. The resulting residue was purified 
by column chromatography (silica, hexane: ethyl acetate, 9: 1) to afford an off white 
solid (2.36 g, 91 %); 1H NMR [CDCl3, 400 MHz, 298 K] δ 10.40 (s, 1H, CHO), 7.79 (d, 
1H, 4J(HH) = 2.8 Hz, CHAr), 7.43 (dd, 1H, 
4J(HH) = 2.8 Hz, 3J(HH) = 8.8 Hz, CHAr), 
6.86 (d, 1H, 3J(HH) = 8.8 Hz, CHAr), 1.04 (s, 9H, 3 x CH3), 0.30 (s, 6H, 2 x CH3); 
13C{1H} NMR [CDCl3] 188.9 (C=O), 157.4 (CArO), 135.4 (CHAr), 128.1 (CAr), 127.9 
(CHAr), 127.1 (CAr), 121.7 (CHAr), 25.6 (3 x CH3), 18.4 (C(CH3)3), −4.3 (2 x CH3); MS 
[ESI] m/z 293.07 (M+Na)+ 
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8.9.10. 2-(tert-butyldimethylsilyloxy)-5-chloro 
benzyl alcohol 
 
To a solution of 2-(tert-butyldimethylsilyloxy)-5-chloro benzaldehyde (2.26 g, 8.34 
mmol, 1 eq.) in MeOH (30 mL) at ~ 15 °C was added NaBH4 (474 mg, 12.5 mmol, 1.5 
eq.) portionwise and the mixture was stirred at r.t. for 30 mins. MeOH was removed 
under reduced pressure and water was added. The mixture was extracted with DCM and 
the organic layers were dried over MgSO4, filtered and concentrated to afford a pale 
yellow oil (1.97 g, 86 %); 1H NMR [CDCl3, 500 MHz, 298 K] δ 7.32 (d, 1H, 4J(HH) = 
2.8 Hz, CHAr), 7.12 (dd, 1H, 
4J(HH) = 2.8 Hz, 3J(HH) = 8.6 Hz, CHAr), 6.73 (d, 1H, 
3J(HH) = 8.6 Hz, CHAr), 4.64 (d, 2H, 
3J(HH) = 6.1 Hz, CH2), 1.97 (t, 1H, 
3J(HH) = 6.1 
Hz, OH), 1.01 (s, 9H, 3 x CH3), 0.24 (s, 6H, 2 x CH3); 
13C{1H} NMR [CDCl3] 151.9 
(CArO), 133.2 (CAr), 128.4 (CHAr), 128.2 (CHAr), 126.2 (CAr), 119.5 (CHAr), 61.3 
(CH2OH), 25.7 (3 x CH3), 18.2 (C(CH3)3), −4.2 (2 x CH3); MS [ESI] m/z 295.09 
(M+Na)+ 
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8.9.11. 2-(tert-butyldimethylsilyloxy)-5-chloro 
benzyl bromide 
 
To a solution of 2-(tert-butyldimethylsilyloxy)-5-chloro benzyl alcohol (1.85 g, 6.78 
mmol, 1 eq.) in DCM (30 mL) under N2 in an ice-water bath, was added PBr3 (1.16 mL, 
12.2 mmol, 1.8 eq.) dropwise and the mixture was stirred for 1 h. The mixture was 
poured into ice and ethyl acetate was added. The mixture was extracted with ethyl 
acetate and the organic layers were dried over MgSO4, filtered and concentrated. The 
product was purified by column chromatography (silica, hexane: ethyl acetate, 9: 1) to 
afford a pale yellow oil (700 mg, 31 %); 1H NMR [CDCl3, 400 MHz, 298 K] δ 7.33 (d, 
1H, 4J(HH) = 2.7 Hz, CHAr), 7.15 (dd, 1H, 
4J(HH) = 2.7 Hz, 3J(HH) = 8.7 Hz, CHAr), 
6.76 (d, 1H, 3J(HH) = 8.7 Hz, CHAr), 4.47 (s, 2H, CH2), 1.07 (s, 9H, 3 x CH3), 0.30 (s, 
6H, 2 x CH3); 
13C{1H} NMR [CDCl3] 152.5 (CArO), 130.9 (CHAr), 130.1 (CAr), 129.7 
(CHAr), 125.9 (CAr), 119.8 (CHAr), 28.0 (CH2), 25.8 (3 x CH3), 18.3 (C(CH3)3), −4.2 (2 
x CH3) 
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8.9.12. 3-(5-chloro-2-hydroxybenzyl)-1-(2,4,6-
trimethylphenyl) imidazolium bromide 
 
2-(tert-butyldimethylsilyloxy)-5-chloro benzyl bromide (400 mg, 1.19 mmol, 1 eq.) and 
mesityl imidazole (222 mg, 1.19 mmol, 1 eq.) were dissolved in toluene (10 mL) and 
the solution was heated at 110 °C for 48 h. the solution was cooled to r.t. and diethyl 
ether was added. The precipitate was filtered and washed with diethyl ether to afford a 
brown solid (360 mg, 74 %); 1H NMR [DMSO, 400 MHz, 298 K] δ 10.43 (s, 1H, OH), 
9.51 (s br, 1H, CHimidazole), 7.99 (ps t, 1H, 
4J(HH) = 1.5 Hz, CHimidazole), 7.91 (ps t, 1H, 
4J(HH) = 1.5 Hz, CHimidazole), 7.48 (d, 1H, 
4J(HH) = 2.6 Hz, CHAr), 7.32 (dd, 1H, 
4J(HH) = 2.6 Hz, 3J(HH) = 8.6 Hz, CHAr), 7.16 (s, 2H, 2 x CHmesityl), 6.92 (d, 1H, 
3J(HH) = 8.6 Hz, CHAr), 5.40 (s, 2H, CH2), 2.34 (s, 3H, CH3), 2.01 (s, 6H, 2 x CH3);
 
13C{1H} NMR [DMSO] δ 155.5 (CAr), 140.7 (CAr), 138.4 (CHimidazole), 134.7 (2 x CAr), 
131.5 (CAr), 130.6 (CHAr), 130.5 (CHAr), 129.5 (2 x CHmesityl), 124.4 (CHimidazole), 123.5 
(CHimidazole), 123.0 (CAr), 122.7 (CAr), 117.5 (CHAr), 48.9 (CH2), 21.0 (CH3), 17.3 (2 x 
CH3); MS [ESI] m/z 327.3 (M−Br)+ 
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8.9.13. Iridium(I) (3-(5-chloro-2-methylene 
phenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(cyclooctadiene), 4 
 
To a Schlenk flask containing 3-(5-chloro-2-hydroxybenzyl)-1-(2,4,6-trimethylphenyl) 
imidazolium bromide (150 mg, 0.368 mmol, 1 eq), silver(I) oxide (171 mg, 0.736 
mmol, 2 eq.) and molecular sieves 4 Å (600 mg) under an atmosphere of N2 in the dark, 
was added DCM (10 mL) and the mixture was stirred at r.t. for 3 h. To this was then 
added [Ir(COD)Cl]2 (124 mg, 0.184 mmol, 0.5 eq) and the mixture was stirred at r.t. for 
a further 1 h. The mixture was then filtered over Celite and silica, washed with DCM: 
acetone, 4: 1 and concentrated under reduced pressure to afford an orange solid (190 
mg, 83 %); 1H NMR [CD2Cl2, 400 MHz, 243 K] δ 7.09 (d, 1H, 4J(HH) = 2.8 Hz, CHAr), 
7.07 (d, 1H, 3J(HH) = 1.9 Hz, CHimidazole), 7.03 (s br, 1H, CHmesityl), 6.97 (dd, 1H, 
4J(HH) = 2.8 Hz, 3J(HH) = 8.9 Hz), 6.94 (s br, 1H, CHmesityl), 6.69 (d, 1H, 
3J(HH) = 1.9 
Hz, CHimidazole), 6.51 (d, 1H, 
3J(HH) = 8.9 Hz, CHAr), 6.44 (d, 1H, 
2J(HH) = 13.7 Hz, 
CH2 linker), 4.60 (d, 1H, 
2J(HH) = 13.7 Hz, CH2 linker), 4.32 (m, 1H, CHCOD), 4.27 (m, 
1H, CHCOD), 3.09 (m, 1H, CHCOD), 2.35 (s, 3H, CH3), 2.26 (m, 1H, CHCOD), 2.16 – 2.09 
(m, 2H, CH2(COD)), 2.01 (s br, 3H, CH3), 1.98 (m, 1H, CH2(COD)), 1.96 (s br, 3H, CH3), 
1.69 – 1.45 (m, 4H, 2 x CH2(COD)), 1.36 (m, 1H, CH2(COD)); 13C{1H} NMR [CD2Cl2, 248 
K] δ 175.0 (C-Ir), 166.9 (C-OIr), 138.8 (CAr), 136.2 (CAr), 135.8 (CAr), 134.2 (CAr), 
129.3 (CHAr), 129.1 (CHmesityl), 128.6 (CHAr), 128.3 (CHmesityl), 125.6 (CAr), 123.3 
(CHimidazole), 122.4 (CHAr), 119.5 (CHimidazole), 116.7 (CAr), 84.4 (CH), 84.1 (CH), 50.9 
(CH2), 47.5 (CH), 46.4 (CH), 34.5 (CH2), 33.9 (CH2), 28.9 (CH2), 28.3 (CH2), 21.0 
(CH3), 18.6 (CH3), 17.7 (CH3); MS [ESI] m/z 627.2 (M
+.) 
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UV-vis absorption data for complex 4 at seven different concentrations are given 
in Table 59 with the corresponding absorption spectra shown in Figure 253. 
Table 59: Concentration and absorbance values for seven samples of 4 in DCM at different 
concentrations 
 Concentration / μmol dm−3 Absorbance 
Sample 
 
At 381 nm At 430 nm At 491 nm 
A 319 0.79 0.51 0.16 
B 256 0.64 0.42 0.13 
C 204 0.52 0.34 0.11 
D 164 0.42 0.28 0.10 
E 131 0.34 0.23 0.08 
F 105 0.28 0.19 0.07 
G 63 0.17 0.12 0.05 
 
 
Figure 253: Visible region of the absorption spectra for 4 in DCM at different concentrations as 
listed in Table 59 
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The calibration graph in Figure 254 was used to gain the molar absorption 
coefficients for the absorption bands of 4 as described in Section 2.6.1. 
  
Figure 254: Calibration graph used to calculate the molar absorption coefficients for the three 
absorption bands of 4 at 381, 430 and 491 nm using the data in Table 59 
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8.9.14. Iridium(III) (3-(5-chloro-2-methylene 
phenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(dihydride)(pyridine)2, 12A 
and 12B 
 
To a Young’s NMR tube was added 4 (10 mg, 16 μmol, 1 eq.), pyridine (3.8 μL, 47 
μmol, 3 eq.) and CD2Cl2 or CD3OD (0.6 mL). The solution was then degassed three 
times on a high vacuum line using a freeze-thaw procedure with either liquid N2 (for 
CD2Cl2) or a dry ice/acetone bath (for CD3OD), before the addition of 3 bars of H2. The 
mixture was then left to react at r.t. for 2 days. 
12A: 1H NMR [CD2Cl2, 400 MHz, 298 K] δ 9.02 (m, 2H, 2 x CHpy ortho), 8.46 (m, 2H, 2 
x CHpy ortho), 7.63 (m, 2H, 2 x CHpy para), 7.09 (d, 1H, 
3J(HH) = 2.1 Hz, CHimidazole), 7.07 
(m, 2H, 2 x CHpy meta), 7.06 (d, 1H, 
4J(HH) = 3.2 Hz, CHAr), 7.00 (dd, 1H, 
4J(HH) = 3.2 
Hz, 3J(HH) = 8.7 Hz, CHAr), 6.99 (s, 1H, CHmesityl), 6.70 (d, 1H, 
3J(HH) = 8.7 Hz, 
CHAr), 6.62 (s, 1H, CHmesityl), 6.61 (d, 1H, 
3J(HH) = 2.1 Hz, CHimidazole), 5.95 (d br, 1H, 
2J(HH) = 12.0 Hz, CH2 linker), 4.48 (d br, 1H, 
2J(HH) = 12.0 Hz, CH2 linker), 2.33 (s, 
3H, CH3), 2.10 (s, 3H, CH3), −22.08 (s br, 1H), −28.12 (d br, 1H, 2J(HH) = 7.0 Hz); 
13C{1H} NMR [CD2Cl2] δ 168.8 (C-O), 154.9 (CHpy ortho), 154.0 (CHpy ortho), 137.5 
(CAr), 135.1 (CHpy para), 128.7 (CHAr), 128.6 (CHmesityl), 128.0 (CHmesityl), 126.7 (C-
NO2), 124.2 (CHAr), 124.2 (CHpy meta), 122.8 (CHAr), 120.0 (CHimidazole), 119.8 
(CHimidazole), 114.2 (CAr), 51.6 (CH2), 20.7 (CH3), 18.8 (CH3) 
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12A: 1H NMR [CD3OD, 400 MHz, 298 K] δ 8.92 (m, 2H, 2 x CHpy ortho), 8.29 (m, 2H, 2 
x CHpy ortho), 7.76 (m, 2H, 2 x CHpy para), 7.73 (m, 2H, 2 x CHpy para), 7.22 (d, 1H, 
4J(HH) = 2.3 Hz, CHAr), 7.40 (d, 1H, 
3J(HH) = 2.0 Hz, CHimidazole), 7.18 (m, 2H, 2 x 
CHpy meta), 7.04 (dd, 1H, 
4J(HH) = 2.3 Hz, 3J(HH) = 8.6 Hz, CHAr), 7.04 (m, 2H, 2 x 
CHpy meta), 7.00 (s br, 1H, (CHmesityl), 6.81 (d, 1H, 
3J(HH) = 8.6 Hz, CHAr), 6.75 (d, 1H, 
3J(HH) = 2.0 Hz, CHimidazole), 6.56 (s br, 1H, CHmesityl), 6.11 (d br, 1H, 
2J(HH) = 13.1 
Hz, CH2 linker), 4.60 (d br, 1H, 
2J(HH) = 13.1 Hz, CH2 linker), 2.32 (s, 3H, CH3), 2.13 
(s, 3H, CH3), 1.16 (s, 3H, CH3), −21.72 (s br, 1H), −28.72 (s br, 1H); 13C{1H} NMR 
[CD3OD] δ 166.9 (C-O), 154.8 (CHpy ortho), 154.1 (CHpy ortho), 137.4 (CAr), 136.3 (CAr), 
135.7 (CHpy para), 135.5 (CAr), 135.1 (CHpy para), 128.9 (CHAr), 128.5 (CAr), 128.4 
(CHAr), 128.2 (CHmesityl), 127.7 (CHmesityl), 124.4 (CHpy meta), 124.2 (CHpy meta), 123.4 
(CHAr), 120.2 (CHimidazole), 119.9 (CHimidazole), 117.3 (CAr), 50.2 (CH2), 19.6 (CH3), 17.8 
(CH3), 15.9 (CH3) 
12B: 1H NMR [CD2Cl2, 400 MHz, 298 K] δ 8.81 (m, 2H, 2 x CHpy ortho), 8.75 (m, 2H, 2 
x CHpy ortho), 7.65 (m, 1H, CHpy para), 7.60 (m, 2H, 2 x CHpy para), 7.22 (dd, 1H, 
4J(HH) = 
2.7 Hz, 3J(HH) = 8.6 Hz, CHAr), 7.19 (d, 1H, 
4J(HH) = 2.7 Hz, CHAr), 7.03 (m, 2H, 2 x 
CHpy meta), 7.01 (m, 2H, 2 x CHpy meta), 6.96 (s, 1H, CHmesityl), 6.86 (d, 1H, 
3J(HH) = 8.6 
Hz, CHAr), 6.50 (s, 1H, CHmesityl), 5.76 (d, 1H, 
2J(HH) = 14.6 Hz, CH2 linker), 5.34 (d, 
1H, 2J(HH) = 14.6 Hz, CH2 linker), 2.26 (s, 3H, CH3), 2.19 (s, 3H, CH3), 1.81 (s, 3H, 
CH3), −22.55 (d, 1H, 2J(HH) = 8.0 Hz), −25.50 (d, 1H, 2J(HH) = 8.0 Hz); 13C{1H} 
NMR [CD2Cl2] δ 155.7 (CHpy ortho), 154.2 (CHpy ortho), 135.4 (CHpy para), 135.2 (CHpy 
para), 130.7 (CHAr), 128.2 (CHmesityl), 129.5 (CHAr), 124.4 (CHpy meta), 123.9 (CHAr), 
119.6 (CAr), 52.2 (CH2), 20.5 (CH3), 18.2 (CH3), 17.9 (CH3) 
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8.9.15. Iridium(III) (3-(5-chloro-2-methylene 
phenoxide)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(dihydride)(pyridine)3, 16 
 
To a Young’s NMR tube was added 4 (10 mg, 16 μmol, 1 eq.), pyridine (3.8 μL, 47 
μmol, 3 eq.) and CD3OD (0.6 mL). The solution was then degassed three times on a 
high vacuum line using a freeze-thaw procedure with a dry ice/acetone bath, before the 
addition of 3 bars of H2. The mixture was then left to react at r.t. for 2 days; 
1H NMR 
[CD3OD, 400 MHz, 298 K] δ 8.44 (m, 2H, 2 x CHpy ortho), 8.23 (m, 2H, 2 x CHpy ortho), 
7.85 (m, 2H, 2 x CHpy para), 7.81 (m, 2H, 2 x CHpy para), 7.26 (m, 2H, 2 x CHpy meta), 7.25 
(d, 1H, 4J(HH) = 2.3 Hz, CHAr), 7.13 (m, 2H, 2 x CHpy meta), 7.06 (s br, 1H, CHimidazole), 
7.05 (dd, 1H, 4J(HH) = 2.3 Hz, 3J(HH) = 8.6 Hz, CHAr), 6.77 (s br, 2H, 2 x CHmesityl), 
6.68 (d, 1H, 3J(HH) = 8.6 Hz, CHAr), 6.63 (s br, 1H, CHimidazole), 4.88 (s, 2H, CH2 
linker), 2.27 (s, 3H, CH3), 2.13 (s, 6H, 2 x CH3), −22.29 (s, 2H); 13C{1H} NMR 
[CD3OD] δ 154.2 (CHpy ortho), 153.9 (C-O), 153.7 (CHpy ortho), 138.4 (CAr), 137.6 (CAr), 
136.5 (CHpy para), 136.5 (CHpy para), 136.3 (2 x CAr), 128.5 (2 x CHmesityl), 127.0 
(CHimidazole), 125.8 (CAr), 125.7 (CHpy meta), 125.4 (CHpy meta), 123.2 (CAr), 122.6 (CHAr), 
121.5 (CHAr), 115.7 (CHAr), 48.0 (CH2), 19.7 (CH3), 17.4 (2 x CH3) 
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8.9.16. Iridium(I) (3-(5-chloro-2-methylene 
phenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(dicarbonyl), 19 
 
Iridium(I) (3-(5-chloro-2-methylenephenolate)-1-(2,4,6-trimethylphenyl) 
imidazolylidene)(cyclooctadiene) (20 mg, 0.0348 mmol, 1eq.) was dissolved in DCM (2 
mL) and the mixture was stirred at r.t. whilst CO was bubbled through for 2 min. 
Stirring under an atmosphere of CO was continued for 10 min before the solution was 
purged with N2 and the solvent was removed. The residue was triturated with hexane to 
afford a beige solid (15 mg, 83 %); 1H NMR [CD2Cl2, 500 MHz, 298 K] δ 7.21 (d, 1H, 
3J(HH) = 1.9 Hz, CHimidazole), 7.15 (d, 1H, 
4J(HH) = 2.8 Hz, CHAr), 7.08 (dd, 1H, 
4J(HH) = 2.8 Hz, 3J(HH) = 8.8 Hz, CHAr), 7.04 (s, 2H, 2 x CHmesityl), 6.90 (d, 1H, 
3J(HH) = 1.9 Hz, CHimidazole), 6.68 (d, 1H, 
3J(HH) = 8.8 Hz, CHAr), 5.28 (s br, 2H, CH2), 
2.39 (s, 3H, CH3), 2.00 (s, 6H, 2 x CH3); 
13C{1H} NMR [CD2Cl2] δ 182.2 (C=O), 173.3 
(C-Ir), 169.2 (C=O), 164.4 (OCAr), 139.7 (CAr), 135.4 (2 x CAr), 129.8 (CHAr), 129.1 (2 
x CHmesityl), 128.6 (CAr), 128.4 (CHAr), 125.6 (CAr), 123.4 (CHimidazole), 122.9 (CHAr), 
120.9 (CHimidazole), 119.1 (CAr), 50.7 (CH2), 20.8 (CH3), 17.9 (2 x CH3); MS [ESI] m/z 
575.0 (M+H)+; IR νCO (cm−1): 2058.9, 1974.8 
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Abbreviations 
ALTADENA 
Adiabatic Longitudinal Transport After Dissociation 
Engenders Net Alignment 
BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl 
tBu Tert-butyl 
Bz Benzyl 
COA Cyclooctane 
COD Cyclooctadiene 
COE Cyclooctene 
CORM CO-Releasing Molecule 
COSY Correlation Spectroscopy 
Cy Cyclohexyl 
DCM Dichloromethane 
DFT Density Functional Theory 
DMF Dimethylformamide 
DNP Dynamic Nuclear Polarisation 
EPR Electron Paramagnetic Resonance 
EtOH Ethanol 
ESI Electrospray Ionisation 
EXSY Exchange Spectroscopy 
HMBC Heteronuclear Multiple Bond Correlation 
HMQC Heteronuclear Multiple Quantum Correlation 
IMes 1,3-bis(2,4,6-trimethylphenyl)imidazole-2-ylidene 
INEPT Insensitive Nuclei Enhanced by Polarisation Transfer 
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LCMS Liquid Chromatography Mass Spectrometery 
LIFDI Liquid Injection Field Desorption Ionisation 
MeOH Methanol 
MRI Magnetic Resonance Imaging 
MS Mass Spectrometry 
NHC N-Heterocyclic Carbene 
NMR Nuclear Magnetic Resonance 
nOe Nuclear Overhauser Effect 
NOESY Nuclear Overhauser Effect SpectroscopY 
OPSY Only Parahydrogen SpectroscopY 
ORTEP Oak Ridge Thermal Ellipsoid Plot Program 
PASADENA 
Parahydrogen And Synthesis Allow Dramatically Enhanced 
Nuclear Alignment 
Ph Phenyl 
p-H2 Parahydrogen 
PHIP ParaHydrogen Induced Polarisation 
PHOX Phosphinooxazoline-type ligand 
iPr Isopropyl 
PTF Polarisation Transfer Field 
py Pyridine 
SABRE Signal Amplification By Reversible Exchange 
THF Tetrahydrofuran 
UV-vis Ultraviolet-visible light 
XRD X-ray Diffraction 
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